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Personalised medicine is replacing the one-drug-fits-all approach with many prognostic 
models incorporating biomarkers available for risk stratifying patients. Evidence has been 
emerging that the effects of biomarkers change over time and therefore violate the assumption 
of proportional hazards when performing Cox regression. Analysis using the Cox model when 
the assumptions are invalid can result in misleading conclusions. 
This thesis reviews existing approaches for the analysis of non-proportional effects with 
respect to survival data. A number of well-developed approaches were identified but to date 
their uptake in practice has been limited. There is a need for more widespread use of flexible 
modelling to move away from standard analysis using a Cox model when the assumption of 
proportional hazards is violated. 
Two novel approaches were applied to investigate the impact of follow-up duration on two 
residual risk models, IHC4 and Mammostrat, for predicting risk in early breast cancers using 
two studies with different lengths of follow up; the Edinburgh Breast Conservation Series 
(BCS) and the Tamoxifen versus Exemestane Adjuvant Multinational (TEAM) trial.  
Similar results were observed between the two approaches that were considered, the 
multivariable fractional polynomial time (MFPT) approach and Royston-Parmer flexible 
parametric models, with their respective advantages and disadvantages being discussed.  
The analyses identified a strong time-varying effect of IHC4 score with the prognostic effect 
of IHC4 score on time-to distant recurrence decreasing with increasing follow-up time. 
Mammostrat score identified a group of patients with an increased risk of distant recurrence 
over full follow-up in the TEAM and Edinburgh BCS cohorts. The results suggest a combined 
IHC4 and Mammostrat risk score could provide information on the risk of recurrence and 





















Prognostic models are tools that have been developed which attempt to stratify patients into 
low or high risk groups to aid clinical decision making. These tools often incorporate 
biomarkers, measurements that are indicators of a particular disease state.  The Cox model is 
the most commonly used approach for analysing survival time data in medical research. The 
underlying assumption of this type of modelling is that of proportional hazards, assuming the 
effect of the biomarkers are constant over time. Analysis using the Cox model when the 
assumptions are invalid can result in misleading conclusions. 
This thesis reviews alternatives to the Cox model which allow effects to vary over time with 
respect to survival data. A number of well-developed approaches were identified but to date 
their uptake in practice has been limited. There is a need for more widespread use of flexible 
modelling to move away from standard analysis using a Cox model when the model 
assumptions are violated. 
Two novel approaches were applied to investigate the impact of follow-up duration on two 
residual risk models, IHC4 and Mammostrat, for predicting risk in early breast cancers using 
two studies with different lengths of follow up.  
Similar results were observed between the two approaches that were considered, the 
multivariable fractional polynomial time (MFPT) approach and Royston-Parmer flexible 
parametric models, with their respective advantages and disadvantages being discussed.  
The analyses identified a strong time-varying effect of IHC4 score with the prognostic effect 
of IHC4 score on time-to distant recurrence decreasing with increasing follow-up time. 
Mammostrat score identified a group of patients with an increased risk of distant recurrence 
over full follow-up in the TEAM and Edinburgh BCS cohorts. The results suggest a combined 
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IHC4 and Mammostrat risk score could provide information on the risk of recurrence and 
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Chapter 1:  Introduction and Outline of Thesis 
Breast cancer is a worldwide public health problem and is an extremely heterogeneous disease, 
with varied genotypic and phenotypic features, behaviour and response to therapy. Whilst the 
mortality rate has decreased, the incidence of breast cancer is on the rise and investigation into 
long-term effects of adjuvant therapy is becoming more important as people are surviving 
longer. Personalised medicine is replacing the one-drug-fits-all approach with many 
prognostic models incorporating biomarkers available for risk stratifying patients.  
A standard approach to model the time to a certain event such as relapse or death is the Cox 
proportional hazards model. Evidence has been emerging that the effects of biomarkers change 
over time and therefore violate the assumption of proportional hazards when performing Cox 
regression. Analysis using the Cox model when the assumptions are invalid can result in 
misleading conclusions. 
Compared with other clinical subgroups, ER-positive patients have the best overall prognosis, 
however many recurrences occur in patients who remain disease-free for 5 years. Assessment 
of risk of recurrence over time is clinically important to identify patients with a low risk of 
recurrence for avoidance of chemotherapy and those with high risk of recurrence beyond 5 
years for the decision of whether to extend adjuvant endocrine therapy. 
The first aim of this thesis is to review existing methods for the analysis of survival data when 
there is evidence of non-proportional effects. The second aim is a comparison of two residual 
risk models, IHC4 and Mammostrat, to determine which provides more information on the 
risk of recurrence in the context of additional clinical factors or whether combining both 
approaches would increase the information available to patients and clinicians. The main 
approach of this thesis is the application of novel methods to real data. 
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The thesis is arranged in the following order. First, the clinical background is introduced in 
chapter 2. A brief overview of the statistical methods used when analysing time-to-event data 
is given in chapter 3 with an emphasis on the assumptions in the Cox proportional hazards 
model. 
Chapter 4 is a detailed review of existing methods for the analysis of survival data when the 
proportional hazards assumption does not hold. Advantages and disadvantages are 
summarised with an interest in whether the methods have been applied in practice. 
The two residual risk models of interest in this thesis are described in chapter 5, with detail on 
the development and previous evaluation of the models.  The two data sets used for analysis 
throughout the thesis are described in chapter 6, with detail on the multiple imputation 
performed on one of the cohorts. 
The first data analysis, in Chapter 7, involves the comparison of the two residual risk models, 
with a focus on fitting the standard Cox proportional hazards model and assessing the validity 
of the model assumptions.  
Chapter 8 applies two of the methods identified in the literature review chapter for the analysis 
of IHC4 and Mammostrat incorporating non-proportional effects. The individual markers from 
the two residual risk models are then analysed in Chapter 9 to determine which have a 
prognostic effect on the outcome and which, if any, show evidence of a non-proportional 
effect. 
In the final chapter (Chapter 10), the main findings of the thesis are discussed and suggestions 





Chapter 2:  Clinical Background 
2.1 Breast Cancer  
Breast cancer is a worldwide public health problem and is an extremely heterogeneous disease, 
with varied genotypic and phenotypic features, behaviour and response to therapy (Rakha et 
al., 2012). It is the most frequently diagnosed cancer among women in the western world and 
is a leading cause of mortality, second to lung cancer (Cancer Research UK, 2012). In 2011 
there were 50,285 new cases of breast cancer diagnosed in the UK (Cancer Research UK, 
2015). The large numbers of cases and complexity of treatment options makes decisions about 
the correct treatment to give to patients difficult.  
Whilst the mortality rate has decreased, the incidence of breast cancer is on the rise (Figure 
2.1). Ten year relative survival rate for women has increased from 41% for those diagnosed 
with breast cancer in 1971-1975 in England and Wales to 73% for those diagnosed between 
1996 and 2000 (Cancer Research UK, 2012). The incidence rate of breast cancer increased 
from 74.2 per 100,000 in 1975 to 124.1 per 100,000 in 2008, whereas mortality rate decreased 
from 38.6 per 100,000 in 1975 to 26.1 per 100,000 in 2008 (Figure 2.1). Investigation into 
long-term effects of adjuvant therapy is therefore becoming more and more important as 
people are surviving longer. 
As a result of improvements in routine breast cancer screening, a shift toward the detection of 
early-stage node-negative breast cancer with better prognosis has occurred (Weigel and 
Dowsett, 2010). This creates challenges for clinicians in determining the best choice of 
adjuvant treatment.  
Adjuvant therapy is defined by oncologists as ‘treatment for presumed microscopic disease’, 




Figure 2.1 Breast Cancer European Age-Standardised Incidence and Mortality Rates for Females in Great Britain 
between 1975 and 2008 (Cancer Research UK, 2012). 
 
the UK is to offer chemotherapy to most postmenopausal women with axillary node 
involvement (NICE, 2015). However, chemotherapy has serious side effects and is also 
expensive. Therefore it is of benefit to determine which patient characteristics may optimize 
the treatment selection process. 
2.2 Biomarkers 
Research investigating biomarkers for early detection, prognosis and the prediction of 
treatment responses in breast cancer is rapidly expanding (Pultz et al., 2014).  
2.2.1 Definition 
Biological markers, more commonly known as biomarkers, are often defined as a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention 
(Atkinson et al., 2001).  Biomarkers theoretically have the advantage of improved specificity 
and reduction of heterogeneity that is present in grouping the population by a phenotypic 
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marker (European Medicines Agency, 2011). They can be used in multiple research phases, 
such as non-clinical laboratory development, preclinical animal studies and all phases of a 
clinical trial.  
Biomarkers can generally be distinguished into three types: classifier, prognostic or predictive. 
A classifier marker is used to select an appropriate target population, such as a DNA marker 
that does not change over the course of the study (Cosmatos and Chow, 2008).  
Prognostic markers have been defined as markers that “classically identify patients with 
differing risks of a specific outcome, such as progression or death” (Sargent et al., 2005). They 
inform about the clinical outcomes, independent of treatment, and can be used as a tool for 
staging of the disease or classification of the extent of the disease. For example, patients with 
smaller tumours have a better long-term survival than those with larger tumours (Elston et al., 
1999) thus making tumour size a prognostic marker.  
A predictive marker has been defined as a marker that “predicts the differential efficacy 
(benefit) of a particular therapy based on marker status”. They inform about the treatment 
effect on the clinical endpoint and predict how individual patients will respond to specific 
treatments. An example of this is hormone receptor status predicts response to endocrine 
therapies in breast cancer (Elston et al., 1999). Personalised medicine is replacing the one-
drug-fits-all approach with the use of predictive biomarkers to distinguish those who will 
benefit from a treatment and those who will not and even those who may potentially be harmed 
(Califf et al., 2010). Improving the ability to predict which patients will benefit from a 






2.2.2 Established Biomarkers in Breast Cancer 
Classic clinicopathological features 
Classical clinicopathological features which indicate a patient’s prognosis include tumour size, 
histological subtype and grade, lymph node metastases, and lymphovascular invasion, which 
are derived from careful histological analysis of primary breast cancer samples (Weigel and 
Dowsett, 2010). The TNM (tumour size, nodes, metastasis) system integrates these into 
tumour stages that have major prognostic value defined by four broad categories: 
Stage 1 - early stage breast cancer where the tumour is less than 2 cm across and has not spread 
beyond the breast. 
Stage II – early stage breast cancer where the tumour is either less than 2 cm across and has 
spread to the lymph nodes under the arm; or the tumour is between 2 and 5 cm (with or without 
spread to the lymph nodes under the arm); or the tumour is greater than 5 cm and has not 
spread outside the breast. 
Stage III – locally advanced breast cancer where the tumour is greater than 5 cm across and 
has spread to the lymph nodes under the arm; or the cancer is extensive in the underarm lymph 
nodes; or the cancer has spread to lymph nodes near the breastbone or to other tissues near the 
breast. 
Stage IV – metastatic breast cancer where the cancer has spread outside the breast to other 
organs in the body. 
Estrogen Receptor 
One of the most established and important biomarkers in breast cancer is Estrogen Receptor 
(ER) expression. It is a prognostic marker with ER-positive tumours associated with better 
survival than ER-negative tumours in the short-term (Fisher et al., 1988). It is also a recognised 
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predictive marker with ER-positive tumours indicating benefit from endocrine therapy 
(Goldhirsch et al., 2005).  
Progesterone Receptor 
Estrogen and progesterone receptors (PgR) are strongly linked, with tumours expressing PgR 
but not ER being uncommon. PgR is also a prognostic factor with higher levels of PgR 
associated with better outcome compared to lower levels of PgR (Ravdin et al., 1992). 
However there is no evidence to demonstrate PgR as a predictive marker of treatment with 
endocrine therapy.  
HER2 
HER2 (human epidermal growth factor receptor 2) is a gene that can play a role in the 
development of breast cancer (oncogene). It is another prognostic marker, where over 
expression of HER2 (HER2-positive) has been associated with an increase in the chance of 
relapsing and tend to have a shorter overall survival (Slamon et al., 1987). It is also a highly 
predictive marker and HER2-positive breast cancer has been shown to benefit from treatment 
with trastuzumab (Herceptin)(Romond et al., 2005).  
2.3 Prognostic Models 
Prognostic models are widely used in cancer for investigating patient outcome in relation to 
multiple patient and disease characteristics (Altman, 2009). Such a model may allow the 
(reasonably) reliable classification of patients into two or more groups with different 
prognoses. It may be of particular interest to identify patients with a good prognosis that 
adjuvant therapy would not be (cost-)beneficial, or a group with a poor prognosis that more 
aggressive adjuvant therapy would be justified (Clark, 1994). 
Defining a prognostic model as a combination of at least two different variables to predict 
patient outcome, Altman in 2009 identified 54 studies presenting one or more new prognostic 
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models in a review of published prognostic models in breast cancer (Altman, 2009). However, 
very few of the prognostic models had been independently evaluated in separate data sets.  
In the past 10 years new diagnostic assays have emerged that promise to allow the 
identification of some women with invasive breast cancer who are at low risk of recurrence 
and for whom chemotherapy offers toxicity without a clinically meaningful benefit (Bartlett 
et al., 2013). These diagnostic assays can be put into two groups based on their respective 
methodology: multiparametric gene expression measurements or extended 
immunohistochemistry (IHC) testing. The former being more complex and more expensive 
compared to standard IHC testing. 
Nottingham Prognostic Index (NPI) 
The NPI is one of the oldest prognostic models for breast cancer patients and is often used in 
clinical practice (Haybittle et al., 1982). It is a simple combination of histopathological 
examination of tumour size, lymph-node (LN) stage and tumour grading assembled into a 
prognostic index formula. Several studies have been performed on NPI and confirmed its’ 
prognostic ability (Galea et al., 1992, Balslev et al., 1994, Todd et al., 1987, Guerra et al., 
2003, Sundquist et al., 1999). 
Adjuvant! Online 
Adjuvant! Online is a tool for assessing the risks of an individual patient developing recurrent 
disease and/or dying within 10 years and the magnitude of benefit to be gained by adjuvant 
therapy for individual patients (Ravdin et al., 2001). It uses the same factors as the NPI as well 
as ER status, age and comorbidity. Several studies have assessed the validity of the Adjuvant! 
Online tool (Campbell et al., 2009, Mook et al., 2009, Olivotto et al., 2005, Hajage et al., 2011, 
Bhoo-Pathy et al., 2012) with limitations including overoptimistic predictions in other 
populations, overoptimistic results in young and high grade patients, and the need to consider 




Oncotype  DX is a PCR (polymerase chain reaction)-based expression assay testing 21 genes 
found in breast cancer (Paik et al., 2004). The results are reported as a ‘recurrence score’, 
ranked between 0 and 100, estimating the risk of recurrence after tamoxifen treatment in node-
negative breast cancers. The recurrence score has been proven to be a predictor of outcome 
and response to adjuvant chemotherapy (Paik et al., 2006, Albain et al., 2010, Dowsett et al., 
2009, Mamounas et al., 2010) and has been shown to provide additional prognostic 
information to Adjuvant! Online (Tang et al., 2011). An American Society of Clinical 
Oncology Expert Panel reviewed the evidence and recommended the use of Oncotype DX in 
routine care in 2007 (Harris et al., 2007) and in 2013 NICE (National Institute for Health and 
Care Excellence) issued guidance for use of Oncotype DX in England and Wales as an option 
to help doctors decide whether to offer chemotherapy (NICE, 2013). Oncotype DX is being 
assessed in a randomised trial called TAILORx (Trial Assigning IndividuaLised Options for 
Treatment)(Zujewski and Kamin, 2008) to evaluate the ability of the recurrence score to guide 
therapeutic decisions in patients with an intermediate recurrence score. Over 10,000 patients 
have been recruited into the trial with recruitment complete. Oncotype DX is also being 
assessed in another trial, the RxPONDER Trial (Rx for Positive Node, Endocrine Responsive 
Breast Cancer) to determine whether node positive breast cancer patients with low to 
intermediate recurrence score benefit from chemotherapy. Recruitment began in 2011 with an 
aim to recruit 4000 women. 
MammaPrint 
MammaPrint is a 70-gene microarray-based expression signature used to estimate the 
recurrence risk for early-stage breast cancer (van't Veer et al., 2002). It has been shown to 
provide prognostic information and response to adjuvant chemotherapy (van't Veer et al., 
2002, Buyse et al., 2006, Drukker et al., 2013, Drukker et al., 2014, Bueno-de-Mesquita et al., 
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2009, van de Vijver et al., 2002). The accuracy of MammaPrint in selecting patients for 
adjuvant chemotherapy is being compared to Adjuvant! Online in a randomized trial called 
MINDACT (Microarray In Node-negative and 1–3 node positive Disease may Avoid 
ChemoTherapy)(Bogaerts et al., 2006) where over 6600 patients have been enrolled and 
recruitment is complete. 
PAM50 
PAM50 is a multiplex PCR assay that translates expression array data into a clinically viable 
diagnostic assay (Nielsen et al., 2010, Chia et al., 2012, Parker et al., 2009), using 50 genes to 
identify molecular subtypes of early breast cancer. Similar to Oncotype DX, this assay also 
generates a numerical risk score (risk of recurrence), which has been shown to provide more 
prognostic information in endocrine-treated patients with ER-positive, node-negative disease 
compared with Oncotype Dx in the trans-ATAC cohort (Dowsett et al., 2013). 
Mammostrat 
The Mammostrat assay relies on the IHC analysis of five markers (p53, NDRG1, SLC7A5, 
CEACAM5 and HTF9C)(Ring et al., 2006, Bartlett et al., 2010) and classifies patients into 
three risk groups. First described in 2006, this assay was validated across multiple 
retrospective institutional and clinical trial cohorts, including the NSABP B-14 and NSABP 
B-20 trials (Ross et al., 2008). Recent evidence from the TEAM trial suggests that this assay 
also provides information on residual risk in patients treated with aromatase inhibitors 
(AI)(Bartlett et al., 2012). After Federal Drug Administration approval of this test as a marker 







The IHC4 residual risk model is an extension of longstanding evidence on the ability of four 
conventional IHC markers, ER, PgR, HER2 and Ki67 to select patients at increased residual 
risk after adjuvant endocrine therapy. An algorithm has been developed that integrates these 
data into a predictor of risk, which has been claimed to provide information equivalent to that 
from the more complex and expensive Oncotype DX assay (Cuzick et al., 2011). The IHC4+C 
(IHC markers plus clinicopathologic parameters) score also provides additional information 
on residual risk of distant recurrence to ER-positive primary breast cancer patients receiving 
adjuvant endocrine therapy, supplementary to that provided by the Adjuvant! Online and NPI 
intermediate-risk groups (Barton et al., 2012). 
2.4 Time-Dependency of Effects 
Long-term treatment decisions such as extended adjuvant endocrine therapy beyond 5 years 
may still rely on biomarker data from the primary diagnostic specimen. This assumes the 
effects of the markers over long periods of time are constant with no time-dependent effects 
but there is evidence to suggest this is not the case. 
The annual hazard rates for breast cancer deaths (percentage per year) after initial diagnosis 
among women in the National Cancer Institute's Surveillance, Epidemiology, and End Results 
13 Registries database (SEER, 2010) show the risk of breast cancer recurrence and death varies 
over time, i.e. it is non-proportional according to prognostic and predictive factors (Figure 
2.2). The hazard curve for breast cancer deaths peaks between 2 and 3 years after initial 
diagnosis and then declines sharply suggesting the biological mechanisms responsible for 
early and late cancer-specific events are fundamentally different (Jatoi et al., 2011).  
The effects of estrogen receptor is a well-established marker proven to change over time 
(Hilsenbeck et al., 1998, Mulligan et al., 2008, Coradini et al., 2000). Patients with ER-





Figure 2.2 Annual Hazard Rates for Breast Cancer Death : All cases combined, ER-negative and ER-positive breast 
cancers using the National Cancer Institute’s Surveillance, Epidemiology, and End Results 13 Registries Databases 
(SEER, 2010, Jatoi et al., 2011) 
 
positive tumours. However, overtime the risk of relapse in ER-negative patients decreases 
whilst the risk in ER-positive patients remains constant. This is displayed in Figure 2.2. The 
hazard rates for breast cancer death for patients with ER-negative and ER-positive tumours 
peak between the first and third years after diagnosis with more than a 3-fold difference in 
risk. However, after the seventh and eighth years their hazard curves cross, after which women 
with ER-negative tumours have a lower rate of breast cancer death than women with ER-
positive tumours.  
A classic example discussing time-varying effects is the paper by Gore and colleagues where 
it was stated that non-monotone convergent hazard functions are associated with most clinical 
covariates in breast cancer and contradicts the use of proportional hazards models (Gore et al., 
1984). Models that assume proportional hazards (e.g. the Cox model) are a popular class of 
models for analysing survival data that have the assumption that the effects of the covariates 
do not change over time (introduced in chapter 3). The gene signature MammaPrint has already 
13 
 
been shown to have possible time-dependent effects with better prediction of patients at high 
risk of early relapse rather than those at risk of later disease progression(Buyse et al., 2006, 
Desmedt et al., 2007).   
It is important to understand time-dependent effects as the different patterns in mortality over 
time suggests biological mechanisms responsible for early and late breast cancer events differ 
and may result in differences in responses to treatments. Time-dependence may suggest de 
novo resistance mechanisms and identify patients who would benefit from switching to 
another treatment. Subtypes that have time-dependent effects could then potentially be 
categorised further into two clinically distinctive groups: those with risk of relapse/death at an 
early stage and those expected to show long-term survival and help find preferential treatment 
options. Understanding time-dependent effects is also important for trial designs. To fully 
determine the long-term effects of new therapies, long-term follow up of patients enrolled in 
breast cancer clinical trials might be necessary. If effects are non-proportional, adaptive trial 
designs that allow early stoppage of trials may prevent finding important late effects. On the 
other hand some adjuvant treatments may only have early benefits and longer follow-up may 
dilute those effects. This will need to be considered in both the design and analysis of such 
trials.  
In a clinical setting, time-dependency of risk-factors is relevant as it is important to identify 
patients who are at high risk of late recurrence. Clinicians must consider whether the long-
term risk of recurrence of primary or secondary breast cancer is the same in all patients and 
therefore consider the best treatment options. Two studies, the Adjuvant Tamoxifen: Longer 
Against Shorter (ATLAS) trial and the Adjuvant Tamoxifen—To Offer More? (aTTom) study 
now support longer-term tamoxifen use for up to 10 years (Davies et al., 2013, Gray et al., 
2013). It has also been shown that extended adjuvant endocrine therapy with letrozole 
improves disease-free survival of postmenopausal women with estrogen receptor or 




Compared with other clinical subgroups, ER-positive, lymph-node negative patients have the 
best overall prognosis, however many recurrences occur in patients who remain disease-free 
for 5 years (Early Breast Cancer Trialists' Collaborative, 2005, Blows et al., 2010, Cheng et 
al., 2012). 
Assessment of risk of recurrence over time is clinically important to identify patients with a 
low risk of recurrence for avoidance of chemotherapy and those with high risk of recurrence 




Chapter 3:  Survival Analysis 
3.1 Introduction 
This project involves analysis of time-to-event data and therefore requires the use of survival 
analysis, a class of statistical methods for studying the occurrence and timing of events (Ata 
and Sozer, 2007). It is widely used in oncology since we are often interested in studying a 
delay, such as the time from cancer diagnosis or treatment commencement to cancer 
recurrence or death (Bellera et al., 2010). In this chapter, the basic concepts and theories 
involved will be introduced with a focus on the Cox proportional hazards model.  
3.2 General Principles 
In survival analysis the term ‘failure’ is used to define the occurrence of the event of interest 
and ‘survival time’ is the length of time taken for the failure to occur.  
Traditional statistical methods, such as ordinary least squares regression, cannot be used as 
not everyone experiences the event of interest (censoring) and the distribution of time-to-event 
outcome is usually not normally distributed. Throughout this project we will be concerned 
with right-censoring. Right-censoring is when it is known that the event of interest occurs 
sometime after the recorded follow-up period or the event might never occur. So at the time 
of observation (or end of follow-up) the relevant event has not yet occurred (the event-date is 
unknown) and so the total length of time between entry and exit is unknown. Given entry at 
time 0 and observation at time t, we only know that the completed spell is of length T > t, i.e. 
their time-to-event will be longer than their time in the study.  
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3.3 The Survival Function and Hazard Rate 
The survival function, S(t), measures the proportion of subjects who have not experienced the 
event as a function of time. Let T be a continuous non-negative random variable denoting the 
time of occurrence of the event of interest. The survival function can then be written as 
 𝑆(𝑡) = 𝑃(𝑇 ≥ 𝑡)  , 
3.1.  
with probability density function (pdf) 𝑓(𝑡) and cumulative distribution function (cdf)  𝐹(𝑡) 
defined as  
 𝐹(𝑡) = 𝑃(𝑇 < 𝑡)  , 
3.2.  
the probability that the event has occurred by time t, sometimes referred to as the failure 
function. The survival function is related to the cdf: 
 
𝑆(𝑡) = 1 − 𝐹(𝑡) = ∫ 𝑓(𝑥)𝑑𝑥  ,
∞
𝑡
 3.3.  
the probability that the event of interest has not occurred by time t. The survival function can 
only decrease and at time 0 none of the subjects have experienced the event giving S(t)=1.  




𝑃(𝑡 ≤ 𝑇 ≤ 𝑡 + 𝜕|𝑇 ≥ 𝑡)
𝜕
   . 3.4.  
The hazard is the instantaneous failure rate at time t which is the probability of the event 
occurring in the next instant given that the subject is currently alive. The hazard function can 











log(𝑆(𝑡))  , 3.5.  
17 
 
and the survival function can therefore be written in terms of the hazard function: 
 
𝑆(𝑡) = exp (− ∫ ℎ(𝑢)𝑑𝑢
𝑡
0
)   . 3.6.  
The hazard function is an estimate of the incidence rate (as a function of time) and is measured 
in events per unit time. It is not a probability and therefore can take values between 0 and 
infinity. A lower hazard rate implies a higher survival function. 
Another quantity of interest is the cumulative hazard function, defined as 
 
𝐻(𝑡) = ∫ ℎ(𝑢)𝑑𝑢  
𝑡
0
. 3.7.  
The cumulative hazard function is a measure of how much ‘hazard’ a subject has been exposed 
to at time t and is used as the basis for a number of residuals. The survivor function is related 
to the cumulative hazard function by 
 𝑆(𝑡) = exp(−H(t))   . 
3.8.  
3.4 Non-Parametric Estimates 
The survival function is often estimated non-parametrically, a simple approach which is free 
of assumptions. 
3.4.1 Kaplan-Meier 
The most commonly used method is the Kaplan-Meier (or product-limit) estimate (Kaplan and 
Meier, 1958) which involves estimating S(t) at discrete values of time t. It is based on 
conditional probabilities as we are interested in the probability of a patient surviving the next 
unit of time given that they have survived so far.  
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The Kaplan-Meier estimate only needs to be estimated at each unique failure time. Let tk be 
the survival time for the kth unique failure time. We then need to obtain an estimate of pk, the 
probability a subject survives the interval (k-1,k) given they were alive at time (k-1): 
 𝑝𝑘 =
𝑁𝑜.𝑜𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑤ℎ𝑜 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑 𝑡ℎ𝑒 𝑡𝑖𝑚𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙 (𝑘−1,𝑘)
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑘−1
  




       = 1 −
𝑑𝑘
𝑛𝑘
 ,   
 
3.9.  
 where 𝑛𝑘 is the number of patients alive at the start if the interval of interest and 𝑑𝑘 is the 
number of patients dying in the interval. 
The Kaplan-Meier survival function estimate at the kth time point is 
 
?̂?(𝑡𝑘) = ∏ 1 −
𝑑𝑖
𝑛𝑖




            = ?̂?(𝑡𝑘−1) (1 −
𝑑𝑘
𝑛𝑘
)    . 
3.10.  
The Kaplan-Meier estimator is a useful descriptive tool but it has not been designed to 
incorporate several covariates simultaneously.  
3.4.2 Nelson-Aalen Estimator 








    , 3.11.  
where this expression is estimating the hazard at each distinct time of death 𝑡𝑗 as the ratio of 
the number of deaths to the number exposed. The cumulative hazard up to time t is simply the 
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sum of the hazards at all death times up to t, and has an intuitive interpretation as the expected 
number of deaths in (0, t] per unit at risk (Rodriguez, 2005). 
3.5 Proportional Hazards Models 
Considering two types of proportional hazards models: parametric, which assume some 
functional form for the baseline hazard e.g. Exponential and Weibull models; and semi-
parametric models, which make no assumption about the shape of the baseline hazard function, 
e.g. the Cox proportional hazards model.  
3.5.1 The Exponential Model 
The simplest assumption for the hazard is when we assume that it is constant over time. Thus 
 ℎ(𝑡) = λ    , 
        ⇒  𝑆(𝑡) = exp(−𝜆𝑡)  , 
         ⇒   𝑓(𝑡) = λ exp(−𝜆𝑡) . 
3.12.  
This gives 𝑓(𝑡) to be the same as the pdf of the exponential distribution, therefore assuming 
the hazard rate is constant assumes the survival times have an exponential distribution.  
3.5.2 The Weibull Model 
An alternative and more flexible form of the hazard function is  
 ℎ(𝑡) = λγ𝑡𝛾−1     , 
⇒  𝑆(𝑡) = exp(−𝜆𝑡𝛾)  , 
                 ⇒  𝑓(𝑡) =  λγ𝑡𝛾−1 exp(−𝜆𝑡𝛾)   . 
3.13.  
This gives 𝑓(𝑡) to be the same as the pdf of the Weibull distribution and if 𝛾 = 1 then the 
Weibull model reverts to the exponential model. Although this model is more flexible in 
modelling the hazard function it restricts the function for the hazard to be monotonic. 
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3.5.3 The Cox Model 
The Cox model introduced by David R. Cox in 1972 (Cox, 1972) is one of the most cited 
statistical papers (Ryan and Woodall, 2005) and is the most commonly used approach for 
analysing survival time data in medical research (Bradburn et al., 2003). The Cox proportional 
hazards model is a semi-parametric model as it makes no assumption about the shape of the 
underlying hazard. The result derives from innovative use of the proportional hazard 
assumption and a partial likelihood (PL) method of estimation rather than maximum 
likelihood. 
Let 𝑥1, 𝑥2 ⋯ ⋯ , 𝑥𝑝 be the values of p covariates 𝑋1, 𝑋2 ⋯ ⋯ , 𝑋𝑝. The Cox model models the 
hazard function and parameters are estimated on a log scale: 
 
ℎ(𝑡; 𝑥) = ℎ0(𝑡)𝑒𝑥𝑝 (∑ 𝛽𝑗𝑥𝑗
𝑝
𝑗=1
) , 3.14.  
where 𝛽 = (𝛽1, 𝛽2, ⋯ , 𝛽𝑝) is a 1 x p vector of regression parameters and  ℎ0(𝑡) is the baseline 
hazard function. This model has the assumption of log-linearity i.e. the effect of the predictors 
act linearly on the log-hazard. The proportional hazards (PH) assumption corresponds to 
assuming that the hazard ratio comparing one level of a covariate to another is constant over 
time. The effect of a covariate 𝑥1 can be expressed by the hazard ratio: 
 ℎ(𝑡, 𝑥1 + 1)
ℎ(𝑡, 𝑥1)
⁄ = exp(𝛽1) , 3.15.  
and is a measure of the change in the hazard function with respect to a unit increase in  𝑥1.  
If we integrate both sides of equation 3.14 between 0 and t we get 
 𝐻𝑖(𝑡) = 𝐻0(𝑡) exp(𝛽
𝑇𝑋𝑖)   , 3.16.  
and we have proportional cumulative hazards. Changing signs and exponentiation gives  
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 exp (−𝐻𝑖(𝑡)) = exp (−𝐻0(𝑡)exp (𝛽
𝑇𝑋𝑖))    , 
𝑆𝑖(𝑡) = 𝑆0(𝑡)
exp (𝛽𝑇𝑋𝑖)      . 
3.17.  
This is a complex function and it is difficult to assess proportional hazards from a graph of 
survival curves.  
Since ℎ0(𝑡) is free from parametric assumption, it is not possible to apply the full likelihood 
function for estimating β’s. Cox suggested an estimation procedure in which the analysis 
concentrates only on the effect of covariates and leaving ℎ0(𝑡) completely unspecified (Cox, 
1972, Cox, 1975),. The coefficients (β) in a Cox proportional hazards model can be estimated 













  . 3.18.  
Where 𝑖 = 1,2 ⋯ 𝑛, denote the n ordered exact failure times for each subject i, and 𝑅(𝑡(𝑖)) 
consists of all individuals whose survival times are at least 𝑡(𝑖). The summation in the 
denominator of the likelihood is the sum of the values of exp(∑ 𝛽𝑗𝑥𝑗
𝑝
𝑗=1 ) over all individuals 
who are at risk at this time. The likelihood depends only on the rank of failure times and the 
variance of the partial likelihood is larger than the variance of the complete likelihood. Tied 
survival times can be handled using the likelihood form of Breslow (Breslow, 1974), the 
default method in most statistical packages, however the bias can be substantial if the number 
of ties is large (HertPicciotto and Rockhill, 1997).  
3.5.3.1 Assessment of Log-Linearity Assumption 
The inclusion of non-linear covariate effects in Cox regression is common with many straight-
forward options available to implement them.  
A graphical approach involves the use of Martingale residuals (Therneau et al., 1990). Most 
residuals are based around each subject’s cumulative hazard at their event (or censoring) time. 
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The interest is in whether some subjects have a large amount of hazard without having the 
event while others have the event quickly. The cumulative hazard for the ith subject up to the 
time of their death or censoring is estimated from a Cox PH model as  
 ?̂?𝐶𝑖 = ?̂?𝑜(𝑡𝑖) exp(?̂?
′𝑥𝑖)    , 3.19.  
known as Cox-Snell residuals but they have no easy interpretation. Martingale residuals can 
be defined by  
 𝑟𝑀𝑖 = 𝑑𝑖 − 𝑟𝐶𝑖 , 3.20.  
where 𝑑𝑖 = 1 if the i
th subject had an event and 𝑑𝑖 = 0 if the i
th subject had a censored 
observation. These can be interpreted as the observed number of events for the ith individual 
minus the total amount of hazard experienced by that individual, a type of observed minus 
expected. Plotting the Martingale residuals against the continuous variables allows you to 
check the functional form of the covariate.  
A simple method is to categorise a continuous variable into several groups, estimate a separate 
effect for each group and check if the estimates show a linear trend. However, the usual 
disadvantages of categorising a continuous variable arise such as discarding potentially 
important quantitative information, thus reducing the power to detect a true association with 
survival, the choice of interval is subjective and results in an un-realistic step function. Another 
common practice is to transform the variable using some common mathematical functions, 
such as logarithm, polynomial, fractional polynomial (Royston and Altman, 1994) etc. and 
determine if this provides a better fit to the model. Regression spline methods can also be used 
to characterise non-linear effects (Gray, 1992, Osullivan, 1988).  
3.5.3.2 Assessment of Proportional Hazards Assumption 
Assessment of the proportional hazards assumption can be done by many numerical or 
graphical approaches. There are a large variety of methods to check for non-PH and Ng’Andu 
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provides an overview of five test statistics to check the PH assumption of the Cox model 
(Ngandu, 1997).   
Some of the methods, briefly, are as follows: In his original paper, Cox suggested testing the 
PH assumption by including a time-dependent covariate  (interaction terms with time) in the 
model and determining whether this improved the fit of the model (Cox, 1972). A test was 
developed by Harrell based on the correlation between the Schoenfeld partial residuals 
(Schoenfeld, 1982) and the rank order of the failure time (Harrell, 1986). There are a set of 
Schoenfeld residuals for each covariate in the model and are defined as 
 𝑟𝑆𝑖𝑗 = 𝑑𝑖 (𝑥𝑖𝑗 − 𝐸(𝑥𝑖𝑗|𝑅𝑖))  , 3.21.  




  . The 
Schoenfeld residual for a particular subject and particular covariate is the difference between 
the observed value of the covariate and the expected, conditional on the risk set 𝑅𝑖 of subjects 
at risk at time 𝑡𝑖 .  
Grambsch & Therneau developed a score test which is a test of non-zero slopes in a generalised 
linear regression of the scaled Schoenfeld residuals on chosen function(s) of time (Grambsch 
and Therneau, 1994). Therneau and colleagues also considered a score process using 
Martingale residuals (Therneau et al., 1990). Finally omnibus goodness-of-fit tests, such as 
those developed by Moreau and colleagues have been developed to detect non- proportional 
hazards by approximating the functional form for the time-dependence with a piecewise linear 
function constant over a priori specified time intervals (Moreau et al., 1985, Moreau et al., 
1986),.  
Graphical approaches have been criticised; interpreting graphical plots can be arbitrary and 
the conclusions from the graphs depend on the subjectivity of the researcher. Some of the 
graphical approaches are log-minus-log survival plots of survivor functions, comparison 
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between survival curves based on the Cox regression model and Kaplan-Meier estimates and 
a smoothed plot of scaled Schoenfeld residuals versus time (Ata and Sozer, 2007).  
3.5.3.3 Limitations of the Cox model 
The assumptions of the traditional Cox PH model are often violated when modelling 
prognostic factors in cancer studies. With classic examples given by Valsecchi in ovarian 
cancer and Gore in breast cancer (Valsecchi et al., 1996, Gore et al., 1984). Often the 
assumptions are not verified. In a 1995 review of cancer publications using a Cox model, 
Altman and colleagues reported that most studies did not report attempts to verify the PH 
assumption (Altman et al., 1995); similar findings were reported more recently in 2008 by 
Mathoulin-Pelissier and colleagues (Mathoulin-Pelissier et al., 2008). 
When the assumptions of the Cox PH model are not met, it is possible that subsequent analyses 
and risk estimates will be biased.  
Bellera et al. state 
‘for variables not satisfying the proportionality assumption, the power of the corresponding 
tests is reduced, that is, we are less likely to conclude for a significant effect when there is 
actually one. If the hazard ratio is increasing over time, the estimated coefficient assuming PH 
is overestimating at first and underestimating later on. For those variables of the model with a 
constant hazard ratio, the power of tests is also reduced as a consequence of an inferior fit of 
the model’ (Bellera et al., 2010). 
Spurious non-proportional effects may also be introduced by incorrectly modelling other parts 
of the data, such as omission of an important covariate, an incorrect functional form of a 
continuous covariate or an inappropriate survival model (Buchholz and Sauerbrei, 2011). 
Therefore it is important to consider both the assumption of linearity and proportional hazards. 
As stated by Abrahamowicz et al. 
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‘[T]he proportional hazards (PH) assumption… implies that the impact of each covariate on 
hazard remains constant during the entire follow-up time. While testing the PH assumption is 
interesting in its own right, simultaneous modelling of nonlinear and time dependent effects 
of the exposure of interest may be necessary to avoid biased estimates and incorrect 
conclusions’ (Abrahamowicz et al., 2003). 
The baseline hazard function is completely unspecified in the Cox PH model. This can be seen 
as a great advantage (one avoids potential problems from specifying the wrong shape), but 
some may also see it as a disadvantage if one is particularly interested in the shape of the 
baseline hazard function for its own sake. For instance, the behaviour of the hazard function 
is of potential medical interest because it is directly related to the time-course of an illness 
(Royston and Parmar, 2002b). Modelling the baseline hazard also allows estimation of 
















Chapter 4:  Literature Review 
4.1 Introduction 
The limitations of the Cox model have been discussed in chapter 3, in particular the assumption 
of proportional hazards which is often invalid for current prognostic models and biomarkers. 
A review of existing approaches for the analysis of non-proportional effects with respect to 
survival data was performed. The aim was to identify available approaches for investigating 
non-proportional effects, summarise advantages and disadvantages and perform citation 
searching to determine which approaches have been used in practice.  
4.2 Methods 
A literature search was conducted on the 27/02/12 using EMBASE (1947 to present), 
MEDLINE (1946 to present) and Web of Science (WoS) (1899 to present), which are online 
information sources of published literature, using the search strategy in Figure 4.1. 
The search strategy was developed based on the following inclusion and exclusion criteria: 
Inclusion Exclusion 
 
 Articles that discuss and propose 
statistical approaches 
(methodological papers) for the 
analysis of time-dependent/non-
proportional effects in survival 
data. 
 
 Studies investigating time-
dependent covariates - i.e. 
covariates whose values change 
over time. 
 Approaches based on different 
methodological assumptions – e.g. 
case-control studies, relative 







EMBASE and MEDLINE 
1. A search for terms time-dependent or time-varying or non-proportional or time-by-
covariate interaction or time-by-treatment interaction in titles or abstracts (non-
hyphenated terms also used). 
2. A search for statistics as topic (major focus of the article) mapped to: biostatistics 
(mesh) OR data interpretation, statistical (mesh) OR models, statistical (mesh, major 
focus) OR statistical distributions (mesh) OR statistics, nonparametric (mesh) OR 
survival analysis (mesh, major focus) OR survival (mesh, major focus) OR 
proportional hazards model (mesh, major focus). 
3. A search for the term flexible in titles or abstracts and survival analysis or survival as 
a major focus of the article. 
4. A combined search of 1 and 2 or 3.  
5. Exclusion of studies found in 4 if they contained the terms relative survival or case-
control or competing risks in titles or abstracts. 
6. Further exclusion of remaining studies in 5 if they contained the terms repeated 
measures or longitudinal data or longitudinal covariate in the title or abstract.  
Web of Science 
7. A search for terms time-dependent or time-varying or non-proportional or time-by-
covariate interaction or time-by-treatment interaction in titles (non-hyphenated terms 
also used). 
8. A search for survival or Cox or proportional or hazards in titles and abstracts. 
9. A search for the term flexible in titles. 
10. A combined search of 7 and 8 or 8 and 9. 
11. Exclusion of studies found in 10 if they contained the terms relative survival or case-
control or competing risks in titles or abstracts. 
12. Further exclusion of remaining studies in 11 if they contained the terms repeated 
measures or longitudinal data or longitudinal covariate in the title or abstract. 





Figure 4.2 Flowchart of Eligibility Assessment and Inclusion 
Potentially relevant articles 
identified in MEDLINE 
(N=1008)
Potentially relevant articles 
identified in EMBASE 
(N=1470)
Potentially relevant articles 




Full Text Retrieved 
(N=57)
Included (N=39)





- Time-dependent covariates not effects (N=1)
- Review/Applications of existing methodologies (N=12)
- 2-sample approach – not adjusting for covariates (N=3)
- Testing for time-dependent effects not modelling (N=2)
Studies excluded after reading 
title and abstract (N=2082)
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4.3 Results  
The search was carried out in February 2012 and returned 2,139 potentially relevant articles 
from MEDLINE, EMBASE and WoS after excluding duplicates (Figure 4.2). Titles and 
abstracts were screened and 57 full text papers were retrieved for further evaluation. A further 
18 papers were excluded, mainly due to the articles being reviews or applications of existing 
methodologies. The references were screened for additional papers and this resulted in a 
further 19 papers being included in the final review.  
The 58 papers included in the final review highlighted five broad classifications of models for 
investigating non-proportional effects: multiplicative hazards models (Table 4.1), additive 
hazards models (Table 4.5), additive-multiplicative hazards models (Table 4.5), parametric 
models and others (Table 4.7).  
4.4 Multiplicative Hazards Models (Table 4.1) 
Multiplicative hazard models are models where the effects of the covariates are modelled on 
a multiplicative scale. The Cox model introduced by Cox in 1972 (Cox, 1972), is an example 
of a multiplicative hazards model with the assumption that the hazard ratios are constant over 
time:  
 





The literature search identified 4 multiplicative hazard models for incorporating non-
proportional effects (Table 4.1) and the advantages and disadvantages of these approaches are 
given in Table 4.2.  
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Table 4.1 Multiplicative Hazard Models 
Model Name Formula Author (Year) Citation Searching* 
 
Stratified Cox Model 
 
 
𝜆(𝑡; 𝑋, 𝑍) = 𝜆0𝑘(𝑡) exp{𝑋1(𝑡)𝛽2 + ⋯ + 𝑋𝑝(𝑡)𝛽𝑝} 
 
Dabrowska (1997)  





















Kalbfleisch & Prentice (1981)  
Schemper  (1992)  










𝑟𝑆𝑖𝑗 = 𝑑𝑖 (𝑥𝑖𝑗 − 𝐸(𝑥𝑖𝑗|𝑅𝑖)) 
Pettitt & Daud (1990)  







Extended Cox Model 
 
 







See Table 4.3 
 
 
See Table 4.3 




Table 4.2 Advantages/Disadvantages of Multiplicative Hazards Models 
Model Name Advantages Disadvantages 
Stratified Cox 
Model 
 Simple and straightforward approach                        
 Useful when covariate with non-
proportional effect is not of direct interest 
 
 Does not provide information on the non-proportional effect 
 Loss of power due to categorisation of the data 
 More than one covariate with a time-varying effect will further 




 Intuitive interpretability of the resulting 
average hazard ratio 
 Reduces complexity of analysis and 
therefore more suitable for small sample 
sizes 





 Use as either a diagnostic or estimation 
technique 
 Uncertainty estimates that go along with these estimates are not 




 See Table 4.4 
 
 See Table 4.4 
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4.4.1 The Stratified Cox Model 
A simple option is to use a Cox model stratified by the variable suspected to have a time-
varying effect. The variable needs to be categorical or if continuous it must be categorised. 
Each stratum k has a distinct baseline hazard but common values for the coefficient vector β. 
If a categorical covariate 𝑍1, with levels 𝑘 = 1, … . , 𝐾, is responsible for the non-
proportionality, the model can be extended to include K strata: 
 𝜆(𝑡; 𝑋, 𝑍) = 𝜆0𝑘(𝑡) exp{𝑋1(𝑡)𝛽2 + ⋯ + 𝑋𝑝(𝑡)𝛽𝑝} . 4.2.  
Stratifying assumes that the other covariates are acting in the same way in each stratum and 
therefore hazard ratios are similar across strata (Bellera et al., 2010). Dabrowska (1997) 
studied a general stratified Cox’s regression model and Wei & Schaubel (2008) proposed an 
estimator for the aggregate treatment effect under non-proportional hazards based on 
treatment-specific baseline cumulative hazards estimated under a stratified Cox model 
(Dabrowska, 1997, Wei and Schaubel, 2008). The main disadvantage is it does not provide 
information on the time-dependent effect. 
4.4.2 The Weighted Cox Model 
When the proportional hazards assumption is violated, the average hazard ratio from a Cox 
model is often under- or overestimated (Schemper et al., 2009). One approach to deal with this 
is using weighted estimation in Cox regression (Schemper, 1992) and the methodology has 
been reviewed, including recent developments, by Schemper and colleagues (Schemper et al., 
2009) They state their preferred definition of an average hazard ratio (AHR), introduced by 















where ℎ0(𝑡) and ℎ1(𝑡) denote the hazards of groups 𝐺0 and 𝐺1 at time t, respectively, and 
ℎ(𝑡) = ℎ0(𝑡) + ℎ1(𝑡) .The weight function w(t) is chosen to reflect the relative importance 
attached to the hazard ratios in different time periods, with the most basic choices being w(t)=1 
and w(t)=S(t), the survival function. In the population definition of the AHR the density of the 
events in time (which result in contributions to the partial likelihood in Cox’s model) is needed 
and symbolised by 𝑓(𝑡). This is the simple two-sample case without censoring and is extended 
to weighted estimation within Cox’s model where a vector 𝛽 of k regression parameters is to 
be estimated. Weighted maximum likelihood estimates ?̂?𝑟 of regression parameters 𝛽𝑟 , 1 ≤










where 𝑙𝑗 is the contribution to the log-likelihood at failure time 𝑡𝑗. With censored samples, 
𝑤(𝑡) = ?̂?(𝑡)𝐺(𝑡)−1 is required for a weighted Cox regression where 𝐺(𝑡) denotes the Kaplan-
Meier estimator of the censoring or potential follow-up distribution. This weighting allows an 
intuitive interpretability of the resulting average hazard ratio exp (?̂?), independent of 
proportional hazards.  
4.4.3 Smoothed Schoenfeld Residuals 
Pettitt & Daud and Grambsch & Therneau considered smoothing the Schoenfeld residuals to 
estimate the time-varying regression effects (Pettitt and Daud, 1990, Therneau et al., 1990, 
Grambsch and Therneau, 1994). Firstly a Cox model is fitted with the relevant predictors. 
There are a set of Schoenfeld residuals for each covariate in the model and are defined as 
 𝑟𝑆𝑖𝑗 = 𝑑𝑖 (𝑥𝑖𝑗 − 𝐸(𝑥𝑖𝑗|𝑅𝑖))  , 4.5.  




  . The Schoenfeld residual for a particular subject and particular covariate 
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is the difference between the observed value of the covariate and the expected, conditional on 
the risk set 𝑅𝑖 of subjects at risk at time 𝑡𝑖 . Grambsch & Therneau showed that 𝐸(𝑟𝑆𝑖𝑗
∗ ) + ?̂? ≈
𝛽(𝑡𝑗), where 𝑟𝑆𝑖𝑗
∗  is the scaled Schoenfeld residual (Grambsch and Therneau, 1994). The 
residuals are then smoothed, with Pettitt & Daud considering a class of smoothers which fit 
lines or curves to the points using local information and take into account the differing 
variances (Pettitt and Daud, 1990). A smoothed plot of the scaled Schoenfeld residuals versus 
respectively observed failure times and their ranks is then used to estimate the shape of the 
non-proportional effect. This approach is more advantageous as the use of a diagnostic plot to 
test the PH assumption. 
4.4.4 The Extended Cox Model 
An extension of the Cox model is to let the effects depend on time: 
 
𝜆(𝑡; 𝑥) = 𝜆0(𝑡)𝑒𝑥𝑝 (∑ 𝛽𝑖(𝑡)𝑥𝑖
𝑝
𝑖=1
)   , 
4.6.  
where 𝛽(𝑡) = (𝛽1(𝑡), … , 𝛽𝑝(𝑡)) is a p-dimensional time-varying regression coefficient. 
All covariates might not have non-proportional effects and this leads on to the semi-parametric 
version of the extended Cox model: 
 






)    , 
4.7.  
where X and Z are p and q dimensional covariates respectively and the parameters of the model 
are the non-parametric p-dimensional 𝛽(𝑡) and q-dimensional regression parameter 𝛾.  
Various approaches for estimation of 𝛽(𝑡) are available (Table 4.3) with their respective 
advantages and disadvantages given in Table 4.4. 
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Table 4.3 Approaches for Estimation of 𝜷(𝒕) in the Extended Cox Model 
Approach Formula/Notes Author (Year) Citation 
Searching* 




Murphy & Sen (1991)  
Verweij & Houwelingen (1995)  
Zucker & Karr (1990)  
Hastie & Tibshirani (1993)  
Martinussen et al. (2002)  
Cai & Sun (2003)  









Piecewise Constant Effects 
𝜆(𝑡; 𝑥) = {
𝜆0(𝑡) exp(𝛼
𝑇𝑥) ,   𝑡 ≤ 𝑩
𝜆1(𝑡) exp(𝛾
𝑇𝑥),   𝑡 > 𝑩
} 
 
Anderson & Senthilselvan (1982)  





Simple Time-by-Covariate Interactions 𝜆(𝑡; 𝑥) = 𝜆0(𝑡)𝑒𝑥𝑝 (∑ 𝛽𝑖𝑥𝑖𝑓𝑖(𝑡)
𝑝
𝑖=1
)   
 








𝜆𝑜(𝑡) exp[𝑋(𝛽0 + 𝛽1𝑡
𝑞1 + 𝛽2𝑡
𝑞2)] , 𝑞1 ≠ 𝑞2
𝜆𝑜(𝑡) exp[𝑋(𝛽0 + 𝛽1𝑡
𝑞 + 𝛽2𝑡
𝑞log (𝑡))] , 𝑞1 = 𝑞2 = 𝑞
 
Stablein et al. (1981)  
Berger et al. (2003)  








𝜆(𝑡; 𝑥) = 𝜆0(𝑡) exp(∑ 𝑓𝑗(𝑡)𝑥𝑖𝑗𝑗 )  , 
where the functions 𝑓𝑗(𝑡) = ∑ 𝜃𝑗𝑘𝛽𝑗𝑘(𝑡)𝑘  are modelled with 
spline basis functions. 
Gray (1992)  
Hess (1994)    
Abrahamowicz et al. (1996)  
Brown et al. (2007)  









Table 4.3 (Continued) Approaches for Estimation of 𝜷(𝒕) in the Extended Cox Model 




Reduced Rank Regression Models 
 









Neural Networks Biganzoli et al. (1998)  128 
Bayesian Approaches 
Bayesian Dynamic Survival Model 
Hierarchical Cox Model 
Hierarchical Bayes Model 
Nonparametric Bayesian Approach 
Hierarchical Nonparametric Bayesian Approach 
Geoadditive Survival models 
Fully Bayesian framework 
Empirical Bayes approach 
Bayesian penalised spline models 
Linear Bayesian (LB) estimation method 
Monotone hazard ratio using Cox’s model 
Gamerman (1991)  
Sargent (1997)  
Gustafson (1998)  
Mckeague & Tighiouart (2000)  
Haneuse et al. (2008)  
 
Hennerfeind et al. (2006)  
Kneib & Fahrmeir (2007)  
Costa & Shaw (2009)  
He et al. (2010)  

















Table 4.4 Advantages/Disadvantages of the Approaches for Estimation of 𝜷(𝒕) in the Extended Cox Model 
Model Name Advantages Disadvantages 
Non-Parametric 
Estimation 
 Flexible tools for testing the PH 
assumption 
 Complicates investigation into shape of non-proportional effect 




 Simple approach; represent as short and 
long term effects 
 
 Need sufficient numbers of events in each step of the time scale 
 Choice of cut-points are subjective 
 Reduction of power due to categorisation of the data 




 Easy to implement 
 Inference dependent on parametric function of time 
 Simple options restrictive on available shape of non-proportional effect 






 FPs allow a flexible family of shapes to 
model the non-proportional effects 
 Implementation and inference is 
straightforward using standard 
estimation techniques as the approach 
preserves the linear structure of the 
predictor 
 
 The global (non-local) definition of FPs still suffers from the same restrictions 
as other non-local definitions for smooth function estimation. 






Table 4.4 (Continued) Advantages/Disadvantages of the Approaches for Estimation of 𝜷(𝒕) in the Extended Cox Model 
Model Name Advantages Disadvantages 
Splines 
 Flexible functions 
 Allows easily verifying the existence of 
time-variation 
 They demand prespecifications which influence the shape of the non-
proportional effect, such as the choice of the number and location of knots or 




 Reduces the number of parameters in 
order to obtain more stable and 
parsimonious models depending on the 
rank of the model 
 Does not allow for selection of covariates and non-linear effects 
 All effects are modelled as time-varying based on the same time functions 
Neural 
Networks 
 Provides smoothed hazard function 
estimation and allows for non-linear 
covariate effects 
 Requires discrete survival times 
 Complex computer-intensive process 
 Not straightforward 
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4.4.4.1 Non-Parametric Estimation of Time-Varying Coefficients.  
When 𝛽(𝑡) in the extended Cox model is assumed to be non-parametric, there exist several 
methods for estimation. 
Murphy & Sen proposed a histogram sieve estimator procedure by assuming that the 
coefficient functions, 𝛽(𝑡), are piecewise constant (Murphy and Sen, 1991). Verweij & 
Houwelingen proposed estimating the coefficients at each event time using a penalised partial 
likelihood approach and smoothing parameters based on the Akaike’s Information Criteria 
(AIC)(Verweij and van Houwelingen, 1995). However, the assumption that the baseline 
hazard function and coefficient functions are piecewise constant may not be appropriate in real 
applications.  
The coefficient functions, 𝛽(𝑡), can be estimated smoothly: Zucker & Karr considered 
nonparametric penalised partial likelihood of time-dependent effects using spline fitting (see 
section 4.4.4.5 for an explanation of splines), leaving  𝜆0(𝑡) unspecified (Zucker and Karr, 
1990). This was further developed by Hastie & Tibshirani in 1993 who used a smoothing 
spline partial likelihood method to estimate 𝛽(𝑡) based on natural cubic splines with knots at 
unique failure times (Hastie and Tibshirani, 1993). 
More recently, Martinussen and colleagues developed an efficient estimation procedure for 
the cumulative parameter functions of the fully time-varying extended Cox model 
(Martinussen et al., 2002). They were the first to study in detail the semi-parametric version 
in which the influence of some of the covariates varies with time while the effects of the 
remaining covariates are constant.  
Cai & Sun proposed estimating the time-dependent coefficient functions using a local partial 
likelihood technique and Tian and colleagues followed on from this proposing a simple 
estimation procedure based on a kernel-weighted partial likelihood approach (Cai and Sun, 
2003, Tian et al., 2005).  
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4.4.4.2 Piecewise Constant Effects 
A simple adaptation of the Cox model to handle non-proportional effects is by partitioning of 
the time axis, called piecewise constant effects, resulting in a step function for 𝛽(𝑡). In 1982, 
Anderson & Senthilselvan proposed using a two-step regression model for hazard functions 
(Anderson and Senthilselvan, 1982). It is assumed that 𝛽𝑖(𝑡) = 𝛼𝑖 for 𝑡 ≤ 𝑩 and 𝛽𝑖(𝑡) = 𝛾𝑖 
for 𝑡 > 𝑩  , 𝑖 = 1, … , 𝑝 , for some B, which is not assumed known a priori. The corresponding 
hazard function is 
 
𝜆(𝑡; 𝑥) = {
𝜆0(𝑡) exp(𝛼
𝑇𝑥) ,   𝑡 ≤ 𝑩
𝜆1(𝑡) exp(𝛾
𝑇𝑥),   𝑡 > 𝑩
}  . 
4.8.  
Moreau and colleagues generalised the approach by Anderson & Senthilselvin to a larger 
number of intervals (Moreau et al., 1985). The assumption that the baseline hazard function 
and coefficient functions are piecewise constant may not be appropriate in real situations. 
However, it is a simple approach in terms of statistical application and interpretation and is 
widely used in practice. 
4.4.4.3 Simple Time-By-Covariate Interactions 
Simple interactions with the covariate x and a pre-defined function of time f(t) was first 
introduced by Cox in 1972 which allowed smooth estimation of 𝛽(𝑡) (Cox, 1972): 
 
𝜆(𝑡; 𝑥) = 𝜆0(𝑡)𝑒𝑥𝑝 (∑ 𝛽𝑖𝑥𝑖𝑓𝑖(𝑡)
𝑝
𝑖=1
)  . 
4.9.  
Monotonic functions for f(t) were initially used such as linear, logarithmic or rank functions 
of time. The main disadvantage is the simple options are restrictive on the available shape of 
the non-proportional effect. 
4.4.4.4 Polynomials and Fractional Polynomials 
The simple monotonic functions of t can be extended to polynomials, e.g. (𝑡) = 𝛾1𝑡 + 𝛾2𝑡
2 +
⋯ , used by Stablein and colleagues (Stablein et al., 1981). Fractional polynomials (FP) allow 
a more flexible family of shapes to model the non-proportional effects compared with 
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polynomials as they allow negative and non-integer powers (Royston and Altman, 1994). An 
FP1 transformation of an argument  𝑥 > 0 with power q is defined as  𝑥𝑞, where q belongs to 
the standard set of powers  𝑆 = {−2, −1, −0.5, 0, 0.5, 1, 2, 3} with 𝑥0 = log (𝑥) rather than usual 
notation 𝑥0 = 1 . An FP2 transformation of 𝑥 with powers 𝒒 = (𝑞1, 𝑞2) is the vector 𝑥
𝒒 with  
 
𝑥𝒒 = 𝑥(𝑞1,𝑞2) = {
(𝑥𝑞1 , 𝑥𝑞2) ,                 𝑞1 ≠ 𝑞2
𝑥𝑞 , 𝑥𝑞 log(𝑥),    𝑞1 = 𝑞2 = 𝑞    .
 
4.10.  
This gives the time-varying Cox model based on untransformed X and an FP2 function of t 
with powers  𝒒 = (𝑞1, 𝑞2) : 
 𝜆(𝑡; 𝑋) = 𝜆𝑜(𝑡) exp[𝑋𝜑2(𝑡; 𝒒)]
= {
𝜆𝑜(𝑡) exp[𝑋(𝛽0 + 𝛽1𝑡
𝑞1 + 𝛽2𝑡
𝑞2)] ,    𝑞1 ≠ 𝑞2
𝜆𝑜(𝑡) exp[𝑋(𝛽0 + 𝛽1𝑡
𝑞 + 𝛽2𝑡




The use of fractional polynomials in the time-varying Cox model have been considered by 
Berger and colleagues in 2003 and Sauerbrei and colleagues in 2007 (Berger et al., 2003, 
Sauerbrei et al., 2007). Berger introduced the time-dependent covariate model (or dynamic 
Cox model) as 
 





with 𝛽𝑖(𝑡) = 𝛾𝑖0 + ∑ 𝛾𝑖𝑗𝑡
(𝑞𝑗)𝑀
𝑗=1  being an FP of maximum degree M=2 and 𝛾𝑖𝑗 are the 
regression coefficients. This approach allows detecting and simultaneously modelling 
dynamic effect structures as the PH model is nested within the dynamic Cox model and can 
therefore be tested using a likelihood ratio test. 
It has been shown that a covariate may appear to have a time-dependent effect due to miss 
modelling another part of the model, for example the wrong functional form of a covariate or 
omission of an important covariate. Sauerbrei and colleagues introduced a method for 
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multivariable modelling of time-varying effects called a multivariable fractional polynomial-
time (MFPT) approach which can address both the violation of the linearity and PH 
assumptions. It is a multivariable strategy to select variables which have an effect on the 
outcome, determine the functional form of continuous variables and determine whether the 
PH assumption is sensible or if time-varying effects are present. As described by Sauerbrei et 
al., it involves three stages: 
 Stage 1. Determine time-fixed model 𝑀0 
o Select model 𝑀0 using the multivariable fractional polynomial (MFP) 
algorithm (Sauerbrei and Royston, 1999) assuming PH (full time-period). 
 Stage 2. If necessary, add covariate with short-term effect 
o Start with model 𝑀0. 
o Restrict time period to (0, ?̃?), e.g. ?̃? defined by first half of events. 
o Run the MFP algorithm for (0, ?̃?) and add, if necessary, significant covariates 
to 𝑀0. This gives model 𝑀1. 
 Stage 3. Investigate possible time-varying effects of variables in 𝑀1 
o For each covariate (with selected FP transformation) of 𝑀1 run the FPT 
algorithm to investigate time-varying effect adjusting for all covariates of 𝑀1. 
o Use a forward selection procedure to add significant time varying effects to 
model 𝑀1. This gives the final model 𝑀2.  
The MFP algorithm combines the determination of FP functions with backward elimination. 
The maximum complexity (degree) of FP for each continuous predictor must be specified with 
Sauerbrei et al. suggesting the use of degree 2.  Initially, the model includes a linear term for 
each of the continuous variables and all the binary and categorical variables. The ‘best’ fitting 
FP for each of the continuous variables is found based on deviance differences, while adjusting 
for all continuous, binary and categorical predictors already in the model. Variables that are 
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not significant predictors of outcome are dropped from the model using backward elimination 
and a pre-defined significance level. For the continuous covariates the best fit second-degree 
FP (FP2) is tested at the α-level against the best fit first-degree FP (FP1). If this is non-
significant, the FP1 is tested against a straight line. If the linear term is not significant the 
variable is eliminated. Convergence occurs when no further changes to selected variables and 
their FP transformations take place.   
The FPT approach in stage 3 is based on a model of the type  
 
𝜆(𝑡; 𝑥) = 𝜆0(𝑡)𝑒𝑥𝑝 (∑ 𝛽𝑖(𝑡)𝑓𝑖(𝑥𝑖
𝑝
𝑖=1
))   , 
4.13.  
allowing non-linear functional forms of the covariates 𝑓𝑖(𝑥𝑖) and time-varying effects 𝛽𝑖(𝑡). 
The FPT algorithm mimics the MFP algorithm for selecting an FP function of a continuous 
covariate. The best fitting FP1 and FP2 functions to model the time-varying effects are 
determined based on the deviances of the models. The best fitting FP2 is compared with a 
constant effect. If non-significant, the PH assumption is accepted otherwise model reduction 
is performed to find the most parsimonious representation of the non-proportional effect. The 
best FP2 is compared with the default (logarithmic) function, a FP1 based on log(t). If non-
significant, the logarithmic function is accepted. If significant, the best fitting FP2 is compared 
to the best fitting FP1. If significant the more complex FP2 is chosen, otherwise the simpler 
FP1 function is selected.   
4.4.4.5 Splines 
Another option to model time-by-covariate interactions smoothly is through the use of splines. 
Splines are flexible mathematical functions defined by piecewise polynomials. The points at 
which the polynomials join are called knots and certain constraints are imposed to ensure the 
function is smooth. The most common splines used in practice are cubic splines, in particular 
cubic B(asis)-splines, where the fitted function is forced to have continuous 0th,1st and 2nd 
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derivatives. B-splines can be evaluated in a numerically stable way by the de Boor algorithm 
(de Boor, 1978). 
Defining K knots, 𝑡1, … , 𝑡𝐾 the cubic spline function is  
 











where the “+” notation means that 𝑢+ = {
𝑢    𝑖𝑓 𝑢 > 0
0    𝑖𝑓 𝑢 ≤ 0
  resulting in K+4 parameters needed in 
the linear predictor. Cubic splines can sometimes behave poorly in the tails where there is 
often a small amount of data. They can be extended to restricted cubic splines which are forced 
to be linear before the first knot and after the final knot.  
The choice of the number and location of knots is often arbitrary; a better option is to use 
smoothing splines where knot selection is based on a mean squared criterion. The level of 
smoothness is chosen based on selecting the degrees of freedom for each spline fit and can be 
controlled using the Akaike’s Information Criteria (AIC)(Akaike, 1974).  
The choice of the number of knots has been subject to a large body of published research, with 
too few or too many knots resulting in under- or over-fitting of the data. One option is to use 
penalised splines (P-splines); splines with a penalty for the model complexity which can be 
seen as a compromise between smoothing and regression splines. The number of knots 
defining the spline function is larger than that justified by the data but the level of over-fitting 
is controlled by a roughness penalty over the curve. The most common choice is a penalty 
based on the integral of a squared derivative of the spline curve (Costa and Shaw, 2009). 
Time-dependent effects are modelled simply by introducing an interaction between the 








where the functions 𝑓𝑗(𝑡) = ∑ 𝜃𝑗𝑘𝛽𝑗𝑘(𝑡)𝑘  are modelled with spline basis functions.  
These various spline methods were used to model time-dependent effects by numerous authors 
(Gray, 1992, Hess, 1994, Abrahamowicz et al., 1996, Brown et al., 2007). 
Similar to the approach by Sauerbrei and colleagues, except with the use of splines rather than 
fractional polynomials, Abrahamowicz & Mackenzie suggested a generalisation of the Cox 
model with relaxations of the assumptions of log-linearity and proportional hazards, called the 
product model (Abrahamowicz and MacKenzie, 2007):  
 
λ(𝑡; 𝑥) = 𝜆0(𝑡)𝑒𝑥𝑝 ∑ 𝛽𝑚(𝑡)𝑟𝑚(𝑥𝑚)
𝑀
𝑚=1
  , 
4.16.  
where m indexes the predictors 𝑥1, … , 𝑥𝑀. It is based on the product of two flexible estimates, 
the dose-response function 𝑟𝑚(𝑥𝑚) used to relax the log-linearity assumption and the time-
dependent function 𝛽𝑚(𝑡) to relax the PH assumption, using a quadratic B-spline basis. The 
product model is a flexible regression spline-based model which allows simultaneously 
relaxing assumptions of PH and linearity regarding the impact of the continuous predictor on 
the log-hazard and helps avoid finding spurious non-proportional effects by miss modelling 
other parts of the data. When using flexible methods it is often difficult not to over-fit the 
model to the data and a trade-off between model parsimony and goodness-of-fit must be 
determined. To overcome this they suggest using model selection criteria based on AIC and 
the model can be reduced to the conventional Cox PH model if appropriate. Further work is 
needed to develop a general model selection strategy to identify the correct model for each of 
several, possibly correlated, predictors.  
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4.4.4.6 Reduced Rank Regression Models 
The problem of the choice of time functions being data driven was addressed by Perperoglou 
and colleagues who introduced a more general technique for fitting time-by-covariate 
interactions with the use of reduced rank regression models (Perperoglou et al., 2006a). A 
model with time-varying effects of the covariates can be described by the structure matrix Θ 
that contains the coefficients of the covariates and their interactions with the time functions. 
The structure matrix can be factorised in different ways, resulting in a matrix of lower rank r 
(i.e. the number of parameters to be estimated). Consider B a 𝑝 × 𝑟 matrix and Γ a 𝑞 × 𝑟 matrix 
of coefficients, that factorise the Θ matrix as Θ = BΓ𝑇 . The rank r model is written as 
 𝜆(𝑡; 𝑿) = 𝜆0(𝑡) exp(𝑿𝑩𝚪
𝑇𝑭𝑇(𝑡)) 
                                         = 𝜆0(𝑡)𝑒𝑥𝑝{∑ (𝑿𝜷𝑘)(𝑭(𝑡)𝜸𝑘)
𝑟
𝑘=1 }   , 
4.17.  
where 𝜷𝑘 is the k
th column of B and 𝜸𝑘 is the k
th column of Γ.  Thus, the parameters consist 
of a set of r linear combinations of time functions 𝑭(𝑡)𝜸𝑘  and r linear combinations of 
covariates 𝜷𝑘 . For flexible time-varying effects a full rank is most appropriate (equivalent to 
the extended Cox model), while for more parsimonious modelling and more rigid time effects 
a smaller rank should be preferred using  AIC to determine the optimal rank. The main 
disadvantage of this approach is that all effects are modelled as time-varying. 
4.4.4.7 Other Approaches 
Another approach suggested by Biganzoli and colleagues is the use of an artificial neural 
network (ANN) for the estimation of the functional relationships between covariates and time 
in survival data (Biganzoli et al., 1998). It provides smoothed hazard function estimation and 
allows for non-linear covariate effects however this method requires discrete survival times, it 
is a complex computer-intensive process and is not a straightforward model.  
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4.4.4.8 Bayesian Inference 
Bayesian inference for approaches to analyse non-proportional effects in survival data have 
also been investigated, which makes inferences on the posterior distribution and allows 
making direct probability statements.  
In 1991, Gammerman proposed a Bayesian dynamic survival model (BDSM) using a 
sequential analysis based on factorisation of the likelihood over the time intervals which the 
parameters are allowed to vary between (assuming a piecewise constant baseline hazard 
function) (Gamerman, 1991). In 1997, Sargent proposed a Bayesian approach defining a 
hierarchical Cox model with a state-space structure using Markov Chain Monte Carlo 
(MCMC) methods to estimate the time-varying coefficients (Sargent, 1997). Sargent’s method 
is similar to the Cox model in that no assumption is made about the baseline hazard function. 
Gustafson proposed a hierarchical Bayes model which relaxes both assumptions of 
proportionality and the additive effects assumption of the Cox model in 1998; where the 
additivity assumption specifies that the effect associated with a particular explanatory variable 
does not depend on the levels of the other explanatory variables (Gustafson, 1998). Time-
dependent effects are explicitly modelled and the additivity of the effects is relaxed through 
the use of a modified neural network structure.  
Mckeague & Tighiouart proposed a nonparametric Bayesian approach to the extended Cox 
model where the baseline hazard function 𝜆0(𝑡) and the covariate effect 𝛽(𝑡) are specified as 
piecewise constant effects, where the number and position of jump times are taken as random, 
and modelled as independent stochastic processes with sample paths taking the form of step 
functions (McKeague and Tighiouart, 2000). A disadvantage to this method is that the model 
assumes the same time scale and jump times for both the baseline hazard function and the 
covariate effect. Haneuse and colleagues extended this approach to allow for separate 
timescales for the baseline hazard and the time-varying effect of a time-dependent covariate 
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(Haneuse et al., 2008). They use a hierarchical model for the hazard function with separate 
timescales being incorporated via conditionally independent stochastic processes.  
New developments include geoadditive survival models where the common linear predictor 
in the Cox model is generalised to an additive predictor, including non-parametric components 
for the log-baseline hazard, time-varying effects and possibly non-linear effects of continuous 
covariates. Hennerfeind and colleagues proposed flexible continuous-time geoadditive models 
with inference developed within a fully Bayesian framework using penalised regression 
splines and Kneib & Fahrmeir develop inference based on an empirical Bayes approach 
(Hennerfeind et al., 2006, Kneib and Fahrmeir, 2007).  
Recently Costa & Shaw estimated time-varying regression coefficients from the extended Cox 
model through penalised cubic spline functions using the partial likelihood and considered 
both empirical and full Bayesian inference methods (Costa and Shaw, 2009). He and 
colleagues further explored the BDSM introduced by Gamerman in 1991 and suggested the 
linear Bayesian (LB) estimation method; where the coefficients are modelled using first-order 
random walks only, meaning all coefficient functions are piecewise constant (He et al., 2010). 
The main difficulty with this method is that smoothing parameters must be pre-specified. Kim 
and colleagues proposed a Bayesian approach for estimating hazard functions under the 
constraint of a monotone hazard ratio using Cox’s model with a monotone time-dependent 
coefficient (Kim et al., 2011). They used a signed gamma process prior for the time-dependent 
coefficient and the Bayesian bootstrap prior for the baseline hazard function and developed an 
efficient MCMC algorithm for estimation.  
4.5 Additive Hazards Models (Table 4.5) 
It is possible the covariates add to, rather than multiply, the baseline hazard resulting in 
additive hazards models. The additive hazards models found in the literature search are shown 
in Table 4.5 with their respective advantages and disadvantages given in Table 4.6. 
50 
 
The Aalen additive model introduced by Aalen in 1980 is less well known than the Cox model 
but it is useful when the interest lies in the risk difference rather than the relative risk and when 
modelling time-dependent effects (Aalen, 1980). It is a fully additive and non-parametric 
model whose regression coefficients are allowed to vary over time. The model is  
 𝜆(𝑡; 𝑋) = 𝑋𝑇𝛽(𝑡) , 4.18.  
where X is a p-dimensional covariate and 𝛽(𝑡) is a p-dimensional regression coefficient. The 
additive risk model specifies that the hazard function associated with a set of possibly time-
varying covariates is the sum of, rather than the product of, the baseline hazard function and 
the regression function of the covariates (Lin and Ying, 1994). The model is non-parametric 
in the sense that no functional form is assumed for the baseline hazard or the regression 
functions. It was further studied by Aalen in 1989 and 1993 (Aalen, 1989, Aalen, 1993) and 
estimation properties of the model were given by McKeague and Huffer & McKeague 
(McKeague, 1988, Huffer and McKeague, 1991). In the Aalen additive hazard model all 
covariates are incorporated as time-varying and a more parsimonious approach is available 
through the partly-parametric version of Aalen’s additive model.  
Mckeague & Sasieni introduced the partly-parametric version of Aalen’s model where some 
of the covariates are allowed to vary non-parametrically with time where as others remain 
constant (McKeague and Sasieni, 1994):   
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Table 4.5 Additive Hazard Models and Multiplicative-Additive Hazard Models 
Model Name Formula Author (Year) Citation Searching* 
Additive Hazard Models 
Aalen Additive Model 
 
𝜆(𝑡; 𝑋) = 𝑋𝑇𝛽(𝑡) 
Aalen (1980, 1989,1993) 
Mckeague (1988)  




Partly-Parametric Additive Risk Model 
 
𝜆(𝑡; 𝑋, 𝑍) = 𝑋𝑇𝛽(𝑡) + 𝑍𝑇𝛾 
 
Mckeague & Sasieni (1994)  
Lin & Ying (1994)  




















Cox-Aalen Model 𝜆(𝑡; 𝑋, 𝑍) = [𝑋𝑇𝛼(𝑡)] exp(𝑍𝑇𝛽) Scheike & Zhang (2002)  44 





Table 4.6 Advantages\Disadvantages of Additive Hazards Models and Additive-Multiplicative Hazards Models 





 Useful when interest lies in risk difference rather than 
relative risk 
 Flexible model with easy interpretation of excess risk of 
the covariates 
 Easier estimation of survival function 
 Does not require use of smoothing parameters 
 Does not provide parameters or formulae that are easily 
reported 
 Non-parametric nature of the model results in  
 - large standard errors 





 Compromise between bias and variance compared to 
fully non-parametric model 
 Semi-parametric method, leaving the baseline 
unspecified, resulted in an alternative to Cox PH  model 
 More complicated inference 
 











 Useful when the baseline mortality expressed in the 




 More complex interpretation of the model 
Cox-Aalen Model 
 Flexible class of models 
 Easy estimation and interpretation of covariate effects 
on the baseline hazard 
 Does not require smoothing parameters 
 
 Interpretation of baseline hazard more complicated  
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 𝜆(𝑡; 𝑋, 𝑍) = 𝑋𝑇𝛽(𝑡) + 𝑍𝑇𝛾 , 4.19.  
where 𝛽(𝑡) is a p-dimensional time-varying regression coefficient and γ is a q-dimensional 
time-invariant coefficient. Therefore, allowing some covariates to be time-varying and others 
to remain constant, giving a good compromise between variance and bias compared to the 
fully non-parametric model (Cortese et al., 2010). Lin & Ying developed a simple semi-
parametric method to make inference about the regression parameters with an unspecified 
baseline hazard function similar to the partial-likelihood-based methods used for the Cox 
proportional hazards model (Lin and Ying, 1994). 
Dunson & Herring developed an approach for Bayesian inference in the additive hazards 
model and overcame the problem of negative hazards being produced (Dunson and Herring, 
2005). They also proposed an approach that facilitates selection and formally accommodates 
uncertainty between proportional and additive hazards. 
4.6 Additive-Multiplicative Hazards Models (Table 4.5) 
The additive and multiplicative models discussed previously can be used simultaneously to 
complement each other to model covariates that lead to relative risk and covariates that need 
additional flexibility. The additive Aalen model and the multiplicative Cox model can be 
added together to give proportional excess hazards models or multiplied together to give the 
Cox-Aalen model with their respective advantages and disadvantages given in Table 4.6. 
Martinussen & Scheike studied a general class of additive-multiplicative hazard models (or 
excess hazards models) assumed to have the form 
 𝜆(𝑡; 𝑋, 𝑍) = 𝑋𝑇𝛼(𝑡) + 𝜆0(𝑡) exp{𝑍
𝑇𝛽}  , 4.20.  
where 𝛼(𝑡) is a q-vector of time-varying regression functions, 𝜆0(𝑡) is the baseline hazard of 
the excess risk term, and 𝛽 is a p-dimensional vector of relative-risk coefficients (Martinussen 
and Scheike, 2002). The background mortality is unknown and modelled by Aalen’s additive 
model. The excess risk due to the covariates is described by the Cox PH model.  
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Scheike & Zhang introduced the Cox-Aalen model  given by (Scheike and Zhang, 2002): 
 𝜆(𝑡; 𝑋, 𝑍) = [𝑋𝑇𝛼(𝑡)] exp(𝑍𝑇𝛽)  . 4.21.  
Thus, allowing some covariate effects to be non-parametric and time-varying and other effects 
to be included as time constant. It extends the Cox and Aalen models, providing a very flexible 
class of models with easy estimation and interpretation of covariate effects on the baseline 
hazard.  
4.7 Parametric Models (Table 4.7) 
The use of the Cox model and other semi-parametric methods involves ignoring the baseline 
hazard, treating it as a high-dimensional nuisance parameter. It has been suggested that not 
modelling the baseline hazard results in missing important information directly related to the 
time-course of an illness (Royston and Parmar, 2002a). Therefore parametric approaches, 
which model the baseline hazard, may provide additional information with advantages and 
disadvantages of the various parametric approaches given in Table 4.8.  
Mackenzie suggested the use of a parametric family of continuous survival distributions for 
the analysis of non-proportional hazards: the generalised time-dependent logistic model 
(Mackenzie, 1996). The baseline hazard takes the functional form  
 
𝜆0(𝑡|𝜆, 𝛼, 𝛾) =
𝜆exp (𝑡𝛼 + 𝛾)
1 + exp (𝑡𝛼 + 𝛾)
  , 
4.22.  
where 𝜆 > 0 and 𝛼 and 𝛾 are scalars. This model differs from its standard parametric 
competitors, such as the exponential and Weibull models, as it allows the time-dependence to 
follow a more flexible, sigmoid pattern and allows the effects of the covariates to diminish 
with time in an intuitively appealing way.  
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Table 4.7 Parametric Models and Others 
Model Name Formula Author (Year) Citation Searching* 
Parametric Models 
Generalised Time-
Dependent Logistic Family 
 
λ0(t|λ, α, γ) =
λexp (tα + γ)
1 + exp (tα + γ)
 
 





ln{H(t|xi)} =  s{ln(t) | γ, k0} + ∑ s{ln(t) | γ, δkkj}
D
j=1




S(t|X, X∗) = [1 − π(X∗)]Su(t|X) + π(X
∗)   
Farewell (1982)  
Peng et al. (1998)  





Frailty Models λ(t|X) =
λ0(t)exp (Xβ)
1 + F(t|δ)exp (Xβ)
 
 
Perperoglou et al. (2006b)  
 
5 





Extension to Penalised Poisson Regression 
Generalised Odds-Rate Hazards (GORH) models 
Dependent Dirichlet Process model 
Bayesian Random-Effects Threshold Regression 
Gustafson et al. (2003)  
Lambert & Eilers (2005)  
Banerjee et al. (2007)  
De Iorio et al. (2009)  






* Refer to section 4.9 
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Table 4.8 Advantages/Disadvantages associated with Parametric and Other Models 






 Allows the time-dependence to follow a more flexible, 
sigmoid pattern 
 Allows the effects of the covariates to diminish with time in 
an intuitively appealing way 
 Relaxes the assumption of PH while preserving the linear 
influence of the regression parameter on the log-odds scale 
 Does not allow modelling of more 
complex time-dependent effects 
Flexible Parametric 
Models 
 Ease of which non-proportional effects can be fitted 
 Parametric model allows easy prediction of hazard and 
survival rates 
 Difficulties associates with choosing the 
number and location of knots for the 




 Able to explain the unexpectedly large survival times 
 Potential to identify outliers 
 In breast cancer studies the patients are 
often never actually considered cured and 
so this must be carefully considered 
 
Frailty Models 
 Does not follow the assumption of proportionality by 
assuming each person has their own frailty 
 Leads to a complex model where covariate 
effects are hard to interpret 
Tree-Based Approach 
 Time-varying regression effects estimated in simplistic way 
 Gives clear indication of important variables 
 Provides exploratory tool for finding multiple change points  
 Different split points for different 
covariates is possible but relies on 
subjective judgment  
 Difficulty in interpreting covariate effects 
 Highly data-dependent  
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In 2002, Royston & Parmar developed flexible parametric models based initially on the 
assumption of proportional hazards or proportional odds scaling of covariate effects (Royston 
and Parmar, 2002a). This was then extended to include time-varying effects modelled using 
spline functions. The approach involves modelling on the log cumulative hazard scale (rather 
than the log hazard) which under the PH assumption covariate effects can still be interpreted 
as hazard ratios and allows easy transformation of the survival and hazard functions. The 
logarithm of the baseline cumulative hazard function is modelled as a natural (restricted) cubic 
spline function of log time, with the general function 𝑠(𝑥; 𝛾) to be approximated by a spline. 
Natural cubic splines are defined as cubic splines constrained to be linear beyond boundary 
knots kmin, kmax. In addition, m distinct internal knots are specified (see section 4.4.4.5 for more 
detail) 
A natural cubic spline function of ln(t) with knots K0 may be written as 𝑠{ln(𝑡) | 𝛾, 𝑘0} which 
is then used to model the baseline log cumulative hazard in a proportional (cumulative) hazards 
model: 
 ln{𝐻(𝑡|𝑥𝑖)} =  𝑠{ln(𝑡) | 𝛾, 𝑘0} + 𝑥𝑖𝛽, 4.23.  
Non-proportional effects are modelled simply by introducing an interaction between the 
covariate and the spline variables. If there are D time-dependent effects, this can be written as  
 




+ 𝑥𝑖𝛽 . 
4.24.  
 
4.8 Other Models (Table 4.7) 
Several modelling techniques have been proposed so far for the problem of non-proportional 
hazards. Other approaches are also available including cure and frailty models, tree based 
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methods and Bayesian approaches with their respective advantages and disadvantages given 
in Table 4.8. 
4.8.1 Cure and Frailty Models 
One such approach to model long-term survival studies is with the use of mixture models, 
known as cure models (Perperoglou et al., 2007). In mixture models the overall survival of the 
patients consists of two parts, a survival function 𝑆𝑢(𝑡|𝑋) that models the survival of not-cured 
patients, denoted by the subscript u, and a probability a patient has been cured 𝜋(𝑋∗) which 
depends on some covariates X* and takes the logistic form log [
𝜋(𝑋∗)
{1−𝜋(𝑋∗)}
] .This gives the 
overall survival function at time t for patients with covariates X and X* as 
 𝑆(𝑡|𝑋, 𝑋∗) = [1 − 𝜋(𝑋∗)]𝑆𝑢(𝑡|𝑋) + 𝜋(𝑋
∗)  . 4.25.  
The survival of uncured patients has been described by parametric forms (Farewell, 1982, 
Peng et al., 1998) and the proportional hazards model (Peng, 2003).  
In some cases it may be possible to use a frailty model to adjust for possible lack of fit and 
departure from proportionality (Perperoglou et al., 2007). Frailty models are used in survival 
analysis to describe individual heterogeneity. Since individual heterogeneity is not observable 
a random effect Z, which is often assumed to follow a gamma distribution (resulting in the 
Burr model), is entered into the model: 
 𝜆(𝑡|𝑋, 𝑍) = 𝑍𝜆0(𝑡) exp(𝑋𝛽)   . 4.26.  
 
The covariate effects are now assumed to disappear over time, i.e. the hazard ratio converges 
to 1. This model also has the assumption that the frailties are assumed constant. However, with 
long follow up this assumption may not hold and Perperoglou and colleagues introduced the 
relaxed Burr model as an approximation to a frailty model with time-varying effects 






1 + 𝐹(𝑡|𝛿)exp (𝑋𝛽)
   , 
4.27.  
with (𝑡|𝛿) = 𝑓(𝑡)𝛿 , where 𝑓(𝑡) can be a simple time function multiplied by an unknown but 
estimable coefficient 𝛿. 
In terms of cure and frailty models, the interpretation of each model must be distinguished as 
they are designed to answer different questions. Although they are useful alternatives to the 
Cox proportional hazards model, the user must determine whether they answer the research 
question.  
4.8.2 Tree-Based Method 
Xu & Adak developed a tree-based method to handle survival data for the assessment and 
estimation of time-dependent regression effects under a Cox-type model (Xu and Adak, 2002). 
The time-varying regression effects are estimated in a simplistic way, more suitable for clinical 
applications, using the step-function approach. An algorithm is used that maximises score 
statistics for recursive segmentation of the time axis. A pruning algorithm is then applied to 
determine a sparse segmentation with bootstrap resampling to correct for over optimism due 
to split point optimism. The algorithm for growing the binary tree is as follows: 
(1) Start with the root node, i.e. the entire data and fit the model: 
𝑀0: 𝛽(𝑡) = 𝛽 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑡. 
Determine the point, 𝛾1, at which the score test is maximised. Define the 
children of the node as the segments resulting from adding the change point 











 𝑀1: 𝛽(𝑡) = {
𝛽1 ,     𝑓𝑜𝑟 𝑡 < 𝛾1 
𝛽2 ,    𝑓𝑜𝑟 𝑡 ≥ 𝛾1
 
(2) Determine the optimal change points, 𝛾2 , by maximising the score test for 
node 2, and 𝛾3 , for node 3. Define the children of the node as the segmants 






Al  𝑀1: 𝛽(𝑡) = {
𝛽1 ,     𝑓𝑜𝑟  0 ≤ 𝑡 < 𝛾1 
𝛽2 ,     𝑓𝑜𝑟  𝛾1 ≤ 𝑡 < 𝛾2
𝛽3 ,    𝑓𝑜𝑟 𝛾2 ≤ 𝑡 < 𝛾3
𝛽4 ,    𝑓𝑜𝑟            𝑡 ≥ 𝛾3
 
(3) The recursive segmentation procedure can be continued. In general, determine 
the optimal change points at depth d by fitting model 𝑀𝑑. Then obtain model 
𝑀𝑑+1 by determining the optimal change points at depth d. The stopping rule 
for the splitting of the tree can be determined by specifying (1) a maximum 
allowable depth, (2) a minimum number of events within each node or (3) a 
threshold for the maximised score statistic for each node.  
(4) The growing algorithm results in over-segmentation of the data and a pruning 
algorithm from classification and regression trees (CART) can be used to 
merge the intervals that do not provide a sufficient increase in the log partial 
likelihood.  
Node=1 




Node=4  node=5     node=6   node=7  Depth=2 
𝛾1 𝛾2 𝛾3 
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4.8.3 Bayesian Approaches 
Gustafson and colleagues proposed a simple approach to fitting Bayesian survival models with 
the use of the normal approximation to the log-gamma distribution which yields easy and 
efficient computational methods for estimating the baseline log-hazards and time-dependent 
effects (Gustafson et al., 2003).  
Lambert & Eilers proposed an extension to the penalised Poisson regression approach where 
the number of events in each narrow time bin is described using a Poisson distribution with 
the log mean specified using a flexible penalised B-splines model with a large number of 
equidistant knots (Lambert and Eilers, 2005). They extend this approach to allow the 
regression coefficients to vary smoothly over time. The regression parameters and penalty 
weights are estimated efficiently using Bayesian inference tools.  
Banerjee and colleagues consider a Bayesian approach to a class of generalised odds-rate 
hazards (GORH) models (Banerjee et al., 2007). This class of models is governed by a non-
proportionality parameter and is general enough to include proportional hazards model and the 
proportional odds model. The GORH models are given as  
 𝑆(𝑡; 𝑥) = {1 + 𝜃𝑒𝑥𝑝(𝜑0(𝑡) + 𝑥
𝑇𝛽)}−𝜃
−1
  , 4.28.  
thus the hazard rate is given by 
 𝜆𝜃(𝑡; 𝑥) = 𝜑0
′ (𝑡) exp(𝜑0(𝑡)
+ 𝑥𝑇𝛽){1 + 𝜃 exp(𝜑0(𝑡) + 𝑥
𝑇𝛽)}−1 , 
4.29.  
where 𝜃 > 0 is the GORH parameter while 𝜑0(𝑡) controls the form of the baseline hazard 
function.  
De Iorio and colleagues developed a Bayesian nonparametric approach through a dependent 
Dirichlet process model with inferences easily obtained using MCMC (De Iorio et al., 2009). 
This approach does not require the resulting survival curve to satisfy the proportional hazards 
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assumption. The Dirichlet process (DP) is a tool frequently used in nonparametric Bayesian 
inference and is a probability model for random probability distributions.  
An alternative approach, which again does not require the assumption of proportional hazards, 
is to use a first hitting time model which treats a subject’s health status as a latent stochastic 
process that fails when it reaches a threshold value (Pennell et al., 2010). Pennell and 
colleagues propose a random-effects threshold regression model and Bayesian methodology 
for inference (Pennell et al., 2010).  
The motivation of this literature search is to determine what other approaches are available 
when the assumption of proportional hazards in the Cox model is not valid. Due to the time 
constraints of this project and the extra conceptual leap to Bayesian inference I have decided 
the various Bayesian approaches will not be considered further. I will focus on promoting the 
use of alternative approaches to the Cox PH model without the added complexity of 
introducing Bayesian concepts.  
4.9 Application of novel methods to data analysis 
An interesting part of this literature review was to determine which of the approaches available 
for investigating non-proportional effects for survival data have been used in practice. This 
was investigated through forward citation searching in Google Scholar and the number of 
citations for each of the models can been seen in Table 4.1 through Table 4.7.  
The extended Cox model first introduced in Cox’s 1972 paper was by far the most cited paper 
with over 30,000 citations (Cox, 1972). However this paper also introduces the popular Cox 
proportional hazards model which explains the high number of citations. Popular approaches 
such as the extended Cox model and the use of piecewise constant effects through splitting of 
the time scale are often not cited so the focus of this forward citations search was on 
approaches with potential interest and developed after the year 2000.  
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Based on the advantages and disadvantages discussed previously, the approaches that were of 
interest were: 
Multiplicative Models 
- The MFPT approach proposed by Sauerbrei and colleagues (Sauerbrei et al., 
2007) 
- The product model introduced by Abrahamowicz and colleagues (Abrahamowicz 
and MacKenzie, 2007) 
Additive-Multiplicative Hazards Models 
- The Cox-Aalen model developed by Scheike & Zhang (Scheike and Zhang, 2002) 
Parametric Models 
- Flexible parametric models introduced by Royston & Parmer (Royston and 
Parmar, 2002a). 
4.9.1 Fractional Polynomials 
The MFPT approach proposed by Saurerbrei and colleagues involved the use of fractional 
polynomials in the extended Cox model for selection of non-linear and non-proportional 
effects and was cited by 23 papers. In their original paper they applied the MFPT approach to 
2982 patients from the Rotterdam breast cancer series with follow up time ranging from 1 to 
231 months (median 107 months), the outcome was event-free survival and they observed 
1,518 events. They identified several variables to have time-dependent effects: tumour size, 
number of positive lymph nodes, hormonal therapy, chemotherapy and progesterone having 
the strongest time-varying effect. The forward citations of the MFPT approach by Saurerbrei 




4.9.2 Regression Splines 
The approach by Abrahamowicz & Mackenzie involved the use of regression splines in the 
extended Cox model. They applied their model to 2,404 breast cancer patients enrolled by the 
Eastern Cooperative Oncology Group, 1,116 recurrences occurred during a median follow-up 
time of 4.2 years. They found no violation of the PH or log-linearity assumption for the 
covariates: tumour size, body mass index and log-transformed number of positive nodes. Their 
main focus was on the effect of age which was identified to violate the log-linearity assumption 
but satisfied the PH assumption.  
Published in 2007, the product model they proposed has been cited by 35 papers. Application 
of the product model has been used in practice. Binquet and colleagues used this approach to 
investigate the effects of prognostic factors on mortality in gastric cancers (Binquet et al., 
2009). The flexible modelling revealed the effect of age was most important in the first year 
after diagnosis and mortality increased for both the youngest and the oldest patients. Gagnon 
and colleagues used the product model to assess C-reactive protein (CRP) and other 
biomarkers as a prognostic factor for non-small cell lung cancer (NSCLC) and found 
violations of both linearity and the PH assumption (Gagnon et al., 2010). The importance of 
testing the assumptions of the Cox proportional hazards model was highlighted as the Cox PH 
model failed to identify albumin as a prognostic factor and flexible modelling allowed 
determining that the prognostic value of CRP and albumin does not extend beyond 6 or 12 
months, respectively.  
4.9.3 Additive and Additive-Multiplicative Models  
The Cox-Aalen model introduced by Scheike & Zhang was cited by 44 papers. They applied 
their model to 4000 patients with myocardial infarction from the Trace study group, 2020 
deaths were observed in a 3-year period after entering the study. Ventricular fibrillation was 
identified to have a very strongly time-varying effect; it is an important predictor for death 
within the first couple of months but after this time-period its effect vanishes.  
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In 2006 Baldi and colleagues used the Cox-Aalen model for breast cancer survival on 
Piedmont cancer registry data (Baldi et al., 2006). Their resulting model had an additive part 
consisting of a baseline, age at diagnosis and tumour size and the proportional part of the 
model containing regional lymph nodes involvement and comorbidity score. This model 
allowed identifying tumour size as having a time-varying effect; during the first 18 months 
after diagnosis its effect was found not to be significant but later it becomes an important 
predictor for death.  
4.9.4 Parametric Models 
Royston & Parmer introduced flexible parametric models which allowed simultaneously 
modelling the baseline hazard and non-proportional effects through the use of splines (Royston 
and Parmar, 2002a). They analysed recurrence-free survival time of 686 patients with primary 
node positive breast cancer from the German Breast Cancer Study Group, 299 events were 
observed with a median follow-up of nearly 5 years. They created three prognostic groups 
(representing good, medium and poor outcome) based on a linear predictor of standard 
prognostic factors: age, menopausal status, tumour size, tumour grade, number of positive 
lymph nodes (constrained to be monotonic with an asymptote), progesterone receptor 
concentration and estrogen receptor concentration. The use of the flexible parametric model 
indicated time-varying effects of the prognostic groups. Patients in the poor prognostic group 
experienced a high hazard of recurrence or death during the first 2 to 3 years after diagnosis. 
After that time the hazard diminished quite quickly and gradually converged toward that of 
the other two prognostic groups.  
The flexible parametric models is a popular approach due to the parametric nature of the model 
by modelling the baseline hazard and was cited by 115 papers. It has been used in practice due 
to the well-established and simple to use software available. For example, the approach has 
been used to model the absolute difference between the treatment groups over time (Dearnaley 
et al., 2007) and for more robust prediction of survival probabilities and corresponding 
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confidence intervals due to modelling of the baseline hazard (Dowsett et al., 2010, Nygard et 
al., 2004). The approach was used to investigate the effect of tumour characteristics (lymph 
node status, ER status and tumour size) over time by Colzani and colleagues (Colzani et al., 
2011). They found that positive lymph node status conferred an increased hazard of dying as 
a result of breast cancer, even 10 years after diagnosis, the influence of ER status decreased 
over time and was not significant 5 years after diagnosis and a pattern of decreasing HR was 
seen for women with tumours larger than 20 mm compared with women diagnosed with 
tumours between 1 and 20 mm. 
4.9.5 Source of Citations 
The lack of applications of the approaches highlighted through the forward citation searching 
can be explained by the majority of the citations being in methodological rather than clinical 
journals. For example the majority of the citations were papers published in the Statistics in 
Medicine journal which focuses on influencing practice in medicine and its associated sciences 
through the publication of new statistical and other quantitative methods. Other journals that 
also appeared regularly in the forward citations were the Biometrical journal, the BMC 
Medical Research Methodology journal, the Statistical Modelling journal and the 
Scandinavian journal of Statistics which all generally focus on statistical methods. Forward 
citations frequently discussed the methodological aspects of the approach with extension to 
other areas (e.g. relative survival models). 
4.10 Reviews of the approaches for modelling non-proportional effects 
Four reviews were found in the literature search that compared approaches to deal with non-
proportional hazards (Table 4.9) with key points of the reviews given in Table 4.10. 
4.10.1 Data Sets and Approaches Compared 
The four reviews compared several different approaches for analysing non-proportional effects 
in survival data but all included the extended Cox model.  
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Lehr & Schemper focused on the extended Cox model and looked at various approaches for 
the representation of relative risks over time from this model (Lehr and Schemper, 2007). 
Their data set contained only 90 subjects and 11 events which is too small for any real analyses 
of time-dependent effects but their main focus was on a simulation study of over-fit and power 
when adding extra parameters to model the time-dependent effects. Cortese and colleagues 
focused on the limitations of the Cox proportional hazards model and Perperoglou and 
colleagues considered approaches in modelling long-term survival (Cortese et al., 2010, 
Perperoglou et al., 2007). Buchholz & Sauerbrei compared five recently published strategies 
to assess whether and how the effects of covariates from a multivariable model vary in time 
(Buchholz and Sauerbrei, 2011). 
4.10.2 Summary of Findings 
Lehr & Schemper and Buchholz & Sauerbrei both determined the use of fractional 
polynomials with an algorithm for selection of the best fitting FP to be a good approach as it 
allowed maintaining the power of the standard proportional hazards model if effects were 
constant and adequately modelled non-proportional effects. The MFPT approach 
recommended by Buchholz & Sauerbrei also incorporated selection of non-linear functional  
68 
 
Table 4.9 Summary of Review Papers of Approaches for Dealing with Non-Proportional Hazards 





Gastric cancer study 
N=90 (events=11) 
Max length of follow up=5 years 
approx. 
Extended Cox Model  - 
Interactions with Time 
Simple monotonic functions 
Polynomials and FP 
Piecewise constant effects 
Splines 
Penalised likelihood approaches 
 
Fractional polynomials and penalised likelihood 
approaches are the tools of choice. 
 
Perperoglou et 
al. (2007)  
 
IASO breast cancer study 
N=2433 (events=602) 
Max length of follow-up=25 years 
approx. 
Reduced rank models 
Frailty models 
Cure rate models 
 
If there are not enough events and long-follow up, it is 
hard to tell the difference between time-dependent, 
frailty and cure rate models. 
 
Cortese et al. 
(2010)  
 
Norwegian Register breast cancer 
data 
N=9041 (events=6202) 
Median follow-up time=10 years 
Max follow-up time=26 years 
Cox model 
Extended Cox model 
Aalen Additive hazards model 
Cox-Aalen model 
Excess Hazards model 
 
Both flexible multiplicative and additive hazards 
models provide useful instruments for investigating if 







Rotterdam breast cancer survival 
N=2982 (events=1518) 
Median follow-up time=8.9 years 
Max follow-up time=19.25 years 
MFPT approach 
Dynamic Cox model 
Reduced Rank model 
Empirical Bayes model 
Semi-parametric extended Cox model 
 
When the interest lies on the shape of non-proportional 
effects the MFPT approach seems to preferable. 
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Table 4.10 Key Points of Review Papers of Approaches for Dealing with Non-Proportional Hazards 





Schemper (2007)  
 
 Investigation into over-fitting of non-proportional effects 
 Consequence of over fit  
o Increase in width of pointwise confidence intervals 
o Loss of power to confirm non-proportional effect 
 Increased variability of effect when adding additional parameters 
o Piecewise constant approach most variable 
 FP approach  
o allowed maintaining power if effects were constant 
o adequately modelled non-proportional effects 
o chose most parsimonious representation of the non-
proportional effect 




Perperoglou et al. 
(2007)  
 
 Emphasis on plots of hazards and survival rather than the coefficients 
 Direct comparison was difficult due to the different properties and 
background assumptions 
 Reduced Rank Models 
o Helped identify true nature of time-dependency 
o Provided means for parsimonious modelling through fitting 
fewer parameters 
o Difficult to express coefficients for the time-varying effects 
o Poor predictive performance with evidence of some over-
fitting 
 Frailty Models 
o Do not assume proportional hazards 
o Complex model due to interaction of baseline hazard with 
main effects 
o Important to plot survival and hazard curves, not only draw 
conclusions from coefficients 
 Cure Models 
o Can explain unexpectedly large survival times 
o Potential to identify outliers 
o However, breast cancer patients are never considered cured 
 
 
Cortese et al. 
(2010)  
 
 Cox PH model 
o Clear violation of model assumptions 
o Did not capture all important aspects of the data 
 Multiplicative flexible models 
o Rely on smoothing techniques which makes a description of 
the uncertainty difficult 
 Additive models 
o Easy to fit and require no assumptions on the degree of 
smoothing 







Table 4.10 (Continued) Key Points of Review Papers of Approaches for Dealing with Non-Proportional Hazards 




Sauerbrei (2011)  
 
 Demonstrated that  
o mismodelling of the functional form of a continuous 
covariate may induce spurious non-proportional effects 
o omission of covariates can have a severe influence on the 
assessment of the non-proportional effect 
 MFPT approach 
o Easy to use 
o Addressed variable selection, selection of non-linear 
functional forms as well as non-proportional effects 
 Dynamic Cox model 
o Equally flexible and easy to use 
o Problems with enlargements of data sets 
 Reduced Rank model 
o Theoretically a flexible tool 
o However algorithm does not include variable selection, 
selection of non-linear effects, nor selection of non-
proportional effects 
 May result in serious over-fitting and limits 
transferability of selected models 
 Empirical Bayes model 
o Easily applied 
o Combinations of non-linear and time-varying effects are not 
allowed 
 Semi-parametric extended Cox model 
o Theoretically flexible tool 




forms through the use of fractional polynomials to avoid finding spurious non-proportional 
effects. 
Perperoglou and colleagues and Buchholz & Sauerbrei both determined that the reduced rank 
model is theoretically a flexible tool for investigating time-dependence but it results in over-
fitting due to all effects being fitted as time-varying.  
Cortese and colleagues were focused on the limitations of the Cox model and provided a good 
example of fitting the Cox PH model and various methods for examining how well this model 
fitted the data and investigating the PH assumption. They briefly mentioned investigating the 
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functional form of the continuous covariates but results and further implications were not 
given. Although they investigated several different approaches these were compared to results 
from the Cox PH model and so a clear comparison of the various approaches was not available. 
Therefore they did not conclude on a preferred approach but determined all were an 
improvement on the Cox PH model.  
4.11 Discussion  
The disadvantages of the Cox model are continually being discussed yet it is still being used 
with the underlying assumptions often not being checked and possibly not valid. The use of 
the Cox model when the assumptions are not valid can result in misleading conclusions. 
Bellera and colleagues found variables not satisfying the PH assumption results in a reduction 
in power of the corresponding tests and so are more likely to make a type II error (accept the 
null hypothesis when it is false) (Bellera et al., 2010). Testing of the PH assumption should be 
an integral part of an analysis using the Cox model with both graphical and numerical 
approaches available to do this (see chapter 3).  
Many of those who do check the assumption of proportional hazards and find it not valid use 
the simple approach of splitting the time scale, known as piecewise constant effects, but the 
drawbacks of this approach are well established. The categorising of the time-scale results in 
a reduction of power and the number of intervals chosen can have an impact on the conclusions 
made. Piecewise models yield ‘jumpy’, clinically implausible, estimates with difficulties 
implementing in multivariable modelling (Quantin et al., 1999).  
A large number of alternatives to piecewise constant effects were highlighted by this review; 
from fully parametric to non-parametric models, multiplicative effects of the covariates to 
additive effects, different methodological assumptions such as cure and frailties, as well as an 
expanding body of literature on Bayesian approaches.  
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A key point that was continually made was that the functional form of the covariate on the 
log-hazard must be correct to avoid spurious evidence of non-proportional effects. Two 
approaches that specifically mentioned incorporating non-linear effects of continuous 
covariates on the log-hazard as well as non-proportional effects: the multivariable fractional 
polynomial time (MFPT) approach by Sauerbrei and colleagues and the product model 
proposed by Abrahamowicz & Mackenzie (Sauerbrei et al., 2007, Abrahamowicz and 
MacKenzie, 2007). They both made use of the extended Cox model with fractional 
polynomials and regression splines respectively. Buchholz & Sauerbrei recommended the use 
of the MFPT approach which they compared to other multiplicative models (Buchholz and 
Sauerbrei, 2011). This approach has not been found to be used in practice and it will be of 
interest to apply to data analyses throughout this project.  
Royston & Parmer proposed a flexible parametric approach which involved modelling the 
baseline hazard and non-proportional effects through the use of regression splines (Royston 
and Parmar, 2002a). It was a popular approach with a relatively large number of citations and 
has been used in practice due the parametric nature of the model and the readily available 
software to implement this approach. They state “The Cox model is convenient with its 
strength lying in estimating relative hazards for covariate effects. It is semi-parametric in 
nature and was never intended for the task of comprehensive prediction of survival 
probabilities and other important quantities”(Royston et al., 2010). They therefore recommend 
the use of adequately flexible parametric models for estimation and validation of prognostic 
models. This will be a key approach for modelling the baseline hazard and estimating non-
proportional effects. 
The citation searching highlighted the lack of application of the available approaches for 
modelling non-proportional effects to data sets. Binquet and colleagues state the need for more 
methodological research in this area, more widespread use of flexible modelling in prognostic 
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studies and encourage others to explore similar flexible analyses on prognostic studies 
(Binquet et al., 2008, Binquet et al., 2009).  
4.11.1 Limitations 
The limitations of this literature review include the reliance on published research and finding 
of the studies using the method outlined in the search strategy (section 4.2). The search strategy 
included finding terms in the title and abstract of studies and the use of focus terms limited the 
results returned and possibly omitted important studies. However, references of studies that 
were highlighted as relevant were searched and a relatively large number of papers were 
included in the final review, giving a broad and comprehensive overview of approaches for 
analysing non-proportional effects.  
Limitations were involved in the citation searching to determine which of the approaches 
available for investigating non-proportional effects for survival data had been used in practice. 
Often well-known approaches such as the extended Cox model and piecewise constant effects 
are not explicitly cited so it was decided to focus on newer approaches that are more likely to 
be cited. Although the citations revealed a lack of using the approaches in practice this does 













Chapter 5:  IHC4 and Mammostrat 
5.1 Introduction 
The focus of this project is on two residual risk marker panels, IHC4 and Mammostrat. This 
chapter will cover the development of these two models and the statistical methods applied in 
previous evaluations of the models.   
This chapter will also cover some of the recent prognostic models for breast cancer which have 
investigated time-dependent effects. 
5.2 Model Development and First Validation 
5.2.1 IHC4 
5.2.1.1 Development 
IHC4 score was developed by Cuzick and colleagues to combine four conventional IHC 
markers, ER, PgR, HER2 and Ki67 to select patients at increased residual risk after adjuvant 
endocrine therapy (Cuzick et al., 2011).  
The risk score was developed on women from the tamoxifen and anastrozole arms of the 
Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial reported to be ER-positive 
and/or PgR-positive. Women who received chemotherapy before trial entry and those found 
to be both ER-negative and PgR-negative on central review of the sections were excluded, 
leaving 1,125 eligible patients (145 distant recurrences) with measurements for all parameters. 
The primary end-point was time to distant recurrence (TTDR) and was based on a median 
follow-up of 8.3 years.  
The contribution of each of the four variables was evaluated by the change in likelihood ratio 
in three ways: by univariate Cox analyses, as an addition to a model containing only the clinical 
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variables, and as a decrease in likelihood ratio when the variable was removed from the full 
model containing clinical variables (age, nodal status, tumour size, centrally read grade, and 
randomised treatment) and all four IHC variables. In the paper it states ‘a model was then 
created that used all the data to give the best IHC4 score when combined with the classical 
variables, leading to an overall prognostic score. To allow for the small amount of over-fitting 
of the IHC4 score, a shrinkage correction was used for the final score’. It is not clear what they 
mean by ‘best’ IHC4 score and how this was determined. All clinical variables were 
categorical, which results in a loss of information from continuous age, number of positive 
nodes and tumour size, which could have inflated the prognostic information added by the 
IHC markers. 
An aim of their paper was to compare the added information from their newly developed IHC4 
score to Oncotype Dx. To do this, the IHC4 score was then generated using half the data, and 
the comparison between IHC4 and Oncotype Dx in the remaining half. It is not clear what the 
differences were when ICH4 was developed using the full dataset.  
It was not mentioned in the paper whether the assumptions of linearity or proportional hazards 
were assessed when performing the Cox regression. The final score comprised a 
transformation of one of the IHC markers, suggesting that different functional forms were 
explored and perhaps this was what was implied by determining the ‘best’ model.  
5.2.1.2 Validation 
The first validation was performed as a comparison to the Oncotype Dx test on the remaining 
half of the data not used in the development of IHC4. The comparison between IHC4 and 
Oncotype Dx was assessed for all patients and those node-negative by changes in the 
likelihood ratio statistic and a comparison of Kaplan-Meier survival curves for each score. 
They found that the ICH4 score provide additional prognostic information that is at least as 
informative as the Oncotype Dx test.  
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Further validation of the IHC4 score was performed using a cohort of 786 women treated in 
Nottingham from 1990 to 1998. All of these patients were ER-positive and received either 
tamoxifen or no endocrine treatment. There were 174 distant recurrences in this cohort with a 
median follow-up of 9.5 years. IHC4 was assessed by univariate and multivariate Cox 
regression analysis, and a comparison between observed and predicted time to distant 
recurrence. The IHC4 score was significantly prognostic of outcome in a univariate analysis 
and after adjustment for clinical factors (nodal status, tumour size, grade, age and treatment). 
There was no mention of testing the modelling assumptions of linearity and proportional 
hazards in the Cox model. 
5.2.2 Mammostrat Score 
5.2.2.1 Development 
Mammostrat score was developed by Ring and colleagues, to explore whether insights from 
gene expression studies could be translated into robust IHC-based assays by generating 
hundreds of novel antibody reagents targeted to predicted protein products of genes selected 
on the basis of their gene expression patterns (Ring et al., 2006).  
The development cohort was 466 patients (122 recurrences) with primary invasive breast 
cancer seen at the Comprehensive Cancer Institute of Huntsville (CCIH). Close to 700 gene 
targets for generation were chosen on the basis of interesting gene expression patterns in 
published data sets. Prognostic models were derived using 195 ER-positive, node-negative 
patients in the CCIH training cohort and the subset of 20 antibodies that had a significant 
association (based on a log-rank test) with outcome in this patient set. The number of 
recurrences in this subgroup of patients and the median length of follow-up were not provided 
in the paper. An explicit statement of the primary outcome was not given, however it is 
assumed that disease-free survival was used, due to discussion of disease-free survival rates in 
the paper.  
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Cox proportional hazards regression model building used initially all of the antibodies 
nominated by the univariate tests. A backward selection method was used to remove antibodies 
that did not add significantly to the fit of the model, until removal of antibodies caused a 
significant reduction in the strength of the model. This resulted in a final model consisting of 
five antibodies. The prognostic score was classified into three prognostic categories, but it was 
not stated how they determined the cut-points for these categories. There was no mention of 
testing the modelling assumptions of linearity and proportional hazards in the Cox model. 
5.2.2.2 Validation 
In their initial paper, Ring and colleagues presented the results of the validation of 
Mammostrat score in two independent cohorts: 299 consecutive primary invasive breast 
cancer patients (61 recurrences) seen at the Cleveland Clinic Foundation (CCF); 344 
consecutive primary invasive breast cancer patients (56 deaths – recurrences not available) 
seen at Vancouver General Hospital then linked to an anonymous British Columbia Cancer 
Agency (BCCA) database containing follow-up information. For the CCF data set, disease-
free survival was assessed. For the BCCA data set, overall survival was assessed (disease-free 
survival was unavailable), and death from other causes was censored. Follow-up time in both 
validation cohorts was limited to 5 years. 
The prognostic ability of Mammostrat score was assessed using Kaplan-Meier plots, univariate 
and multivariate Cox regression (adjusted for stage, grade and lymph node status), sensitivity, 
specificity and positive and negative predicted values. Overall, Mammostrat score was found 
to provide good stratification of patients into prognosis groups and remained an independent 
predictor of outcome in multivariable cox regression.  
5.3 Independent Evaluations of IHC4 Score 




5.3.1 Contribution of the IHC4+C score to decision making in clinical practice 
Barton and colleagues compared the prognostic information gained from IHC4+C with that 
from Adjuvant! Online (AoL) and NPI, in a group of postmenopausal women with early breast 
cancer receiving treatment (Barton et al., 2012). Their aim was to determine whether 
assessment of IHC4+C assists in the selection of patients who may be safely treated with 
adjuvant hormone therapy alone and spared the side-effects of chemotherapy. 
The primary endpoint was the proportion of patients re-allocated from AoL-defined 
intermediate risk of distant recurrence at 10 years, to either high or low risk, by application of 
the IHC4+C score. The first secondary endpoint was the proportion of patients reallocated 
from NPI-defined moderate risk to either high or low risk, by application of the IHC4+C score.  
The analysis was performed on 101 hormone receptor-positive, HER2-negative early breast 
cancer patients with ≤3 axillary lymph nodes containing metastases.  
The IHC4+C score downgraded more than half of the patients in the AoL-defined 
intermediate-risk group to a low-risk group. Nearly two-thirds in the NPI-defined 
intermediate-risk group were reallocated into either a low- or high-risk group, with risk 
stratification most often lowered. They concluded the use of IHC4+C may substantially 
improve decision-making on adjuvant therapy. 
5.3.2 Comparison of PAM50 Risk of Recurrence Score with Oncotype DX and 
IHC4  
Dowsett and colleagues compared the ability of the risk of recurrence (ROR) score generated 
from the 50-gene PAM50 test with that of the Oncotype DX 21-gene recurrence score (RS) 
and IHC4 score in predicting risk of distant recurrence (DR) after endocrine therapy (Dowsett 
et al., 2013). 
The analysis was performed on the same dataset from the development of IHC4, women from 
the tamoxifen and anastrozole arms of the ATAC trial reported to be ER positive and/or PgR 
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positive. Therefore the comparison between IHC4 and PAM50 was performed using a sample-
splitting approach. . 940 patients had data on all three scores with 154 distant recurrences. 
Subgroup analysis was performed on node-negative patients and HER2-negative/node-
negative patients. 
To assess the prognostic value of each score (ROR, RS, IHC4), two approaches were used: 
the changes in the likelihood ratio values to measure quantitatively the relative amount of 
information of one score compared with another; and the concordance index (c index) measure 
of concordance for time-to-event data.  
IHC4 added as much information to clinical factors (nodal status, tumour size, histopathologic 
grade, age, and treatment) as ROR but in the HER2-negative/node-negative subgroup, ROR 
added significantly more information than IHC4.  
Sestak and colleagues then continued the analysis of ROR, RS and IHC4 for early (0-5 year) 
and late (5-10 year) distant recurrence (Sestak et al., 2013). After adjustment for the clinical 
treatment score (tumour size and grade, lymph node status, age, and treatment), IHC4, RoR 
and RS were prognostic of early recurrence with IHC4 providing more prognostic information 
than RoR and RS. The scores also remained prognostic in the 5-10 year interval, with RoR 
providing more prognostic information than IHC4 and RS. 
5.3.3 Comparison of the breast-cancer index (BCI) assay, Oncotype Dx, and 
IHC4 
Sgroi and colleagues compared the prognostic ability of the breast-cancer index (BCI) assay, 
21-gene recurrence score (Oncotype DX), and IHC4 for both early and late recurrence in 
patients with ER-positive, node-negative disease who took part in the Arimidex, Tamoxifen, 
Alone or in Combination (ATAC) clinical trial (Sgroi et al., 2013). Again the analysis was 




Distant recurrence was the primary endpoint and the primary analysis population was patients 
with ER-positive, node-negative breast cancer, with the secondary analysis populations 
including patients with ER-positive, node-negative, HER2-negative breast cancer and those 
with ER-positive, node-positive breast cancer. The analysis included 665 patients with 72 
distant recurrences. 
The primary objective was to determine the prognostic ability of the BCI model for distant 
recurrence. Secondary objectives were to assess the BCI model and it’s components for overall 
(0-10 year), early (0-5 year) and late (5-10 year) distant recurrence and compare with that of 
RS and IHC4.  
Likelihood ratio tests based on Cox proportional hazards regression models were used to test 
for a significant difference between a reduced proportional hazards model based on clinical 
treatment score and a full proportional hazards model, including BCI, RS, or IHC4. The 
improvement in prediction was quantified by the change in the likelihood ratio chi-squared 
value, which measures the amount of information added to the proportional hazards model by 
the gene signatures compared with clinical treatment score. 
BCI was significantly associated with both early and late distant recurrence with adjustment 
for clinical treatment score (tumour size and grade, lymph node status, age, and treatment). 
For early recurrence, in all node-negative patients, IHC4 was more prognostic than RS and 
BCI. However, neither IHC4 nor RS were prognostic of late distant recurrence.  
5.3.4 Clinical Impact of using the IHC4 Score 
Yeo and colleagues presented their results of ‘the clinical impact of using the IHC4 score: our 
MDT experience in a prospective series of postmenopausal women with ER-positive early 
breast cancer’ at the IMPAKT Breast Cancer Conference (Yeo et al., 2014). Their study aim 
was to prospectively evaluate the change in adjuvant treatment decision making based on the 
availability of the IHC4 score. The primary endpoint was the percentage change in the MDT 
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recommendation for systemic therapy before and after the availability of the IHC4 score. They 
concluded the IHC4 score has the potential to change a significant proportion of patients’ 
adjuvant treatment recommendations given through the MDT in this small prospective study. 
5.4 Independent Evaluations of Mammostrat Score 
5.4.1 Chemo-sensitivity and Stratification of Mammostrat in the NSABP B14 and B20 
Trials 
Ross and colleagues aimed to determine the association between the Mammostrat test and 
clinical outcomes in ER-positive, node-negative tamoxifen-treated breast cancer patients and 
to determine whether the test identified patients who would have selectively benefited from 
adjuvant chemotherapy treatment (Ross et al., 2008).  
The NSABP B14 and B20 studies were randomized prospective studies of the role of adjuvant 
tamoxifen and adjuvant chemotherapy in the treatment of node-negative, ER-positive breast 
cancer, respectively.  The analysis included 711 patients with number of events and median 
length of follow-up not stated. 
The primary aim was to test on tamoxifen treated patients from both the B14 and B20 trials 
that the Mammostrat risk groups were significantly associated with recurrence-free interval 
(RFI) in a univariate Cox model and was tested using the likelihood ratio test. 
Prediction of chemotherapy benefit was carried out by comparing patients treated with 
tamoxifen only to those treated with tamoxifen plus chemotherapy using patients from the B20 
trial. The primary aim was to test that the distribution of recurrence events in comparison 
between tamoxifen-treated and tamoxifen plus chemotherapy-treated patients during the 10-
year study period was significantly distinct and was tested with an interaction between 
Mammostrat risk groups and chemotherapy. 
The Mammostrat score was shown to be associated with RFI in a univariate analysis and after 
adjustment for age and tumour size. It was shown patients in both the low and high-risk groups 
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benefited from chemotherapy with an improvement in a univariate analysis, but there was no 
significant interaction between the risk groups and chemotherapy. 
5.4.2 Mammostrat as a tool to stratify breast cancer patients at risk of 
recurrence during endocrine therapy 
Bartlett and colleagues explored the relationship of Mammostrat risk stratification on patients 
from the Edinburgh Breast Conservation Series (BCS), where patients were those considered 
suitable for breast-conserving therapy with a tumour size of < 3 cm, node-negative or positive, 
and no metastases on conventional TNM (tumour size, nodes, metastases) staging (Bartlett et 
al., 2010). The analysis included 1,540 patients treated with adjuvant tamoxifen, other 
hormonal therapy and with both hormonal therapy and chemotherapy, excluding patients 
treated with chemotherapy only. The number of events and median length of follow-up was 
not stated in the paper. 
The primary analysis was to assess the association with Mammostrat risk groups on distant-
recurrence free survival (DRFS) in ER-positive, node-negative cases treated with tamoxifen 
only and in ER-positive, tamoxifen-treated cases irrespective of nodal status. Univariate and 
multivariate Cox regression analysis was used to estimate hazard ratios and 95% confidence 
intervals and corresponding p-value.  
Mammostrat risk score as a predictor of DRFS was of borderline significance for ER-positive, 
node-negative cases treated with tamoxifen only after adjustment for nodal status, grade, size, 
multifocality, menopausal status, age, HER2, PgR and ER. Mammostrat score remained an 
independent predictor when ER-positive, tamoxifen-treated cases irrespective of nodal status 
were considered.  
It was concluded the data added support for the potential role of Mammostrat in management 
of early-stage breast cancer. 
84 
 
5.4.3 Mammostrat as a predictor of Early Relapse Risk in the TEAM Study 
Bartlett and colleagues then explored the effect of Mammostrat on residual risk of relapse after 
treatment with either 5 years of exemestane (steroidal aromatase inhibitor) or 5 years of 
endocrine therapy by using a switch strategy with tamoxifen (2 to 3 years) followed by 
exemestane (3 to 2 years) within the large clinical trial cohort, the Tamoxifen versus 
Exemestane Adjuvant Multicenter (TEAM) trial of postmenopausal hormone-receptor 
positive patients (Bartlett et al., 2012). The TEAM pathology substudy consisted of 4,598 
cases suitable for TMA construction and Mammostrat staining, with 954 disease relapses with 
a median follow-up of 5.1 years. 
The primary analyses were to test that Mammostrat was an independent marker of residual 
risk of DRFS after 5 years of adjuvant endocrine therapy (either exemestane or tamoxifen 
followed by exemestane): in ER-positive, node-negative patients treated with endocrine 
therapy (but not with chemotherapy), in ER-positive patients irrespective of nodal status 
treated with endocrine therapy (but not chemotherapy), and in all patients with hormone 
receptor-positive breast cancer treated with endocrine therapy. Univariate and multivariate 
Cox regression analysis was used to estimate hazard ratios and 95% confidence intervals and 
corresponding p-value.  
Mammostrat was an independent predictor of DRFS after adjustment for PgR, HER2, age, 
grade, size, nodes and chemotherapy in all patient subgroups. 
It was concluded for postmenopausal women with ER-positive early breast cancers, 
irrespective of nodal status, the Mammostrat panel provided independent information on 
residual risk of distant recurrence or death as a result of breast cancer after treatment with 
exemestane or a switch regimen (tamoxifen followed by exemestane) in a retrospective 
analysis of the TEAM pathology study cohort.  
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5.5 Time-dependent analysis of other prognostic scores 
It was of interest to examine any previous analyses of prognostic models in breast cancer in 
relation to evidence of non-proportional effects. 
5.5.1 Validation and Clinical Utility of MammaPrint 
Buyse and colleagues aimed to validate the 70-gene signature, MammaPrint (Buyse et al., 
2006).  
Participants in this study included 326 patients from five European centres who were younger 
than 61 years old at diagnosis, diagnosed before 1999 with node-negative, T1 – T2 (≤ 5 cm) 
breast cancer, and had not received adjuvant systemic therapy.  
Three main endpoints were analysed: time from surgery to distant metastases; overall survival; 
and disease-free survival. There was a median follow-up of 13.6 years and events included 68 
recurrences, 31 second primary cancers, 77 distant metastases, and 82 deaths. 
Validation was based on the estimation of hazard ratios and 95% confidence intervals and 
sensitivity and specificity were estimated for distant metastases within 5 years and for death 
within 10 years. The impact of follow-up duration was evaluated by looking at different time-
points with arbitrary censoring of all observations at increasing time points.  
The gene signature was shown to be a strong prognostic factor for time to distant metastases 
and overall survival in untreated patients with node-negative breast cancer after adjustment 
for various risk classifications that take into account clinicopathologic factors (Adjuvant! 
Online). The gene signature was shown to have the greatest prognostic value at identifying 
patients at high risk of an event within 5 years. 
5.5.2 Strong Time Dependence of the 76-Gene Prognostic Signature 
Desmedt and colleagues aimed to independently validate the 76-gene signature, identified by 
Erasmus Medical Center and Veridex  that could be used to predict the development of distant 
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metastases within 5 years in node-negative primary breast cancer patients (irrespective of age 
and tumor size) who did not receive systemic treatment (Desmedt et al., 2007).  
198 patients from the TRANSBIG study were included in the analysis who were younger than 
the age of 61 years and had node-negative, T1-T2 (≤5 cm) tumours. Patients in this series had 
been diagnosed between 1980 and 1998 (median follow-up, 13.6 years) and had been seen at 
six centres. 
The study end-points were time from diagnosis to distant metastases (TDM) and overall 
survival. The median follow-up for the 198 patients included was 14.0 years, with 51 distant 
metastases and 35 with progression within 5 years. 
Hazard ratios were calculated from Cox proportional hazards models, stratified by clinical risk 
as defined by Adjuvant! Online to estimate the prognostic effect of the signature above that 
provided by clinicopathological variables. Sensitivity and specificity was calculated for distant 
metastasis within 5 or 10 years. The effect of the duration of follow-up on HRs was analysed 
by censoring all observations at increasing time points. 
The signature was found to be prognostic of outcome after adjustment for clinical risk when 
considering 10-year follow-up, but a strong time-dependence of the signature was identified 
providing the most prognostic information in the first 5 years of follow-up. 
It was concluded the prognostic ability of the 76-gene signature was confirmed. However, 
again there was no mention of assessing the proportional hazards assumption and all hazard 
ratio estimates had very wide confidence intervals. 
5.5.3 Comparison of prognostic gene expression signatures for breast cancer 
Haibe-Kains and colleagues aimed to statistically compare three gene signatures in terms of 
predicting clinical outcome for the individual patient. The signatures were the 70-gene 
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signature, MammaPrint, the 76-gene signature and the Gene expression Grade Index (GGI) 
score based on 97 genes (Haibe-Kains et al., 2008).  
198 patients from the TRANSBIG study were included in the analysis. The patients were 
younger than the age of 61, had node-negative, T1–T2 (≤ 5 cm) tumours and did not receive 
any adjuvant treatment. The endpoints considered were distant metastases free survival, time 
to distant metastases and overall survival. The number of events and length of follow-up were 
not stated in the paper. 
Survival analysis was performed considering 10-year and full follow-up (25 years) using Cox 
regression models to estimate hazard ratios and the C-index to quantify concordance. 
Sensitivity and specificity was estimated at several lengths of follow-up (3, 5, 10, 15 years and 
full follow-up).  
The three signatures added significant information to the traditional parameters (age, tumour 
size, ER status, and grade) when follow-up was censored at 10-years. The 76-gene signature 
was not prognostic of outcome when full follow-up was considered. A decrease in model 
performance was observed, according to the sensitivity and specificity, with increasing follow-
up duration (10 years and more) for all gene signatures. 
It was concluded that the gene signatures showed similar prognostic performance with a strong 
time dependence of the classification performance. However, there was no mention of 
assessing the proportional hazards assumption when the Cox regression analysis was 
performed over the 10 or 25-year follow-up.  
5.5.4 EndoPredict prognostic of late distant metastases  
Dubsky and colleagues assessed whether the prognostic EndoPredict (EP) score, a multigene 
score that combines the expression levels of proliferative and ESR1 signalling/differentiation-
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associated genes, identifies late relapse events in ER+/HER2- breast cancer patients (Dubsky 
et al., 2013). 
1701 patients were included in this study who participated in the ABCSG6 (tamoxifen-only 
arm) or ABCSG8 trial and received either tamoxifen for 5 years or tamoxifen for 2 years 
followed by anastrozole for 3 years. None of the patients received adjuvant chemotherapy. 
The primary end-point used in the analysis was distant metastases with number of events not 
stated in the paper. 
Kaplan-Meier survival estimates were estimated in two different time periods: 0-5 years and 
>5 years. Multivariable Cox regression analysis was also performed on the two time intervals. 
The c-index was used to assess the prognostic information provided by the EP signature and 
clinicopathological variables.  
In the multivariate analysis EP was an independent predictor of distant metastases after 
adjustment for age, grade, lymph node status, tumour size and Ki67 in the first and second 
time interval. The prognostic performance as assessed by the C-index was significantly 
improved by adding the molecular information of the EP test to the clinicopathological 
variables.  
It was concluded that the EPclin (EP score combined with tumour size and nodal status) 
reliably identified a subgroup of patients who have an excellent long-term prognosis after 5 
years of endocrine therapy.  
5.5.5 Breast Cancer Index Identifies Breast Cancer Patients at Risk for Early- 
and Late-Distant Recurrence 
Zhang and colleagues aimed to develop an optimized BCI risk model and validate its 
prognostic performance with pre-specified risk groups for predicting early (0–5 years) and late 
(>5 years) distant recurrences (Zhang et al., 2013). 
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This BCI model was validated in a retrospective analyses of two cohorts: first, 808 tamoxifen-
treated ER+, LN- patients enrolled in the Stockholm trial and second, a multi-institutional 
cohort consisting of ER+, LN- tamoxifen-treated patients from 2 academic medical centres 
which included 265 and 93 patients respectively.  
The study endpoint was distant recurrence-free survival. The Stockholm cohort had a median 
follow-up time for all patients of 17 years and the numbers of distant recurrences were 56 and 
33 for untreated and tamoxifen-treated patients, respectively, with 52% and 61% of the 
recurrences occurring after 5 years. The multi-institutional cohort had an overall median 
follow up time for all patients of 10 years and 57 distant recurrences with 40% of the 
recurrences occurring after 5 years. 
Multivariate Cox proportional hazard models were used to evaluate whether BCI provided 
prognostic information independent of traditional clinical and pathologic factors (age, tumour 
size, tumour grade, HER2 status, PR status, and chemotherapy if appropriate) using likelihood 
ratio tests.  
BCI was a significant predictor of overall (0-10 years), early (0-5 years) and late distant 
recurrence risk (5-10 years) after adjustment for clinicopathological variables in both cohorts.  
It was concluded that the prognostic ability of BCI to assess early- and late-distant recurrence 
risk at diagnosis has clinical use for decisions of chemotherapy at diagnosis and for decisions 
for extended adjuvant endocrine therapy beyond five years. 
5.5.6 Long-term impact of MammaPrint on breast cancer outcome 
Drukker and colleagues aimed to evaluate the effect of the 70-gene signature, MammaPrint 
after longer follow-up (Drukker et al., 2014).  
The cohort included 295 patients, who were females diagnosed at the Netherlands Cancer 
Institute between 1984 and 1995, younger than 53 years with histologically proven, operable, 
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invasive breast cancer (tumour size <3cm, node-negative or positive, no metastases). All 
patients were primarily treated with breast conserving surgery or mastectomy. Adjuvant 
treatment consisted of radiotherapy, chemotherapy and/or endocrine therapy as indicated by 
guidelines used at the time of treatment. 
End-points included overall survival (OS) and distant metastasis-free survival (DMFS). There 
was a median follow-up of 18.5 years, with 121 distant metastasis events, 127 deaths of which 
114 were attributed to death due to breast cancer.  
Hazard ratios and 95% confidence intervals and p-values were calculated from the Cox 
regression analysis for the full follow-up (max 25 years) and per 5 year intervals. 
The 70-gene signature was shown to have the largest prognostic value for DMFS and OS in 
the first 5 years of follow-up. A prognostic effect for distant metastases was claimed over the 
25 year follow-up, despite a significant hazard ratio confined to first five years of follow-up 
and no mention of assessing the proportional hazards assumption when full follow-up (25 
years) was considered. The analysis was also not adjusted for any known prognostic clinical 
factors. 
5.6 Discussion 
IHC4 has been shown to provide significant prognostic information which is at least as 
informative as the Oncotype Dx test, the PAM50 test and BCI when considering 10 year 
follow-up. When considering early (0-5 years) and late (5-10 years) distant recurrence, IHC4 
provided more prognostic information on early distant recurrence compared to Oncotype Dx 
and PAM50 but PAM50 was the stronger predictor for late distant recurrence. Similarly IHC4 
was the stronger predictor of early distant recurrence compared with BCI but only BCI 
remained prognostic in the 5-10 year period. 
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However, the majority of evaluations of the IHC4 residual risk model have been performed on 
the same dataset as it was developed, performing the analysis on half of the dataset not used 
in the development of IHC4 score. It is therefore of benefit to evaluate this model on 
completely independent datasets. The IHC4 score has also not been evaluated after longer 
follow-up. 
Mammostrat has been shown to provide prognostic information on residual risk of distant 
recurrence or death as a result of breast cancer after treatment in several cohorts, but it has not 
been compared with other prognostic models. The impact of follow-up time has also not been 
explored for this score. 
Overall, there is no mention of assessing the proportional hazards assumption despite all of 
the papers using the Cox proportional hazards model. The only method used to evaluate the 
time-dependence of the scores was with splitting of the time-scale into 5 year intervals and 















Chapter 6:  The Data 
In this work data analyses will be performed on two breast cancer patient series.  
6.1 Materials 
6.1.1 The Edinburgh Breast Conservation Series  
The Edinburgh Breast Conservation Series (BCS) represents a fully documented, consecutive 
cohort of 1,812 patients treated by breast conservation surgery, axillary node sampling or 
clearance, and whole breast radiotherapy at the Edinburgh Cancer Centre between 1981 and 
1998 (Bartlett et al., 2010, Thomas et al., 2009). Following ethical approval (Lothian Local 
Research Ethics 04) tissue blocks were retrieved from all cases and sufficient material was 
available from 1,686 cases for assembly into tissue microarrays (TMAs)(see section 6.2.2.1 
for more detail). For all cases with available tissue, tumours were regraded on whole sections 
by a single pathologist (Thomas et al., 2009). Data were not available on patients treated with 
chemotherapy only (n=146) and patients treated with non-tamoxifen based endocrine therapy 
(n=91) resulting in 1,449 patients available for analyses  
6.1.2 The Tamoxifen Exemestane Adjuvant Multinational Trial 
The TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial is a multinational 
randomised, open-label, phase III trial in postmenopausal women with hormone receptor-
positive early breast cancer testing the efficacy of 5 years of exemestane (25 mg once per day) 
versus tamoxifen (20 mg once per day for 2.5-3 years) followed by exemestane for a total of 
5 years (van de Velde et al., 2011). Patients were recruited in the years 2001 to 2006. Five of 
nine participating countries provided paraffin-embedded tumour samples for pathology sub-




6.2 Variables  
6.2.1 Clinical Variables 
Prognostic clinical variables that will be used in the analyses   areage (continuous), tumour 
size (continuous), number of positive nodes (a count), histological grade (grade I-III), 
treatment (exemestane/tamoxifen in TEAM) and chemotherapy (yes/no). 
6.2.2 Biomarkers 
The IHC4 model (Cuzick et al., 2011) utilized a linear combination of multiple markers: ER, 
PgR, HER2 and Ki67. Continuous marker scores were normalised prior to inclusion in the 
IHC4 model. ER histoscores were divided by 30 and PgR as a percentage of cells staining 
positive were divided by 10 to obtain continuous values between 0 and 10. Ki67 scores were 
represented as percentage positive cells and HER2 was treated as a dichotomous variable. The 
IHC4 risk score was generated according to the previously specified algorithm(Cuzick et al., 
2011): 
𝐼𝐻𝐶4 𝑆𝑐𝑜𝑟𝑒 = 94.7 ∗ (−0.1 ∗ 𝐸𝑅10 − 0.079 ∗ 𝑃𝑔𝑅10 + 0.586 ∗ 𝐻𝐸𝑅20 1⁄ + 0.24 ∗
𝐿𝑛(1 + 10 ∗ 𝐾𝑖67%𝑝𝑜𝑠)) . 
The IHC4 score is analysed as a continuous risk score, except for Kaplan-Meier analyses 
where the IHC4 score is categorised into three groups using two cutoff points that correspond 
to a 10 year distant recurrence rate of 10% and 20% from the original study, however these 
cutoffs have not been prospectively validated (Cuzick et al., 2011). 
The Mammostrat model (Ring et al., 2006) used five IHC markers: SLC7A5, CEACAM5, 
NDRG1, HTF9C and p53. The Mammostrat risk score was generated by combining binary 
staining results for all markers as either positive or negative according to the previously 
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specified algorithm (Bartlett et al., 2010, Ring et al., 2006, Ross et al., 2008, Bartlett et al., 
2012): 
𝑀𝑎𝑚𝑚𝑠𝑜𝑡𝑟𝑎𝑡 𝑆𝑐𝑜𝑟𝑒 = (1.54 ∗ 𝑆𝐿𝐶7𝐴5) + (1.12 ∗ 𝑝53) + (1.06 ∗ 𝑁𝐷𝑅𝐺1) + (0.72 ∗
𝐻𝑇𝐹9𝐶) + (0.50 ∗ 𝐶𝐸𝐴𝐶𝐴𝑀5) − 0.86 . 
The Mammostrat score was categorised into low (≤ 0), medium (>0 and <0.7) and high (≥ 0.7) 
risk categories as previously specified (Ring et al., 2006, Bartlett et al., 2010, Bartlett et al., 
2012, Ross et al., 2008). The Mammostrat score is not analysed as a continuous score due to 
the skewed distribution (Figure 6.1). Model fit of continuous versus categorical variable was 
assessed by the AIC (Akaike information criterion(Akaike, 1974)). It is an index used to aid 
in choosing between competing models and is defined as −2𝐿𝑚 + 2𝑚 where  𝐿𝑚 is the 
maximised log-likelihood and m is the number of parameters in the model.  The AIC will be 
used in further analyses as well as the BIC (Bayes information criterion(Schwarz, 1978)) 
which is defined as −2𝐿𝑚 + 𝑚 × ln(𝑛) where n is the number of observations. Analysing 
Mammostrat score as a categorical variable improves the model fit as assessed by the AIC 
from a univariate Cox regression model whereas categorising IHC4 results in a loss of 
information (Table 6.1).  
 
Table 6.1 Comparison of scores as categorical or continuous predictors as assessed by AIC from a univariate Cox 
regression model. 
  Mammostrat   IHC4 
AIC Cont. Cat. Diff.   Cont. Cat. Diff. 
Edinburgh BCS 3347 3340 7   2575 2593 -18 
TEAM 7666 7644 22   9242 9281 -39 
NOTE. Difference (diff.) of continuous (cont.) minus categorical (cat.). 





Figure 6.1 Distribution of Mammostrat Score in the Edinburgh BCS and Team Cohorts.  
 
6.2.2.1 Staining Methodology 
Tissue microarray (TMA) is a recent innovation in the field of pathology that overcomes 
problems with standard histopathological techniques that they are time consuming and labour 
intensive and therefore costly. It is a robust method of tissue analysis, where a large number 
of patient samples can be examined in a short time using a minimum number of slides. The 
method was designed as a high-throughput molecular biology technique for researchers that 
allows for assessment of expression of interesting candidate disease related genes or gene 
products simultaneously on hundreds of tissue samples (Jawhar, 2009). It also allows parallel 
molecular profiling of clinical samples at the DNA, RNA, and protein level. In a TMA, 
cylinders of tissue are cored out of formalin-fixed, paraffin-embedded tissue blocks and slotted 
in a regular grid pattern into a blank recipient paraffin wax block. The TMA block is then cut 
using a standard laboratory microtome (Chandler et al., 2011). The number and size of cores 
in a TMA block can be varied from approximately forty 2 mm cores to hundreds of 0.6 mm 
cores. This technique enables pathologists to perform large-scale analyses using 
immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), or RNA in situ 
hybridization (ISH) at substantially faster and at markedly lower costs compared with 
conventional approaches (Skacel et al., 2002, Richani et al., 2006).   
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IHC refers to the process of detecting antigens (e.g., proteins) in cells of a tissue section by 
exploiting the principle of antibodies binding specifically to antigens in biological tissues 
(Ramos-Vara and Miller, 2014). It is widely used for diagnosis of cancers because specific 
tumour antigens are expressed de novo or up-regulated in certain cancers (Duraiyan et al., 
2012). FISH is a cytogenetic technique that can be used to visualize specific genes or portions 
of genes.  
IHC staining was performed for a panel of biomarkers including ER, PgR, HER2, Ki67, 
HTF9C, CEACAM5, NDRG1, p53 and SLC7A5 and FISH for HER2 was performed using 
either sextuplet (ER, PgR) or triplicate (all other markers) 0.6 mm2 TMA cores. Results were 
derived from dual scoring by expert observers (as described by Kirkegaard snd colleagues 
(Kirkegaard et al., 2006)) for the Edinburgh BCS cohort for all markers. For TEAM patients, 
ER, PgR and Ki67 scores were derived by quantitative image analysis using the Ariol system 
using algorithms validated against both whole sections and manual assessment (Bartlett et al., 
2011a, Faratian et al., 2009). Data for ER were recorded as a histoscore (Kirkegaard et al., 
2006) and for Ki67 and PgR as percentage positive cells (ATAC and Ki67 guidelines (Dowsett 
et al., 2011)). Results for HER2 were scored according to the UK guidelines (Bartlett et al., 
2011b, Walker et al., 2008) with cases regarded as HER2 amplified if any core showed 
amplification/overexpression. Positivity for p53, HTF9C (recently re-named TRIMT2A), 
CEACAM5, NDRG1, and SLC7A5 was recorded as previously described (Ring et al., 2006, 
Bartlett et al., 2010, Ross et al., 2008, Bartlett et al., 2012).   
6.2.3 Survival Outcome 
The primary end point selected for this study was time to distant recurrence (TTDR) as this is 
the event which drives subsequent death from breast cancer. TTDR was defined as the interval 
between operation (Edinburgh BCS) or randomisation (TEAM)  and distant metastasis (van 
de Velde et al., 2011) or death with evidence of recurrent breast cancer with patients censored 
at the time of last follow-up. 
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Of the 1,449 (ER-negative and ER-positive) patients in the Edinburgh BCS cohort, there were 
273 distant recurrences with a median follow-up of 12.9 years (max 25 years). Of the 6,120 
(ER-positive) patients in the TEAM cohort, with a recently updated clinical database, there 
were 770 distant recurrences with a median follow-up of 6.2 years (max 10 years). 
Similar TTDR was observed between the Edinburgh BCS and TEAM cohorts (Figure 6.2A) 
when including all patients with observed 10 year freedom from distant recurrence estimates 
of 83.3% (95% CI 81.2-85.2) and 80.5% (95% CI 77.5-83.2) respectively. Better survival was 
observed in the Edinburgh BCS cohort compared to the TEAM cohort when only ER-positive 
patients were considered (Figure 6.2B) with 10 year freedom from distant-recurrence estimates 
of 85.0% (95% CI 82.7-87.0) and 78.8% (95% CI 74.8-82.3) respectively. Longer follow-up 
was observed for the Edinburgh BCS cohort (Figure 6.2C) with observed 20 year freedom 
from distant recurrence estimates of 77.1% (95% CI 74.0-79.8) and 78.5% (95% CI 75.1-81.5) 
for all patients and ER-positive patients respectively. 
6.3 Patient Demographics 
Baseline characteristics of patients in both the Edinburgh BCS and TEAM cohorts are given 
in Table 6.2. The TEAM cohort is a higher risk population compared with the Edinburgh BCS 
cohort with higher mean tumour size (24mm vs 16mm respectively), a smaller proportion of 
low grade tumours (grade 1: 10% vs 27% respectively), higher proportion of node-positive 
pateints  ( 57% vs 23% respectively) and higher proportion of patients given chemotherapy 






Figure 6.2 Kaplan-Meier curves for time to distant recurrence. Plots represent (A) All patients in the Edinburgh 
BCS and TEAM cohorts up to 10 years follow-up, (B) ER-positive patients in the Edinburgh BCS and TEAM 
cohorts up to 10 years follow-up and (C) All patients and ER-positive patients in the Edinburgh BCS cohort with 




Table 6.2 Baseline Characteristics of Patients 
  Edinburgh BCS (n=1449)  TEAM (n=6120) 
  
n (%) 
mean (std. dev) or 
median (Q1-Q3) 
  n (%) 
mean (std. dev) or 
median (Q1-Q3) 
Age (Years) 1449 (100.0) 56.4 (10.1)   6120 (100%) 64.5 (8.9) 
Tumour size (cm) 1376 (95.0) 1.6 (0.7)   5760 (94.1%) 2.4 (1.3) 
Grade           
I 396 (27.3) -   616 (10.1) - 
II 664 (45.8) -   3168 (51.8) - 
III 352 (24.3) -   1835 (30.0) - 
Nodal Status           
Negative 1116 (77.0) -   2624 (42.9) - 
Positive 333 (23.0) -   3496 (57.1) - 
       
HER2 Status           
Negative 1190 (87.2) -   3825 (62.5) - 
Positive 175 (12.8) -   560 (9.2) - 
ER Status           
Negative 256 (17.7) -   41 (0.9) - 
Positive 1103 (76.1) -   4422 (99.1) - 
ER Histoscore 1360 (93.9) 87.5 (4.0-157.1)   4464 (72.9) 190.6 (159.6-212.5) 
PgR Histoscore 1355 (90.4) 116.3 (3.5-190.4)   4401 (71.9) 138.2 (26.1-197.0) 
PgR Percent 
Positive 984 (67.9) 63.9 (6.9-97.3)   4526 (74.0) 64.0 (13.0-86.6) 
Mammostrat Score           
Low 673 (46.5) -   1530 (25.0) - 
Medium 289 (19.9) -   896 (14.6) - 
High 254 (17.5) -   1160 (19.0) - 
IHC4 Score       
Low 41 (4.4) -  281 (6.6) - 
Medium 310 (33.3) -  2136 (49.9) - 
High 580 (62.3) -  1863 (43.5) - 
Treatment           
Exe NA -   3075 (50.3) - 
Tam & Exe NA -   3045 (49.8) - 
Chemotherapy           
No 1300 (89.7) -   3863 (63.1) - 
Yes 149 (10.3) -   2253 (36.8) - 
Note. Nodal status defined as negative when number of positive nodes equal zero and positive 
otherwise. ER Status defined as negative with an Allred score of zero and positive otherwise. 
Abbreviations: n, number; std. dev, standard deviation; Q, quartile; Exe, exemestane; Tam, tamoxifen; 






The distributions of the IHC4 and Mammostrat scores were different between the two cohorts, 
with the median IHC4 scores being 54 and 27 in the Edinburgh BCS and TEAM cohorts 
respectively (Figure 6.3). A larger proportion of patients (47%) were allocated to the low 




Figure 6.3 Distribution of IHC4 Score in the Edinburgh BCS and Team Cohorts, displaying quartiles (Q) 1 and 3 
and the median. 
 
6.4 Missing Data 
6.4.1 Edinburgh BCS Cohort 
The technical limitations of TMAs, such as loss of tissue cores during processing and the 
unreliability of IHC staining (Avninder et al., 2008), inevitably result in missing data. A large 
amount of data was missing (32.1%) for the PgR variable measured as percentage of positive 
cells.  Due to correlations between the missingness of TMA data and tumour characteristics 
such as size, complete case analysis would result in bias (Hoppin et al., 2002). Therefore, 
multiple imputation was performed. 
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6.4.1.1 Multiple Imputation 
We used the mi impute chained command in Stata to perform multiple imputation using 
chained equations (MICE) (Biagini et al., 1991) (Biagini et al., 1991) (Biagini et al., 1991) 
(Biagini et al., 1991) (Biagini et al., 1991) to generate 42 imputed datasets. Multiple 
imputation was performed using all predictors plus the outcome variable to avoid bias towards 
the null (White and Royston, 2009). This involves creating multiple copies of the data and 
imputing the missing values for each dataset with sensible values randomly selected from their 
predicted distribution. The number of imputed datasets was based on the rule of thumb 
suggested by White and colleagues that the number of imputations should be at least equal to 
the percentage of incomplete cases (see Table 6.3)(White et al., 2011). Data were available on 
the PgR variable measured as histoscores and due to the high correlation between the 
histoscores and percentage of positive cells, this variable was also included in the imputation 
model to improve the imputations and hence reduce the standard errors of the estimates in the 
analysis. The event indicator and the Nelson-Aalen estimator (see section 3.4) of the 
cumulative baseline hazard were included in the imputation model as recommended by White 
& Royston (White and Royston, 2009). The results from analyses on each of the imputed 
datasets were combined using Rubin’s rules (Rubin, 1987) which involves incorporating both 
the within and between imputation variability to produce estimates and confidence intervals 
that incorporate the uncertainty of imputed values. Suppose that ?̂?𝑗 is an estimate of a scalar 
quantity of interest (e.g. a regression coefficient) obtained from data set j (j=1,2,..,m) and 𝑈𝑗 
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Table 6.3 Information on Completeness of Data 
 
Statistics that cannot be combined using Rubin’s rules 
Regression coefficients can be combined easily across imputations using Rubin’s rules, 
however some statistics cannot and others require a transformation to ensure that they are 
approximately normally distributed. Provided by White and colleagues, Table 6.4 summarizes 
some common statistics which can and cannot be combined using Rubin’s rules (White et al., 
2011). 
Table 6.4 Statistics that can and connot be combined using Rubin’s rules 
 
No. Risk Factors* not 
recorded (per patient)
No. (%) of All 
Patients (n=1,449)











* Risk factors are ER, PgR, HER2, Ki67, SLC7A5, 
p53, NDRG1, HTF9C, CEACAM5, age, grade, 
size and nodal status. 
Statistics that can be combined without any 
transformation
Mean, proportion, regression coefficient, linear predictor, C-
index, area under the ROC curve
Statistics that may require sensible transformation 
before combination
Odds ratio, hazard ratio, baseline hazard, survival 
probability, standard deviation, correlation, proportion of 
variance explained, skewness, kurtosis
Statistics that cannot be combined
P-value, likelihood ratio test statistic, model chi-squared 




6.4.1.2 Distribution of Continuous Variables 
The first step is to assess the distribution of the continuous variables as an approximate normal 
distribution is required for imputation models. ER, PgR and Ki67 showed departures from 
normality (Figure 6.4A), however even after a shifted log transformation (Figure 6.4B) ER 
and PgR still did not satisfy the normality assumption due to the large number of zero values 
(and values of 100 for PgR measured as % positive cells).  
 
 
Figure 6.4 Distribution of the continuous covariates. Plots represent (A) Distribution of the continuous covariates 
with missing data and (B) Distribution of the transformed continuous covariates.  
 
 
The essence of the MICE algorithm is regression of an incomplete variable on other variables 
(Royston and White, 2011). A summary of the variables and their associated regression 
command is given in Table 6.5. The default method is logistic regression when there are two 
distinct values of the variable to be imputed, multinomial or ordinal logistic regression when 
there are 3-5 values and linear regression otherwise. To avoid values being predicted outside 
the possible range of values, truncated regression was used. Due to the problems with non-
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normal distributions of ER and PgR even after transformation, predictive mean matching 
(PMM) was also considered as the imputation method. PMM imputes missing values of a 
continuous variable z such that imputed values are sampled only from the observed values of 
z by matching predicted values as closely as possible. The resulting distribution of imputed z 
often closely matches that of observed z. 





6.4.1.3 Non-Linear Terms 
Another issue to consider is non-linear covariate effects as they cannot be correctly assessed 
if they have not been included in the imputation model.  
A starting point to determine the functional form of the continuous variables involves the use 
of Martingale residuals defined in section 3.5. Plotting the martingale residuals from the null 
model against the continuous covariates can give an indication of the functional form of the 
Variable Type Levels/Range (min-max) % missing Imputation Method
ER Histoscore Continuous 0-300 6.1 truncated regression/pmm
PgR Histoscore Continuous 0-300 6.5 truncated regression/pmm
PgR % Pos. Cells Continuous 0-100 32.1 pmm
HER2 Binary 2 5.8 logistic
Ki67 % Pos Cells Continuous 0-100 7.7 truncated regression
SLC7A5 Binary 2 8.8 logistic
CEACAM5 Binary 2 9.2 logistic
NDRG1 Binary 2 8.8 logistic
HTF9C Binary 2 8.7 logistic
p53 Binary 2 10.3 logistic
Age Continuous 24-91 0 NA
Tumour Size (mm) Continuous 1-60 5 linear regression
Tumour Grade Ordinal 3 0.8 ordinal
No. Positive Nodes Continuous 0-28 0 NA
Survival Outcomes included in imputation model
Event Indicator Event/Censored 0 NA
   Nelson-Aalen estimator of the cumulative baseline hazard 0 NA
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covariate, a linear effect when the fitted smooth curve is flat. The plots (Figure 6.5) indicate a 
strong non-linear functional form for tumour size and number of positive nodes as well as a 
slight non-linear functional form for age.  
Fractional polynomials were then used to determine the transformation which best modelled 
the non-linear effect in a complete case analysis, based on the model with the lowest deviance 
(defined as minus twice the log likelihood). The addition of non-linear effects significantly 
improved the fit of the model for tumour size and number of positive nodes, with the effects 
on the log-hazard displayed in Figure 6.6.  
The transformed tumour size and number of positive nodes were included in the imputation 
model. If any convincing non-linear terms were found in the analysis of the imputed data, the 
imputations would be re-created including the non-linear terms. However, no further non-






Figure 6.5 Plots of martingale residuals versus continuous covariates. The red line is a smoothed curve produced 
by locally weighted regression. 
 
  
Figure 6.6 Comparison of linear and non-linear effects. Plots represent linear (solid line) and non-linear (dashed 





6.4.1.4 Comparison between observed and imputed values 
We compared the observed and imputed data for continuous variables using box plots over the 
imputations (Figure 6.7). For variables satisfying the normality assumption (transformed Ki67 
and tumour size), similar distributions were observed between observed and imputed values. 
ER and PgR histoscores have skewed distributions, with a large number of zero values and 
using truncated regression has resulted in differences in the distribution between the observed 
and imputed values. The imputation of ER and PgR histoscores was also considered using 
PMM (Figure 6.8). This resulted in more similar distributions between the observed and 
imputed values but still some variation in the median values, especially for PgR histoscores. 
Some differences are to be expected however, as the data are assumed to be missing at random 
(MAR) and therefore any systematic difference between the missing values and the observed 
values can be explained by differences in the observed data (Sterne et al., 2009).  
For categorical variables, we compared the observed and imputed data using frequency tables 
(Figure 6.9). In the majority of imputations a smaller number of patients were predicted to be 
biomarker positive than in the observed data, however quite large variation was observed.  
When performing a univariate Cox regression analysis of IHC4 score on TTDR, similar 
estimated coefficients were observed between a complete case analysis and analysis on 
imputed data (Table 6.6). The imputed analysis had a reduced standard error (0.22 versus 0.19 
respectively) as expected due in part to the larger sample size. A very small difference was 
observed in the estimated coefficient when imputing IHC4 using regression for ER histoscores 
compared to PMM (0.52 versus 0.53), with PMM giving a closer estimate to that of a complete 
case analysis. A larger difference in the estimated coefficient for Mammostrat score from a 
complete case analysis compared to an analysis on imputed data was observed (0.90 versus 
0.97). However the standard error was not reduced, possibly due to the large variation between 






Figure 6.7 Comparison of Observed (0) and Imputed (1-42) data for continuous variables. Imputation methods: 
regression for ER and PgR histoscores, Ki67 and tumour size. Predictive mean matching for PgR % positive cells. 
  
Figure 6.8 Comparison of observed (0) versus imputed (1-42) data using predictive mean matching (PMM) for 





Figure 6.9 Comparison of observed (0) versus imputed (1-42) data for categorical variables. Vertical (red) line 


























































































































































































































































































Table 6.6 Estimated coefficients from a univariate Cox regression of IHC4 and Mammostrat score from a complete 
case analysis and different imputation procedures. 
  IHC4   Mammostrat 
Imputation Procedure Estimate Standard Error   Estimate Standard Error 
Complete Case 0.54 0.22   0.90 0.15 
Regression 0.52 0.19   0.97 0.15 
PMM 0.53 0.19   0.96 0.15 
Note. Estimates represent coefficients calculated between the IQR of the continuous IHC4 
score and high risk compared to low risk as categorised by the Mammostrat score. 
Abbreviations: IQR, interquartile range; PMM, predictive mean matching. 
 
 
6.4.2 TEAM Cohort 
Five of nine countries that participated in the TEAM trial (6,120 randomised patients) provided 
tumour samples for pathology sub-studies. Tissue blocks were received at a central laboratory 
and 4,598 were suitable for TMA construction. Patient tumour characteristics were similar 
among samples from the analysed pathology subset and in all patients from countries 
participating in the pathology substudy (Bartlett et al., 2011a). Multiple imputation was not 
performed on the TEAM cohort due to the large number of patients still available for analysis 
and the difficulties with some patients having no biomarker data at all.  
6.5 Software 











Chapter 7:  Analysis of IHC4 and Mammostrat 
7.1 Introduction 
In this chapter we compare the two prognostic IHC biomarker panels, IHC4 and Mammostrat, 
to determine which provides more information on the risk of recurrence in the context of 
additional clinical factors or whether combining both approaches would increase the 
information available to patients and clinicians.  
This chapter will focus on fitting the standard Cox proportional hazards model and assessing 
the validity of the model assumptions.  
7.2 Methods 
7.2.1 Materials 
The Edinburgh BCS and TEAM cohorts will be used as described in chapter 6.  
7.2.1.1 Clinical subgroups of interest  
The primary analysis was based on ER-positive patients treated with adjuvant endocrine 
therapy only (without chemotherapy) (Figure 7.1). Secondary analysis was performed on all 
ER-positive patients irrespective of treatment. Exploratory analyses were performed on node-
negative and node-positive ER-positive patients treated with adjuvant endocrine therapy 
(without chemotherapy) and node-positive ER-positive patients irrespective of treatment. 
Kaplan-Meier curves for the clinical subgroups are displayed in Figure 7.2. 























Figure 7.1 Clinical subgroups of interest for (A) Edinburgh BCS cohort. 
Data Available for 
Current Study 
(n=1,449) 
ER-Negative Patients (n=256) 
ER-Status Missing (n=90) 
ER-Positive Patients 
(n=1,103) 
ER-Positive, Treated with Chemo 
and Endocrine Therapy (n=97) 
ER-Positive, No Treatment (n=175) 
ER-Positive, Treated 
with Endocrine Therapy 
Only (n=831) 
ER-Positive, Treated with 
Endocrine Therapy only and 
Node-Positive (n=174) 
ER-Positive, Treated 
with Endocrine Therapy 




























Figure 7.1 Clinical subgroups of interest for (B) the TEAM cohort. 
 
Data Available for 
Current Study 
(n=6,120) 
Patients with missing data on 
Mammostrat and IHC4 (n=2354) 
ER-Positive Patients 
(n=3,766) 
ER-Positive, Treated with Chemo 
and Endocrine Therapy (n=1,253) 
ER-Positive, Treated 
with Endocrine Therapy 
Only (n=2,531) 
ER-Positive, Treated with 
Endocrine Therapy only and 
Node-Positive (n=1,296) 
ER-Positive, Treated 
with Endocrine Therapy 





Figure 7.2 Kaplan-Meier curves for time to distant recurrence for clinical subgroups. Plots represent (A) Edinburgh 
BCS with 10 year follow-up, (B) TEAM cohort with 10 year follow-up and (C) Edinburgh BCS cohort with full 
follow-up. Groups represent: All ER-positive patients (ER+); ER-positive patients treated with endocrine therapy 
only (ER+, ET); ER-positive patients treated with endocrine therapy only and either node-negative (ER+, ET, N-) 





Figure 7.2 (Continued) Kaplan-Meier curves for time to distant recurrence for clinical subgroups. Plots represent 
(A) Edinburgh BCS with 10 year follow-up, (B) TEAM cohort with 10 year follow-up and (C) Edinburgh BCS 
cohort with full follow-up. Groups represent: All ER-positive patients (ER+); ER-positive patients treated with 
endocrine therapy only (ER+, ET); ER-positive patients treated with endocrine therapy only and either node-
negative (ER+, ET, N-) and node-positive (ER+, ET, N+); and ER-positive, node-positive patients irrespective of 














Table 7.1 Baseline characteristics of patients in the analysis set 
  ER-Positive Patients 
  Edinburgh BCS (n=1103)  TEAM (n=3766) 
  
n (%) 
mean (std. dev) or 
median (Q1-Q3) 
  n (%) 
mean (std. dev) or 
median (Q1-Q3) 
Age (Years) 1103 (100.0) 56.5 (9.9)   3766 (100.0) 65.1 (9.0) 
Tumour size (cm) 1103 (100) 1.6 (0.7)   3657 (97.1) 2.4 (1.3) 
Grade           
I 354 (32.1) -   391 (10.4) - 
II 542 (49.1) -   1901 (50.5) - 
III 207 (18.8) -   1249 (33.2) - 
Nodal Status           
Negative 843 (76.4) -   1528 (40.6) - 
Positive 260 (23.6) -   2229 (59.2) - 
       
HER2 Status           
Negative 933 (84.6) -   3259 (86.5) - 
Positive 170 (15.4) -   507 (13.5) - 
ER Status           
Negative 0 (0.0) -   38 (1.0) - 
Positive 1103 (100.0) -   3728 (99.0) - 
ER Histoscore 1103 (100.0) 117.1 (37.9-164.6)   3766 (100.0) 191.2 (161.4-213.1) 
PgR Histoscore 1103 (100.0) 140.0 (23.2-195.7)   3766 (100.0) 138.6 (22.9-197.3) 
PgR Percent 
Positive 1103 (100.0) 56.1 (4.2-96.4)   3766 (100.0) 65.7 (12.1-87.5) 
Mammostrat Score           
Low 704 (63.8) -   1606 (42.6) - 
Medium 246 (22.4) -   942 (25.0) - 
High 152 (13.8) -   1218 (32.3) - 
IHC4 Score 1103 (100.0) 44 .4 (12.1-78.1)   3766 (100.0) 26.9 (-0.7-64.7) 
Low 63 (5.7)   239 (6.4)  
Medium 424 (38.4)   1889 (50.2)  
High 616 (55.9)   1638 (43.5)  
Treatment           
Exe NA -   1889 (50.2) - 
Tam & Exe NA -   1877 (49.8) - 
Chemotherapy           
No 1006 (91.2) -   2512 (66.7) - 
Yes 97 (8.8) -   1253 (33.3) - 
Note. Nodal status defined as negative when number of positive nodes equal zero and positive 
otherwise. ER Status defined as negative with an Allred score of zero and positive otherwise. TEAM 
cohort refers to the subset with IHC4 and Mammostrat data. Abbreviations: n, number; std. dev, 




7.2.2 Statistical Analysis 
The primary end point was time to distant recurrence (TTDR) as this is the event which drives 
subsequent death from breast cancer. TTDR was defined as the time to distant metastasis (van 
de Velde et al., 2011) or death with evidence of recurrent breast cancer with patients censored 
at the time of last follow-up. 
Firstly the survival curves were computed for the scores using the Kaplan-Meier product limit 
estimator. 
Cox proportional hazards regression was performed and the added value of the addition of 
either IHC4 or Mammostrat scores or both to clinical factors was assessed using Wald tests.  
The functional form of the continuous covariates on the log-hazard was investigated using the 
multivariable fractional polynomial (MFP) algorithm (Royston and Altman, 1994), step one 
in the MFPT approach described in section 4.4.4, using the Stata mfp command, which selects 
the fractional polynomial (FP) model that best predicts the outcome variable. Assessment of 
the proportional hazards model was assessed using Schoenfeld residuals and the Grambsch-
Therneau test.  
The predictive performance of the IHC4 and Mammostrat risk scores along with conventional 
clinical risk factors was assessed using measures of calibration and discrimination, two 
fundamental measures of evaluating model performance as stated by Royston and Altman 
(Royston and Altman, 2013).  
Model calibration refers to how closely the estimates of survival from the model agree with 
the survival from the observed data (Altman et al., 2009, Moons et al., 2009). This was 
assessed for each decile of predicted risk, ensuring 10 equally sized groups, by producing a 
calibration plot (observed versus predicted probabilities of 5 year distant recurrence) and 
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calculating the calibration slope. An estimate of the baseline hazard function from the original 
study is not available and therefore a strict assessment of calibration is not possible.  
Discrimination is the ability of a risk score to differentiate between patients who do and do not 
experience an event during the study period (McGeechan et al., 2008, Altman et al., 2009). 
However the degree of separation is hard to assess, with several measures available but not 
one seems to be universally accepted. Some recent descriptions and comparisons of measures 
are given by Choodari-Oskooei and Hielscher (Hielscher et al., 2010, Choodari-Oskooei et al., 
2012). We are going to focus on Royston & Sauerbrei’s R2 statistic based on their index of 
discrimination (D)(Royston and Sauerbrei, 2004). The D statistic measures prognostic 
separation of survival curves, and is closely related to the standard deviation of the prognostic 
index (or risk score). It is computed by ordering the prognostic index (PI) across patients, 
calculating the rankits (expected standard normal order statistics) corresponding to these 
values, dividing the latter by a factor 𝑘 = √8 𝜋⁄ ≈ 1.596 and performing Cox regression on 
the scaled rankits. The resulting regression coefficient is D. The conversion to 𝑅𝐷





𝜎2 + 𝐷2 𝑘2⁄
    , 7.1.  
where 𝜎2 = 𝜋2 6⁄ ≈ 1.645. A difference in D of at least 0.1 may be needed to see any 
important difference in separation between the relevant survival curves.  
7.3 Results 
Data were available on 1,103 ER-positive patients with 192 distant recurrences from the 
Edinburgh BCS cohort (median follow-up of 12.2 years) and on 3,766 ER-positive patients 
with 548 distant recurrences from the TEAM cohort (median follow-up of 6.2 years). See 






Table 7.2 Information on number of patients, number of events and median survival time for patient subgroups 
 
7.3.1 Kaplan-Meier Estimates of TTDR 
Lower scores for IHC4 and Mammostrat are associated with better TTDR survival than higher 
scores in both the Edinburgh BCS and TEAM cohorts for ER-positive patients treated with 
endocrine therapy only and all ER-positive patients irrespective of treatment (Figure 7.3) as 
well as for the exploratory subgroups (Figure 7.4). Less separation of the survival curves were 
seen for those categorised as medium and high risk according to the Mammostrat score in the 
Edinburgh BCS cohort. The cut-points from the original study of IHC4 did not validate well, 
allocating a small proportion of patients to low risk in both cohorts (5.7% and 6.3% of all ER-
positive patients in the Edinburgh BCS and TEAM cohorts respectively). The 5-year TTDR 
estimates were similar between studies and 15 year TTDR estimates were only available for 
the Edinburgh BCS cohort (Table 7.3). 
 
Patient Subgroup N No. Events
Median 
Survival Time 




All ER-Positive 1,103 192 12.2 3,766 548 6.2
ER-Positive treated with Endocrine Therapy Only 831 142 12.2 2,513 316 6.2
ER-Positive, Endocrine Only and Node-Negative 657 92 12.6 1,208 104 6.4
ER-Positive, Endocrine Only and Node-Positive 174 50 11.0 1,296 212 6.0





Figure 7.3 Kaplan-Meier curves for time-to distant recurrence up to 10 years for the IHC4 score (solid lines) and 
Mammostrat score (dashed lines). Plots represent ER-positive patients treated with endocrine therapy only (A and 






































116 109(7) 99(7) 91(7) 85(3) 77(5)MAM High
190 174(11) 165(7) 154(10) 147(5) 132(6)MAM Med
525 518(5) 494(14) 473(10) 446(13) 405(5)MAM Low
434 411(19) 390(17) 365(18) 341(15) 311(7)IHC4 High
340 333(4) 312(11) 299(7) 285(5) 259(6)IHC4 Med
57 57(0) 56(0) 54(2) 52(1) 44(3)IHC4 Low
No. at Risk (No. Events)















































796 749(36) 649(62) 445(20) 201(17) 5(6)MAM High
595 557(24) 519(21) 346(21) 133(6) 6(3)MAM Med
1122 1061(27) 980(37) 647(16) 259(14) 14(6)MAM Low
1044 966(57) 852(71) 575(33) 236(19) 6(7)IHC4 High
1301 1242(29) 1146(46) 772(22) 330(16) 15(8)IHC4 Med
168 159(1) 150(3) 91(2) 27(2) 4(0)IHC4 Low
No. at Risk (No. Events)















































152 142(10) 131(8) 123(7) 117(3) 104(6)MAM High
247 225(14) 211(11) 189(16) 180(7) 157(6)MAM Med
704 693(6) 656(24) 631(14) 596(21) 542(5)MAM Low
616 581(26) 543(31) 509(24) 481(19) 433(8)IHC4 High
424 416(4) 393(12) 375(10) 356(10) 323(6)IHC4 Med
63 63(0) 62(0) 59(3) 56(2) 47(3)IHC4 Low
No. at Risk (No. Events)














































1218 1125(75) 984(98) 668(41) 303(30) 9(6)MAM High
942 879(43) 820(38) 531(46) 205(13) 10(6)MAM Med
1606 1526(41) 1420(52) 940(30) 382(22) 20(7)MAM Low
1638 1504(106) 1333(120) 882(73) 380(34) 15(9)IHC4 High
1889 1799(51) 1676(62) 1121(38) 465(29) 20(10)IHC4 Med
239 227(2) 215(6) 136(6) 45(2) 4(0)IHC4 Low
No. at Risk (No. Events)














Figure 7.4 Kaplan-Meier curves for time-to distant recurrence (exploratory subgroups) up to 10 years for the IHC4 
score (solid lines) and Mammostrat score (dashed lines). Plots represent ER-positive patients treated with endocrine 
therapy only and either node-negative (A and B) or node-positive (C and D) and ER-positive, node-positive patients 











































91 88(3) 82(5) 76(5) 72(1) 65(5)MAM High
153 144(6) 137(6) 129(7) 126(2) 113(4)MAM Med
413 409(3) 395(8) 381(7) 363(7) 336(3)MAM Low
350 337(11) 321(14) 300(16) 283(10) 262(6)IHC4 High
262 259(1) 249(5) 242(3) 235(0) 215(4)IHC4 Med
45 45(0) 44(0) 44(0) 43(0) 37(2)IHC4 Low
No. at Risk (No. Events)















































432 414(14) 367(28) 250(10) 113(5) 1(3)MAM High
277 264(6) 252(4) 181(7) 78(3) 3(1)MAM Med
499 480(8) 459(9) 329(2) 122(4) 3(0)MAM Low
544 519(18) 475(28) 331(13) 130(5) 3(3)IHC4 High
599 579(9) 544(13) 389(5) 169(7) 3(1)IHC4 Med
65 60(1) 59(0) 40(1) 14(0) 1(0)IHC4 Low
No. at Risk (No. Events)















































25 21(4) 17(2) 15(2) 13(2) 12(0)MAM High
37 30(5) 28(1) 25(3) 21(3) 19(2)MAM Med
112 109(2) 99(6) 92(3) 83(6) 69(2)MAM Low
84 74(8) 69(3) 65(2) 58(5) 49(1)IHC4 High
78 74(3) 63(6) 57(4) 50(5) 44(2)IHC4 Med
12 12(0) 12(0) 10(2) 9(1) 7(1)IHC4 Low
No. at Risk (No. Events)














































363 334(22) 281(34) 194(10) 88(12) 4(3)MAM High
316 292(18) 266(17) 165(14) 55(3) 3(2)MAM Med
617 575(19) 515(28) 313(14) 135(10) 11(6)MAM Low
498 445(39) 375(43) 243(20) 106(14) 3(4)IHC4 High
696 657(20) 596(33) 378(17) 159(9) 12(7)IHC4 Med
102 99(0) 91(3) 51(1) 13(2) 3(0)IHC4 Low
No. at Risk (No. Events)














































40 34(6) 29(3) 27(2) 25(2) 21(1)MAM High
55 46(6) 43(2) 37(4) 31(5) 24(2)MAM Med
165 161(3) 147(10) 138(5) 129(6) 108(2)MAM Low
137 122(12) 112(8) 107(3) 99(6) 80(2)IHC4 High
108 104(3) 92(7) 82(6) 74(6) 64(2)IHC4 Med
15 15(0) 15(0) 13(2) 12(1) 9(1)IHC4 Low
No. at Risk (No. Events)














































672 606(54) 525(59) 360(26) 162(22) 7(3)MAM High
570 524(35) 479(32) 296(38) 102(9) 5(3)MAM Med
987 929(32) 851(39) 530(26) 228(18) 14(7)MAM Low
937 834(82) 721(79) 461(54) 204(26) 8(5)IHC4 High
1135 1072(39) 992(45) 640(31) 260(21) 15(8)IHC4 Med
157 153(0) 142(6) 85(5) 28(2) 3(0)IHC4 Low
No. at Risk (No. Events)












Table 7.3 Five and Fifteen-year freedom from distant recurrence estimates stratified by IHC4 and Mammostrat 
scores 
    All ER-Positive   ER-Positive Endocrine Onlya 
  
Edinburgh BCS 
(n=1,103)   
TEAM        
(n=3,766)   
Edinburgh BCS 
(n=831)   
TEAM         
(n=2,513) 
5-Year                 
IHC4 L   96.7 (87.7-99.2)   96.0 (92.5-97.9)   98.2 (88.0-99.8)   96.8 (92.5-98.7) 
IHC4 M   94.9 (92.3-96.7)   92.4 (91.1-93.6)   94.0 (90.8-96.1)   92.9 (91.3-94.2) 
IHC4 H   87.7 (84.8-90.1)   83.1 (81.2-84.9)   88.6 (85.1-91.2)   85.3 (83.0-87.4) 
Mam L   94.4 (92.4-95.8)   92.9 (91.5-94.1)   94.8 (92.5-96.4)   93.4 (91.7-94.7) 
Mam M   84.9 (79.6-88.8)   88.0 (85.7-90.0)   86.4 (80.6-90.6)   89.5 (86.7-91.8) 
Mam H   85.4 (78.7-90.2)   83.4 (81.1-85.4)   84.3 (76.3-89.8)   85.6 (82.9-87.9) 
15-Year                 
IHC4 L   79.3 (65.1-88.3)   NA   81.1 (66.1-89.9)   NA 
IHC4 M   84.5 (79.8-88.2)   NA   85.8 (80.7-89.6)   NA 
IHC4 H   78.8 (75.1-82.0)   NA   78.3 (73.8-82.1)   NA 
Mam L   85.0 (81.7-87.8)   NA   85.9 (82.0-89.0)   NA 
Mam M   72.5 (65.7-78.2)   NA   73.7 (65.9-80.0)   NA 
Mam H   75.0 (66.8-81.4)   NA   73.3 (64.1-80.5)   NA 
NOTE. Freedom from DR estimates with 95% CIs for patients with low (L), medium (M) 
or high (H) risk as stratified by IHC4 or Mammostrat scores. Abbreviations: DR, distant-
recurrence; CI, confidence interval; IHC4, IHC4 score; Mam, Mammostrat score; NA, not 
applicable. aEndocrine only, patients treated with adjuvant endocrine therapy without 
adjuvant chemotherapy  
 
7.3.2 Classification of patients according to IHC4 and Mammostrat score 
Table 7.4 illustrates the classification of all ER-positive patients according to the prognostic 
scores. Agreement in classification was only seen in 251 of 1,103 patients (23%) in the 
Edinburgh BCS cohort and 1,291 of 3,766 patients (34%) in the TEAM cohort. The largest 
proportion of patients were classified as low Mammostrat and either medium or high IHC4 
score (60% and 40% in the Edinburgh BCS and TEAM cohorts respectively) with 11 and 18% 
classified as high Mammostrat and high IHC4 in the Edinburgh BCS and TEAM cohorts 
respectively. Figure 7.5 illustrates the Kaplan-Meier estimates of TTDR for different risk 
categories assigned by the two scores by collapsing the low and intermediate ICH4 score to 
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low risk and intermediate and high Mammostrat score to high risk. Good separation between 
the curves is observed, with having an overall low score (IHC4 and Mammostrat  




Figure 7.5 Kaplan-Meier curves for TTDR for IHC4 score vs Mammostrat score. Plots represent all ER-positive 
patients in the (A) Edinburgh BCS and (B) TEAM cohorts. Categorisations refer to: IHC4 Low (low/intermediate 
risk); IHC4 High (high risk); Mam Low (low risk); Mam High(intermediate/high risk). 
 
low risk) associated with better TTDR than an overall high score (ICH4 and Mammostrat high 
risk). Discordant scores (low risk IHC4 and high risk Mammostrat and vice versa) have more 
similar outcomes. This potentially identifies three risk groups from a combined IHC4 and 
Mammostrat risk score. 
7.3.3 Assumption of Linearity 
The functional form of the continuous covariates was investigated using step 1 of the MFPT 
approach described in section 4.4.4. The MFP algorithm identified tumour size and number of 
IHC4 L M H L M H
L 48 (4.4) 11 (1.0) 4 (0.4) 134 (3.6) 51 (1.4) 54 (1.4)
M 305 (27.7) 87 (7.9) 32 (2.9) 944 (25.1) 469 (12.5) 476 (12.6)
H 351 (31.8) 149 (13.5) 116 (10.5) 528 (14.0) 422 (11.2) 688 (18.3)
Note: Values represent number (percentage of total) for each combination of IHC4 and 







































265 241(20) 224(15) 201(18) 194(6) 171(7)IHC4 H \ MAM H
351 340(6) 319(16) 308(6) 287(13) 262(1)IHC4 H \ MAM L
134 126(4) 118(4) 111(5) 103(4) 90(5)IHC4 L \ MAM H
353 353(0) 337(8) 323(8) 309(8) 280(4)IHC4 L \ MAM L
No. at Risk (No. Events)
0 2 4 6 8 10
Time(years)
IHC4 Low \ MAM Low
IHC4 Low \ MAM High
IHC4 High \ MAM Low







































1110 1007(85) 880(95) 581(57) 251(26) 7(8)IHC4 H \ MAM H
528 497(21) 453(25) 301(16) 129(8) 8(1)IHC4 H \ MAM L
1050 997(33) 924(41) 618(30) 257(17) 12(4)IHC4 L \ MAM H
1078 1029(20) 967(27) 639(14) 253(14) 12(6)IHC4 L \ MAM L
No. at Risk (No. Events)
0 2 4 6 8 10
Time(years)
IHC4 Low \ MAM Low
IHC4 Low \ MAM High
IHC4 High \ MAM Low




positive nodes to have non-linear effects on the log-hazard in both the Edinburgh BCS and 
TEAM cohorts (Figure 7.6). The plots show the unrealistic estimated hazard ratio for 
increasing tumour size and number of positive nodes if a linear effect on the log-hazard is  
 
 
Figure 7.6 Results of the MFP algorithm along with plots of the linear and non-linear effects of tumour size and 
number of positive nodes in the (A) Edinburgh BCS and (B) TEAM cohorts.  
  
assumed. The FP1 model was not statistically significantly different from the FP2 model and 
therefore the simpler FP1 transformations were chosen to model the effects of tumour size and 
number of positive nodes. This was true except for the number of positive nodes in the TEAM 
cohort where the FP2 model was chosen, however the FP2 model results in a clinically 
unrealistic decrease in hazard for higher values of number of positive nodes and suggests an 
over-fitting of the data. This is due to the skewed distribution of the number of positive nodes 
and highlights the need for an initial exploration of the functional form with the use of 
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martingale residuals (Figure 7.7). FP1 transformations of tumour size and number of positive 
nodes will be used in all further analyses.  
 
Figure 7.7 Plot of martingale residuals versus number of positive nodes for all ER-positive patients in the TEAM 
cohort. The red line is a smoothed curve produced by locally weighted regression. 
7.3.4 Comparison of IHC4 and Mammostrat 
7.3.4.1 Separate analysis of scores 
Both scores were significant independent predictors of outcome when analysed in separate 
multivariate regression (Table 7.5 and Table 7.6) with other recognised prognostic factors 
(histologic grade, tumour size, age, number of positive nodes, treatment and chemotherapy) 
for all ER-positive patients and ER-positive patients treated with endocrine therapy only in the 
TEAM cohort. In this cohort, the IHC4 score provided more prognostic information beyond 
that of clinical factors compared to the Mammostrat score  (increase in R2: 3.3% vs 1.4% and 
D-statistic: 0.11 vs 0.05 for ER-positive patients treated with endocrine therapy only and 
increase in R2: 3.5% vs 2.2% and D-statistic: 0.11 vs 0.07 for all ER-positive patients).  
In the Edinburgh BCS cohort, the Mammostrat score was the stronger predictor of outcome 
with the prognostic information added by the IHC4 score being not statistically significant 
(HR (95% CI): 1.02 (0.99-1.05), p-value 0.1) and resulted in a negligible increase in R2 and 
D-statistic of 0.6% and 0.02 respectively for all ER-positive patients treated with endocrine 
therapy only.  
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The Mammostrat score did not provide independent information regarding the risk of TTDR 
for any of the exploratory subgroups in the Edinburgh BCS cohort, although the small sample 
sizes should be noted: node-negative (n=657) and node-positive (n=174) ER-positive patients 
treated with endocrine therapy only and node-positive ER-positive patients irrespective of 
treatment (n=260) (Table 7.7 and Table 7.8). However, the IHC4 score was a predictor of 
outcome for ER-positive node-negative patients treated with endocrine therapy only (n=657) 
(p-value: <0.01; increase in R2: 2.7% and D-statistic: 0.09).   
Despite not adding statistically significant information based on the Wald test, possibly due to 
the small sample size of ER-positive, node-positive patients treated with endocrine therapy 
only (n=174), the addition of IHC4 to clinical factors statistically improved the ability to 
discriminate between events and non-events (increase in R2: 3.7% and D-statistic: 0.12). In the 
TEAM cohort, both scores remained significant predictors of outcome in multivariate analysis 
for all exploratory subgroups except for the Mammostrat score in ER-positive, node-positive 
patients treated with endocrine therapy only (n=1,296) which was not statistically significant 
(HR (95% CI) MvL : 1.16 (0.81-1.68); HvL : 1.18 (0.83-1.67); p-value 0.2), and provided only 
a small increase in model performance (increase in R2: 0.5% and D-statistic: 0.02).  
Good agreement between observed and predicted risk of TTDR was seen in the TEAM cohort 
with no clear trend in improvement when adding either score to clinical factors (Figure 7.8). 
In the Edinburgh BCS cohort, the models under-estimated then over-estimated the risk of 
distant recurrence at 5 years when the observed risk was less than or greater than 10% 
respectively.  This suggests the models tend to under-predict risk in the low-risk groups and 
over-predict risk in the high-risk groups. However, the addition of Mammostrat score to 
clinical factors improved the calibration compared with the IHC4 score.
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Table 7.5 Multivariate Cox regression of IHC4 score and Mammostrat score 
  All ER-Positive   ER-Positive Endocrine Only 
  
Edinburgh BCS 
(n=1,103)   
TEAM                  
(n=3,766)   
Edinburgh BCS 
(n=831)   
TEAM                  
(n=2,513) 
Main Effect HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Separate*               
IHC4 1.02 (0.99-1.05)   1.06 (1.05-1.08)   1.03 (0.99-1.06)   1.06 (1.04-1.09) 
MvL 1.59 (1.13-2.24)   1.42 (1.12-1.81)   1.64 (1.10-2.44)   1.28 (0.94-1.75) 
HvL 1.31 (0.86-2.00)   1.89 (1.52-2.36)   1.44 (0.90-2.31)   1.57 (1.18-2.07) 
Combined*               
IHC4 1.02 (0.99-1.05)  1.06 (1.04-1.07)  1.02 (0.99-1.06)  1.06 (1.03-1.08) 
MvL 1.56 (1.11-2.20)   1.34 (1.05-1.71)   1.63 (1.09-2.43)   1.19 (0.87-1.63) 
HvL 1.21 (0.78-1.88)   1.67 (1.34-2.10)   1.33 (0.81-2.17)   1.35 (1.01-1.81) 
NOTE. Multivariate analysis for Mammostrat score and IHC4 entered separately or simultaneously 
(combined analysis) into a Cox regression model. Values represent hazard ratios and 95% CIs for 
risk of TTDR calculated as a ten-unit increase in  IHC4 score and either high-risk or moderate-risk 
Mammostrat score compared with low Mammostrat scores at baseline for all ER-positive patients 
and ER-positive patients who received no chemotherapy in the Edinburgh BCS and TEAM cohorts. 
Abbreviations: TTDR, time-to distant recurrence; CI, confidence interval; HvL, high risk v low risk 
Mammostrat  score; MvL, moderate risk v low risk Mammostrat score. *Adjusted for age, grade, 










Table 7.6 Wald tests and performance data for assessing the amount of information added by the IHC4 score or the Mammostrat score or both to clinical factors 
  Edinburgh BCS    TEAM 
Model 
Wald test       
(p-value) 
Increase 
in R2 (%) 
Increase 
in D 
Statistic   
Wald test           
(p-value) 
Increase 




All ER-Positive (n=1,103)   (n=3,766) 
C vs. Null (7 df) 13.1 (<0.001) 24.0 1.15   326.1 (<0.001) 27.5 1.26 
C + IHC4 vs. C (1 df) 2.6 (0.1) 0.5 0.01   56.1 (<0.001) 3.5 0.11 
C + Mam vs. C (2 df) 3.6 (0.03) 1.4 0.04   32.5 (<0.001) 2.2 0.07 
C + IHC4 + Mam vs. C (3 df) 3.0 (0.03) 1.8 0.06   76.4 (<0.001) 4.8 0.15 
C + IHC4 + Mam vs. C + IHC4 (2 df) 3.3 (0.04) 1.3 0.04   20.3 (<0.001) 1.3 0.04 
C + IHC4 + Mam vs. C + Mam (1 df) 1.9 (0.2) 0.4 0.01   42.3 (<0.001) 2.6 0.08 
ER-Positive Endocrine Only (n=831)   (n=2,513) 
C vs. Null (6 df) 16.1 (<0.001) 25.7 1.20   217.3 (<0.001) 29.5 1.33 
C + IHC4 vs. C (1 df) 2.5 (0.11) 0.6 0.02   30.1 (<0.001) 3.3 0.11 
C + Mam vs. C (2 df) 3.1 (0.04) 1.4 0.05   9.9 (0.007) 1.4 0.05 
C + IHC4 + Mam vs. C (3 df) 2.7 (0.04) 2.2 0.07   34.4 (<0.001) 3.8 0.12 
C + IHC4 + Mam vs. C + IHC4 (2 df) 2.9 (0.06) 1.6 0.05   4.2 (0.12) 0.5 0.02 
C + IHC4 + Mam vs. C + Mam (1 df) 1.9 (0.17) 0.8 0.02   23.6 (<0.001) 2.4 0.08 
NOTE. Values represent Wald tests (significance level) and the increase in R2 and D statistic for the addition of IHC4 or 
Mammostrat score or both with a difference in D of at least 0.1 indicating improved prognostic separation. Results are given for 
ER-positive patients and ER-positive patients who received no chemotherapy in the Edinburgh BCS and TEAM cohorts. 
Abbreviations: C, clinical model with age, grade, tumour size, nodes positive, treatment and chemotherapy; Null, null model 







Table 7.7 Multivariate Cox regression of IHC4 score and Mammostrat score for Exploratory Subgroups 
  
ER-Positive Endocrine Only and Node-
Negative   
ER-Positive Endocrine Only and Node-
Positive   




(n=657)   
TEAM                  
(n=1208)   
Edinburgh BCS 
(n=174)   
TEAM                  
(n=1,296)   
Edinburgh BCS 
(n=260)   
TEAM                  
(n=2,229) 
Main Effect HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Seperate*                       
IHC4 1.06 (1.02-1.11)   1.10 (1.06-1.14)   0.96 (0.90-1.02)   1.05 (1.02-1.08)   0.99 (0.94-1.04)   1.05 (1.03-1.07) 
MvL 1.71 (1.04-2.81)   1.44 (0.78-2.65)   1.54 (0.77-3.08)   1.25 (0.87-1.79)   1.48 (0.82-2.67)   1.42 (1.09-1.86) 
HvL 1.58 (0.88-2.85)   2.37 (1.42-3.97)   1.36 (0.59-3.12)   1.33 (0.94-1.86)   1.39 (0.70-2.77)   1.62 (1.25-2.09) 
Combined*                       
IHC4 1.06 (1.02-1.11)   1.08 (1.04-1.13)   0.95 (0.89-1.01)   1.05 (1.02-1.08)   0.99 (0.93-1.04)   1.05 (1.03-1.07) 
MvL 1.69 (1.02-2.78)   1.32 (0.72-2.44)   1.51 (0.75-3.03)   1.16 (0.81-1.68)   1.48 (0.82-2.68)   1.35 (1.03-1.77) 
HvL 1.38 (0.76-2.51)   1.95 (1.16-3.30)   1.74 (0.74-4.08)   1.18 (0.83-1.67)   1.48 (0.72-3.07)   1.48 (1.14-1.92) 
NOTE. Multivariate analysis for Mammostrat score and IHC4 entered seperately or simultaneously (combined analysis) into a Cox regression 
model. Hazard ratios for risk of TTDR for patients with a ten-unit increase in IHC4 score and with either high-risk or moderate-risk Mammostrat 
score compared with low Mammostrat scores at baseline. Abbreviations: TTDR, time-to distant-recurrence; CI, confidence interal; HvL, high risk 







Table 7.8 Wald tests and performance data for assessing the amount of information added by IHC4 score or 
Mammostrat score or both to clinical factors for exploratory subgroups. 
  Edinburgh BCS  
Model 
Wald test       
(p-value) 
Increase 
in R2  
Increase in 
D Statistic 
ER-Positive Endocrine Only and Node-Negative     
C vs. Null (7 df) 7.0 (<0.001) 17.8 0.95 
C + IHC4 vs. C (1 df) 8.7 (0.003) 2.7 0.09 
C + Mam vs. C (2 df) 2.5 (0.08) 1.4 0.05 
C + IHC4 + Mam vs. C (3 df) 4.2 (0.006) 4.3 0.14 
C + IHC4 + Mam vs. C + IHC4 (2 df) 2.1 (0.12) 1.6 0.05 
C + IHC4 + Mam vs. C + Mam (1 df) 7.8 (0.005) 2.9 0.09 
ER-Positive Endocrine Only and Node-Positive     
C vs. Null (7 df) 5.1 (<0.001) 23.7 1.14 
C + IHC4 vs. C (1 df) 2.0 (0.15) 3.7 0.12 
C + Mam vs. C (2 df) 0.8 (0.47) 0.9 0.03 
C + IHC4 + Mam vs. C (3 df) 1.4 (0.24) 4.5 0.14 
C + IHC4 + Mam vs. C + IHC4 (2 df) 1.1 (0.34) 0.8 0.03 
C + IHC4 + Mam vs. C + Mam (1 df) 2.7 (0.1) 4.6 0.10 
ER-Positive Any Treatment and Node-Positive     
C vs. Null (7 df) 5.0 (<0.001) 21.5 1.07 
C + IHC4 vs. C (1 df) 0.1 (0.8) -0.2 0.00 
C + Mam vs. C (2 df) 1.0 (0.4) 1.3 0.04 
C + IHC4 + Mam vs. C (3 df) 0.7 (0.5) 1.1 0.03 
C + IHC4 + Mam vs. C + IHC4 (2 df) 1.1 (0.3) 1.3 0.04 












Table 7.8 Continued Wald tests and performance data for assessing the amount of information added by IHC4 
score or Mammostrat score or both to clinical factors for exploratory subgroups. 
  TEAM 
Model 
Wald test         
(p-value) 
Increase 
in R2  
Increase in 
D Statistic 
ER-Positive Endocrine Only and Node-Negative     
C vs. Null (7 df) 35.0 (<0.001) 19.9 1.02 
C + IHC4 vs. C (1 df) 23.3 (<0.001) 9.9 0.32 
C + Mam vs. C (2 df) 11.8 (0.003) 5.3 0.17 
C + IHC4 + Mam vs. C (3 df) 29.5 (<0.001) 11.4 0.36 
C + IHC4 + Mam vs. C + IHC4 (2 df) 6.7 (0.03) 1.5 0.04 
C + IHC4 + Mam vs. C + Mam (1 df) 17.4 (<0.001) 6.1 0.19 
ER-Positive Endocrine Only and Node-Positive     
C vs. Null (7 df) 125.1 (<0.001) 28.1 1.28 
C + IHC4 vs. C (1 df) 12.0 (<0.001) 2.1 0.07 
C + Mam vs. C (2 df) 2.9 (0.2) 0.5 0.02 
C + IHC4 + Mam vs. C (3 df) 13.0 (0.005) 2.1 0.07 
C + IHC4 + Mam vs. C + IHC4 (2 df) 1.0 (0.6) 0.02 0.00 
C + IHC4 + Mam vs. C + Mam (1 df) 9.9 (0.002) 1.6 0.05 
ER-Positive Any Treatment and Node-Positive     
C vs. Null (7 df) 200.4 (<0.001) 25.5 1.2 
C + IHC4 vs. C (1 df) 26.4 (<0.001) 2.4 0.08 
C + Mam vs. C (2 df) 13.8 (0.001) 1.3 0.04 
C + IHC4 + Mam vs. C (3 df) 35.3 (<0.001) 3.2 0.10 
C + IHC4 + Mam vs. C + IHC4 (2 df) 9.0 (0.01) 0.8 0.03 
C + IHC4 + Mam vs. C + Mam (1 df) 20.9 (<0.001) 1.9 0.06 
NOTE. Values represent Wald tests (significance level) and the increase in R2 and D 
statistic for the addition of IHC4 or Mammostrat score or both with a difference in 
D of at least 0.1 indicating improved prognostic separation. Results are given for 
exploratory subgroups in the Edinburgh BCS and TEAM cohorts. Abbreviations: C, 
clinical model with age, grade, tumour size, nodes positive, treatment and 
chemotherapy; Null, null model with no covariates; IHC4, IHC4 score; Mam, 





Figure 7.8 Calibration slope estimates of observed versus predicted 5 year risk of distant recurrence (DR). Plots 
represent ER-positive patients treated with endocrine therapy only (A and C), all ER-positive patients (B and D) in 
the Edinburgh BCS (A and B) and TEAM (C and D) cohorts. Black line shows perfect agreement between observed 
and predicted risk. Abbreviations: C, clinical model with age, grade, tumour size, number of positive nodes, 
treatment and chemotherapy; IHC4 + C, IHC4 score plus clinical model; MAM+C, Mammostrat score plus clinical 
model; IHC4+MAM+C, IHC4 and Mammostrat score plus clinical model. 
 
7.3.4.2 The addition of both scores to clinical factors 
The scores were entered simultaneously into a multivariate Cox regression model (Table 7.5 
and Table 7.6) and the addition of both scores to clinical factors provided statistically 
significant information (p<0.05) for both subsets of patients across both cohorts with increases 
of R2 between 2 and 5% and increases in D-statistic of between 0.06 and 0.15. Similarly in the 
exploratory subgroup analysis (Table 7.7 and Table 7.8), the addition of both scores provided 
significant additional prognostic information to clinical factors only in the TEAM cohort but 
this was not seen in those with node-positive disease in the Edinburgh BCS cohort.  
The Mammostrat score remained the stronger predictor of TTDR in the Edinburgh BCS cohort 
with the IHC4 score not providing any statistically significant information beyond that of 
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Mammostrat and clinical factors combined for both patient subsets (increase in R2: 0.8 and 
0.4% and D-statistic: 0.02 and 0.01 for ER-positive patients treated with endocrine therapy 
only and all ER-positive patients respectively). 
In the TEAM cohort, the IHC4 provided more prognostic information than the Mammostrat 
score in both subgroups (increase in R2: 2.4 vs 0.5% and D-statistic: 0.08 vs 0.02 for ER-
positive patients treated with endocrine therapy only (n=2,513) and increase in R2: 2.6 vs 1.3% 
and D-statistic: 0.08 vs 0.04 for all ER-positive patients (n=3,766)). The Mammostrat score 
offered prognostic information beyond that of IHC4 score and clinical factors combined in all 
ER-positive patients (p<0.001), although only a small improvement in model discrimination 
was observed (increase in R2: 1.3% and D-statistic: 0.04). The prognostic information added 
by Mammostrat score was not significant in ER-positive patients treated with endocrine 
therapy only (p=0.1, increase in R2: 0.5% and D-statistic: 0.02).  
Again varied results were seen for the exploratory analysis depending on the subgroup and 
study: the IHC4 score was the stronger predictor of TTDR in the TEAM cohort but additional 
information was gained from including Mammostrat score for ER-positive, node-negative 
patients treated with endocrine therapy (p=0.03, increase in R2: 1.5% and D-statistic: 0.04) and 
ER-positive, node-positive patients irrespective of treatment (p=0.01, increase in R2: 0.8% and 
D-statistic: 0.03).  
Model calibration was also investigated with no clear improvements observed from the 
combined use of both scores in addition to clinical factors (Figure 7.8). 
7.3.5 Assumption of Proportional Hazards 
A graphical procedure can be used which plots Schoenfelds residuals against time (or the 
logarithm of time), with patterns in these plots indicating non-proportional effects. The plots 
of the residuals are given in Figure 7.9. In the Edinburgh BCS cohort several explanatory 
variables showed evidence of a non-proportional effect (IHC4 score, Mammostrat score and 
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grade). IHC4 score and Mammostrat high risk also showed evidence of a non-proportional 
effect in the TEAM cohort, however the effect was more prominent in the longer follow-up of 
the Edinburgh BCS cohort.  
 
 
Figure 7.9 Plots of Schoenfeld residuals for each explanatory variable versus survival time in the (A) Edinburgh 
BCS and (B) TEAM cohorts with red (solid) line indicating the fitted linear regression line and the blue (dashed) 
line a reference line at zero.  
 
A formal test can also be performed which tests, for individual covariates and globally, the 
null hypothesis of zero slope, which is equivalent to testing that the log-hazard function is 
constant over time. The formal tests identify IHC4 to have a non-proportional effect in both 
cohorts (Table 7.9). It is however important to look at plots as well as the significance of the 
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tests as significant results may not be clinically important and tests will not be good at 
detecting curved relationships.  
Table 7.9 Grambsch-Therneau test of non-proportional hazards 
  P-value of Grambsch-Therneau Test 
  Edinburgh BCS   TEAM 
Variable Univariable Multivariable   Univariable Multivariable 
IHC4 <0.001 <0.001   <0.001 0.02 
MAM Medium 0.10 0.31   0.79 0.89 
MAM High 0.01 0.10   0.07 0.49 
Age 0.44 0.71   0.82 0.54 
Size 0.03 0.13   0.31 0.80 
Grade 2 0.04 0.23   0.90 0.74 
Grade 3 0.01 0.44   0.42 0.80 
No. Pos. Nodes 0.71 0.94   0.19 0.35 
 
It is also important to note the differences when variables are analysed in a univariable model, 
with Mammostrat high risk and tumour size violating the PH assumption in a univariate but 
not multivariate analysis. This relates to the issue of spurious non-proportional effects when 







To our knowledge, these prognostic algorithms have not been evaluated in a head-to-head 
comparison before. Assessment was complicated as IHC4 was a continuous risk score and 
Mammostrat was considered as a risk category (high, moderate or low). The results showed 
that the scores have different capabilities in predicting TTDR depending on the cohort and the 
subgroup of patients. As a single panel IHC4 provided more information than Mammostrat in 
the TEAM cohort whereas in the Edinburgh BCS cohort the Mammostrat score was the 
stronger predictor of TTDR. However, particularly in the larger TEAM cohort and when all 
ER-positive patients were considered, statistically significant benefit in estimation of residual 
recurrence risk after treatment was observed from a combined use of both marker panels.  
We have shown that two distinct IHC marker panels provide independent information on risk 
of distant recurrence following treatment with tamoxifen or aromatase inhibitors within the 
Edinburgh BCS and TEAM cohorts. In multivariate analysis, the “IHC4 algorithm” derived 
from a mathematical transformation of quantitative scores for ER, PgR, HER2 and Ki67 and 
Mammostrat risk score derived from a panel of five antibodies p53, NDRG1,CEACAM5, 
SLC7A5 and HTF9C were significantly associated with risk of distant recurrence. These 
results would appear to provide an independently generated validation of both the “IHC4 
algorithm” (Cuzick et al., 2011) and Mammostrat score (Ring et al., 2006).   
The IHC4 is analysed as a continuous score, but for Kaplan-Meier analysis cut-points are 
required. To avoid the biases that occur from choosing our own cut-points, we used those from 
the original study (Cuzick et al., 2011). However, these did not validate well in our cohorts, 
allocating only a small number of patients to the low risk group (<10%). 
From this initial analysis, the IHC4 and Mammostrat risk scores were significantly associated 
with risk of time to distant recurrence and added prognostic information beyond that provided 
by clinical factors. The combined use of IHC4 and Mammostrat in choosing patients to be 
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treated with chemotherapy warrants further study and could be a much more cost-effective 
option than the considerably more expensive mRNA based assays currently available. 
Depending on the study and the subgroup of patients analysed, the scores demonstrated 
different capabilities in predicting TTDR. One potential reason for the difference between 
study cohorts could be the differences in the lengths of follow-up, with the studies having 
median follow-ups of 6.2 years and 12.9 years for the TEAM and Edinburgh BCS cohorts 
respectively. The Cox analysis performed in this study has the assumption of proportional 
hazards (PH) which corresponds to assuming that the hazard ratio comparing one level of a 
covariate to another is constant over time. The misleading conclusions that can be inferred if 
this assumption has been violated has been well documented such as poor parameter estimates 
and we are less likely to conclude for a significant effect when there actually is one (Bellera 
et al., 2010). Violations of the PH assumption were found and a detailed analysis looking at 















Chapter 8:  Analysis of IHC4 and Mammostrat 
Incorporating Non-Proportional Effects 
8.1 Introduction 
We have previously shown in chapter 7, that when assessed as a single panel IHC4 provided 
consistently more residual risk information than Mammostrat. However, particularly in the 
wider TEAM cohort including all ER-positive patients (irrespective of treatment), significant 
benefit in estimation of residual recurrence risk after treatment was obtained by a combined 
use of both maker panels. However, differences were observed in the performance of the 
scores across the two studies and it was thought this could be due to differences in length of 
follow-up and the impact of non-proportional (time-dependent) effects. 
In this chapter we investigate the impact of follow-up duration on the IHC4 and Mammostrat 
scores to determine whether these two prognostic panels provide information on the risk of 
early or late recurrence.  
8.2 Piece-wise constant effects 
The most simple and often used approach when dealing with non-proportional effects is the 
use of piece-wise constant effects (see section 4.4.4), where time is partitioned into intervals 
resulting in a step function for 𝛽(𝑡) in the extended Cox model.  
A cut-point of 5 years was pre-specified due to the clinical relevance as a decision point for 




8.2.1.1 Model Performance 
We assessed the performance of the scores, using measures of discrimination and calibration 
as described in section 7.2.2, in addition to clinical factors at differing lengths of follow-up. 
Measures of discrimination are given in Table 8.1 for full follow-up (using all available data 
rather than censoring at a specific time point) and follow-up censored at 5 years. In the 
Edinburgh BCS cohort the models performed statistically better with shorter follow-up (5 
years) compared to full follow-up (25 years) with differences in D statistic between 0.4 and 
0.5 and R2 between 7 and 13%. There was a small improvement in model performance with 
shorter follow-up in the TEAM cohort, with increases in R2 between 1.5 and 3% and 
differences in D statistic between 0.05 and 1. Plots of observed versus predict risk of distant 
recurrence are displayed in Figure 8.1 and Figure 8.2 for all ER-positive patients and ER-
positive patients treated with endocrine therapy respectively. The calibration of the combined 
model (IHC4 and Mammostrat score in addition to clinical factors) was improved censoring 
follow-up at 5 years in the Edinburgh BCS cohort only. The combined model calibration slope 
estimate was 1.0 (95% CI, 0.8-1.1) for follow-up censored at 5 years versus 1.2 (95% CI, 0.8-













Table 8.1 Performance data on IHC4 and Mammostrat score in addition to clinical factors 
  All ER-Positive   ER-Positive Endocrine Only 
Model 
R2                   
(95 % CI) 
D Statistic    
(95% CI)   
R2                    
(95 % CI) 
D Statistic        
(95% CI) 
Edinburgh BCS         
Full Follow-up         
Clinical 24.0 (16.2-31.7) 1.15 (0.91-1.39)   25.7 (16.7-34.6) 1.20 (0.92-1.48) 
IHC4 24.4 (16.7-32.1) 1.16 (0.92-1.41)   26.3 (17.4-35.1) 1.22 (0.94-1.50) 
MAM 25.4 (17.6-33.2) 1.19 (0.95-1.44)   27.1 (18.1-36.1) 1.25 (0.97-1.53) 
Comb 25.7 (18.0-33.5) 1.21 (0.96-1.45)   27.9 (19.0-36.8) 1.27 (0.99-1.56) 
5 Years         
Clinical 31.1 (20.8-41.4) 1.51 (1.17-1.85)   35.3 (23.3-47.4) 1.51 (1.12-1.91) 
IHC4 33.7 (23.6-43.8) 1.63 (1.28-1.98)   39.0 (27.2-50.7) 1.63 (1.23-2.04) 
MAM 33.6 (23.4-43.8) 1.58 (1.23-1.92)   38.5 (26.8-50.3) 1.62 (1.22-2.02) 
Comb 36.5 (26.4-46.5) 1.69 (1.34-2.04)   41.3 (29.9-52.7) 1.72 (1.31-2.12) 
TEAM           
Full-Follow-up         
Clinical 27.5 (23.0-32.0) 1.26 (1.12-1.40)   29.5 (23.6-35.3) 1.33 (1.14-1.51) 
IHC4 31.0 (26.5-35.4) 1.37 (1.23-1.52)   32.8 (27.0-38.4) 1.43 (1.24-1.62) 
MAM 29.8 (25.3-34.2) 1.33 (1.19-1.48)   31.0 (25.1-36.7) 1.37 (1.18-1.56) 
Comb 32.3 (27.8-36.7) 1.41 (1.27-1.56)   33.3 (27.5-38.9) 1.45 (1.26-1.63) 
5 Years                       
Clinical 29.0 (23.8-34.1) 1.31 (1.14-1.47)   30.5 (23.7-37.0) 1.36 (1.14-1.57) 
IHC4 34.0 (28.9-38.9) 1.47 (1.31-1.63)   34.9 (28.3-41.2) 1.50 (0.29-1.71) 
MAM 31.5 (26.4-36.5) 1.39 (1.23-1.55)   32.2 (25.5-38.6) 1.41 (1.20-1.62) 
Comb 35.4 (30.3-40.2) 1.51 (1.35-1.68)   35.5 (28.9-41.7) 1.52 (1.31-1.73) 
NOTE. Measures of discrimination for patients in the Edinburgh BCS and TEAM cohorts. 
The four models being assessed are: Clinical, age, grade, tumour size, nodal status, 
treatment and chemotherapy; IHC4, IHC4 score in addition to clinical factors; Mammostrat 
(MAM), Mammostrat score in addition to clinical factors; Combined (Comb), IHC4 score 







Figure 8.1 All ER-positive patients. Observed versus predicted 5 year risk of distant recurrence (DR) and the 
calibration slope estimate for the combined model (IHC4, Mammostrat and clinical factors, age, grade, nodes 
positive, grade, size, treatment and chemotherapy) with full follow-up (right column) and follow-up censored at 5 
years (right column) for all ER-positive patients in the Edinburgh BCS (A and B) and TEAM (C and D) cohorts. 





Figure 8.2 ER-positive patients treated with endocrine therapy only. Observed versus predicted 5 year risk of 
distant recurrence (DR) and the calibration slope estimate for the combined model (IHC4, Mammostrat and clinical 
factors, age, grade, nodes positive, grade, size, treatment and chemotherapy) with full follow-up (right column) and 
follow-up censored at 5 years (right column) for ER-positive patients treated with endocrine therapy only in the 
Edinburgh BCS (A and B) and TEAM (C and D) cohorts. Dashed line represents perfect agreement between 




8.2.1.2 Prognostic Value of Scores within the first 5 years and beyond 5 years 
after diagnosis 
Cox regression was performed with follow-up time divided into the intervals 0-5 years and 5-
10 years for both the Edinburgh BCS and TEAM cohorts.   
Period specific K-M curves are displayed for all ER-positive patients in Figure 8.3 and ER-
positive patients treated with endocrine therapy in Figure 8.4. Clear separation of the survival 
curves can be seen in the 0-5 year interval, however this separation does not remain in the 5-
10 year interval.  
Both scores were significant independent predictors of outcome restricted to the first five years 
of follow-up, after which there was no evidence the scores were associated with TTDR (Table 
8.2). For example, the HR for a ten-unit increase in IHC4 score was 1.07 (95% CI, 1.03-1.12) 
in the first five years following diagnosis compared with 0.97 (95% CI, 0.92-1.02) after 5 years 
for all ER-positive patients in the Edinburgh BCS cohort. Despite categorising the time 
interval there are a sufficient number of events, especially in the TEAM cohort, in both time 
intervals suggesting that the finding of no evidence of a prognostic effect of the scores in the 
5-10 year time interval does not just reflect a lack of endpoints.  
There was evidence of a prognostic effect after 5 years for Mammostrat high risk versus low 
risk for all ER-positive patients (Table 8.2) and ER-positive node-negative patients treated 
with endocrine therapy (Table 8.3) in the TEAM cohort with HRs of 1.6 (95% CI, 1.0-2.4) 
and 3.3 (95% CI, 1.1-10.5) respectively. This effect of Mammostrat high versus low risk was 
also seen in the Edinburgh BCS cohort for ER-positive node-negative patients treated with 
endocrine therapy only (Table 8.3) for the 5-10 year time period after diagnosis with a HR of 




Figure 8.3 All ER-positive patients. Period-specific Kaplan-Meier curves for time to distant recurrence for IHC4 
score and Mammostrat score. Plots represent (A and B) Edinburgh BCS dataset and (C and D) TEAM dataset. 
Curves are shown for the period 0-5 years, censoring follow-up of all patients at 5 years after diagnosis. The 5-10 
year interval is assessed from the subset of patients who remained distant-recurrence free for at least 5 years and 





Figure 8.4 ER-positive patients treated with endocrine therapy only. Period-specific Kaplan-Meier curves for time 
to distant recurrence for IHC4 score and Mammostrat score. Plots represent (A and B) Edinburgh BCS dataset and 
(C and D) TEAM dataset. Curves are shown for the period 0-5 years, censoring follow-up of all patients at 5 years 
after diagnosis. The 5-10 year interval is assessed from the subset of patients who remained distant-recurrence free 
for at least 5 years and censoring follow-up of patients at 10 years. 
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Table 8.2 Period-Specific Multivariate Cox Regression of IHC4 and Mammostrat score 
  All ER-Positive    ER-Positive Endocrine Only 
  0-5 Years   5-10 Years   0-5 Years   5-10 years 
Main Effect* HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Edinburgh BCS (97 events)   (61 events)   (70 events) (45 events) 
IHC4 1.07 (1.03-1.12)   0.97 (0.92-1.02)   1.06 (1.01-1.11)   0.99 (0.93-1.05) 
MvL 1.84 (1.14-2.97)   1.50 (0.80-2.80)   2.00 (1.13-3.54)   1.50 (0.72-3.13) 
HvL 1.65 (0.94-2.92)   1.36 (0.65-2.85)   1.87 (0.98-3.57)   1.68 (0.75-3.77) 
TEAM (416 events)   (132 events)   (242 events) (74 events) 
IHC4 1.08 (1.06-1.10)   1.02 (0.99-1.06)   1.08 (1.05-1.10)   1.01 (0.97-1.06) 
MvL 1.44 (1.09-1.90)   1.38 (0.86-2.21)   1.41 (0.98-2.01)   0.96 (0.51-1.81) 
HvL 2.01 (1.56-2.60)   1.57 (1.02-2.44)   1.72 (1.24-2.38)   1.18 (0.69-2.04) 
NOTE. Separate multivariate analysis of IHC4 and Mammostrat scores with conventional histopathologic variables for 
TTDR before 5 years and after 5 years for patients in different subgroups. Values represent estimated hazard ratios and 
95% CIs calculated as a ten-unit increase in IHC4 score and high and medium risk compared to low risk as categorised 
by Mammostrat score for all patients with ER-positive breast cancer  and ER-positive patients who received no 
chemotherapy in the Edinburgh BCS and TEAM cohorts. *Adjusted for age, grade, tumour size, nodes positive, treatment 
and chemo. Abbreviations: IHC4, IHC4 score; MvL, medium v low risk Mammostrat score; HvL, high v low risk 






Table 8.3 Period-Specific Multivariate Cox Regression of IHC4 and Mammostrat score for Exploratory Subgroup Analysis 
  
ER-Positive, Endocrine Only and 
Node-negative   
ER-Positive, Endocrine Only and 
Node-Positive   
ER-Positive, Any Treatment and Node-
Positive 
  0-5 Years   5-10 Years   0-5 Years   5-10 Years   0-5 Years   5-10 Years 
Main Effect* HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Edinburgh BCS (44 events)   (28 events)   (26 events)   (17 events)   (36 events)   (23 events) 
IHC4 1.10 (1.04-1.17)   1.04 (0.97-1.12)   0.99 (0.91-1.07)   0.89 (0.79-1.00)   1.04 (0.98-1.12)   0.92 (0.84-1.01) 
MvL 2.16 (1.06-4.40)   1.79 (0.67-4.75)   1.61 (0.60-4.35)   1.35 (0.43-4.29)   1.21 (0.52-2.83)   2.09 (0.79-5.52) 
HvL 1.81 (0.78-4.19)   2.82 (1.02-7.76)   1.85 (0.63-5.42)   0.77 (0.15-4.08)   1.83 (0.74-4.48)   0.97 (0.25-3.83) 
TEAM (81 events)   (23 events)   (161 events)   (51 events)   (306 events)   (97 events) 
IHC4 1.11 (1.07-1.16)   1.04 (0.95-1.14)   1.06 (1.03-1.10)   1.01 (0.95-1.07)   1.07 (1.04-1.09)   1.00 (0.96-1.05) 
MvL 1.34 (0.67-2.68)   1.80 (0.48-6.78)   1.43 (0.94-2.17)   0.84 (0.40-1.77)   1.51 (1.10-2.07)   1.22 (0.72-2.08) 
HvL 2.15 (1.20-3.82)   3.33 (1.06-10.5)   1.57 (1.05-2.34)   0.84 (0.43-1.62)   1.83 (1.35-2.47)   1.11 (0.66-1.85) 
NOTE. Multivariate analysis of IHC4 and Mammostrat scores entered separately into a Cox regression model with conventional 
histopathologic variables for TTDR before 5 years and after 5 years for patients in the exploratory subgroups. Values represent 
estimated hazard ratios and 95% CIs calculated as a ten-unit increase in IHC4 score and high and medium risk compared to low 
risk as categorised by Mammostrat score. *Adjusted for age, grade, tumour size, nodes positive, treatment and chemo. 
Abbreviations: IHC4, IHC4 score; MvL, medium v low risk Mammostrat score; HvL, high v low risk Mammostrat score; CI, confidence 





Table 8.4 Wald tests and performance data for assessing the amount of information added by the IHC4 score or the Mammostrat score or both to 
clinical factors in the first 5 years of follow-up. 
  Edinburgh BCS    TEAM 
Model 
Wald test         
(p-value) 
Increase 
in R2 (%) 
Increase in 
D Statistic   
Wald test            
(p-value) 
Increase 
in R2 (%) 
Increase in 
D Statistic 
All ER-Positive (n=1,103)   (n=3,766) 
C vs. Null (7 df) 9.5 (<0.001) 31.1 1.51   272.1 (<0.001) 29 1.31 
C + IHC4 vs. C (1 df) 12.1 (<0.001) 6.6 0.12   61.2 (<0.001) 5.0 0.16 
C + Mam vs. C (2 df) 3.3 (0.04) 2.5 0.07   29.2 (<0.001) 2.5 0.08 
C + IHC4 + Mam vs. C (3 df) 5.5 (<0.001) 5.4 0.18   78.5 (<0.001) 6.4 0.20 
C + IHC4 + Mam vs. C + IHC4 (2 df) 2.4 (0.09) 2.8 0.06   17.3 (<0.001) 1.4 0.04 
C + IHC4 + Mam vs. C + Mam (1 df) 10.1 (0.002) 2.9 0.11   47.4 (<0.001) 3.9 0.12 
ER-Positive Endocrine Only (n=831)   (n=2,513) 
C vs. Null (6 df) 11.6 (<0.001) 35.3 1.51   172.0 (<0.001) 30.5 1.36 
C + IHC4 vs. C (1 df) 6.4 (0.01) 3.7 0.12   34.5 (<0.001) 4.4 0.14 
C + Mam vs. C (2 df) 3.2 (0.04) 3.2 0.11   10.5 (0.005) 1.7 0.05 
C + IHC4 + Mam vs. C (3 df) 3.8 (0.01) 6 0.21   38.7 (<0.001) 5 0.16 
C + IHC4 + Mam vs. C + IHC4 (2 df) 2.6 (0.07) 2.3 0.09   4.4 (0.11) 0.6 0.02 
C + IHC4 + Mam vs. C + Mam (1 df) 5.1 (0.02) 2.8 0.10   27.1 (<0.001) 3.3 0.11 
NOTE. Values represent Wald tests (significance level) and the increase in R2 and D statistic for the addition of IHC4 or Mammostrat 
score or both. Results are given for ER-positive patients and ER-positive patients who received no chemotherapy in the Edinburgh 
BCS and TEAM cohorts with follow-up censored at 5 years. Abbreviations: C, clinical model with age, grade, tumour size, nodes 





Table 8.5 Period-Specific Multivariate Cox Regression of IHC4 and Mammostrat score Combined 
  All ER-Positive    ER-Positive Endocrine Only 
  0-5 Years   5-10 Years   0-5 Years   5-10 Years 
Main Effect* HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Edinburgh BCS (97 events)   (61 events)   (70 events) (45 events) 
IHC4 1.07 (1.03-1.11)   0.96 (0.91-1.02)   1.06 (1.01-1.11)   0.98 (0.92-1.04) 
MvL 1.72 (1.06-2.79)   1.56 (0.84-2.93)   1.95 (1.10-3.48)   1.49 (0.71-3.12) 
HvL 1.30 (0.72-2.37)   1.61 (0.76-3.42)   1.53 (0.77-3.04)   1.85 (0.81-4.22) 
TEAM (416 events)   (132 events)   (242 events)   (74 events) 
IHC4 1.07 (1.05-1.09)   1.02 (0.98-1.05)   1.07 (1.04-1.10)   1.01 (0.96-1.06) 
MvL 1.33 (1.01-1.77)   1.36 (0.85-2.18)   1.28 (0.89-1.84)   0.95 (0.50-1.79) 
HvL 1.73 (1.33-2.24)   1.52 (0.97-2.36)   1.43 (1.02-2.00)   1.15 (0.66-2.01) 
NOTE. Multivariate analysis of IHC4 and Mammostrat scores entered simultaneously into a Cox regression 
model with conventional histopathologic variables for TTDR before 5 years and after 5 years for patients in 
different subgroups. Values represent estimated hazard ratios and 95% CIs calculated as a ten-unit increase 
in IHC4 score and high and medium risk compared to low risk as categorised by Mammostrat score for all 
patients with ER-positive breast cancer and ER-positive patients who received no chemotherapy in the 
Edinburgh BCS and TEAM cohorts. *Adjusted for age, grade, tumour size, nodes positive, treatment and 
chemo. Abbreviations: IHC4, IHC4 score; MvL, medium v low risk Mammostrat score; HvL, high v low risk 







Table 8.6 Period-Specific Multivariate Cox Regression of IHC4 and Mammostrat score Combined for Exploratory Subgroup Analysis 
  
ER-Positive, Endocrine Only and 
Node-negative   
ER-Positive, Endocrine Only and 
Node-Positive   
ER-Positive, Any Treatment and  
Node-Positive 
  0-5 Years   5-10 Years   0-5 Years   5-10 Years   0-5 Years   5-10 Years 
Main Effect* HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Edinburgh BCS (44 events)   (28 events)   (26 events)   (17 events)   (36 events)   (23 events) 
IHC4 1.10 (1.03-1.17)   1.03 (0.96-1.11)   0.97 (0.89-1.06)   0.89 (0.78-1.00)   1.03 (0.96-1.11)   0.92 (0.83-1.02) 
MvL 2.08 (1.01-4.25)   1.68 (0.62-4.54)   1.59 (0.59-4.29)   1.99 (0.64-6.19)   1.20 (0.51-2.82)   3.06 (1.17-7.98) 
HvL 1.48 (0.63-3.48)   2.79 (1.01-7.71)   2.16 (0.69-6.74)   1.38 (0.21-8.85)   1.58 (0.59-4.21)   1.30 (0.28-5.95) 
TEAM (81 events)   (23 events)   (161 events)   (51 events)   (306 events)   (97 events) 
IHC4 1.10 (1.06-1.15)   1.03 (0.94-1.12)   1.06 (1.02-1.09)   1.01 (0.95-1.08)   1.06 (1.04-1.08)   1.00 (0.96-1.05) 
MvL 1.20 (0.60-2.40)   1.78 (0.47-6.67)   1.31 (0.86-2.01)   0.82 (0.39-1.75)   1.41 (1.03-1.93)   1.22 (0.71-2.08) 
HvL 1.66 (0.92-3.00)   3.20 (1.01-10.1)   1.36 (0.90-2.05)   0.81 (0.41-1.61)   1.63 (1.20-2.20)   1.10 (0.66-1.86) 
NOTE. Multivariate analysis of IHC4 and Mammostrat scores entered simultaneously into a Cox regression model with conventional histopathologic 
variables for TTDR before 5 years and after 5 years for patients in different subgroups. Values represent estimated hazard ratios and 95% CIs 
calculated as a ten-unit increase in IHC4 score and high and medium risk compared to low risk as categorised by Mammostrat score for patients with 
ER-positive breast cancer treated with endocrine therapy only and either node-positive or node-negative and  ER-positive, node-positive patients 
irrespective of treatment  in the Edinburgh BCS and TEAM cohorts. *Adjusted for age, grade, tumour size, nodes positive, treatment and chemo. 





8.2.1.3 Comparison of IHC4 and Mammostrat 
The IHC4 score provided more prognostic information beyond that of clinical factors 
compared to the Mammostrat score for all ER-positive patients in both patient cohorts in the 
first five years of follow-up (Table 8.4; increase in R2: 6.6% vs 2.5% and D-statistic: 0.12 vs 
0.07 in the Edinburgh BCS cohort and increase in R2: 5.0% vs 2.5% and D-statistic: 0.16 vs 
0.08 in the TEAM cohort). Likewise for ER-positive patients treated with endocrine therapy 
in the TEAM cohort, the IHC4 score was the stronger predictor of outcome whereas in the 
Edinburgh cohort the prognostic information provided by either score was similar (increase in 
R2: 3.7% vs 3.2% and D-statistic: 0.12 vs 0.11).   
8.2.1.4 The addition of both scores to clinical factors 
The scores were entered simultaneously into a multivariate Cox regression model and in the 
first 5 years of follow-up, the addition of both scores to clinical factors provided statistically 
significant information (p<0.05) for both subsets of patients across both cohorts with increases 
in R2 between 5 and 6% and increases in D-statistic between 0.16 and 0.21 (Table 8.4). 
However, both scores only remained significant independent predictors of TTDR restricted to 
the first 5 years of follow-up when simultaneously entered into a multivariate Cox regression 
model for all ER-positive patients in the TEAM cohort with a HR for a ten-unit increase in 
ICH4 score of 1.07 (95% CI 1.05-1.09) and HRs for medium and high versus low Mammostrat 
score of 1.3 (95% CI 1.0-1.8) and 1.7 (95% CI 1.3-2.2) respectively (Table 8.5). Only the 
IHC4 score provided significant independent prognostic information on TTDR in the first 5 
years of follow-up for all ER-positive patients treated with endocrine therapy in the TEAM 
cohort and both patient subgroups in the Edinburgh BCS cohort. Although not statistically 
significant, the Mammostrat score provided some improvement in model discrimination over 
and above that provided by IHC4 score and clinical factors with an increase in R2 and D-
statistic of 2.3% and 0.09 respectively for ER-positive patients treated with endocrine therapy 
only in the Edinburgh BCS cohort. There was evidence of an effect of Mammostrat high risk 
versus low risk after 5 years of survival after adjustment for IHC4 and clinical factors for ER-
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positive, node-negative patients treated with endocrine therapy only in the TEAM and 
Edinburgh BCS cohorts with HRs of 3.2 (95% CI 1.0-10.1) and 2.8 (95% CI 1.0-7.7) 
respectively (Table 8.6).  
8.2.1.5 Test of PH assumption 
Despite the categorisation of the time interval, it is still important to test the PH assumption 
within these time intervals. If the interval is too large, violation of the PH assumption may still 
occur and give biased results. 
For these data, there was no evidence to reject the PH assumption in each 5 year time 
interval as indicated by the Grambsch-Therneau test of proportional hazards (data not 
shown).   
8.2.1.6 Combined IHC4 and Mammostrat Risk Groups 
In section 7.3.2, three risk groups from the combined IHC4 and Mammostrat scores were 
identified: low risk, IHC4 and Mammostrat low risk; medium risk, IHC4 low risk and 
Mammostrat high risk and vice versa; high risk, IHC4 and Mammostrat high risk.  
Period-specific K-M curves for this combined score are shown for all ER-positive patients and 
ER-positive patients treated with endocrine therapy in Figure 8.5. Very good separation of the 
survival curves was observed in the first 5 years of follow up in both the Edinburgh BCS and 
TEAM cohorts. Good stratification also remained in the 5-10 year interval for all ER-positive 
patients in the TEAM cohort. 
The combined score was an independent predictor of time to distant-recurrence in the first five 
years of follow-up for both subgroups in the Edinburgh BCS and TEAM cohorts (Table 8.7). 
Patients with high risk had an increased hazard of 3.3 (95% CI, 1.7-6.5) and 2.9 (95% CI, 2.1-







ER-Positive, Endocrine Only only 
 
Figure 8.5 Period-specific Kaplan-Meier curves for time to distant recurrence for the combined score for all ER-
positive patients and ER-Positive patients treated with endocrine therapy only. Plots represent (A) Edinburgh BCS 
and (B) TEAM cohorts. Curves are shown for the period 0-5 years, censoring follow-up of all patients at 5 years 
after diagnosis. The 5-10 year interval is assessed from the subset of patients who remained distant-recurrence free 
for at least 5 years and censoring follow-up of patients at 10 years.  
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Table 8.7 Period Specific Multivariate Cox Regression of the Combined Score 
  All ER-Positive    ER-Positive Endocrine Only 
  0-5 Years   5-10 Years   0-5 Years   5-10 Years 
Main Effect* HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Edinburgh BCS (97 events)   (95 events)   (70 events) (72 events) 
Comb MvL 1.94  (1.00-3.77)   1.32 (0.66-2.65)   1.50 (0.72-3.10)   1.87 (0.81-4.28) 
Comb HvL 3.32 (1.69-6.53)   1.22 (0.55-2.70)   3.14 (1.51-6.54)   1.75 (0.67-4.57) 
TEAM (416 events)   (132 events)   (242 events) (74 events) 
Comb MvL 1.63 (1.18-2.27)   1.05 (0.64-1.73)   1.73 (1.15-2.61)   0.91 (0.49-1.67) 
Comb HvL 2.91 (2.10-4.03)   1.81 (1.10-2.97)   2.69 (1.79-4.06)   1.34 (0.72-2.50) 
NOTE: Multivariate analysis of Combined score with conventional histopathologic variables for TTDR 
before 5 years and after 5 years. Values represent estimated hazard ratios and 95% CIs calculated as  
high and medium risk compared to low risk as categorised by the combined  score *Adjusted for age, 
grade, tumour size, nodes positive, treatment and chemo. Abbreviations: Comb, combined score; MvL, 







Table 8.8 Period-Specific Multivariate Cox Regression of the Combined Score for Exploratory Subgroup Analysis 
  
ER-Positive, Endocrine Only and Node-
Negative   
ER-Positive, Endocrine Only and 
Node-Positive   
ER-Positive, Any Treatment and 
Node-Positive 
  0-5 Years   5-10 Years   0-5 Years   5-10 Years   0-5 Years   5-10 Years 
Main Effect* HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
Edinburgh 
BCS (44 events)   (28 events)   (26 events)   (17 events)   (36 events) (23 events) 
Comb MvL 2.43 (0.79-7.44)   1.87 (0.81-4.28)   0.95 (0.34-2.66)   0.97 (0.33-2.84)   1.23 (0.50-3.04)   0.98 (0.38-2.55) 
Comb HvL 5.70 (1.88-17.31)   1.75 (0.67-4.57)   1.46 (0.48-4.56)   0.31 (0.05-1.89)   1.64 (0.62-4.35)   0.65 (0.18-2.37) 
TEAM (81 events)   (23 events)   (161 events)   (51 events)   (306 events) (97 events) 
Comb MvL 2.05 (0.93-4.55)   2.77 (0.60-12.79)   1.67 (1.03-3.69)   0.69 (0.34-1.40)   1.55 (1.07-2.25)   0.82 (0.47-1.42) 
Comb HvL 3.51 (1.60-7.69)   3.86 (0.82-18.19)   2.49 (1.53-4.04)   1.08 (0.53-2.20)   2.75 (1.90-3.97)   1.40 (0.80-2.44) 
NOTE: Multivariate analysis of Combined score with conventional histopathologic variables for TTDR before 5 years and after 5 years for patients in 
the exploratory subgroups. Values represent estimated hazard ratios and 95% CIs calculated as  high and medium risk compared to low risk as 
categorised by the combined  score *Adjusted for age, grade, tumour size, nodes positive, treatment and chemo. Abbreviations: Comb, combined 
score; MvL, medium v low risk; HvL, high v low risk; CI, confidence interval. 
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positive patients in the Edinburgh BCS and TEAM cohorts respectively. For all ER-positive 
patients in the TEAM cohort, the combined score remained a significant independent predictor 
of survival in the 5-10 year interval (p=0.01). Patients with high risk had 1.8 (95% CI, 1.1-3.0) 
times the hazard of patients with a low risk combined score.  
Exploratory Subgroups 
In the exploratory subgroups (Table 8.8), the combined score was an independent predictor of 
time-to-distant recurrence restricted to the first five years of follow-up in all exploratory 
subgroups in the TEAM cohort. In the Edinburgh BCS cohort, the combined score was an 
independent predictor of outcome in the first five years of follow-up in those ER-positive, 
node-negative patients treated with endocrine therapy only. Although not statistically 
significant, in node-positive subgroups in the Edinburgh BCS cohort, the combined score 
showed a trend towards a protective effect of higher scores in the 5-10 year interval with 
hazard ratio estimates of 0.3 (95% CI, 0.1-1.9) and 0.7 (95% CI, 0.2-2.35) for ER-positive, 
node-positive patients treated with endocrine therapy and any treatment respectively.  
8.2.1.7 Two-Year Time Intervals 
The 5 year intervals are clinically relevant, however perhaps smaller intervals could provide 
more insight into the pattern over time. 
The estimated hazard ratios for all ER-positive patients for two year intervals are displayed in 
Figure 8.6. The smaller time intervals results in a significantly reduced number of events in 
each interval and therefore wide confidence intervals, especially in the smaller Edinburgh BCS 
cohort. The IHC4 and Mammostrat scores remained significant predictors of TTDR up to 6 
years in the TEAM cohort, after which the 95% confidence interval crosses the value of 1, 







Figure 8.6 All ER-positive patients. Two-yearly adjusted hazard ratio estimates and 95% confidence intervals for 
a ten-unit increase in IHC4 score and medium and high Mammostrat score compared to low Mammostrat score. 
Plots represent (left-column) Edinburgh BCS cohort and (right column) TEAM cohort. Adjusted for age, grade, 

























































































































































Figure 8.7 ER-positive patients treated with endocrine therapy only. Two-yearly adjusted hazard ratio estimates 
and 95% confidence intervals for a ten-unit increase in IHC4 score and medium and high Mammostrat score 
compared to low Mammostrat score. Plots represent (left-column) Edinburgh BCS cohort and (right column) 





















































































































































statistically significant in the first four years of follow-up. Up to 6 years, the effect of ICH4 is 
estimated to be above 1, i.e. higher IHC4 score is associated with an increased risk in TTDR. 
After 6 years and especially in the 8-10 year period, the HR is estimated to be below one 
indicating a reduced risk of TTDR with higher IHC4 score (HR (95% CI): 0.9 (0.8-1.0)). 
Mammostrat score was prognostic of outcome in the 0-2 year and 4-6 year time intervals only. 
However wide confidence intervals were associated with the Mammostrat score estimates in 
the Edinburgh BCS cohort. 
For all ER-positive patients treated with endocrine therapy only (Figure 8.7), IHC4 score was 
not prognostic for any of the two-year time intervals in the Edinburgh BCS cohort except for 
the final 8-10 year interval where higher scores were associated with a reduced hazard, which 
was also seen in all ER-positive patients. IHC4 score was prognostic up to 4 years in the 
TEAM cohort. Mammostrat score was prognostic up to two years in the Edinburgh BCS cohort 
and between 2-6 years in the TEAM cohort. 
Due to the already small sizes of the exploratory subgroups, two-year intervals were not 
considered. 
Combined Score 
The estimated hazard ratios for the two-yearly intervals are displayed in Figure 8.8 for all ER-
positive patients and ER-positive patients treated with endocrine therapy only. The combined 
score was prognostic in the 4-6 year time interval only in the Edinburgh BCS cohort for both 
patient subgroups. Due to those assigned to low risk having no events in the first two-year 
time interval, hazard ratios were not estimated for this time period. In the TEAM cohort, the 
combined score was prognostic up to 6 years in both patient subgroups. The effect was 
strongest in the 4-6 year interval with hazard ratio estimates of 4.1 (95% CI, 2.1-7.7) and 5.3 
(95% CI, 2.0-14.0) for all ER-positive patients and ER-positive patients treated with endocrine 







Figure 8.8 Combined Score. Two-yearly adjusted hazard ratio estimates and 95% confidence intervals for medium 
and high risk combined score compared to low risk combined score for all ER-positive patients (left-column) and 
ER-positive patients treated with endocrine therapy only (right-column). Plots represent (A and B) Edinburgh BCS 
cohort and (C and D) TEAM cohort. Adjusted for age, grade, tumour size, number of positive nodes, treatment and 





































































































































































































A summary of whether IHC4 or Mammostrat were significant predictors of outcome in the 0-
5 year and 5-10 year intervals is displayed in Table 8.9. In the first five years of follow-up, 
IHC4 and Mammostrat were independent predictors of outcome when analysed in separate 
Cox regression models for all ER-positive patients and ER-positive patients treated with 
endocrine therapy only.  
Table 8.9 Significant predictors of TTDR in the 0-5 and 5-10 year time intervals by patient subgroup 
 
Both scores remained independent predictors of outcome when entered simultaneously into a 
Cox regression model in the first five years of follow-up for all ER-positive patients in the 
TEAM cohort only. Despite Mammostrat not having an overall significant prognostic effect 
in the Edinburgh BCS cohort and ER-positive patients treated with endocrine therapy only in 
the TEAM cohort, those medium risk had a significantly increased hazard compared to those 
low risk in the Edinburgh BCS cohort and those high risk had a significantly increased hazard 
compared to those low risk in the TEAM cohort.  
IHC4 IHC4 IHC4 IHC4
Separate IHC4 & MAM
All ER+        (HvL)
ER+, Tam Only       
ER+, Tam Only, N-      (HvL)   (HvL)
ER+, Tam Only, N+       
ER+, N+       
Simulatenous IHC4 & MAM
All ER+  (MvL)      
ER+, Tam Only  (MvL)  (HvL)    
ER+, Tam Only, N-  (MvL)     (HvL)   (HvL)
ER+, Tam Only, N+        
ER+, N+       (MvL)  
MAM MAM
Note. Summary of whether IHC4 or Mammostrat (MAM) were independent predictors of TTDR after adjustment 
for age, grade, tumour size, grade, treatment and chemotherapy. IHC4 & Mammostrat were entered seperately 
or simultaneously into a Cox regression model. Results given for the main analysis subgroups (all ER-positive 
(ER+) and all ER-positive treated with tamoxifen (tam) only) and exploratory subgroups (ER-positive, treated 
with tamoxifen only and either node-negative (N-) or node-positive (N+) or ER-positive, node-positive irresepctive 
of treatment). Where Mammostrat score had an overall non-significant effect but individual level comparisons 
(medium vs. low risk (MvL) or high vs.low risk (HvL) were at a significantly increased risk are illsutrated in 








0-5 Years 5-10 Years
Edinburgh BCS TEAM TEAM
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Despite a sufficient number of events in the 5-10 year interval neither IHC4 nor Mammostrat 
score remained an independent predictor of outcome after 5 years of follow-up. However, 
those classified as Mammostrat high risk were at a significantly increased hazard compared to 
low risk for all ER-positive patients in the TEAM cohort, and for ER-positive patients treated 
with endocrine therapy only and node-negative in the Edinburgh BCS and TEAM cohorts.  
8.3 MFPT Approach 
The next approach that was considered was the MFPT approach described in section 4.4.4. 
Step 3 of the MFPT approach investigates possible non-proportional effects of variables. For 
each covariate, the FPT algorithm determines the best fitting FP function to model the time-
varying effect adjusting for all other covariates in the model. Then a forward selection 
procedure is used to add any significant time varying effects to the model. 
This was performed using the stmfpt command in STATA.  
8.3.1 Splitting the data 
The Cox model is fitted by evaluating the partial likelihood at each failure time. Because the 
time-varying effects are a function of study time, the observations under risk are split into 
episodes at specified time points, ideally at each event time.  
As the investigation of time-varying effects is most sensible with long-term follow-up and 
requires large data sets in order to have some power to detect an interaction with time, splitting 
at each event time may cause technical problems. Sauerbrei ‘categorised’ survival times in 
half-year periods up to year 15 and a final period >15 years (Sauerbrei et al., 2007). Table 8.10 
gives an example of a patient with an event at 1.8 years. Splitting the data into half year 




Table 8.10 Example of splitting data in half year intervals 















1 M 10 0 0.5 0 0 
1 M 10 0.5 1 0 1 
1 M 10 1 1.5 0 2 
1 M 10 1.5 2 1 3 
 
We considered categorisation for half-year periods and also smaller intervals (Table 8.11). The 
first time-period was never considered smaller than 6 months (due to convergence issues) and 
a final period of >20 years for the Edinburgh BCS cohort. This creates an extra 18,501 and 
44,773 observations in the Edinburgh BCS and TEAM cohorts respectively for half year 
periods up to year 10. 
Table 8.11 Number of observations created when categorising the time interval  
  Interval 





































  NA NA NA 
Note. Numbers represent number of observations created (number of distinct observed 
times). Initial period always 0-6 months and a final period of >20 years. NA, not applicable. 
 
8.3.2 Results 
8.3.2.1 10 year follow-up 
In multivariable modelling restricting follow-up to 10 years, IHC4 was determined to have a 
significant time-by-covariate interaction for all ER-positive patients in both cohorts with the 
best fitting FP to be log of time (Figure 8.9). The parameter associated with this interaction 
was negative, suggesting the effect of a unit increase in IHC4 on TTDR decreased over time 




Figure 8.9 Results of the FPT algorithm for ICH4 score , showing the time-varying effects for proportional hazards 
(PH), the best fitting FP1 and FP2 model and the default (log (time)) model. Plots represent all ER-positive patients 
in the (A) Edinburgh BCS and (B) TEAM cohorts.  
 
 
Figure 8.10 All ER-positive patients, IHC4 Score. Time-dependent adjusted hazard ratio estimate (up to 10 years) 
with 95% CIs (dashed lines) for a ten-unit increase in IHC4 score for all ER-positive patients in the (A) Edinburgh 
BCS cohort and (B) TEAM cohorts. Adjusted for age, grade, nodes positive, treatment and chemotherapy. Red line 
at hazard ratio of 1 corresponds to a null effect.  
 
with the adjusted HR crossing the value 1 (corresponding to a null effect) at approximately 6 
years.  
IHC4 was also found to have significant time-by-covariate interaction for ER-positive patients 
treated with endocrine therapy only in the TEAM cohort. However, this significant interaction 
was only found when smaller time intervals were chosen. This highlights the lack of distinct 






unique failure times). Buchholz found that the MFPT procedure gives similar results for small 
categorisation intervals and propose that about 50 to 100 distinct event times can give results 
with sufficient precision (Buchholz, 2010). Even with smaller time-categorisations, IHC4 was 
not identified to have a significant time-varying effect for ER-positive patients treated with 
endocrine therapy only in the Edinburgh BCS cohort resulting in an adjusted hazard ratio 
estimate of 1.03 (95% CI, 1.00-1.07) for a ten-unit increase in IHC4. 
The FPT algorithm did not identify any non-proportional effects of variables when looking at 
the Mammostrat model (Mammostrat and clinical factors) in both cohorts with follow-up 
restricted to 10 years (Figure 8.11) with hazard ratio estimates given in Table 8.12. 
Both Scores 
When IHC4 and Mammostrat score were simultaneously entered into a model, the time-
varying effect of IHC4 score remained for both cohorts for all ER-positive patients. IHC4 was 
prognostic of outcome up to 4 and 7 years (where the lower confidence bound crosses 1) for 
all ER-positive patients in the Edinburgh BCS and TEAM cohorts respectively, after 





Figure 8.11 Results of the FPT algorithm for Mammostrat high risk , showing the time-varying effects for 
proportional hazards (PH), the best fitting FP1 and FP2 model and the default (log (time)) model. Plots represent 




Table 8.12 Multivariate Cox regression of Mammostrat score up to 10-years follow-up 
  All ER-Positive   ER-Positive Endocrine Only 
  
Edinburgh BCS 
(n=1,103)   
TEAM                  
(n=3,766)   
Edinburgh BCS 
(n=831)   
TEAM                  
(n=2,513) 
Main 
Effect HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
MvL 1.59 (1.13-2.24)   1.42 (1.12-1.81)   1.79 (1.14-2.82)   1.28 (0.94-1.75) 
HvL 1.31 (0.86-2.00)   1.89 (1.52-2.36)   1.79 (1.08-2.97)   1.57 (1.18-2.07) 
NOTE. Multivariate analysis for Mammostrat score with follow-up censored at 10 years. 
Hazard ratios for risk of TTDR calculated for either high-risk or moderate-risk Mammostrat 
score compared with low Mammostrat scores at baseline. Values represent estimated hazard 
ratios and 95% CIs for all ER-positive patients and ER-positive patients who received no 
chemotherapy in the Edinburgh BCS and TEAM cohorts. Abbreviations: TTDR, time to 
distant-recurrence; CI, confidence interval; HvL, high risk v low risk Mammostrat  score; MvL, 
moderate risk v low risk Mammostrat score. * Adjusted for age, grade, tumour size, nodes 





Figure 8.12 IHC4 Score – Simultaneous Analysis. Time-dependent adjusted hazard ratio estimate (up to 10 years) 
with 95% CIs (dashed lines) for a ten-unit increase in IHC4 score for all ER-positive patients (A and B) and ER-
positive patients treated with endocrine therapy only (C and D) in the Edinburgh BCS (A and C) and TEAM (B 
and D) cohorts. Adjusted for Mammostrat score, age, grade, nodes positive, treatment and chemotherapy. Red line 
at hazard ratio of 1 corresponds to a null effect. 
 
IHC4 was identified for ER-positive patients treated with endocrine therapy only in the TEAM 
cohort and was prognostic up to 6 years of follow-up. However no time-varying effects were 
identified for ER-positive patients treated with endocrine therapy in the Edinburgh BCS cohort 
and IHC4 was not an independent predictor of outcome (HR 1.0, 95% CI 1.0-1.1). Table 8.13 
gives the hazard ratio estimates for Mammostrat score after adjustment for time-varying IHC4 
score. Mammostrat score was an independent predictor of outcome in the first 10-years of 
follow-up for both patient subgroups in the Edinburgh BCS cohort and all ER-positive patients 
in the TEAM cohort. Mammostrat score was not an independent predictor of outcome after 




Table 8.13 Multivariate Cox regression of Mammostrat score after adjustment for time-varying IHC4 score up to 
10-years follow-up 
  All ER-Positive   ER-Positive Endocrine Only 
  
Edinburgh BCS 
(n=1,103)   
TEAM  
(n=3,766)   
Edinburgh BCS 
(n=831)   
TEAM   
(n=2,513) 
Main 
Effect HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
MvL 1.67 (1.14-2.45)   1.34 (1.05-1.71)   1.78 (1.13-2.80)   1.19 (0.87-1.63) 
HvL 1.37 (0.85-2.21)   1.67 (1.34-2.09)   1.62 (0.95-2.76)   1.35 (1.01-1.81) 
NOTE. Multivariate analysis for Mammostrat score with follow-up censored at 10 years. 
Hazard ratios for risk of TTDR calculated for either high-risk or moderate-risk Mammostrat 
score compared with low Mammostrat scores at baseline. Values represent estimated hazard 
ratios and 95% CIs for all ER-positive patients and ER-positive patients who received no 
chemotherapy in the Edinburgh BCS and TEAM cohorts. Abbreviations: TTDR, time to 
distant-recurrence; CI, confidence interval; HvL, high risk v low risk Mammostrat  score; MvL, 
moderate risk v low risk Mammostrat score. * Adjusted for time-varying IHC4 score, age, 
grade, tumour size, nodes positive, treatment and chemotherapy.  
 
positive patients treated with endocrine therapy only in the TEAM cohort, however those 
classified as high risk compared to low risk had an increased hazard of 1.4 (95% CI, 1.0-1.8). 
8.3.2.2 Full follow-up 
Performing the FPT algorithm on the Edinburgh BCS cohort with full follow-up (max 25 
years), ICH4 score was determined to have a non-proportional effect in both patient subgroups 
(Figure 8.13). For all ER-positive patients, again we see the hazard ratio crossing the value 1, 
but after approximately 11 years there appears to be a significantly reduced hazard of TTDR 
corresponding with higher scores.  
Mammostrat score was determined to have a significant time-by-covariate interaction for high 
risk versus low risk. There was uncertainty in the best fitting FP to model the interaction, with 
log-time chosen for all ER-positive patients and time-cubed chosen for ER-positive patients 
treated with endocrine therapy only (Figure 8.14). The hazard ratio comparing high risk 
patients to low risk as categorised by Mammostrat score crosses the value 1 at approximately 
7 and 9 years for all ER-positive patients and ER-positive patients treated with endocrine 
therapy only respectively. However, the confidence intervals are wide due to the small number 




Figure 8.13 IHC4 Score. Time-dependent adjusted hazard ratio estimate (full follow-up) with 95% CIs (dashed 
lines) for a ten-unit increase in IHC4 score for (A) all ER-positive patients and (B) ER-positive patients treated 
with endocrine therapy only in the Edinburgh BCS cohort. Adjusted for age, grade, nodes positive and 
chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect. 
 
 
Figure 8.14 Mammostrat Score. Time-dependent adjusted hazard ratio estimate (full follow-up) with 95% CIs 
(dashed lines) for high risk compared to low risk Mammostrat score in the Edinburgh BCS cohort for (A) all ER-
positive patients and (B) ER-positive patients treated with endocrine therapy only. Adjusted for age, grade, nodes 
positive and chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect. 
 
Both Scores 
When IHC4 and Mammostrat were entered simultaneously into a model, only IHC4 score was 
identified as having a time-varying effect for all ER-positive patients (Figure 8.15A). 
Suggesting the time-varying effect of high risk Mammostrat score was due to omission of 
important variables (i.e. ER, PgR, Ki67 and HER2 included in the IHC4 score). Higher IHC4 
scores were associated with an increased hazard up to 4 years and then a protective effect for 




Figure 8.15 IHC4 Score – Simultaneous Analysis. Time-dependent adjusted hazard ratio (full follow-up) with 95% 
CIs (dashed lines) for a ten-unit increase in IHC4 score in the Edinburgh BCS cohort for (A) all ER-positive patients 
and (B) ER-positive patients treated with endocrine therapy only. Adjusted for Mammostrat score, age, grade, 
nodes positive, treatment and chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect. 
 
after adjustment for time-varying IHC4 and clinical variables were 1.6 (95% CI, 1.1-2.2) and 
1.2 (95% CI 0.8-1.9) for medium and high risk compared to low risk for all ER-positive 
patients.  
Neither score was identified as having a significant time-by-covariate interaction by the FPT 
algorithm for ER-positive patients treated with endocrine therapy-only. Despite the addition 
of a time-by-covariate interaction for IHC4 not improving the model deviance and therefore 
not identified in the FPT algorithm, there was still a decrease over time (Figure 8.15B) which 
was statistically significant as assessed by a Wald test. It demonstrates that IHC4 is prognostic 
up to 4 years of follow-up only. After adjustment for a time-varying IHC4 score and clinical 
factors, this gave hazard ratio estimates of 1.62 (95% CI, 1.09-2.42) and 1.30 (95% CI, 0.79-
2.13) for medium and high risk compared to low risk Mammostrat score. Not including a time-
varying effect for IHC4 results in an adjusted hazard ratio estimate for a ten-unit increase in 
IHC4 score of 1.02 (95% CI, 0.99-1.06) and very similar Mammostrat score hazard ratio 
estimates of 1.63 (95% CI, 1.09-2.43) and 1.33 (95% CI, 0.81-2.17) for medium and high risk 




8.3.2.3 Exploratory Subgroups 
When IHC4 and Mammostrat were simultaneously entered into the model, IHC4 score was 
found to have a non-proportional effect in the higher risk node-positive subgroups in the 
TEAM cohort. Therefore the results are the same as those found when assuming proportional 
hazards in chapter 7 for ER-positive, node-negative patients treated with endocrine therapy 
only where both scores remained independent predictors of outcome. In those ER-positive and 
node-positive, the effect of IHC4 score decreased as follow-up increased (Figure 8.16). IHC4 
score was prognostic up to 4 years for those treated with endocrine therapy only and 5 years 
irrespective of treatment. Mammostrat remained an independent predictor of TTDR in those 
ER-positive, node-positive patients (irrespective of treatment) in the TEAM cohort with 
adjusted hazard ratio estimates of 1.35 (95% CI, 1.03-1.78) and 1.47 (95% CI, 1.14-1.91) for 
medium and high risk compared to low risk Mammostrat score respectively.  
 
 
Figure 8.16 IHC4 Score – Exploratory Subgroups. Time-dependent adjusted hazard ratio with 95% CIs (dashed 
lines) for a ten-unit increase in IHC4 score for (A) ER-positive, node-positive patients treated with endocrine 
therapy only and (B) ER-positive, node-positive patients, irrespective of treatment in the TEAM cohort. Adjusted 
for Mammostrat score, age, grade, nodes positive, treatment and chemotherapy. Red line at hazard ratio of 1 
corresponds to a null effect. 
 
In the Edinburgh BCS cohort, for the lower risk patients treated with endocrine therapy only 
no variables were identified as having a significant time-by-covariate effect, resulting in the 
same conclusions as from a proportional hazards analysis. IHC4 score was a significant 
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independent of predictor of outcome for those ER-positive, node-negative and treated with 
endocrine therapy only with a hazard ratio estimate of 1.06 (95% CI, 1.02-1.11) for a ten-unit 
increase in IHC4 score. Mammostrat score was not an independent predictor of outcome but 
those classified as medium risk had an increase hazard of 1.69 (95% CI, 1.02-2.78) compared 
to those with low risk Mammostrat score. Neither score remained an independent predictor of 
outcome in those node-positive and treated with endocrine therapy only; however IHC4 score 
showed a trend towards a protective effect for higher scores with a hazard ratio estimate of 
0.95 (95% CI, 0.89-1.01) for a ten-unit increase. Mammostrat score estimates showed a trend 
toward higher risk associated with higher scores with hazard ratio estimates of 1.51 (95% CI, 
0.75-3.03) and 1.74 (95% CI, 0.74-4.08) for medium and high risk compared to low risk 
Mammostrat score. In the higher risk exploratory subgroup of node-positive patients 
(irrespective of treatment), IHC4 was identified as having a significant covariate-time 
interaction (Figure 8.17). The effect of IHC4 decreased over time, higher scores were 
associated with an increased hazard in the first 3 years of follow-up and a significantly 
decreased hazard beyond 6.5 years. Mammostrat score was not an independent predictor (after 
adjustment for time-varying IHC4 score and clinical factors) for those ER-positive, node-
positive patients. However there was a trend towards higher risk associated with higher scores 
with adjusted hazard ratio estimates of 1.55 (95% CI, 0.86-2.79) and 1.41 (95% CI, 0.67-2.98) 




Figure 8.17 IHC4 Score – Simultaneous Analysis (Exploratory Subgroups). Time-dependent adjusted hazard ratio 
estimate with 95% CIs (dashed lined) for a ten-unit increase in IHC4 score for ER-positive, node-positive patients 
in the Edinburgh BCS cohort. Adjusted for Mammostrat score, age, grade, nodes positive and chemotherapy. Red 
line at hazard ratio of 1 corresponds to a null effect.  
 
8.3.2.4 Combined Score 
There was no evidence to reject the proportional hazards assumption for the combined score, 
with no significant time-by-covariate interaction identified by the FPT algorithm in the TEAM 
cohort. The combined score was an independent predictor of outcome up to 10 years follow-
up in both patient subgroups with hazard ratio estimates of 1.4 (95% CI, 1.1-1.9) and 2.6 (95% 
CI, 2.0-3.3) for medium and high risk combined score to low risk combined score for all ER-
positive patients. Similarly, hazard ratio estimates were 1.4 (95% CI, 1.0-2.0) and 2.2 (95% 
CI, 1.6-3.1) for ER-positive patients treated with endocrine therapy only. 
Considering full follow-up in the Edinburgh BCS cohort, medium risk compared to low risk 
combined score was also identified to satisfy the proportional hazards assumption with hazard 
ratio estimates of 1.4 (95% CI, 1.0-2.1) and 1.4 (95% CI, 0.9-2.3) for all ER-positive patients 
and ER-positive patients treated with endocrine therapy only, respectively, over the full 
follow-up. However, high risk compared to low risk was identified to have a significant time-
by-covariate interaction in both patient subgroups with the best fitting model to be log-time. 
The effect was decreasing over time, with the HR estimate crossing the value one at 
approximately 10 years for all ER-positive patients and 15 years for ER-positive patients 
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treated with endocrine therapy only (Figure 8.18). In the first year of follow-up we see a large 
increase in hazard for those classified as high risk compared to low risk, with an estimated 
adjusted hazard ratio at one year of 5.8 (95% CI, 2.7-12.3) for all ER-positive patients and 
similarly 5.8 (95% CI, 2.4-13.8) for ER-positive patients treated with endocrine therapy only.  
However the confidence intervals are very wide. The very large increase in hazard at early 
time points is due to zero events in the low risk group in the first two years of follow-up 
compared with 20 in the high risk group.  
 
 
Figure 8.18 Combined Score. Time-dependent adjusted hazard ratio estimate (full follow-up) with 95% CIs 
(dashed lines) for high risk compared to low risk combined score in the Edinburgh BCS cohort for (A) all ER-
positive patients and (B) ER-positive patients treated with endocrine therapy only. Adjusted for age, grade, nodes 
positive and chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect. 
 
Exploratory Subgroups 
No time-varying effects of variables were identified for the exploratory subgroups in the 
TEAM cohort. Hazard ratio estimates are given in Table 8.14 and the combined score 
remained an independent predictor of outcome in all exploratory subgroups. 
In the Edinburgh BCS cohort, the time-varying effect of high risk combined score remained 
in the exploratory subgroups (Figure 8.19). The combined score was prognostic of outcome in 
those ER-positive, node-negative and treated with endocrine therapy only with a hazard ratio 
estimate of 2.1 (95% CI, 1.1-4.0) for medium compared to low risk combined score and  
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Table 8.14 Multivariate Cox regression of the Combined score for the exploratory subgroups in the TEAM cohort 
  
ER-Positive, 
Endocrine Only and 
Node-Negative   
ER-Positive, 
Endocrine Only and 





Effect HR (95% CI)   HR (95% CI)   HR (95% CI) 
MvL 2.21 (1.09-4.46)   1.29 (0.88-1.90)   1.28 (0.95-1.74) 
HvL 3.57 (1.77-7.19)   1.95 (1.32-2.89)   2.27 (1.67-3.07) 
NOTE. Multivariate Cox regression analysis for the Combined score in the TEAM 
cohort. Hazard ratios for risk of TTDR calculated for either high-risk or moderate-risk 
Combined score compared with low Combined score at baseline. Values represent 
estimated hazard ratios and 95% CIs for all ER-positive patients and ER-positive 
patients who received no chemotherapy in the Edinburgh BCS and TEAM cohorts. 
Abbreviations: TTDR, time to distant-recurrence; CI, confidence interval; HvL, high risk 
v low risk Combined  score; MvL, moderate risk v low risk Combined score. * Adjusted 
for age, grade, tumour size, nodes positive, treatment and chemotherapy.  
 
 
Figure 8.19 Combined Score (exploratory subgroups). Time-dependent adjusted hazard ratio estimate (full follow-
up) with 95% CIs (dashed line) for high risk compared to low risk combined score in the Edinburgh BCS cohort 
for (A) ER-positive, node-negative and treated with endocrine therapy only, (B) ER-positive, node-positive and 
treated with endocrine therapy only, and (C) ER-positive, node-positive irrespective of treatment. Adjusted for age, 
grade, nodes positive and chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect. 
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those high risk had an increase hazard compared to those classified as low risk up to 10 years. 
The combined score was not an independent predictor of outcome in those ER-positive, node-
positive and treated with endocrine therapy only. In ER-positive, node-positive patients 
(irrespective of treatment), those high risk had an increased hazard compared to those low risk 
in the first 3 years of follow-up. 
8.3.2.5 Discrimination of Time-Varying Models 
Now we have identified which variables have non-proportional effects and the functional form 
to model these effects, it is of interest to look at the difference in model discrimination when 
including time-varying effects and also the comparison between IHC4 and Mammostrat score.  
To calculate Royston & Sauerbrei’s index of discrimination (D) and R2 including time-varying 
effects, it is necessary to split the data at each unique event time which allows an interaction 
between time and the covariate to be fitted. 
10-Year Follow-Up 
The results are given in Table 8.15 for follow-up restricted to 10 years. There is improvement 
in model discrimination when including a time-varying effect for IHC4 score with increases 
in D-statistic between 0.08 and 0.32 and increases in R2 between 2.2% and 9.8%. Despite the 
IHC4 score not being prognostic in ER-positive patients treated with endocrine therapy only 
in the Edinburgh BCS cohort (p=0.07) there was still improvement in the model discrimination 
when a time-varying effect was included (increase in D-statistic of 0.11 and R2 of 5.4%). 
IHC4 and Mammostrat score were significant independent predictors of TTDR up to 10 years 
in both cohorts and both patient subgroups (p<0.05), except for IHC4 score in ER-positive 
patients treated with endocrine therapy in the Edinburgh BCS cohort (p=0.07). The IHC4 score 
consistently provided more improvement in model discrimination over clinical  
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Table 8.15 Wald tests and performance data for assessing the amount of information added by the time-varying IHC4 score or the Mammostrat score 
or both to clinical factors in the first 10 years of follow-up. 
  Edinburgh BCS    TEAM 
Model 
Wald test       
(p-value) 
% Increase 
in R2  
Increase 
in D 
Statistic   
Wald test         
(p-value) 
% Increase 




All ER-Positive (n=1,103)   (n=3,766) 
C vs. Null (7 df) 13.1 (<0.001) 27.5 1.26   326.1 (<0.001) 26.7 1.23 
C + IHC4 vs. C (1 df) 4.3 (0.04) 0.9 0.03   56.1 (<0.001) 3.4 0.11 
C + IHC4 (TV) vs. C + IHC4 (1 df) 9.2 (0.002) 9.8 0.32   9.4 (0.002) 2.6 0.09 
C + Mam vs. C (2 df) 4.1 (0.02) 1.5 0.05   32.5 (<0.001) 2.2 0.08 
C + IHC4 (TV) + Mam vs. C (4 df) 5.0 (<0.001) 11.2 0.37   86.4 (<0.001) 7.3 0.24 
C + IHC4 (TV) + Mam vs. C + IHC4 (TV) (2 df) 3.5 (0.03) 0.5 0.02   20.2 (<0.001) 1.3 0.04 
C + IHC4 (TV) + Mam vs. C + Mam (2 df) 6.0 (0.003) 9.7 0.32   52.3 (<0.001) 5.1 0.16 
ER-Positive Endocrine Only (n=831)   (n=2,513) 
C vs. Null (7 df) 16.8 (<0.001) 24.3 1.35   217.3 (<0.001) 28.7 1.30 
C + IHC4 vs. C (1 df) 3.2 (0.07) 0.6 0.03   30.1 (<0.001) 3.3 0.10 
C + IHC4 (TV) vs. C + IHC4 (1 df) 2.2 (0.14) 5.4 0.11   5.7 (0.02) 2.2 0.08 
C + Mam vs. C (2 df) 4.0 (0.02) 1.3 0.06   9.9 (<0.007) 1.4 0.04 
C + IHC4 (TV) + Mam vs. C (4 df) 3.0 (0.02) 6.8 0.18   40.6 (<0.001) 6.1 0.19 
C + IHC4 (TV) + Mam vs. C + IHC4 (TV) (2 df) 3.4 (0.03) 0.8 0.04   4.3 (0.12) 0.6 0.01 
C + IHC4 (TV) + Mam vs. C + Mam (2 df) 2.01 (0.13) 5.5 0.12   29.8 (<0.001) 4.7 0.15 
NOTE. Values represent Wald tests (significance level) and the increase in R2 and D statistic for the addition of IHC4 or Mammostrat score or 
both. IHC4 (TV) refers to including a time-varying effect for IHC4, with an interaction between IHC4 and log (time). Results are given for ER-
positive patients and ER-positive patients who received no chemotherapy in the Edinburgh BCS and TEAM cohorts with follow-up restricted to 
10 years. Abbreviations: C, clinical model with age, grade, tumour size, nodal status, treatment and chemotherapy; Null, null model with no 
covariates; IHC4, IHC4 score; Mam, Mammostrat score; df, degrees of freedom; TV, time-varying. 
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factors than the Mammostrat score (e.g. increase in D-statistic: 0.20 versus 0.08 and increase 
in R2: 6.0% versus 2.2%, for all ER-positive patients in the TEAM cohort). 
Both scores remained significant independent predictors of TTDR restricted to the first 10 
years of follow-up when simultaneously entered into a multivariate Cox regression for all ER-
positive patients. Whereas for ER-positive patients treated with endocrine therapy, only 
Mammostrat score remained an independent predictor of outcome (p=0.03) in the Edinburgh 
BCS cohort. Oppositely in the TEAM cohort, only IHC4 score remained an independent 
predictor of outcome where the addition of Mammostrat score did not provide any prognostic 
information over and above that provided by IHC4 and clinical factors (p=0.1, increase in D-
statistic: 0.01, increase in R2: 0.6%). However, after adjustment for IHC4 and clinical factors, 
those classified as high risk Mammostrat score had an increased hazard of 1.4 (95% CI, 1.0-
1.81) compared with low risk Mammostrat score.  
25-Year Follow-Up 
Results are given in Table 8.16 for full-up in the Edinburgh BCS cohort. Again we see a large 
improvement in model discrimination when a time-varying effect of IHC4 score is included 
in the model with increases in D-statistic of 0.4 and 0.2 and R2 of 12 and 5% for all ER-positive 
patients and ER-positive patients treated with endocrine therapy only respectively. The same 
is not seen however for including a time-varying effect of Mammostrat score, with increases 
in D-statistic of 0.06 and 0.01 and R2 of 2 and 2.1% for all ER-positive patients and ER-
positive patients treated with endocrine therapy only respectively.  
Over the full follow-up, both scores remained significant predictors of outcome when 
simultaneously entered into a multivariate Cox regression for all ER-positive patients only. 
Only IHC4 score remained an independent predictor of outcome for ER-positive patients 
treated with endocrine therapy only but this is driven by the high risk Mammostrat score  
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Table 8.16 Wald tests and performance data for assessing the amount of information added by the time-varying 
IHC4 score or the Mammostrat score or both to clinical factors for full-follow-up in the Edinburgh BCS cohort. 
  Edinburgh BCS  
Model 
Wald test       
(p-value) 
% Increase 




All ER-Positive (n=1,103) 
C vs. Null (7 df) 13.1 (<0.001) 22.7 1.11 
C + IHC4 vs. C (1 df) 2.6 (0.11) 0.4 0.01 
C + IHC4 (TV) vs. C + IHC4 (1 df) 16.7 (<0.001) 12.0 0.38 
C + Mam vs. C (2 df) 3.6 (0.03) 1.2 0.04 
C + Mam (TV) vs. C + Mam (1 df) 4.5 (0.03) 2.0 0.06 
C + IHC4 (TV) + Mam vs. C (4 df) 6.5 (<0.001) 13.1 0.42 
C + IHC4 (TV) + Mam vs. C + IHC4 (TV) (2 df) 3.2 (0.04) 0.6 0.02 
C + IHC4 (TV) + Mam vs. C + Mam (2 df) 9.3 (0.001) 9.8 0.32 
ER-Positive Endocrine Only (n=831) 
C vs. Null (7 df) 16.1 (<0.001) 24.3 1.16 
C + IHC4 vs. C (1 df) 2.5 (0.11) 0.6 0.02 
C + IHC4 (TV) vs. C + IHC4 (1 df) 5.1 (0.02) 5.4 0.17 
C + Mam vs. C (2 df) 3.1 (0.04) 1.3 0.04 
C + Mam (TV) vs. C + Mam (1 df) 3.7 (0.06) 2.1 0.07 
C + IHC4 (TV) + Mam vs. C (4 df) 3.3 (0.01) 6.9 0.22 
C + IHC4 (TV) + Mam vs. C + IHC4 (TV) (2 df) 2.8 (0.06) 0.8 0.03 
C + IHC4 (TV) + Mam vs. C + Mam (2 df) 3.5 (0.03) 3.5 0.11 
NOTE. Values represent Wald tests (significance level) and the increase in R2 and D 
statistic for the addition of IHC4 or Mammostrat score or both. (TV) refers to including a 
time-varying effect for either IHC4 or Mammostrat score. Results are given for ER-
positive patients and ER-positive patients who received no chemotherapy in the 
Edinburgh BCS cohort with full follow-up. Abbreviations: C, clinical model with age, 
grade, tumour size, nodal status, treatment and chemotherapy; Null, null model with no 
covariates; IHC4, IHC4 score; Mam, Mammostrat score; df, degrees of freedom; TV, 
time-varying. 
 
patients, with patients classified as medium risk having a significantly increased hazard of 1.6 
(95% CI, 1.1-2.4) compared with those classified as low risk Mammostrat score. 
8.3.3 Summary 
A summary of time-varying effects identified by the FPT algorithm is displayed in Table 8.17. 
IHC4 had a strong time-varying effect for all ER-positive patients and ER-positive patients 
treated with endocrine therapy only in the TEAM cohort. Despite IHC4 being identified as 
having a time-varying for all ER-positive patients in the Edinburgh BCS cohort,  
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Table 8.17 Time-varying effects identified by the FPT algorithm 
  10-Year Follow-Up   Full Follow-Up 
  Edinburgh BCS   TEAM   Edinburgh BCS 
  IHC4 MAM   IHC4 MAM   IHC4 MAM 
Separate IHC4 & MAM               
All ER+          
ER+, Endocrine Only          
Simultaneous IHC4 & MAM               
All ER+          
ER+, Endocrine Only          
Note. Summary of whether IHC4 or Mammostrat (MAM) were identified as 
having a time-varying effect by the FPT algorithm after adjustment for age, 
grade, tumour size, grade, treatment and chemotherapy. IHC4 & Mammostrat 
were entered separately or simultaneously into a Cox regression model. Results 
are given for the main analysis subgroups: all ER-positive (ER+) and all ER-
positive treated with endocrine therapy only. 
 
this was not the case for ER-positive patients treated with endocrine therapy only. Figure 8.20 
illustrates the results for the different subgroups. Plot A illustrates a time-varying effect of 
IHC4 compared to a time-constant, with a large over-lap of confidence intervals. Plot B 
illustrates the comparison of effects for all ER-positive patients and ER-positive patients 
treated with endocrine therapy only. The effect of a ten-unit increase in IHC4 for the lower 
risk ER-positive patients treated with endocrine therapy only is not as large at early time-points 
as the higher risk group of all ER-positive patients. This makes clinical sense with those treated 
with chemotherapy at an increased risk of early events. However, there is a large overlap in 
confidence intervals suggesting results are not dissimilar for the two patient subgroups. 
A summary of whether IHC4 or Mammostrat were significant predictors of outcome with 
inclusion of time-varying effects previously identified (Table 8.17) is displayed in Table 8.18. 
Overall, IHC4 and Mammostrat were independent predictors of outcome when analysed 




Figure 8.20 Comparison of adjusted effect and 95% CIs (dashed lines) for a ten-unit increase in IHC4. Plots 
represent (A) Time-constant (PH) versus time-varying (TV) for ER-positive patients treated with endocrine 
therapy in the Edinburgh BCS cohort and (B) Time-varying effect for all ER-positive patients versus ER-positive 
patients treated with endocrine therapy only in the Edinburgh BCS cohort. Red line at hazard ratio of 1 indicates 
null effect.   
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Table 8.18 Significant predictors of TTDR after identification of time-varying effects 
  10-Year Follow-Up   Full Follow-Up 
  Edinburgh BCS   TEAM   Edinburgh BCS 
  IHC4 MAM   IHC4 MAM   IHC4 MAM 
Separate IHC4 & MAM               
All ER+          
ER+, Endocrine Only *         
Simultaneous IHC4 & MAM               
All ER+          
ER+, Endocrine Only          *
Note. Summary of whether IHC4 or Mammostrat (MAM) were independent 
predictors of TTDR after adjustment for age, grade, tumour size, grade, 
treatment and chemotherapy. IHC4 & Mammostrat were entered separately or 
simultaneously into a Cox regression model with time-varying effects as 
previously identified. Results are given for the main analysis subgroups: all ER-
positive (ER+) and all ER-positive treated with endocrine therapy only only. * 





Figure 8.21 Comparison of estimated effects between subgroups. Hazard ratios and 95% CIs for Mammostrat 
medium vs. low risk (MvL) and high vs. low risk (HvL) for all ER-positive (ER+) patients and ER-positive 




overall not an independent predictor of outcome for ER-positive patients treated with 
endocrine therapy in the TEAM cohort, however those Mammostrat high risk had a 
significantly increased hazard compared to Mammostrat low risk. The difference in the 
significance of Mammostrat score between the two subgroups may be due to the reduced 
number of events in the ER-positive, endocrine therapy  only subgroup with overlaps in the 
estimated confidence intervals (Figure 8.21). 
8.4 RP Flexible Parametric Models 
So far, we have focussed on the Cox proportional hazards model and it’s extensions to 
accommodate non-proportional effects. The literature review identified a parametric approach: 
flexible parametric models developed by Royston & Parmer (RP flexible parametric models) 
(see section 4.7).  
These models involve modelling on the log-cumulative hazard scale and the baseline hazard 
is fitted using restricted cubic splines. They are fitted using the stpm2 command in STATA. 
8.4.1 Results 
8.4.1.1 Baseline hazard 
The first step of fitting an RP model is to determine the degree of flexibility for the baseline 
hazard function. In both the Edinburgh BCS and TEAM cohorts, the simplest model with 2 
degrees of freedom corresponded to the lowest AIC and BIC values (Figure 8.22). The 
Edinburgh BCS cohort had a consistently lower distant recurrence rate than the TEAM cohort 
(Figure 8.23) but the trend over time was similar. The recurrence rate peaked at 2 years with 
approximately 29 distant recurrences per 1000 person-years and a ten-year estimate of 19 per 
1000 person-years for the TEAM cohort. In the Edinburgh BCS cohort the recurrence rate 
peaked at 24 distant recurrences per 1000 person-years at almost 3 years with a ten-year 




Figure 8.22 Modelling the baseline hazard (distant recurrence rate per 1000 person-years (PY)) with different 





Figure 8.23 Comparison of baseline hazard rates (per 1000 person-years (PY)) for the Edinburgh BCS and TEAM 
cohorts. 
 
8.4.1.2 Non-proportional effects 
Time-varying effects are included easily by creating an interaction with the covariate and the 
spline terms. They are chosen using a specified degrees of freedom and a forward selection 
algorithm. This was performed using the stpm2t command in STATA. Once the time-varying 
effects are identified, the degree of flexibility needed to model the time-varying effect is 
determined by examining the AIC and BIC values.  
10-Year Follow-up 
The algorithm identified IHC4 to have a time-varying effect for all ER-positive patients in 
both cohorts with 1 degrees of freedom identified as the best fitting model indicated by the 
lowest AIC and BIC values (Figure 8.24). The hazard ratio estimate crosses the value 1 at 
approximately 6.5 years in the Edinburgh BCS cohort (Figure 8.25). The hazard ratio estimate 
does not cross the value 1 in the TEAM cohort but the lower confidence bound crosses 1 at 
approximately 9 years. We can see a stronger effect of IHC4 score in the first 2 years, with a 
two-year hazard ratio estimate of 1.8 (95% CI, 1.3-2.3) and 1.6 (95% CI, 1.4-1.8) in the 




Figure 8.24 Different degrees of freedom (df) for the time-varying ICH4 score and the proportional hazards 
estimate (PH). Hazard ratio calculated from between the 75th centile to the 25th centile of IHC4 score. Plots represent 
all ER-positive patients in the (A) Edinburgh BCS and (B) TEAM cohorts. 
 
Figure 8.25 All ER-positive patients. Time-dependent adjusted hazard ratio estimate (up to 10 years) with 95% 
CIs (dashed lines) for the 75th percentile to the 25th percentile of IHC4 score for all ER-positive patients in the (A) 
Edinburgh BCS cohort and (B) TEAM cohorts. Adjusted for age, grade, nodes positive, treatment and 
chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect.  
 
 
Figure 8.26 ER-positive patients treated with endocrine therapy. Time-varying effect of IHC4 score for in the 
TEAM cohort. Plots represent (A) different degrees of freedom (df) for the time-varying ICH4 score and the 
proportional hazards estimate (PH) and (B) the time-dependent adjusted hazard ratio estimate with 95% CIs (dashed 
lines) for the 75th percentile to the 25th percentile of IHC4 score. Red line indicating a hazard ratio of 1 
corresponding to a null effect. 
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It is important to note in the extended Cox regression models, the plots of the time-varying 
effects were for a ten-unit increase in IHC4 score. However due to the parametric nature of 
the RP models and the time-varying effects modelled by an interaction between the covariate 
and spline terms, the predictions are based on specific values of IHC4 score. Here we are 
looking at the 75th compared to the 25th centile of IHC4 score. 
Equivalent to the MFPT algorithm, IHC4 score was only identified as having a time-varying 
effect for ER-positive patients treated with endocrine therapy in the TEAM cohort only (Figure 
8.26). This results in a time-constant estimate of 1.04 (95% CI 1.00-1.09) for a ten-unit 
increase in IHC4 score in the Edinburgh BCS cohort.  
Again equivalently to the MFPT approach, no time-varying effects of Mammostrat score was 
identified in the first 10 years of follow-up for both cohorts. Estimated hazard ratios are given 
in Table 8.19. 
 
Table 8.19 Flexible parametric regression of Mammostrat score up to 10-years follow-up 
  All ER-Positive   ER-Positive Endocrine Only 
  
Edinburgh BCS 
(n=1,103)   
TEAM                  
(n=3,766)   
Edinburgh BCS 
(n=831)   
TEAM                  
(n=2,513) 
Main 
Effect HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI) 
MvL 1.59 (1.13-2.24)   1.42 (1.12-1.81)   1.79 (1.15-2.82)   1.28 (0.94-1.75) 
HvL 1.31 (0.86-2.00)   1.90 (1.53-2.37)   1.79 (1.08-2.97)   1.58 (1.20-2.09) 
NOTE. Multivariate analysis for Mammostrat score with follow-up censored at 10 years from 
RP model. Hazard ratios for risk of TTDR calculated for either high-risk or moderate-risk 
Mammostrat score compared with low Mammostrat scores at baseline. Values represent 
estimated hazard ratios and 95% CIs for all ER-positive patients and ER-positive patients 
who received no chemotherapy in the Edinburgh BCS and TEAM cohorts. Abbreviations: 
TTDR, time to distant-recurrence; CI, confidence interval; HvL, high risk v low risk 
Mammostrat  score; MvL, moderate risk v low risk Mammostrat score. * Adjusted for age, 






25 Year Follow-Up 
The time-varying effect of IHC4 score over the full follow-up in the Edinburgh BCS cohort is 
shown in Figure 8.27 for both patient subgroups. The time-varying effect is not as prominent 
in ER-positive patients treated with endocrine therapy and IHC4 is only prognostic of TTDR 
in the first 4 years of follow-up. For all ER-positive patients, IHC4 score is prognostic for the 
first 5 years of follow-up, with higher scores corresponding to an increased hazard (4.5 year 
hazard ratio estimate of 1.2 (95% CI, 1.0-1.5)). After approximately 14.5 years, higher scores 
correspond to a decreased hazard with a 15 year hazard ratio estimate of 0.8 (95% CI, 0.6-1.0). 
 
Figure 8.27 Time-dependent adjusted hazard ratio estimate (full follow-up) with 95% CIs (dashed lines) for 75th 
centile compared to 25th centile of IHC4 score for (A) all ER-positive patients and (B) ER-positive patients treated 
with endocrine therapy only in the Edinburgh BCS cohort. Adjusted for age, grade, nodes positive and 
chemotherapy. Red line at hazard ratio of 1 corresponds to a null effect. 
 
Mammostrat score was not identified as having a non-proportional effect in either patient 
subgroup over full follow-up in the Edinburgh BCS cohort as indicated by similar AIC and 
BIC values between a time-constant and time-varying model (Figure 8.28). Mammostrat score 
was an independent predictor of outcome for both subgroups with hazard ratio estimates for 
medium compared to low risk of 1.59 (95% CI, 1.13-2.42) and 1.64 (95% CI, 1.10-2.44) for 






Figure 8.28 Different degrees of freedom (df) for time-varying Mammostrat high risk and the proportional hazards 
estimate (PH). Hazard ratio estimate comparing high risk Mammostrat score to low risk Mammostrat score. Plots 
represent (A) all ER-positive patients and (B) ER-positive patients treated with endocrine therapy in the Edinburgh 
BCS cohort. Note. Convergence not achieved for 3 degrees of freedom in ER-positive patients treated with 
endocrine therapy only.  
 
Table 8.20 Flexible parametric regression of Mammostrat score over full follow-up in the Edinburgh BCS cohort 
  All ER-Positive   ER-Positive Endocrine Only 
Main Effect HR (95% CI)   HR (95% CI) 
MvL 1.59 (1.13-2.42)   1.64 (1.10-2.44) 
HvL 1.31 (0.86-2.00)   1.44 (0.90-2.31) 
NOTE. Multivariate analysis for Mammostrat score with full follow-up in the Edinburgh BCS cohort from 
an RP model. Hazard ratios for risk of TTDR calculated for either high-risk or moderate-risk Mammostrat 
score compared with low Mammostrat scores at baseline. Values represent estimated hazard ratios and 
95% CIs for all ER-positive patients and ER-positive patients who received no chemotherapy in the 
Edinburgh BCS cohort. Abbreviations: TTDR, time to distant-recurrence; CI, confidence interval; HvL, 
high risk v low risk Mammostrat  score; MvL, moderate risk v low risk Mammostrat score. * Adjusted for 
age, grade, tumour size, nodes positive, treatment and chemotherapy. 
 
Exploratory Subgroups 
The RP models identified the same time-varying effects as the MFPT algorithm: time-varying 
effect of IHC4 score in the higher risk node-positive subgroups in the TEAM cohort and a 
time-varying effect of IHC4 score in the higher risk node-positive (irrespective of treatment) 
subgroup in the Edinburgh BCS cohort.  
8.4.1.3 Absolute Predictions of survival 
A key advantage of using a parametric model over the Cox model is it is easy to transform 
model parameters to make predictions. As well as the predicted hazard ratios over time, which 
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is a relative measure, you can also look at absolute measures such as survival proportions and 
hazard rates.  
The first column of Figure 8.29 illustrates the difference in predicted hazard rates including a 
time-constant or a time-varying effect of IHC4. There is little difference for the 75th centile of 
IHC score but for the 25th centile having a time-constant effect over-estimates the predicted 
hazard rate at earlier time-points and then later on under-estimates the hazard rate in both 
cohorts. The second column of Figure 8.29 illustrates the difference in predicted hazard rates 
between the 75th and 25th centile of IHC4 score, with the difference initially increasing then 
decreasing over time. In the Edinburgh BCS cohort this difference is only significantly 
different from zero until approximately 4 years. The difference in predicted survival 
probability for the 75th to 25th centile of IHC4 score is again more prominent in the TEAM 
cohort (Figure 8.30), with an estimated reduction in survival of 1.7% (95% CI, 0.7-2.7) at 8 
years in the TEAM cohort compared with 0.9% (95% CI, -0.2-1.9) in the Edinburgh BCS 
cohort.  
Absolute predictions for Mammostrat score are shown in Figure 8.31. The issue with low 
numbers allocated to high risk Mammostrat score in the Edinburgh BCS cohort is highlighted 
with a larger difference in predicted hazard rates and survival probabilities for medium versus 
low Mammostrat score compared with high versus low Mammostrat score. In the TEAM 
cohort, high risk compared to low risk Mammostrat score results in an estimated increase in 
distant recurrence rate of 4.4 (95% CI, 1.3-7.5) per 1000 person-years and a decrease in 





Figure 8.29 Predicted distant recurrence rates per 1000 person-years for all ER-positive patients in the Edinburgh 
BCS (A and B) and TEAM (C and D) cohorts. The left column represents the predicted hazard for IHC4 score for 
the 75th centile and the 25th centile with either a time-constant (proportional) effect (dashed lines) or a time-varying 
effect (solid lines). The right column represents the difference in predicted distant recurrence rates and 95% 
confidence interval (dashed lines) between the 75th and 25th centile of IHC4 score. Estimates adjusted for 
Mammostrat score, age, grade, nodes positive, tumour size, treatment and chemotherapy.  
 
 
Figure 8.30 Predicted difference in survival probability and 95% confidence intervals (dashed lines) for the 75th 
centile compared to 25th centile of IHC4 score for all ER-positive patients in the (A) Edinburgh BCS and (B) TEAM 





Figure 8.31 Predicted difference in hazard rates and survival probability for medium and high risk Mammostrat 
score compared to low risk Mammostrat score for all ER-positive patients in the (A and B) Edinburgh BCS and (C 






8.4.1.4 Restricted mean survival time. 
Including non-proportional effects that are a function of continuous time is advantageous as it 
prevents categorising of the time-interval. However, this comes with the difficulty of providing 
an estimate of the effect over time. So far we have plotted the effect over time and read hazard 
ratio estimates at certain points in time.  
When dealing with non-proportional hazards, Royston & Parmer propose to estimate the 
restricted mean survival time (RMST)(Royston and Parmar, 2011). The restricted mean 
survival time, 𝜇(𝑡∗), of a random variable T is the mean of min(T, 𝑡∗). It may be evaluated as 
the area under the survival curve S(t) up to 𝑡∗: 




  . 
8.1.  
When T is time to death, we may think of 𝜇(𝑡∗) as the ‘𝑡∗-life expectancy’. 
Restricted-mean survival time estimates for t* equal to 5 and 10 years are given in Table 8.21. 
The differences in RMST are more prominent over the 10 years. Being in the 25th centile of 
IHC4 score increases the time-to distant-recurrence over 10 years by 0.9 (95% CI, 0.3-1.5) 
years compared to being in the 75th centile of IHC4 score for all ER-positive patients in the 
Edinburgh BCS cohort. Also, comparing low risk Mammostrat score to medium and high risk 
increases time-to distant recurrence by 0.9 (95% CI, 0.3-1.5) and 0.6 (95% CI, 0.3-1.5) years 
respectively. The improvement in time-to distant recurrence holds when IHC4 and 
Mammostrat are included simultaneously in the model. Larger improvements were seen for 
all ER-positive patients in the TEAM cohort, with an improvement of 1.0 (95% CI, 0.5-1.5) 
years for the 25th centile of IHC4 score compared to the 75th centile, and 0.9 (95% CI, 0.3-1.4) 
years and 1.7 (95% CI, 0.3-1.4) years for low risk Mammostrat score compared to medium 
and high risk respectively.  
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Table 8.21 5 and 10-year restricted-mean survival estimates for the Edinburgh BCS and TEAM cohorts 
 
 
With longer follow-up available in the Edinburgh BCS cohort, 15 and 20-year RMST 
differences were available (Table 8.22). The largest improvement in time-to distant recurrence 
was seen in low risk Mammostrat score compared to high risk over 20 years, with a difference 








TEAM                  
(n=2,513)
Diff in RMST 
(95% CI)
Diff in RMST 
(95% CI)
Diff in RMST 
(95% CI)
Diff in RMST 
(95% CI)
t* = 5 Years
Separate*
IHC4 (TV) 0.64 (0.17-1.11) 0.38 (0.03-0.73) 0.51 (0.02-1.00) 0.53 (0.12-0.94)
LvM 0.57 (0.10-1.05) 0.27 (-0.09-0.62) 0.59 (0.11-1.08) 0.26 (-0.15-0.68)
LvH 0.36 (0.09-1.05) 0.54 (-0.09-0.63) 0.53 (0.11-1.08) 0.51 (-0.16-0.68)
Combined*
IHC4 (TV) 0.60 (0.12-1.08) 0.30 (-0.04-0.64) 0.48 (-0.03-0.99) 0.47 (0.10-0.83)
LvM 0.50 (0.02-0.97) 0.17 (-0.16-0.51) 0.60 (0.10-1.11) 0.15 (-0.21-0.51)
LvH 0.20 (0.02-0.97) 0.34 (-0.17-0.51) 0.43 (0.10-1.11) 0.28 (-0.21-0.51)
t* = 10 Years
Separate*
IHC4 (TV) 0.90 (0.31-1.49) 1.01 (0.47-1.56) 0.90 (0.27-1.54) 1.19 (0.59-1.79)
LvM 0.90 (0.32-1.47) 0.85 (0.30-1.40) 0.90 (0.28-1.51) 0.71 (0.10-1.32)
LvH 0.60 (0.31-1.49) 1.65 (0.30-1.40) 0.60 (0.27-1.53) 1.32 (0.11-1.31)
Combined*
IHC4 (TV) 0.91 (0.28-1.53) 0.82 (0.27-1.36) 0.91 (0.24-1.58) 1.06 (0.45-1.66)
LvM 0.95 (0.34-1.55) 0.62 (0.09-1.16) 0.95 (0.30-1.59) 0.46 (-0.14-1.06)
LvH 0.43 (0.32-1.57) 1.17 (0.09-1.16) 0.43 (0.28-1.62) 0.85 (-0.14-1.06)
All ER-Positive ER-Positive Endocrine Only
NOTE. Difference in RMST for t* equal to 5 and 10 years for Mammostrat score and IHC4 
entered separately or simultaneously (combined analysis) into a Royston-Parmer flexible 
paramteric model. Difference in RMST  calculated as the difference in the IQR of the 
continuous IHC4 score and either high-risk or moderate-risk Mammostrat score compared 
with low Mammostrat scores at baseline.  Abbreviations: RMST, restricted mean survival 
time; CI, confidence interval; IHC4 (TV), time-varying IHC4 score; LvH, low risk v high risk 
Mammostrat  score; LvM, low risk v moderate risk Mammostrat score. * Adjusted for age, 
grade, tumour size, nodes positive, treatment and chemotherapy. 
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Diff in RMST 
(95% CI)
Diff in RMST 
(95% CI)
Diff in RMST 
(95% CI)
Diff in RMST 
(95% CI)
Separate*
IHC4 (TV) 1.14 (0.27-2.01) 0.97 (0.14-1.81) 1.23 (0.26-2.21) 1.05 (0.15-1.95)
LvM 1.48 (0.63-2.32) 1.26 (0.48-2.04) 1.85 (0.91-2.79) 1.42 (0.58-2.25)
LvH 0.96 (0.62-2.33) 1.14 (0.47-2.05) 1.22 (0.89-2.81) 1.29 (0.58-2.26)
Combined*
IHC4 (TV) 1.07 (0.19-1.96) 0.95 (0.08-1.83) 1.15 (0.16-2.15) 1.04 (0.09-1.99)
LvM 1.42 (0.56-2.23) 1.41 (0.57-2.25) 1.82 (0.87-2.77) 1.65 (0.75-2.56)
LvH 0.66 (0.55-2.29) 0.99 (0.56-2.27) 0.86 (0.84-2.80) 1.17 (0.73-2.58)
t* = 15 Years t* = 20 Years
NOTE. Difference in RMST for t* equal to 15 and 20 years for Mammostrat score and IHC4 
entered separately or simultaneously (combined analysis) into a Royston-Parmer flexible 
paramteric model. Difference in RMST  calculated as the difference in the IQR of the continuous 
IHC4 score and either high-risk or moderate-risk Mammostrat score compared with low 
Mammostrat scores at baseline.  Abbreviations: RMST, restricted mean survival time; CI, 
confidence interval; IHC4 (TV), time-varying IHC4 score; LvH, low risk v high risk Mammostrat  
score; LvM, low risk v moderate risk Mammostrat score. * Adjusted for age, grade, tumour size, 
nodes positive, treatment and chemotherapy. 
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8.4.1.5 Combined Score 
No time-varying effects were identified for the combined score in the TEAM cohort with 
hazard ratio estimates given in Table 8.23. The combined score was an independent predictor 
of outcome for both patient subgroups. 
Table 8.23 Flexible parametric regression of Combined score up to 10-years follow-up 
  All ER-Positive   ER-Positive Endocrine Only 
Main Effect HR (95% CI)   HR (95% CI) 
MvL 1.45 (1.10-1.90)   1.45 (1.04-2.03) 
HvL 2.55 (1.95-3.34)   2.23 (1.59-3.12) 
NOTE. Multivariate analysis for the Combined score with follow-up censored at 10 years 
from RP model. Hazard ratios for risk of TTDR calculated for either high-risk or 
moderate-risk Combined score compared with low Combined score at baseline. Values 
represent estimated hazard ratios and 95% CIs for all ER-positive patients and ER-
positive patients who received no chemotherapy in the Edinburgh BCS and TEAM 
cohorts. Abbreviations: TTDR, time to distant-recurrence; CI, confidence interval; HvL, 
high risk v low risk Mammostrat  score; MvL, moderate risk v low risk Mammostrat score. 
* Adjusted for age, grade, tumour size, nodes positive, treatment and chemotherapy.  
 
The forward selection algorithm identified the combined score to have a time-varying effect 
in the Edinburgh BCS cohort. The hazard ratio estimate crosses the value 1 at approximately 
9 years for all ER-positive patients and 19 years for ER-positive patients treated with endocrine 




Figure 8.32 Combined Score. Time-dependent adjusted hazard ratio estimate (full follow-up) in the Edinburgh 
BCS cohort with 95% CIs (dashed lines) for high risk compared to low risk combined score for (A) all ER-positive 
patients and (B) ER-positive patients treated with endocrine therapy only. Adjusted for age, grade, nodes positive, 




Again the same time-varying effects were identified as with the MFPT algorithm for the 
exploratory subgroups. There was no evidence to reject the PH assumption for the combined 
score in all exploratory subgroups in the TEAM cohort and was an independent predictor of 
outcome. The time-varying effect of high risk combined score remained in the Edinburgh BCS 
cohort. The combined score was prognostic of outcome for ER-positive, node-negative 
patients treated with endocrine therapy only and those ER-positive, node-positive (irrespective 
of treatment). 
8.4.2 Summary 
Royston-Parmer flexible parametric models were identified in the literature review as an 
alternative to Cox regression models. They explicitly model the baseline hazard with the use 
of restricted cubic splines. We illustrated modelling the baseline hazard using different degrees 
of freedom. The pattern over time that was observed, with a peak in distant recurrences at 
approximately 2-3 years is what has been previously observed in breast cancer. The Edinburgh 
BCS cohort was again highlighted as a lower risk population than the TEAM cohort, with a 
lower distant recurrence rate across all time points. 
RP models allow the inclusion of time-varying effects with an interaction between the 
covariate and the spline terms. Using a forward selection approach, the RP models identified 
the same time-varying effects as was identified with the FPT algorithm in the Cox models. 
One exception was in the Edinburgh BCS cohort considering full follow-up, where the FPT 
algorithm identified a time-varying effect for Mammostrat high risk whereas a time-constant 
effect was identified with the RP models. However, this results are similar with a large overlap 




Figure 8.33 Comparison of time-constant (PH) and time-varying (TV) effect and 95% CIs (dashed lines) for 
Mammostrat high risk versus low risk for all ER-positive patients in the Edinburgh BCS cohort. Red line at hazard 
ratio of 1 indicates null effect.   
 
The parametric nature of the RP models allow easy transformation of model parameters to 
make predictions in particular absolute risk measures rather than relative risk measures (e.g. 
the hazard ratio). This advantage was illustrated producing plots of differences in hazard rates 
and survival proportions for IHC4 and Mammostrat score. 
A novel measure, the restricted mean survival time, was illustrated as an alternative to the 
hazard ratio which has the advantage of a more intuitive interpretation and can also be 





8.5 Comparison of Approaches 
Focussing on the combined model including both scores as well as clinical factors, the 
comparison of the estimated effects from assuming proportional hazards and including time-
varying effects are explored. 
8.5.1 Extended Cox Model versus Proportional Hazards 
IHC4 was identified as having a time-varying effect in both the Edinburgh BCS and TEAM 
cohorts for all ER-positive patients. When assuming proportional hazards, this results in an 
initial under-estimation at earlier time-points then an over-estimation of the effect at later time-
points (Figure 8.34). You would conclude IHC4 and Mammostrat score are independent 
predictors of TTDR for all ER-positive patients over the 10 year follow-up in the TEAM 
cohort. However, when you allow for non-proportional hazards, Mammostrat score remains 
prognostic of outcome over the 10 years but IHC4 is only prognostic up to approximately 7 
years when the lower confidence bound crosses 1. In the Edinburgh BCS cohort, assuming 
proportional hazards you would conclude only Mammostrat score remains an independent 
predictor of outcome. Whereas allowing for non-proportional hazards IHC4 score is 
prognostic of outcome in the first 4 years of follow-up and beyond 11 years of follow-up where 
increasing IHC4 score has a protective effect.  
 
Figure 8.34 Comparison of extended Cox versus Cox PH model. Plots represent adjusted hazard ratio estimate 
from an extended Cox model (solid line) and a Cox model assuming proportional hazards (dashed line) for a ten 




Categorising time results in unrealistic jumps in hazard ratio estimates at cut-points. The five-
yearly intervals give some indication of the pattern over time in the larger TEAM cohort but 
unreliable estimates were observed in the Edinburgh BCS cohort (Figure 8.35). Similarly with 
two-yearly intervals, estimates are unreliable especially towards the end of follow-up where 
numbers of events are small (Figure 8.36).  
 
Figure 8.35 Comparison of extended Cox model and piece-wise constant effects. Adjusted hazard ratio estimate 
from an extended cox model with 95% confidence intervals (dashed lines) and piece-wise constant effects with 5 
year time intervals (red horizontal lines).Plots represent (A) Edinburgh BCS and (B) TEAM cohorts. Note. A final 




Figure 8.36 Comparison of extended Cox model and two-yearly intervals.Adjusted hazard ratio estimate from an 
extended cox model with 95% confidence intervals (dashed lines) and piece-wise constant effects with 2 year time 
intervals (red horizontal lines). Plots represent (A) Edinburgh BCS and (B) TEAM cohorts. Note. Final two 




8.5.2 RP Models versus Extended Cox Models 
In both the flexible parametric RP models and the extended Cox model, the forward selection 
algorithm for the RP models and the FPT algorithm identified the same time-varying effects 
for IHC4 score. Both showed a decreasing effect over time for IHC4 and in both approaches 
the simplest model was chosen, log (time) for the extended Cox model and 1 degrees of 
freedom for the spline term in the RP model. This resulted in almost identical estimates in the 
TEAM cohorts and only slight differences in the Edinburgh BCS cohort at early time-points 
(Figure 8.37).  
Over the 10-year follow-up, no time-varying effects were identified for Mammostrat score. 
The time-constant hazard ratios were almost identical from both models (Table 8.24). 
However, differences in the selection of time-varying effects for Mammostrat score was 
observed in the Edinburgh BCS cohort considering the full follow-up. The FPT algorithm 
identified a time-varying effect for high risk Mammostrat score whereas in the RP models it 
was identified as time-constant. The small number of patients allocated to high risk 
Mammostrat score and after adjustment for IHC4 score the time-varying effect did not remain, 




Figure 8.37 Comparison of extended Cox and RP models. Adjusted hazard ratio estimate with 95% CIs (dashed 
lines) for the 75th percentile to the 25th percentile of IHC4 score for all ER-positive patients from an extended Cox 
model (A and C) and a RP model (B and D) in the Edinburgh BCS (left-column) and TEAM (right-column) cohorts.  
 
Table 8.24 Comparison of hazard ratio estimates for Mammostrat score from an extended Cox or RP model 
 
Extended Cox RP Extended Cox RP
Main Effect HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
MvL 1.67 (1.14-2.45) 1.67 (1.14-2.45) 1.34 (1.05-1.71) 1.34 (1.05-1.71)
HvL 1.37 (0.85-2.21) 1.39 (0.86-2.23) 1.67 (1.34-2.09) 1.68 (1.34-2.11)
Edinburgh BCS TEAM
NOTE. Multivariate analysis for Mammostrat score with follow-up censored at 10 years 
from extended Cox or RP model. Hazard ratios for risk of TTDR calculated for either high-
risk or moderate-risk Mammostrat score compared with low Mammostrat scores at 
baseline. Values represent estimated hazard ratios and 95% CIs for all ER-positive 
patients in the Edinburgh BCS and TEAM cohorts. Abbreviations: TTDR, time to distant-
recurrence; RP, Roytson-Parmer model; CI, confidence interval; HvL, high risk v low risk 
Mammostrat  score; MvL, moderate risk v low risk Mammostrat score. * Adjusted for 




An advantage for the use of RP models over the MFPT approach in extended Cox models is 
avoiding categorising of the time interval to determine the time-varying effects. This avoids 
the loss of power associated with categorisation and the subjective choice of time-intervals. 
The time taken to run the FPT algorithm in STATA is also time-consuming compared to the 
forward selection algorithm in RP models. Running the stmfpt command with time categorised 
into 2 monthly periods, resulting in 134,000 observations in the TEAM cohort, takes 
approximately 36 times more computer time than the stpm2t command for the RP models.  
Another advantage for RP models is the easy calculation of absolute risk estimates, such as 
the differences in predicted hazard rates and survival probabilities.  
The main advantage for the MFPT approach is that it resembles a closed test algorithm: the 
algorithm runs a sequence of tests maintaining the overall type I error rate at a pre-specified 
nominal level, such as 5%. So it simultaneously determines whether time-varying effects 
should be added into the model and the best fitting FP to model the time-varying effect. 
Whereas in the RP models, you need to pre-specify the degrees of freedom for identifying 
time-varying effects and then simplify the functional form of any significant time-varying 
effects.  
A disadvantage of the RP models is due to the model being parametric; difficulties with 
convergence can arise in smaller datasets when more complex models are being fitted, such as 
more degrees of freedom for the baseline hazard or time-varying effects and when more than 
one time-varying effect is selected.  
8.6 Conclusions from various subgroup analyses 
Differences were observed on the prognostic ability of IHC4 and Mammostrat score depending 
on the patient subgroup and cohort (Table 8.25). Overall, IHC4 score had a strong time-
varying effect in the higher risk patient subgroups. Higher scores were associated with
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Table 8.25 Conclusions on whether IHC4 and/or Mammostrat were prognostic of TTDR in various subgroups. 
Subgroup Edinburgh BCS TEAM 
All ER-Positive 
- IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was 
decreasing over time. IHC4 score was prognostic up to 4 
years and then beyond 11 years where higher scores were 
associated with a protective effect. 
- Mammostrat score satisfied the PH assumption (after 
adjustment for time-varying IHC4 score) and was an 
independent predictor of outcome. 
- IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was decreasing 
over time. IHC4 score was prognostic up to 7 years follow-
up. 
- Mammostrat score satisfied the PH assumption and was an 





- IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was 
decreasing over time. IHC4 was prognostic up to 4 years 
follow-up. 
- Mammostrat score satisfied the PH assumption (after 
adjustment for time-varying IHC4 score) and was an 
independent predictor of outcome (borderline 
significance). 
- IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was decreasing 
over time. IHC4 score was prognostic up to 6 years follow-
up. 
- Mammostrat score satisfied the PH assumption but was not 
an independent predictor of outcome (after adjustment for 
time-varying IHC4 score). However, those classified as 
Mammostrat high risk had a significant increased hazard 
compared to those with low risk Mammostrat score. 
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- No time-varying effects were identified. 
- IHC4 score was an independent predictor of TTDR.   
- Mammostrat score did not remain an independent predictor 
of outcome but there was some evidence of an effect for 
Mammostrat medium risk compared to low risk. 
- No time-varying effects were identified. 






- No time-varying effects were identified. 
- Neither score was a significant independent predictor of 
outcome. 
- There was a trend towards higher IHC4 scores associated 
with a protective effect and higher Mammostrat scores 
associated with an increased hazard. 
- IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was decreasing 
over time.  IHC4 was prognostic up to 4 years follow-up. 






-  IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was 
decreasing over time.  Higher scores were associated with 
an increased hazard in the first 3 years of follow-up and a 
significantly decreased hazard beyond 6.5 years. 
- Mammostrat score was not an independent predictor of 
TTDR. There was a trend towards higher risk associated 
with higher scores. 
- IHC4 was identified as having a significant time-by-
covariate interaction, and the effect of IHC4 was decreasing 
over time.  IHC4 was prognostic up to 5 years follow-up. 




an increased risk of early recurrence but were associated with a significantly reduced risk of 
recurrence after 11 years. Mammostrat score satisfied the PH assumption and provided 
prognostic information over the full 10 year follow-up in the TEAM cohort and 25 years in 
the Edinburgh BCS cohort.  
In an exploratory analysis of a combined ICH4/Mammostrat score, the combined score was 
prognostic of outcome (up to 10 years) in all subgroups in the TEAM cohort. In the Edinburgh 
BCS cohort, the combined score had a time-varying effect in all patient subgroups and 
identified a group of patients with a very high risk of distant recurrence within the first two 
years since diagnosis.  
8.7 Discussion 
In this chapter, the impact of follow-up duration on IHC4 and Mammostrat score was explored.  
Piece-wise constant effects, splitting time into intervals, is a commonly used approach to deal 
with non-proportional hazards. The difficulties associated with this approach were 
highlighted, in particular, the loss of power from categorisation which resulted in wide 
confidence intervals for estimates and a lack of power to detect significant effects at later time-
points. However, it is a good starting point for detecting non-proportional effects and can help 
aid interpretation if non-proportional effects are identified. It is recommended that cut-points 
should be pre-specified and have a clinical meaning. Intervals should contain an adequate 
number of individuals and, more importantly, events. The intervals should not be too large as 
to still violate the PH assumption and this should be assessed. It is important not to choose 
intervals based on minimising p-values as this will bias results.  
Creating a continuous time-by-covariate interaction avoids the loss of power from time-
categorisation but difficulties arise in determining the functional form of the time-varying 
covariate. The MFPT algorithm is one approach to deal with this and has the advantage of 
simultaneously determining variables with non-proportional effects and selecting the 
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functional form whilst keeping the overall type I error rate at a pre-specified level. However, 
to determine the functional form of a time-varying covariate, a split at each event time is 
required as the Cox model is fitted by evaluating the partial likelihood at each failure time. In 
larger datasets, splitting at each failure time is problematic and requires categorisation of 
survival times. Consideration to the choice of the time intervals must be given; Buchholz found 
that the MFPT procedure gives similar results for small categorisation intervals and propose 
that about 50 to 100 distinct event times can give results with sufficient precision (Buchholz, 
2010).  
Another method that was applied was the RP flexible parametric model which models the 
baseline hazard and time-varying effects with restricted cubic splines. This approach has the 
advantage that due to the model being parametric, splitting at event times is not required to 
model the time-varying effects and allows absolute predictions of survival and hazard rate. A 
novel measure, restricted mean survival time (RMST) which is the area under the survival 
curve up to a selected time point (t) can also be calculated easily from this method. It has a 
more intuitive interpretation than the hazard ratio and can be thought of as a ‘t-year life 
expectancy’. For example, treatment A increases your life expectancy by 2 years compared 
with treatment B. However, difficulties occur with convergence when fitting these models to 
small samples or fitting complex models with more than one time-varying effect. 
The MFPT and RP models gave very similar results with almost identical hazard ratio 
estimates for variables satisfying the proportional hazards assumption. The estimated time-
dependent hazard ratios were also similar between approaches. 
Our analyses identified a strong time-varying effect of IHC4 score. The prognostic effect of 
IHC4 score on TTDR decreased with increasing follow-up time. IHC4 score appeared to be 
prognostic of early distant recurrence only (0-5 years) when categorising time into 5-yearly 
intervals. Previous analysis by Sgroi and colleagues also confirmed a significant prognostic 
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ability for IHC4 for early distant recurrence only (0-5 years) (Sgroi et al., 2013). However, 
looking at the score continuously over time, IHC4 score was prognostic of outcome up to 
approximately 7 years in the TEAM cohort but only up to 4 years in the Edinburgh BCS cohort 
for all ER-positive patients. The longer follow-up in the Edinburgh BCS cohort identified a 
protective effect of higher IHC4 scores beyond 11 years of follow-up. 
The prognostic effect of Mammostrat score was consistent over time. It identified a group of 
patients with an increased risk of distant recurrence over full follow-up in the TEAM cohort 
(10 years) and the Edinburgh BCS cohort (25 years). These results suggest the possible use of 
Mammostrat score to predict the risk of late recurrence, which will need to be investigated 
further on other patient cohorts with long follow-up. 
The performance of both scores was good, especially in the first 5 years of follow-up, with the 
combination of both scores significantly improving the ability to discriminate between events 
and non-events when compared to clinical factors only and good calibration between observed 
and predicted 5 year risk of TTDR. The IHC4 score provided more prognostic information on 
TTDR than the Mammostrat score in the first 5 years of follow-up except for all ER-positive 
patients in the larger TEAM cohort where the addition of both scores provided statistically 
significant information.  
In a post-hoc analysis of a combined IHC4/Mammostrat score, this risk score was prognostic 
of outcome in all patient subgroups in the TEAM cohort and identified a group of patients at 
an increased risk of recurrence over the 10-year follow-up. In the Edinburgh BCS cohort, the 
combined score identified a group of patients with a high risk of distant recurrence in the first 








Chapter 9:  Analysis of Individual Biomarkers 
9.1 Introduction 
IHC4 score was identified as having a strong time-dependent effect with the prognostic effect 
of IHC4 decreasing over time. A combined IHC4 and Mammostrat score was prognostic of 
outcome and identified a group of patients at an increased risk of recurrence.  
In this chapter, the individual biomarkers from IHC4 and Mammostrat residual risk panels 
were analysed to determine which have a prognostic effect on outcome and which were driving 
the time-dependency. 
The assumptions of linearity and proportional hazards in the Cox proportional hazards model 
was assessed for the individual markers. A multivariable model was developed using the novel 
MFPT approach to identify which markers were prognostic of outcome and whether any of 
the markers demonstrated a time-varying effect. The markers were also assessed using RP 
flexible parametric models to determine any differences or advantages in using a more flexible 
approach of analysis. 
9.2 Materials 
This analysis will focus on the two main patient subgroups, all ER-positive patients and 
patients treated with endocrine therapy only in the Edinburgh BCS and TEAM cohorts. 
9.3 Biomarkers 
The nine IHC biomarkers considered in this analysis are ER (histoscores), PgR (histoscores), 
Ki67 (percentage of positive cells), HER2 (negative/positive) and SLC7A5, CEACAM5, 




Initially, correlations between variables were estimated by Spearman’s rank correlation 
coefficient for continuous–continuous associations, Pearson’s chi-squared test for categorical-
categorical associations and the likelihood ratio test statistic from a regression of a continuous 
variable with a categorical variable as a predictor in the model. Results are given for all ER-
positive patients in Table 9.1 for the Edinburgh BCS cohort and Table 9.2 for the TEAM 
cohort. Strong evidence of modest correlations between the majority of variables was 
observed.  
9.5 Assumptions of Linearity and Proportional Hazards 
9.5.1 Linearity on the Log-hazard 
The functional form of the continuous covariates (ER, PgR and Ki67) were initially assessed 
by plotting the Martingale residuals from a null Cox regression model against the continuous 
covariates (Figure 9.1). The assumption of linearity on the log-hazard appears to be reasonable. 
Next, in a univariate Cox regression model the fractional polynomial algorithm identified ER 
and Ki67 to be non-linear in the TEAM cohort. The best fitting FP to model the non-linear 
effects of ER and Ki67 are illustrated in Figure 9.2. There appears to be some over-fitting of 
the non-linear effects, with an unrealistic decrease in the hazard associated with higher Ki67 
due to a lack of patients with a high percentage of positive Ki67 cells. 
9.5.2 Proportional Hazards 
The proportional hazards assumption was assessed from a univariate Cox regression model by 
plotting the Schoenfeld residuals against survival time, displayed in Figure 9.3 for the 
Edinburgh BCS cohort and Figure 9.4 for the TEAM cohort, and with the Grambsch-Thernaue 
test of proportional hazards (Table 9.3). Several of the markers showed evidence of a non-
proportional effect in the Edinburgh BCS cohort, in particular PgR, Ki67, SLC7A5, NDRG1  
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Table 9.1 Associations between biomarkers and clinical variables in the Edinburgh BCS cohort 
Continuous-Continuous Associations - Spearmans rho (p-value)         
  ER PgR Ki67 Age Tumour Size     
PgR 0.14 (<0.001)             
Ki67 -0.30 (<0.001) -0.05 (0.10)           
Age 0.27 (<0.001) -0.13 (<0.001) -0.10 (0.001)         
Tumour Size -0.10 (<0.001) 0.002 (0.94) 0.23 (<0.001) 0.04 (0.21)       
Nodes Pos. 0.003 (0.93) 0.10 (<0.001) 0.11 (<0.001) 0.06 (0.06) 0.27 (<0.001)     
Categorical-Categorical Associations - Pearson's chi-squared (p-value)       
  HER2 SLC7A5 CEACAM5 NDRG1 HTF9C P53   
SLC7A5 5.4 (0.02)             
CEACAM5 9.0 (0.003) 5.3 (0.02)           
NDRG1 1.5 (0.22) 55.5 (<0.001) 0.07 (0.78)         
HTF9C 16.4 (<0.001) 26.2 (<0.001) 2.9 (0.09) 2.08 (0.15)       
P53 11.8 (0.003) 27.5 (<0.001) 0.06 (0.81) 9.5 (0.002) 28.0 (<0.001)     
Grade 23.1 (<0.001) 100.6 (<0.001) 4.2 (0.13) 68.6 (<0.001) 15.3 (<0.001) 93.4 (<0.001)   
Continuous-Categorical Associations - Likelihood ratio statistic (p-value)       
  HER2 SLC7A5 CEACAM5 NDRG1 HTF9C P53 Grade 
ER 3.4 (0.07) 18.7 (<0.001) 0.8 (0.36) 0.6 (0.43) 17.2 (<0.001) 12.0 (<0.001) 55.3 (<0.001) 
PgR 1.9 (0.16) 17.4 (<0.001) 5.5 (0.02) 7.0 (0.008) 11.5 (<0.001) 2.0 (0.16) 47.1 (<0.001) 
Ki67 34.3 (<0.001) 75.5 (<0.001) 1.9 (0.17) 24.4 (<0.001) 32.0 (<0.001) 49.7 (<0.001) 207.3 (<0.001) 
Age 4.9 (0.03) 0.4 (0.53) 1.2 (0.27) 5.8 (0.02) 0.2 (0.70) 12.4 (<0.001) 5.8 (0.05) 
Tumour Size 3.8 (0.05) 9.9 (0.002) 3.8 (0.05) 38.3 (<0.001) 3.3 (0.07) 5.7 (0.02) 73.5 (<0.001) 
Nodes Pos. 1.3 (0.25) 7.7 (0.005) 0.2 (0.69) 8.6 (0.003) 0.7 (0.41) 9.4 (0.002) 5.7 (0.06) 
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Table 9.2 Associations between biomarkers and clinical variables in the TEAM cohort. 
Continuous-Continuous Associations - Spearmans rho (p-value)         
  ER PgR Ki67 Age Tumour Size     
PgR 0.25 (<0.001)             
Ki67 -0.14 (<0.001) -0.08 (<0.001)           
Age 0.12 (<0.001) 0.05 (0.004) 0.05 (0.003)         
Tumour Size -0.09 (<0.001) -0.06 (<0.001) 0.07 (<0.001) 0.12 (<0.001)       
Nodes Pos. -0.02 (0.26) -0.02 (0.26) -0.04 (0.02) 0.004 (0.83) 0.2 (<0.001)     
Categorical-Categorical Associations - Pearson's chi-squared (p-value)       
  HER2 SLC7A5 CEACAM5 NDRG1 HTF9C P53   
SLC7A5 115.0 (<0.001)             
CEACAM5 15.1 (<0.001) 8.7 (0.003)           
NDRG1 20.1 (<0.001) 74.6 (<0.001) 1.6 (0.21)         
HTF9C 40.2 (<0.001) 122.83 (<0.001) 12.8 (<0.001) 4.1 (0.04)       
P53 47.0 (<0.001) 145.0 (<0.001) 0.03 (0.85) 7.7 (0.006) 52.9 (<0.001)     
Grade 92.9 (<0.001) 281.3 (<0.001) 0.13 (0.94) 83.2 (<0.001) 21.7 (<0.001) 115.3 (<0.001)   
Continuous-Categorical Associations - Likelihood ratio statistic (p-value)       
  HER2 SLC7A5 CEACAM5 NDRG1 HTF9C P53 Grade 
ER 39.2 (<0.001) 63.3 (<0.001) 20.2 (<0.001) 3.6 (0.06) 51.8 (<0.001) 26.7 (<0.001) 59.5 (<0.001) 
PgR 126.0 (<0.001) 89.8 (<0.001) 3.2 (0.07) 48.3 (<0.001) 59.8 (<0.001) 8.1 (0.005) 62.1 (<0.001) 
Ki67 74.6 (<0.001) 233.0 (<0.001) 0.0 (0.97) 47.2 (<0.001) 36.1 (<0.001) 117.7 (<0.001) 265.2 (<0.001) 
Age 8.1 (0.004) 3.5 (0.06) 21.9 (<0.001) 0.4 (0.55) 0.1 (0.76) 8.3 (0.004) 2.3 (0.32) 
Tumour Size 0.5 (0.50) 0.3 (0.58) 0.2 (0.68) 10.0 (0.002) 0.3 (0.61) 10.0 (0.002) 17.2 (<0.001) 
Nodes Pos. 7.0 (0.008) 1.1 (0.31) 0.02 (0.90) 0.01 (0.92) 5.2 (0.02) 5.0 (0.03) 5.6 (0.06) 
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Figure 9.1 Plots of martingale residuals versus continuous covariates. The red line is a smoothed curve produced by locally weighted regression. Plots represent (A) Edinburgh BCS and 





Figure 9.2 Comparison of non-linear (dashed line) and linear (solid line) effects of (A) ER histoscores and (B) Ki67 in the TEAM cohort.  
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Figure 9.3 Plots of Schoenfeld residuals for each explanatory variable versus survival time in the Edinburgh BCS cohort. Red (solid) line indicating the fitted linear regression line and the 
blue (dashed) line a reference line at zero. 
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Figure 9.4 Plots of Schoenfeld residuals for each explanatory variable versus survival time in the TEAM cohort. Red (solid) line indicating the fitted linear regression line and the blue 




Table 9.3 Grambsch-Therneau test of non-proportional hazards  
  P-value of Grambsch-Therneau Test 
Variable Edinburgh BCS   TEAM 
ER 0.37   0.01 
PgR 0.01   0.10 
HER2 0.21   0.10 
Ki67 <0.001   <0.001 
SLC7A5 0.04   0.04 
CEACAM5 0.11   0.80 
NDRG1 0.07   0.91 
HTF9C 0.53   0.84 
P53 0.05   0.001 
Note. Test of non-proportional hazards from a univariate Cox regression analysis. 
and p53. In the TEAM cohort, ER, Ki67, SLC7A5 and p53 showed evidence of a non-
proportional effect.  
9.6 Multivariable Model  
The multivariable fractional polynomial time approach (MFPT) was used to determine which 
variables are associated with TTDR, the functional form of the variables and any variables 
with non-proportional effects.  
Step 1 uses the MFP algorithm to determine variables associated with the outcome over the 
full follow-up and the functional form to model the variables, calling this the time-fixed model.  
Step 2 involves restricting the follow-up to contain the first half of the events, i.e. 3 years in 
the TEAM cohort and 5 years in the Edinburgh BCS cohort. The MFP algorithm is then run 
to determine if any covariates have a significant short-term effect and to determine the 
functional form of the variables. 
Step 3 is then used to determine non-proportional effects of the variables identified in step 1 
and step 2 of the MFPT approach using the FPT algorithm.  
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A 10% significance level was used for the selection of prognostic variables and 5% 
significance level for the selection of time-varying effects. 
9.6.1 10 year follow-up 
The MFPT approach was applied to the Edinburgh BCS cohort with follow-up censored at 10 
years and the TEAM cohort. 
9.6.1.1 Biomarkers only 
The MFPT approach was initially performed including the 9 biomarkers only, not including 
the clinical variables.  
Edinburgh BCS Cohort 
The results of the model building for the Edinburgh BCS cohort are given in Table 9.4. All 
included variables had a linear effect on the log-hazard with Ki67 having a strong non-
proportional effect. An additional marker, PgR, was identified as prognostic of outcome when 
considering ER-positive patients treated with endocrine therapy only. The final model 
contained markers from both the IHC4 and Mammostrat risk panels. 
Table 9.4 MFPT Results for the Edinburgh BCS Cohort (10 year follow-up) – biomarker only model 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER               
PgR         * * * 
Ki67 * * *   * * * 
HER2               
p53 * *     * *   
NDRG1 * *     * *   
HTF9C               
CEACAM5 * *     * *   
SLC7A5               
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 4 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, with 




Results of the model building in the TEAM cohort are given in Table 9.5. All markers except 
HTF9C were identified as being prognostic of outcome over the full follow-up for all ER-
positive patients. In the univariate analysis, section 9.5.1, ER and Ki67 were identified to be 
non-linear but there appeared to be some over-fitting. In the multivariable model all variables 
were determined to have a linear effect on the log-hazard.  
Fewer markers were identified as having a prognostic effect on TTDR for ER-positive patients 
treated with endocrine therapy only. Ki67 was not identified as having a prognostic effect over 
the full follow-up (step 1), but was identified as prognostic of outcome when follow-up was 
censored at 3 years (step 2). This highlights the importance of considering both short and long-
term follow-up. The majority of biomarkers identified by the MFPT approach for ER-positive 
patients treated with endocrine therapy only were from the IHC4 model, with only SLC7A5 
from the Mammostrat model being prognostic of outcome. Again Ki67 was identified as 
having a strong non-proportional effect, with p53 also having a time-varying effect for all ER-
positive patients. The importance of considering other transformations of time was highlighted 










Table 9.5 MFPT Results for the TEAM cohort – biomarker only model 
  TEAM 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER * *     * *   
PgR * *     * *   
Ki67 * * *     * * 
HER2 * *     * *   
p53 * * *         
NDRG1 * *           
HTF9C              
CEACAM5 * *           
SLC7A5 * *     * *   
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 3 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, 
with the best fitting transformation to be log(time) for Ki67 and time2 for p53. 
 
 
Figure 9.5 Illustration of different fractional polynomials to model interaction between p53 and time: log-time 
(solid line) and time-squared (dashed line). Red line at hazard ratio of 1 indicates null effect. 
 
9.6.1.2 Biomarkers and clinical variables 
The MFPT algorithm was then performed forcing the clinical variables (age, grade, non-linear 




Edinburgh BCS Cohort 
Results are given in Table 9.6 for the Edinburgh BCS cohort. Fewer markers remained 
prognostic of outcome when clinical variables were included in the model. For all ER-positive 
patients in the Edinburgh BCS cohort, HTF9C was identified as an important predictor by the 
MFPT model building approach when clinical variables were included in the model, whereas 
it was not prognostic of outcome when only biomarkers were considered. With the inclusion 
of the clinical variables, Ki67 was only prognostic of outcome when follow-up was restricted 
to 4 years (step 2) and again was identified as having a strong non-proportional effect.  
 
Table 9.6 MFPT Results for the Edinburgh BCS cohort (10 year follow-up) – biomarker and clinical model 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER               
PgR               
Ki67   *   *     *  *  
HER2               
p53             
NDRG1         *  
HTF9C * *           
CEACAM5 * *     * *   
SLC7A5               
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 4 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, with 
the best fitting transformation to be log(time) for Ki67. Clinical variables (age, grade, 








Results from model building using the MFPT approach with biomarkers and clinical variables 
for the TEAM cohort are given in Table 9.7. Despite a strong time-varying effect of Ki67 in 
the biomarker only model, Ki67 was not identified as being prognostic of outcome when 
clinical variables were included in the model. This warranted further explanation due to the 
previous strong effect of Ki67 in the short-term (up to 3 years follow-up). The MFP algorithm 
first tests the best fitting degree 2 FP model of Ki67 against not including it in the model and 
this was non-significant (increase in model deviance 4.4, p-value 0.36). We previously 
suspected some over-fitting of ER and Ki67 when modelled with a degree 2 FP (Figure 9.2). 
If we restrict ER and Ki67 to be linear on the log-hazard, Ki67 is prognostic of outcome in the 
short-term and included in step 2 of the MFPT approach (Table 9.8). This identified an issue 
with the MFP algorithm, where a variable is rejected due to over-fitting of the non-linear effect 
in the model.  
 
Table 9.7 MFPT Results for the TEAM cohort – biomarker and clinical model 
  TEAM 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER * *           
PgR * *     * *   
Ki67               
HER2         * *   
p53 * * *         
NDRG1 * *           
HTF9C               
CEACAM5 * *           
SLC7A5 * *     * *   
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 3 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, with 
the best fitting transformation to be time2 for p53. Clinical variables (age, grade, no. 




Table 9.8 MFPT Results for the TEAM cohort restricting ER and Ki67 to be linear – biomarker and clinical model 
  TEAM 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER * *     * *    
PgR * *     * *   
Ki67   * *          
HER2         * *   
p53 * * *         
NDRG1 * *           
HTF9C               
CEACAM5 * *           
SLC7A5 * *     * *   
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 3 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, with 
the best fitting transformation to be log-time for Ki67 and time3 for p53. Clinical 
variables (age, grade, no. positive nodes, tumour size, treatment and chemotherapy) 
were included in the model. 
 
Restricting ER and Ki67 to be linear (or considering degree 1 FPs only) in the biomarker only 
model also resulted in different variable selection (Table 9.9) for ER-positive patients treated 
with endocrine therapy only. Ki67 was identified as prognostic over the full follow-up (step 








Table 9.9 MFPT Results for the TEAM cohort restricting ER and Ki67 to be linear – biomarker only model 
  TEAM 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER * *     * *   
PgR * *     * *   
Ki67 * * *   * * * 
HER2 * *         
p53 * * *         
NDRG1 * *           
HTF9C              
CEACAM5 * *           
SLC7A5 * *     * *   
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 3 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, 
with the best fitting transformation to be log(time) for Ki67 and time2 for p53. 
 
Edinburgh BCS Cohort 
The overfitting of Ki67 with a degree 2 FP then prompted further checks on the model building 
in the Edinburgh BCS cohort. An issue was identified with PgR, with a degree 2 FP resulting 
in a non-significant increase in model deviance compared to not including the marker in the 
model (increase in model deviance 4.4, p-value 0.4). Restricting PgR to be linear, resulted in 
a significant increase in model deviance (increase in model deviance 4.9, p-value 0.03) and 
was included in step 1 of the MFPT model building for all ER-positive patients (Table 9.10). 
However, there does not appear to be any serious over-fitting when comparing a linear effect 





Table 9.10 MFPT Results for the Edinburgh BCS cohort (10 year follow-up) restricting PgR to be linear – 
biomarker only model 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER               
PgR *  *   *    * * * 
Ki67 * * *   * * * 
HER2               
p53 * *     * *   
NDRG1 * *     * *   
HTF9C               
CEACAM5 * *     * *   
SLC7A5               
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 4 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, with 
the best fitting transformation to be log-time for Ki67 and time3 for PgR.   
 
 
Figure 9.6 Comparison of non-linear (dashed line) and linear (solid line) effects of PgR in the Edinburgh BCS 
cohort (10-year follow-up). Red line at hazard ratio of 1 indicates null effect.  
 
 
Restricting PgR to be linear in the biomarker and clinical model also resulted in differences in 
variable selection (Table 9.11), with PgR included as prognostic of outcome over the 10-year 
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follow-up (step 1) and HTF9C no longer being prognostic of outcome for all ER- positive 
patients (step 1) and NDRG1 not prognostic of outcome in the short-term (step 2) for ER-
positive patients treated with endocrine therapy only. 
 
Table 9.11 MFPT Results for the Edinburgh BCS cohort (10 year follow-up) restricting PgR to be linear – 
biomarker and clinical model 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER               
PgR *        *      * *    
Ki67    *   *     *  *  
HER2               
p53             
NDRG1           
HTF9C             
CEACAM5 * *     * *   
SLC7A5               
Note: All variables included in steps 1 and 2 were determined to be linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 4 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, with 
the best fitting transformation to be log(time) for Ki67. Clinical variables (age, grade, 
no. positive nodes, tumour size and chemotherapy) were included in the model.  
 
9.6.1.3 Cox Regression Models 
The estimated coefficients and hazard ratios from the final model identified by the MFPT 
approach are given in Table 9.12 for the Edinburgh BCS cohort and Table 9.13 for the TEAM 
cohort. The time-varying effects are displayed in Figure 9.7 and Figure 9.8 for the Edinburgh 
BCS and TEAM cohorts respectively.  
The markers from the Mammostrat model that were independent predictors of outcome 
(SLC7A5, CEACAM5, NDRG1, p53) in either the Edinburgh BCS and TEAM cohort, having 
a positive marker increased the hazard compared to being marker negative.  
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Table 9.12 Multivariate Cox Regression of biomarkers identified by the MFPT approach in the Edinburgh BCS 
Cohort (10 year follow-up) 
  All ER-Positive   ER-Positive Endocrine Only 
  Coeff (Std. Err.) HR (95% CI)   Coeff (Std. Err.) HR (95% CI) 
Biomarker Only Model         
ER (50 units) - -   - - 
PgR (50 units) -0.14 (0.06) 0.87 (0.77-0.97)   -.20 (0.07) 0.82 (0.71-0.94) 
Ki67 (10 units) 0.37 (0.08) 1.45 (1.23-1.70)   0.37 (0.10) 1.45 (1.19-1.77) 
HER2 - -   - - 
SLC7A5 - -   - - 
CEACAM5 0.45 (0.22) 1.57 (1.03-2.40)   0.56 (0.24) 1.76 (1.09-2.83) 
NDRG1 0.45 (0.18) 1.56 (1.10-2.22)   0.50 (0.20) 1.65 (1.11-2.47) 
HTF9C - -   - - 
p53 0.32 (0.18) 1.37 (0.96-1.96)   0.50 (0.21) 1.66 (1.11-2.48) 
PgR*time3 0.0003 (0.0002) 
1.0003 (0.9999-
1.0007) 
 0.0004 (0.0002) 
1.0004 (0.9999-
1.0008) 
Ki67*log(time) -0.16 (0.06) 0.85 (0.76-0.95)   -0.18 (0.07) 0.84 (0.73-0.96) 
Biomarker and Clinical Model*        
ER (50 units) - -   - - 
PgR (50 units) -0.10 (0.05) 0.90 (0.82-0.99)   -0.11 (0.06) 0.89 (0.80-1.00) 
Ki67 (10 units) 0.30 (0.09) 1.35 (1.13-1.60)   0.29 (0.10) 1.34 (1.10-1.63) 
HER2 - -   - - 
SLC7A5 - -   - - 
CEACAM5 0.41 (0.22) 1.51 (0.98-2.31)   0.54 (0.25) 1.72 (1.06-2.79) 
NDRG1 - -   - - 
HTF9C - -   - - 
p53 - -   - - 
Ki67*log(time) -0.18 (0.06) 0.84 (0.74-0.94)   -0.19 (0.07) 0.83 (0.72-0.95) 
            
NOTE. Multivariate Cox regression of the biomarkers in the final model identified by the MFPT 
algorithm. Coefficients (standard error) and hazard ratios (95% CIs) for risk of TTDR calculated for a 
50 unit increase in ER or PgR, a 10 unit increase in Ki67 and positive compared to negative for all 
other markers. Values calculated for all ER-positive patients and ER-positive patients who received 
no chemotherapy in the Edinburgh cohort with follow-up censored at 10 years. Abbreviations: 
TTDR, time to distant-recurrence; Coeff, coefficient; Std. Err, standard error; CI, confidence interval. 







Table 9.13 Multivariate Cox Regression of biomarkers identified by the MFPT approach in the TEAM Cohort. 
  All ER-Positive   ER-Positive Endocrine Only 
  Coeff (Std. Err.) HR (95% CI)   Coeff (Std. Err.) HR (95% CI) 
Biomarker Only Model         
ER (50 units) -0.08 (0.03) 0.93 (0.86-0.99)   -0.14 (0.05) 0.87 (0.80-0.96) 
PgR (50 units) -0.20 (0.03) 0.82 (0.78-0.86)   -0.17 (0.03) 0.84 (0.79-0.90) 
Ki67 (10 units) 0.11 (0.04) 1.12 (1.05-1.20)   0.12 (0.05) 1.13 (1.03-1.24) 
HER2 0.22 (0.11) 1.25 (1.00-1.55)       
SLC7A5 0.36 (0.36) 1.43 (1.19-1.73)   0.46 (0.12) 1.58 (1.24-2.01) 
CEACAM5 0.30 (0.10) 1.34 (1.11-1.63)   - - 
NDRG1 0.26 (0.09) 1.30 (1.08-1.56)   - - 
HTF9C - -   - - 
p53 0.46 (0.12) 1.59 (1.25-2.02)   - - 
Ki67*log(time) -0.07 (0.03) 0.93 (0.88-0.98)   -0.06 (0.04) 0.94 (0.88-1.01) 
p53*time2 -0.01 (0.005) 0.99 (0.98-1.00)   - - 
            
Biomarker and Clinical Model*         
ER (50 units) -0.08 (0.04) 0.93 (0.86-0.99)   -0.12 (0.05) 0.89 (0.80-0.97) 
PgR (50 units) -0.17 (0.03) 0.84 (0.80-0.89)   -0.12 (0.04) 0.89 (0.83-0.95) 
Ki67 (10 units) 0.09 (0.04) 1.09 (1.01-1.18)   - - 
HER2 - -   0.27 (0.16) 1.31 (0.96-1.77) 
SLC7A5 0.32 (0.10) 1.38 (1.13-1.68)   0.32 (0.13) 1.38 (1.07-1.78) 
CEACAM5 0.27 (0.10) 1.31 (1.07-1.60)   - - 
NDRG1 0.32 (0.10) 1.38 (1.14-1.67)   - - 
HTF9C - -   - - 
p53 0.43 (0.11) 1.54 (1.23-1.92)   - - 
Ki67*log(time) -0.08 (0.03) 0.92 (0.87-0.98)   - - 
p53*time3 -0.002 (0.0007) 0.998 (0.997-0.999)   - - 
NOTE. Multivariate Cox regression of the biomarkers in the final model identified by the MFPT 
algorithm. Coefficients (standard error) and hazard ratios (95% CIs) for risk of TTDR calculated for 
a 50 unit increase in ER or PgR, a 10 unit increase in Ki67 and positive compared to negative for 
all other markers. Values calculated for all ER-positive patients and ER-positive patients who 
received no chemotherapy in the TEAM cohort. Abbreviations: TTDR, time to distant-recurrence; 
Coeff, coefficient; Std. Err, standard error; CI, confidence interval. * Adjusted for age, grade, 







Figure 9.7 Edinburgh BCS cohort. Time-varying adjusted hazard ratios for all ER-positive patients (A and C) and ER-positive patients treated with endocrine therapy only (B and D) in 





Figure 9.8 TEAM cohort. Time-varying adjusted hazard ratios for all ER-positive patients (A and C) and ER-positive patients treated with endocrine therapy only (B) in the TEAM cohort 
from the biomarker only model (A and B) and the biomarker and clinical model (age, grade, tumour size, number positive nodes, treatment and chemotherapy) (C). 
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In both cohorts, a higher percentage of positive Ki67 cells was associated with an increased 
risk of TTDR in the short-term, with the effect decreasing over time. PgR was also identified 
as having a time-varying effect in the biomarker only model in the Edinburgh BCS cohort, 
where higher PgR histoscores were associated with a decreased hazard up to approximately 6 
years compared with lower histoscores. P53 was identified as having a time-varying effect in 
both the biomarker only and biomarker and clinical model for all ER-positive patients in the 
TEAM cohort. P53-positive was associated with an increased hazard up to approximately 4 
years follow-up compared to p53-negative, the effect decreased over time and p53-positive 
was associated with a decreased hazard beyond approximately 8 years.  
ER was only identified as an important predictor of outcome in the TEAM cohort, with higher 
ER histoscores associated with a decreased hazard compared to lower histoscores. 
One issue with the MFPT approach is in the final model there can be non-significant predictors 
due to having 3 steps in the model building. For example, in the biomarker and clinical model 
for all ER-positive patients in the Edinburgh BCS cohort, CEACAM5 was identified as 
prognostic of outcome in step 1 (considering full follow-up) with a hazard ratio estimate of 
1.53 (95% CI, 1.00-2.34). With the addition of Ki67 in step 2 and a time-varying effect 
included in the model, CEACAM5 becomes borderline significant at the 5% level with a 
hazard ratio estimate of 1.51 (95% CI, 0.98-2.31).  
9.6.1.4 Discrimination 
The discrimination was compared using Royston & Sauerbrei’s R2 and D-statistic between the 
model identified in step 1 of the MFPT approach; variables prognostic of outcome over the 
full follow-up, and the final model; variables prognostic of both short and long-term outcome 
and the inclusion of any time-varying effects.  
The biomarker only model was considered with and without adjustment for clinical variables 
as well as the biomarker and clinical model to compare whether the additional markers in the 
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biomarker only model improved the models ability to discriminate between events and non-
events. 
Results are given in Table 9.14 for the Edinburgh BCS cohort with follow-up censored at 10 
years. There was improved prognostic separation between step 1 of the MFPT model building 
approach and the final model for all 3 models and both patient subgroups with increases in R2 
between 3.5 and 8.0% and increases in D-statistic between 0.11 and 0.28. The extra biomarkers 
in the adjusted biomarker model did not improve the prognostic ability compared to the 
biomarker and clinical model with similar R2 and D-statistics for all ER-positive patients (R2: 
29.3 versus 28.4%, D-statistic: 1.32 versus 1.29). There was a larger improvement in model 
discrimination for ER-positive patients treated with endocrine therapy only for the adjusted 
biomarker model, however this was not statistically significant (R2: 32.2 versus 30%, D-
statistic: 1.41 versus 1.34).   
Table 9.14 Edinburgh BCS cohort (10-year follow-up). Comparison of discrimination of model identified in step 
1 of the MFPT approach and the final model. 
  Edinburgh BCS 
  R2 (%)   D-Statistic 
  Step 1 Final Increase   Step 1 Final Increase 
All ER-Positive               
Biomarker Only Model 8.0 15.3 7.3   0.61 0.87 0.27 
Adjusted Biomarker Model 24.3 29.3 5.0   1.16 1.32 0.16 
Biomarker and Clinical Model 24.3 28.4 4.1   1.16 1.29 0.13 
ER-Positive Endocrine Only               
Biomarker Only Model 9.8 17.7 8.0   0.67 0.95 0.28 
Adjusted Biomarker Model 26.7 32.2 5.4   1.24 1.41 0.17 
Biomarker and Clinical Model 26.5 30.0 3.5   1.23 1.34 0.11 
Note. Values represent R2 and D-statistic for the models identified by step 1 and the 
final model of the MFPT approach, with a difference in D of at least 0.1 indicating 
improved prognostic separation. Results are given for all ER-positive patients and ER-
positive patients treated with endocrine therapy only in the Edinburgh BCS cohort with 
follow-up censored at 10 years. The models represent: biomarker only model, model 
selected by MFPT including biomarkers only; Adjusted biomarker model, model selected 
by MFPT including biomarkers only then adjusting for clinical variables (age, grade, 
tumour size, nodes positive, chemotherapy); Biomarker and clinical model, model 





The results for the TEAM cohort are given in Table 9.15. There were no significant 
improvements in model discrimination between the model identified by step 1 of the MFPT 
approach and the final model with increases in R2 between 0 and 2.6% and increases in D-
statistic between 0 and 0.08. There were very similar results between the adjusted biomarker 
model and the biomarker and clinical model.  
 
Table 9.15 TEAM cohort. Comparison of discrimination of model identified in step 1 of the MFPT approach and 
the final model. 
  TEAM 
  R2 (%)   D-Statistic 
  Step 1 Final Increase   Step 1 Final Increase 
All ER-Positive               
Biomarker Only Model 17.2 19.8 2.6   0.93 1.02 0.08 
Adjusted Biomarker Model 32.9 35.2 2.2   1.43 1.51 0.07 
Biomarker and Clinical Model 32.9 34.8 2.0   1.43 1.50 0.06 
ER-Positive Endocrine Only               
Biomarker Only Model 14.5 15.7 1.2   0.84 0.88 0.04 
Adjusted Biomarker Model 33.1 33.6 0.5   1.44 1.46 0.02 
Biomarker and Clinical Model 33.3 33.3 0.0   1.45 1.45 0.00 
Note. Values represent R2 and D-statistic for the models identified by step 1 and the 
final model of the MFPT approach, with a difference in D of at least 0.1 indicating 
improved prognostic separation. Results are given for all ER-positive patients and ER-
positive patients treated with endocrine therapy only in the TEAM cohort. The models 
represent: biomarker only model, model selected by MFPT including biomarkers only; 
Adjusted biomarker model, model selected by MFPT including biomarkers only then 
adjusting for clinical variables (age, grade, tumour size, nodes positive, chemotherapy); 
Biomarker and clinical model, model selected by MFPT including biomarkers and clinical 
variables. 
 
9.6.2 Full follow-up 
The MFPT approach was also applied to the Edinburgh BCS cohort considering full follow-
up (maximum 25 years). 
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9.6.2.1 Biomarkers only 
The results of the model building for the Edinburgh BCS cohort considering full follow-up are 
given in Table 9.16. For all ER-positive patients, the same biomarkers were not identified 
when follow-up was censored at 10 years (see Table 9.10). HTF9C was prognostic of outcome 
and p53 was not identified as being prognostic over the full follow-up (step 1) or the five-year 
follow-up (step 2). PgR and CEACAM5 were not prognostic of outcome over the full follow-
up period (step 1), but were identified as being prognostic of outcome when follow-up was 
censored at 5 years (step 2). Despite only being prognostic in the short-term (adjusted HR for 
the 0-5 year interval 1.73 (95% CI, 1.03-2.90) compared to the 0-25 year interval 1.31 (95% 
CI, 0.87-1.98)), a non-proportional effect was not identified for CEACAM5 by the FPT 
algorithm. 
 
Table 9.16 MFPT Results for the Edinburgh BCS Cohort with Full follow-up – Biomarker only model 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER             
PgR   *  *    * *   
Ki67 * * *    * * * 
HER2               
p53       * *   
NDRG1 * *     * *   
HTF9C  *  *         
CEACAM5 *       *   
SLC7A5               
Note: All variables included in steps 1 and 2 were included as linear. Step 2 
includes variables selected in step 1 (using the whole time-period) and variables 
selected with a short-term effect (patients censored at 5 year follow-up). Step 3 
indicates the variables in step 2 which have evidence of a non-proportional effect, 
with the best fitting transformation to be log(time) for Ki67 and PgR. 
 
Similarities were observed between the variables identified by the MFPT algorithm for ER-
positive patients treated with endocrine therapy only in the Edinburgh BCS cohort with full 
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follow-up and follow-up censored at 10 years. The same markers were identified but PgR was 
not identified as having a time-varying effect when full follow-up was considered.   
9.6.2.2 Biomarkers and Clinical Variables 
Results of the MFPT algorithm including the clinical variables (age, grade, non-linear tumour 
size and number of positive nodes, treatment and chemotherapy) for the Edinburgh BCS cohort 
with full follow-up are given in Table 9.17. Fewer biomarkers remained prognostic of outcome 
when clinical variables were included in the model. HTF9C was the only marker that was 
prognostic over the full follow-up (step 1) with the inclusion of clinical variables. PgR, Ki67 
and CEACAM5 was then included in the model in step 2, as well as SLC7A5 for ER-positive 
patients treated with endocrine therapy only. PgR and Ki67 were identified as having time-
varying effects. 
 
Table 9.17 MFPT Results for the Edinburgh BCS Cohort with Full follow-up 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables STEP 1 STEP 2 STEP 3   STEP 1 STEP 2 STEP 3 
ER               
PgR   *  *        *    
Ki67   *         *      * *  
HER2               
p53              
NDRG1               
HTF9C * *     * *   
CEACAM5 *       *   
SLC7A5             *    
Note: All variables included in steps 1 and 2 were included as linear. Step 2 includes 
variables selected in step 1 (using the whole time-period) and variables selected with 
a short-term effect (patients censored at 5 year follow-up). Step 3 indicates the 
variables in step 2 which have evidence of a non-proportional effect, with the best 
fitting transformation to be log-time for Ki67 and PgR.  Clinical variables (age, grade, 




9.6.2.3 Cox Regression Models 
The estimated coefficients and hazard ratios from the final model identified by the MFPT 
approach are given in Table 9.18 with the time-varying effects displayed in Figure 9.9.  
 
Table 9.18 Multivariate Cox Regression of biomarkers identified by the MFPT approach in the Edinburgh BCS 
Cohort (full follow-up) 
  All ER-Positive   ER-Positive Endocrine Only 
  Coeff (Std. Err.) HR (95% CI)   Coeff (Std. Err.) HR (95% CI) 
Biomarker Only Model         
ER (50 units) - -   - - 
PgR (50 units) -0.22 (0.10) 0.80 (0.67-0.97)   -0.09 (0.05) 0.91 (0.83-1.00) 
Ki67 (10 units) 0.40 (0.08) 1.49 (1.28-1.74)   0.40 (0.09) 1.49 (1.24-1.79) 
HER2 - -   - - 
SLC7A5 - -   - - 
CEACAM5 0.28 (0.21) 1.32 (0.88-2.00)   0.34 (0.24) 1.41 (0.88-2.25) 
NDRG1 0.40 (0.17) 1.49 (1.07-2.06)   0.42 (0.19) 1.52 (1.05-2.21) 
HTF9C 0.36 (0.21) 1.43 (0.95-2.16)   - - 
p53 - -   0.39 (0.19) 1.48 (1.02-2.15) 
PgR*log(time) 0.11 (0.05) 1.11 (1.00-1.24)   - - 
Ki67*log(time) -0.19 (0.05) 0.83 (0.75-0.91)   -0.19 (0.06) 0.83 (0.74-0.93) 
Biomarker and Clinical Model         
ER (50 units) - -   - - 
PgR (50 units) -0.24 (0.10) 0.78 (0.65-0.95)   -0.09 (0.05) 0.92 (0.05) 
Ki67 (10 units) 0.33 (0.08) 1.39 (1.18-1.64)   0.33 (0.10) 1.39 (0.13) 
HER2 - -   - - 
SLC7A5 - -   -0.53 (0.31) 0.59 (0.32-1.08) 
CEACAM5 0.23 (0.21) 1.26 (0.83-1.90)   0.38 (0.24) 1.46 (0.91-2.35) 
NDRG1 - -   -   
HTF9C 0.36 (0.21) 1.43 (0.95-2.16)   0.37 (0.24) 1.45 (0.91-2.33) 
p53 - -   - - 
PgR*log(time) 0.11 (0.05) 1.12 (1.01-1.25)   - - 
Ki67*log(time) -0.21 (0.05) 0.81 (0.73-0.90)   -0.20 (0.06) 0.82 (0.73-0.92) 
NOTE. Multivariate Cox regression of the biomarkers in the final model identified by the MFPT 
algorithm. Coefficients (standard error) and hazard ratios (95% CIs) for risk of TTDR calculated for 
a 50 unit increase in ER or PgR, a 10 unit increase in Ki67 and positive compared to negative for 
all other markers. Values calculated for all ER-positive patients and ER-positive patients who 
received no chemotherapy in the Edinburgh cohort with full follow-up. Abbreviations: TTDR, 
time to distant-recurrence; Coeff, coefficient; Std. Err, standard error; CI, confidence interval. * 




Figure 9.9 Edinburgh BCS cohort – full follow-up. Time-varying adjusted hazard ratios for a ten-unit increase in Ki67 and fifty-unit increase in PgR. Plots represent (A and C) all ER-
positive patients and (B and D) ER-positive patients treated with endocrine therapy only in the Edinburgh BCS cohort from the biomarker only model (A and B) and the biomarker and 





Again the discrimination was compared between the model identified in step 1 of the MFPT 
approach; variables prognostic of outcome over the full follow-up, and the final model; 
variables prognostic of both short and long-term outcome and the inclusion of any time-
varying effects. The same 3 models were also compared: the biomarker only model with and 
without adjustment for clinical variables and the biomarker and clinical model. 
 
Table 9.19 Edinburgh BCS cohort (full follow-up). Comparison of discrimination of model identified in step 1 of 
the MFPT approach and the final model. 
  Edinburgh BCS 
  R2 (%)   D-Statistic 
  Step 1 Final Increase   Step 1 Final Increase 
All ER-Positive               
Biomarker Only Model 7.3 14.8 7.51   0.57 0.85 0.28 
Adjusted Biomarker Model 23.4 29.1 5.64   1.13 1.31 0.18 
Biomarker and Clinical Model 23.5 29.0 5.50   1.13 1.31 0.17 
                
ER-Positive Endocrine Only               
Biomarker Only Model 9.3 14.8 5.45   0.66 0.85 0.20 
Adjusted Biomarker Model 25.8 29.5 3.73   1.21 1.33 0.12 
Biomarker and Clinical Model 25.1 30.1 5.00   1.18 1.34 0.16 
Note. Values represent R2 and D-statistic for the models identified by step 1 and the 
final model of the MFPT approach, with a difference in D of at least 0.1 indicating 
improved prognostic separation. Results are given for all ER-positive patients and ER-
positive patients treated with endocrine therapy only in the Edinburgh BCS cohort with 
full follow-up. The models represent: biomarker only model, model selected by MFPT 
including biomarkers only; Adjusted biomarker model, model selected by MFPT 
including biomarkers only then adjusting for clinical variables (age, grade, tumour size, 
nodes positive, chemotherapy); Biomarker and clinical model, model selected by MFPT 
including biomarkers and clinical variables. 
 
There was improved prognostic separation between step 1 of the MFPT model building 
approach and the final model for all 3 models and both patient subgroups with increases in R2 
between 3.7 and 7.5% and increases in D-statistic between 0.12 and 0.28. The extra biomarkers 
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in the adjusted biomarker model did not improve the prognostic ability compared to the 
biomarker and clinical model with similar R2 and D-statistics. 
9.7 RP Flexible Parametric Models 
The RP models also allow fitting on different scales, so far we have only considered the 
hazards scale.  
Returning to the mathematical formulas, the basic Weibull model is written as: 
 𝑙𝑛𝐻(𝑡; 𝑥) = ln𝐻0(𝑡) + 𝑥𝛽   . 9.1.  
The survival function S(t) is related to the cumulative hazard function H(t) by H(t)=-ln S(t) 
allowing us to rewrite (9.1) as: 
 ln {−𝑙𝑛 𝑆(𝑡)} = ln {− ln 𝑆0(𝑡)} + 𝑥𝛽   , 9.2.  
Which generalises to: 
 𝑔𝜃{𝑆(𝑡)} = 𝑔𝜃{𝑆0(𝑡)} + 𝑥𝛽   , 9.3.  
Where 𝑔𝜃(. ) is a monotonic increasing function, depending on a parameter θ. Royston and 
Parmer took 𝑔𝜃(. ) to be Aranda-Ordaz’s (Aranda-Ordaz, 1981) function (Royston and 
Parmar, 2002b) 
 
𝑔𝜃(𝑥) = ln (
𝑥−𝜃 − 1
𝜃
)  , 9.4.  
where θ > 0. The limit of 𝑔𝜃(𝑥) as θ tends to 0 is ln (-ln x), so that with θ = 0 we get the 
proportional hazards model (9.1). 
When θ = 1, the model becomes the proportional odds model: 
 𝑙𝑜𝑔𝑖𝑡{1 − 𝑆(𝑡)} = 𝑙𝑜𝑔𝑖𝑡{1 − 𝑆0(𝑡)} + 𝑥𝛽  . 9.5.  
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The proportional model is structurally similar to a Cox model, but with the feature that the 
hazard ratio for a covariate converges to 1 as t → ∞. This may be an advantage when we 
observe a violation of the proportional hazards assumption in the Cox model. 
The probit class of models can also be considered with the RP family of survival models. The 
θ parameter is redundant and 𝑔𝜃(. ) is defined as minus the probit or inverse normal cumulative 
distribution function: 
 𝑔𝜃{𝑆(𝑡; 𝑥)} = −Φ
−1{𝑆(𝑡; 𝑥)} = −Φ−1{𝑆0(𝑡)} + 𝑥𝛽  . 9.6.  
 
The Aranda-Ordaz definition of RP models provides a large number of potential models. 
However, with θ not equal to 0 or 1, the interpretation of covariate effects is difficult.  
In their book Royston and Lambert consider four key issues in developing a prognostic model 
(Royston and Lambert, 2011),: 
1. Choice of scale (hazards, odds, or probit) and baseline complexity (degrees of freedom for 
the spline function). 
2. Selection of influential variables. 
3. Dealing with possible nonlinearity of continuous covariates. 
4. Assessing the need to extend the model for time-dependent effects. 
 
9.7.1  Choice of scale 
The choice of scale for the model was considered using a preliminary model with all 9 
biomarkers. The choice of scale and number of knots for the baseline spline function was 
assessed using the Akaike information criterion (AIC) and Bayes information criterion (BIC) 
with lower values indicating a better fit of the model.  
Results are given in Table 9.20 for the Edinburgh BCS cohort with follow-up censored at 10 
years. Except for the AO model, a model with 2 degrees of freedom optimised both AIC and 
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BIC. The PH model is the poorest fitting model, however the PO and probit only marginally 
improve the model fit. The scale minimising the AIC and BIC is the AO scale. Similar results 
were seen were considering the full follow-up for the Edinburgh BCS cohort (Table 9.21). 
Table 9.20 Edinburgh BCS cohort (10-year follow-up). Choice of scale and baseline complexity for multivariable 
model containing the 9 biomarkers. 
d.f. PH PO probit AO 
  AIC  BIC AIC BIC AIC BIC AIC BIC 
1 176.8 238.1 170.1 231.3 156.3 217.6 140.0 204.3 
2 157.8 222.1 153.9 218.2 149.7 214.0 140.3 207.7 
3 159.2 226.5 155.2 222.6 149.9 217.3 141.6 212.0 
4 160.6 231.0 156.6 227.1 151.8 222.2 143.0 216.5 
5 160.4 233.9 156.5 230.0 152.7 226.2 143.6 220.1 
Note. For legibility, 1,000 has been subtracted from all AIC and BIC values. Lowest values 
of AIC and BIC have been underlined for each scale and the overall lowest AIC and BIC 
values have been shaded. Abbreviations: d.f, degrees of freedom; PH, proportional 
hazards; PO, proportional odds; AO, Aranda-Ordaz. 
 
Table 9.21 Edinburgh BCS cohort (full follow-up). Choice of scale and baseline complexity for multivariable 
model containing the 9 biomarkers. 
d.f. PH PO probit AO 
  AIC  BIC AIC BIC AIC BIC AIC BIC 
1 287.8 351.0 278.4 341.7 260.0 323.3 225.3 291.7 
2 256.3 322.7 251.7 318.2 246.0 312.5 226.4 296.0 
3 258.2 327.9 253.6 323.3 246.9 316.5 228.0 300.8 
4 260.2 333.0 255.6 328.4 248.9 321.7 230.0 306.0 
5 261.7 337.6 257.0 333.0 250.9 325.8 231.4 310.5 
Note. For legibility, 1,000 has been subtracted from all AIC and BIC values. Lowest values 
of AIC and BIC have been underlined for each scale and the overall lowest AIC and BIC 
values have been shaded.  Abbreviations: d.f, degrees of freedom; PH, proportional 
hazards; PO, proportional odds; AO, Aranda-Ordaz. 
 
The results for the TEAM cohort are given in Table 9.22. More variation is seen in the degrees 
of freedom that optimises both AIC and BIC. Again, the PH model has the highest AIC and 
BIC values, with a probit scale optimising the BIC and AO scale optimising the AIC. 
Similar results were observed when clinical variables (age, grade, tumour size, number of 




Table 9.22 TEAM cohort. Choice of scale and baseline complexity for multivariable model containing the 9 
biomarkers. 
d.f. PH PO probit AO 
  AIC  BIC AIC BIC AIC BIC AIC BIC 
1 801.9 887.4 787.5 873.0 766.2 851.6 763.8 853.5 
2 779.2 868.9 771.6 861.3 766.9 856.6 763.5 857.5 
3 781.6 875.6 774.0 868.0 767.7 861.7 765.6 863.9 
4 778.1 876.4 770.4 868.6 762.3 860.6 761.9 864.5 
5 780.0 882.6 772.2 874.8 764.1 866.7 763.6 870.5 
Note. For legibility, 3,000 has been subtracted from all AIC and BIC values. Lowest values 
of AIC and BIC have been underlined for each scale and the overall lowest AIC and BIC 
values have been shaded. Abbreviations: d.f, degrees of freedom; PH, proportional 
hazards; PO, proportional odds; AO, Aranda-Ordaz. 
 
9.7.2 Selection of variables and functional forms 
The three steps of the MFPT approach was followed where RP flexible parametric models 
were fitted considering each of the different scales where previously the approach was applied 
using Cox models. The MFP algorithm applied in the first two steps of the MFPT approach 
can be used with RP models, but the FPT algorithm in step 3 of the MFPT approach is 
specifically for the Cox model. For step 3 with RP models, the stpm2t command was used 
which tests for time-varying effects using a forward selection criteria and a specified degrees 
of freedom to model the interaction between the covariate and the spline terms.  
Edinburgh BCS Cohort (10 year follow-up) 
Results are given in Table 9.23 for the Edinburgh BCS cohort with follow-up censored at 10 
years. The MFPT approach fitted using a RP model with the hazards, odds or probit scale 
identified the same markers as were identified using the Cox models (see Table 9.10). The 
Cox model however identified time-varying effects for both PgR and Ki67, whereas the RP 
models with hazards or odds scale only identified a time-varying effect for Ki67. There were  
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Table 9.23 Final Biomarker Only Model from the MFPT approach fitting using RP models with different scales 
for the Edinburgh BCS cohort (10-year follow-up) 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables Hazards Odds probit AO   Hazards Odds probit AO 
ER                   
PgR * * * *   * * * * 
Ki67 * (TV) * (TV) * *   * (TV) * (TV) * * 
HER2       *           
p53 * * * *   * * * * 
NDRG1 * * * *   * * * * 
HTF9C                   
CEACAM5 * * *     * * * * 
SLC7A5                   
Note. Final MFPT model fitted using RP models with different choice of scales (hazards, 
odds, probit and Aranda-Ordaz (AO)) for all ER-positive and ER-positive patients treated 
with endocrine therapy only in the Edinburgh BCS cohort with follow-up censored at 10 




Figure 9.10 Time-varying (solid black line) and time-constant (dash-dot blue line) adjusted hazard ratio and  95% 




issues with convergence when it was attempted to fit more than one time-varying effect. If we 
force the model to fit (no convergence achieved), including a time-varying effect of PgR did 
not improve the model fit when compared to time-constant effect (AIC, 141.9 versus 141.5) 
displayed in Figure 9.10. No time-varying effects were identified with the probit RP model, 
and the AO model identified different markers when considering all ER-positive patients with 
HER2 identified as prognostic and CEACAM5 not identified as prognostic of outcome. 
TEAM Cohort 
Results are given in Table 9.24 for the TEAM cohort with all scales selecting the same markers 
as were chosen with the Cox model (see Table 9.9). For all ER-positive patients, Ki67 and p53 
were both identified as having time-varying effects. A disadvantage when modelling on the 
log cumulative-hazard scale compared with the log-hazard scale in the Cox model is that when 
there are two variables with time-varying effects, the hazard ratio of the first variable depends 
on the level of the second variable, displayed in Figure 9.11.There is close agreement between 
the time-varying effect of Ki67 for those p53 negative and p53 positive but they are not 
identical as they would be if modelling on the log-hazard scale (as in a Cox model). However, 









Table 9.24 Final Biomarker Only Model from the MFPT approach fitted using RP models with different scales for 
the TEAM cohort. 
  TEAM 
  All ER-Positive   ER-Positive Endocrine Only 
Variables Hazards Odds probit AO   Hazards Odds probit AO 
ER * * * *   * * * * 
PgR * * * *   * * * * 
Ki67 * (TV) * (TV) *  *   * (TV) * * * 
HER2 * * * *           
p53 * (TV) * (TV) * *           
NDRG1 * * * *           
HTF9C                   
CEACAM5 * * * *           
SLC7A5 * * * *   * * * * 
Note. Final MFPT model fitted using RP models with different choice of scales (hazards, 
odds, probit and Aranda-Ordaz (AO)) for all ER-positive and ER-positive patients treated 
with endocrine therapy only in the TEAM cohort. TV indicates a time-varying effect 
effect (significant covariate-time interaction). 
 
 
Figure 9.11 Time-varying adjusted hazard ratio for Ki67 for those p53-negative (solid line) and p53-positive 






Edinburgh BCS Cohort (full follow-up) 
Results are given in Table 9.25 for the Edinburgh BCS cohort considering full follow-up. The 
hazards and odds scales select the same markers as the Cox model (see Table 9.16) for all ER-
positive patients, with the probit model selecting an additional marker, p53, and the AO model 
selecting fewer markers with HTF9C and CEACAM5 not included in the model. Time-varying 
effects of Ki67 and PgR were identified with the hazards scale, but with the odds scale, only 
Ki67 was identified as having a time-varying effect with PgR not reaching the strict 5% level 
but was of borderline significance (increase in model deviance including PgR as time-varying: 
3.5, p-value 0.06). 
 
Table 9.25 Final Biomarker Only Model from the MFPT approach fitting using RP models with different scales 
for the Edinburgh BCS cohort (full follow-up) 
  Edinburgh BCS 
  All ER-Positive   ER-Positive Endocrine Only 
Variables Hazards Odds probit AO   Hazards Odds probit AO 
ER                   
PgR * (TV) * * *   * * * * 
Ki67 * (TV) * (TV) *  *   * (TV) * (TV) * (TV) * 
HER2                   
p53     * *   * * * * 
NDRG1 * * * *   * * * * 
HTF9C * * *             
CEACAM5 * * *     * * * * 
SLC7A5                   
Note. Final MFPT model fitted using RP models with different choice of scales (hazards, 
odds, probit and Aranda-Ordaz (AO)) for all ER-positive and ER-positive patients treated 
with endocrine therapy only in the Edinburgh BCS cohort with full follow-up. TV 





9.7.3 Comparison of Estimated Effects 
An issue with using the different scales is the interpretation of the coefficients. A comparison 
of the estimated coefficients is given in Table 9.26. There are similar estimates for the hazards 
and odds scales, with the exponential of the coefficients from the hazard model giving the 
well-known hazard ratio estimate but not necessarily an easy interpretation with the need for 
an understanding of the hazard (the rate at which events happen). The introduction of a time-
varying effect in the hazards model also further complicates the interpretation of the 
coefficients. The exponential of the coefficients from the odds model give the odds ratio 
estimate, however odds are not always understood correctly and have the added complexity 
that the ratio converges with time. The coefficients from the probit and Aranda-Ordaz models 
are substantially different with no easy interpretation. 
 
Table 9.26 Comparison of estimated coefficients from a RP model with different choice of scales 
  Hazards Odds Probit AO 
  Coeff (SE) Coeff (SE) Coeff (SE) Coeff (SE) 
ER (50 units) 0.01 (0.06) 0.01 (0.06) -0.0005 (0.03) -0.09 (0.19) 
PgR (50 units) -0.08 (0.05) -0.10 (0.05) -0.06 (0.03) 0.35 (0.14) 
Ki67 (10 units) 0.17 (0.05) 0.18 (0.05) 0.10 (0.03) 0.94 (0.42) 
HER2 0.16 (0.20) 0.17 (0.23) 0.13 (0.12) 1.07 (0.90) 
SLC7A5 -0.26 (0.28) -0.30 (0.31) -0.14 (0.17) -0.20 (1.04) 
CEACAM5 0.45 (0.22) 0.46 (0.25) 0.23 (0.14) 0.70 (0.69) 
NDRG1 0.47 (0.18) 0.54 (0.20) 0.31 (0.11) 1.61 (0.62) 
HTF9C 0.30 (0.23) 0.34 (0.26) 0.15 (0.15) -0.17 (0.83) 
p53 0.30 (0.180 0.37 (0.21) 0.22 (0.11) 1.07 (0.61) 
Ki67 - TV -0.05 (0.02) -0.05 (0.02) -0.02 (0.01) 0.09 (0.09) 
NOTE. Comparison of coefficients from a multivariable RP model including all 9 markers 
and a time-varying effect for Ki67 with different scales (hazards, odds, probit, Aranda-
Ordaz (AO)). Coefficients (standard error) for risk of TTDR calculated for a 50 unit 
increase in ER or PgR, a 10 unit increase in Ki67 and positive compared to negative for 
all other markers. Values calculated for all ER-positive patients in the Edinburgh cohort 
with follow-up censored at 10 years. Abbreviations: TTDR, time to distant-recurrence; 




The difference in the choice of scales for the RP model, can best be demonstrated from plotting 
the exponential of the coefficients against time. This is illustrated in Figure 9.12 for a 
univariate RP model of Ki67. Plot A illustrates a hazards and odds model with no time-varying 
effects. The hazards model produces a time-constant effect whereas we can see for the odds 
model, there is a very subtle convergence towards a null effect (ratio of 1) over time. Plot B 
illustrates including a time-varying effect (covariate-log (time) interaction) of Ki67 in both the 
hazards and odds models resulting in a very similar estimate of the time-varying effect. Plot C 
illustrates the estimated effects from the probit and AO models and the time-varying hazards 
and odds models with plot D giving the AIC and BIC values to assess the model fit. The AO 
model has the lowest AIC and BIC values indicating the best fitting model, suggesting an 
under-estimation of the effect of Ki67 at earlier time-points (less than 4 years) with the time-
varying hazards and odds models. The probit model has the highest AIC value, but the time- 
varying hazards and odds models have the highest BIC due to the penalisation for the extra 








Figure 9.12 Comparison of the effect of Ki67 from a univariate RP model with different choice of scales. Plots 
represent (A) proportional hazards (PH) and proportional odds (PO) model, (B) proportional and time-varying (TV) 
hazards and odds model, (C) time-varying hazards and odds model, probit and Aranda-Ordaz (AO) models and (D) 
AIC and BIC values for the different models illustrated in C. Note, for legibility 1,000 has been subtracted from 
AIC and BIC values. 
 
Edinburgh BCS (10-year follow-up) 
The effects for the multivariable model identified for all ER-positive patients in the Edinburgh 
BCS cohort with follow-up censored at 10-years (markers identified by the hazards model: 
PgR, Ki67, p53, NDRG1, CEACAM5) are displayed in Figure 9.13. There are large 
differences in the way the AO scale models the effect of the covariates over time and suggests 
a time-varying effect for all of the covariates with the AO model having a substantially lower 
AIC and BIC values indicating improved model fit. This highlights the flexibility of the AO 
models, with the ability to model the covariates as time-varying effects without the addition  
D Scale AIC BIC 
  H (TV) 152.6 177.7 
  O (TV) 152.4 177.4 
  Probit 154.1 174.2 




Figure 9.13 Comparison of estimated effects from a multivariable RP model with different scales (hazards (H), 
odds (O), probit and Aranda-Ordaz (AO)) for all ER-positive patients in the Edinburgh BCS cohort with follow-up 
censored at 10-years. The variables in the model were (A) PgR, (B) Ki67, (C) p53, (D) NDRG1 and (E) CEACAM5. 
A covariate-time interaction was included for Ki67 in the hazards and odds model. Model fit was assessed by the 
AIC and BIC displayed in (F). Note, for legibility 1,000 has been subtracted from AIC and BIC values.  Red line 
at hazard ratio of 1 indicates a null effect. 
 
 







of extra parameters to include a covariate-time interaction. It is not possible to fit the hazards 
or odds model with numerous time-varying effects due to issues with model convergence.  
In the model building with the AO scale, a different model was identified by the MFPT 
approach (markers selected: PgR, Ki67, HER2, p53, NDRG1) however no difference in model 
fit was observed (AIC 129.1 vs. 129.0, BIC 169.1 vs. 169.1) with estimated effects and 
confidence intervals displayed in Figure 9.14. HER2 was selected in step 2 and was associated 
with follow-up censored at 4 years, however when modelled over the full follow-up HER2 
was not significant in the final model. Due to the AO model having the flexibility to model 
the covariates as time-varying in step 1, it is not necessary to consider short and long term 
follow-up separately. Overall, we observe large uncertainty in the estimated effects of the 





Figure 9.14 Edinburgh BCS Cohort. Estimated hazard ratios and 95% confidence intervals (dashed lines) from a 
multivariable RP model with Aranda-Ordaz (AO) scale for all ER-positive patients in the Edinburgh BCS cohort 
with follow-up censored at 10 years. Red line at hazard ratio of 1 indicates null effect. 
 
TEAM 
The effects for the multivariable model identified for all ER-positive patients in the TEAM 
cohort (all markers except HTF9C) are displayed in Figure 9.15. In this cohort, the effects 




Figure 9.15 TEAM Cohort. Comparison of estimated effects from a multivariable RP model with different scales 
(hazards (H), odds (O), probit and Aranda-Ordaz (AO)) for all ER-positive patients in the TEAM cohort. A 
covariate-time interaction was included for Ki67 and p53 in the hazards and odds model. Model fit was assessed 
by the AIC and BIC displayed in (I). Note, for legibility 3,000 has been subtracted from AIC and BIC values.  Red 




     
 
 
Figure 9.15 (Continued) Comparison of estimated effects from a multivariable RP model with different scales 
(hazards (H), odds (O), probit and Aranda-Ordaz (AO)) for all ER-positive patients in the TEAM cohort. A 
covariate-time interaction was included for Ki67 and p53 in the hazards and odds model. Model fit was assessed 
by the AIC and BIC displayed in (I). Note, for legibility 3,000 has been subtracted from AIC and BIC values.  Red 
line at hazard ratio of 1 indicates a null effect. 
 
model having the lowest AIC value, but again the extra parameters to model the covariate-
time interactions resulting in higher BIC values.  
The time-varying effect of p53 is modelled differently from that observed in the Cox model 
and with the time-varying hazards (or odds) RP models, displayed in Figure 9.16. A univariate 
model was used to determine the difference in model fit between the AO model and time-
varying hazards model which is due to p53 only. The time-varying hazards model had a 
marginally lower AIC value compared to the AO model (4046.9 versus 4048.1). A comparison 
to AIC and BIC values from the Cox model cannot be made as the RP models explicitly model 
the baseline hazard resulting in much lower AIC and BIC values (approx. 9000 vs. 4000 AIC  









Figure 9.16 Time-varying adjusted hazard ratio for p53 from a Cox model with a time-varying (TV) effect, a RP 
model with hazards (H) scale and Aranda-Ordaz (AO) scale for all ER-positive patients in the TEAM cohort.  
 
Figure 9.17 Estimated hazard ratios and 95% confidence intervals (dashed lines) from a multivariable RP model 





Figure 9.17 Continued Estimated hazard ratios and 95% confidence intervals (dashed lines) from a multivariable 
RP model with Aranda-Ordaz (AO) scale for all ER-positive patients in the TEAM cohort.  
 
value for Cox and RP model respectively). The estimated effects and confidence intervals from 
the AO model are displayed in Figure 9.17. In the TEAM cohort, the confidence intervals are 
much narrower than we observed in the Edinburgh BCS cohort. All markers are showing a 
small decreasing effect over time. 
Edinburgh BCS (full follow-up) 
The effects for the multivariable model identified for all ER-positive patients in the Edinburgh 
BCS cohort (markers identified by the hazards model: PgR, Ki67, NDRG1, HTF9C, 
CEACAM5) with full follow-up are displayed in Figure 9.18. The probit model was the 
poorest fitting model with the highest AIC value, again the AO model had the lowest AIC and 
BIC values but the odds model had a similar AIC (1352.5 versus 1350.4). The main differences 
between the different scales were observed for PgR and NDRG1. In a univariate analysis  
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Figure 9.18 Comparison of estimated effects from a multivariable RP model with different scales (hazards (H), 
odds (O), probit and Aranda-Ordaz (AO)) for all ER-positive patients in the Edinburgh BCS cohort with full follow-
up. A covariate-time interaction was included for Ki67 and PgR in the hazards and odds model. Model fit was 
assessed by the AIC and BIC displayed in (F). Note, for legibility 1,000 has been subtracted from AIC and BIC 
values. Red line at hazard ratio of 1 indicates a null effect. 
 
 







      
       
 
Figure 9.19 Comparison of estimated effects from a univariate RP model of (A) PgR and (B) NDRG1 with different 
scales (hazards (H), odds (O), probit and Aranda-Ordaz (AO)) for all ER-positive patients in the Edinburgh BCS 
cohort with full follow-up. A covariate-time interaction was included for PgR in the hazards and odds model. Model 
fit was assessed by the AIC and BIC. Note, for legibility 1,000 has been subtracted from AIC and BIC values. Red 
line at hazard ratio of 1 indicates a null effect. 
 
(Figure 9.19), the time-varying hazards model for PgR had the lowest AIC value, however a 
very similar value was observed for the AO model (1385.1 vs. 1386.4). Whereas for NDRG1, 
the AO model was an improved model fit compared to the proportional hazards model (1377.3 
vs. 1383.5) suggesting a time-varying effect for NDRG1. Different markers were identified by 
the AO model in the MFPT model building (PgR, Ki67, p53, NDRG1) with an improved 
model fit (AIC 1343.5 vs. 1350.4) and estimated effects and confidence intervals displayed in 
Figure 9.20. Wide confidence intervals were again observed and all estimated effects for the 














Figure 9.20 Estimated effects and 95% confidence intervals (dashed lines) for multivariable RP model with 
Aranda-Ordaz (AO) scale for all ER-positive patients in the Edinburgh BCS cohort with full follow-up. Red line at 
hazard ratio of 1 indicates null effect. 
 
9.7.4 Restricted Mean Survival Time 
The Aranda-Ordaz RP models have the advantage of being flexible and can model numerous 
covariates as time-varying without the need for extra parameters. However, the main drawback 
is the difficult interpretation of the estimated coefficients. Restricted mean survival time 
(RMST) was introduced in chapter 8 as an alternative to estimating the hazard ratio when we 
had non-proportional hazards. It is an estimate of the area under the survival curve up to a pre-
specified time-point (t*) and can be thought of as the ‘t*-life expectancy’. The RMST can also 
be calculated from RP models with the different choice of scales (hazards, odds, probit and 
AO) and could be used as an intuitive outcome measure. 
The RMST estimates for t* equal to 5 and 10 years from the models identified by the MFPT 
approach are given in Table 9.27 for the Edinburgh BCS cohort with follow-up restricted to 
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10-years and Table 9.28 for the TEAM cohort. The larger differences between the modelled 
effects over time from the hazards and AO models in the Edinburgh BCS cohort is shown with 
different estimates in RMST with the two choice of scales. However, in the TEAM cohort 
where we observed more similar estimated effects over time, we observe similar RMST 
estimates. Each individual marker contributes only a small improvement in time-to-distant-
recurrence with many of the estimates containing 0 in the confidence interval. The largest 
effects were observed for PgR, Ki67 and CEACAM5 in the Edinburgh BCS cohort with being 
CEACAM5 negative increasing the time-to distant-recurrence over 10 years by 0.6 (95% CI, 
0.1-1.0) years compared to being CEACAM5 positive. The largest effects observed in the 
TEAM cohort were for PgR, NDRG1 and SLC7A5 with being in the 75th centile of PgR 
increasing the time-to distant-recurrence over 10 years by 1.2 (95% CI, 0.7-1.8) years 
compared to being in the 25th centile. The estimated effect was smaller when modelled using 
the AO model (1.0 years 95% CI, 0.4-1.6).  
The difference in RMST when all markers were considered low risk (ER and PgR 75th centile, 
Ki67 25th centile and all other markers negative) and high risk (ER and PgR 25th centile, Ki67 
75th centile and all other markers positive) was estimated, referred to as ‘overall’ in the tables. 
In the Edinburgh BCS cohort (all ER-positive patients) an increase in time-to distant-
recurrence over 10 years of 1.8 (95% CI, 1.3-2.3) years was observed with the hazards model 
and 1.7 (95% CI, 0.8-2.5) years with the AO model. The improvement in time-to distant-
recurrence over 10-years was much larger in the TEAM cohort, with estimated different in 
RMST of 5.0 (95% CI, 4.6-5.4) years with the hazards model and 3.4 (95% CI, 2.8-4.0) years 





Table 9.27 5 and 10-year restricted-mean survival estimates for the Edinburgh BCS cohort (10-year follow-up) 
from a RP model with hazards and Aranda-Ordaz scales 
  All ER-Positive   ER-Positive Endocrine Only 
  Hazards   AO   Hazards   AO 
  
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI) 
t* = 5 Years             
ER -   -   -     
PgR 0.37 (-0.08-0.82)   0.28 (-0.28-0.84)   0.41 (-0.08-0.89)   0.36 (-0.26-0.99) 
Ki67 0.43 (-0.03-0.89)   0.22 (-0.33-0.77)   0.43 (-0.06-0.93)   0.23 (-0.39-0.85) 
HER2 -   0.06 (-0.51-0.62)   -   - 
p53 0.18 (-0.27-0.62)   0.21 (-0.36-0.78)   0.31 (-0.16-0.79)   0.28 (-0.35-0.90) 
NDRG1 0.17 (-0.28-0.61)   0.21 (-0.36-0.78)   0.20 (-0.28-0.68)   0.27 (-0.36-0.90) 
HTF9C -   -   -   - 
CEACAM5 0.45 ( 0.02-0.88)   -   0.60 ( 0.14-1.06)   0.28 (-0.35-0.90) 
SLC7A5 -   -   -   - 
Overall 1.46 ( 1.04-1.89)   0.90 ( 0.34-1.46)   1.69 ( 1.24-2.14)   1.32 ( 0.70-1.94) 
t* = 10 Years             
ER -   -   -   - 
PgR 0.51 ( 0.00-1.03)   0.52 (-0.31-1.35)   0.55 (-0.01-1.11)   0.64 ( 0.26-1.53) 
Ki67 0.53 ( 0.00-1.07)   0.41 (-0.41-1.23)   0.51 (-0.06-1.09)   0.41 (-0.49-1.30) 
HER2 -   0.11 (-0.73-0.94)   -   - 
p53 0.23 (-0.27-0.73)   0.38 (-0.45-1.22)   0.40 (-0.13-0.92)   0.48 (-0.42-1.38) 
NDRG1 0.22 (-0.28-0.72)   0.38 (-0.45-1.22)   0.26 (-0.28-0.79)   0.47 (-0.43-1.37) 
HTF9C -   -   -   - 
CEACAM5 0.56 ( 0.08-1.04)   -   0.72 ( 0.21-1.22)   0.48 (-0.42-1.38) 
SLC7A5 -   -   -   - 
Overall 1.81 ( 1.30-2.31)   1.66 ( 0.83-2.49)   2.01 ( 1.48-2.54)   2.29 ( 1.41-3.17) 
NOTE. Difference in RMST and 95% CI for t* equal to 5 and 10 years for a multivariable Royston-
Parmer flexible parametric model with the hazards or Aranda-Ordaz (AO) scale. Difference in 
RMST calculated as the difference in the IQR of the continuous markers and negative compared 
to positive for dichotomous markers. Overall represents the difference between all markers are 
low (PgR 75th centile, Ki67 25th centile, all other markers negative) and all markers high (PgR 
25th centile, Ki67 75th centile, all other markers positive). Abbreviations: RMST, restricted mean 
survival time; CI, confidence interval. Model is adjusted for age, grade, tumour size, nodes 







Table 9.28 5 and 10-year restricted-mean survival estimates for the TEAM cohort from a RP model with hazard 
and Aranda-Ordaz scales 
  All ER-Positive   ER-Positive Endocrine Only 
  Hazards   AO   Hazards   AO 
  
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI) 
t* = 5 Years             
ER 0.05 (-0.28-0.38)   0.08 (-0.29-0.45)   0.13 (-0.29-0.54)   0.17 (-0.28-0.61) 
PgR 0.34 ( 0.01-0.68)   0.45 ( 0.07-0.82)   0.44 ( 0.03-0.85)   0.42 (-0.03-0.86) 
Ki67 0.08 (-0.25-0.41)   0.05 (-0.31-0.42)   0.12 (-0.29-0.53)   0.07 (-0.38-0.51) 
HER2 0.06 (-0.27-0.40)   0.13 (-0.24-0.51)   -   - 
p53 0.26 (-0.09-0.60)   0.22 (-0.16-0.60)   -   - 
NDRG1 0.21 (-0.13-0.55)   0.19 (-0.18-0.57)   -   - 
HTF9C -   -   -   - 
CEACAM5 0.16 (-0.17-0.51)   0.21 (-0.17-0.58)   -   - 
SLC7A5 0.21 (-0.13-0.55)   0.29 (-0.09-0.67)   0.38 (-0.03-0.80)   0.32 (-0.13-0.77) 
Overall 2.08 ( 1.73-2.43)   1.69 ( 1.31-2.08)   1.12 ( 0.71-1.53)   0.96 ( 0.52-1.41) 
t* = 10 Years             
ER 0.17 (-0.37-0.70)   0.19 (-0.38-0.76)   0.36 (-0.25-0.97)   0.32 (-0.33-0.98) 
PgR 1.21 ( 0.68-1.75)   1.01 ( 0.44-1.58)   1.22 ( 0.61-1.83)   0.81 ( 0.15-1.46) 
Ki67 0.06 (-0.48-0.60)   0.12 (-0.45-0.69)   0.13 (-0.48-0.74)   0.13 (-0.52-0.79) 
HER2 0.23 (-0.31-0.77)   0.29 (-0.28-0.86)   -   - 
p53 0.62 ( 0.07-1.16)   0.48 (-0.09-1.06)   -   - 
NDRG1 0.71 ( 0.17-1.26)   0.43 (-0.15-1.00)   -   - 
HTF9C -   -   -   - 
CEACAM5 0.57 ( 0.03-1.12)   0.46 (-0.12-1.03)   -   - 
SLC7A5 0.71 ( 0.17-1.25)   0.63 ( 0.05-1.20)   1.01 (0.40-1.61)   0.61 (-0.05-1.27) 
Overall 5.04 ( 4.55-5.41)   3.39 ( 2.82-3.96)   2.71 (2.12-3.29)   1.84 (1.19-2.49) 
NOTE. Difference in RMST and 95% CI for t* equal to 5 and 10 years for a multivariable Royston-
Parmer flexible parametric model with the hazards or Aranda-Ordaz (AO) scale. Difference in 
RMST calculated as the difference in the IQR of the continuous markers and negative compared 
to positive for dichotomous markers. Overall represents the difference between all markers are 
low (ER and PgR 75th centile, Ki67 25th centile, all other markers negative) and all markers high 
(ER and PgR 25th centile, ki67 75th centile, all other markers positive) Abbreviations: RMST, 
restricted mean survival time; CI, confidence interval. Model is adjusted for age, grade, tumour 







Table 9.29 5, 10 and 15-year restricted-mean survival estimates for the Edinburgh BCS cohort (full follow-up) 
from a RP model with hazards and Aranda-Ordaz scales 
  All ER-Positive   ER-Positive Endocrine Only 
  Hazards   AO   Hazards   AO 
  
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI)   
Diff in RMST 
(95% CI) 
t* = 5 Years             
ER -       -   - 
PgR 0.62 ( 0.15-1.08)   0.24 (-0.32-0.80)   0.29 (-0.21-0.78)   0.31 (-0.32-0.94) 
Ki67 0.37 (-0.10-0.84)   0.20 (-0.35-0.75)   0.49 (-0.02-0.99)   0.21 (-0.41-0.83) 
HER2 -   -   -   - 
p53 -   0.17 (-0.39-0.74)   0.22 (-0.27-0.71)   0.21 (-0.42-0.84) 
NDRG1 0.14 (-0.32-0.60)   0.21 (-0.35-0.78)   0.15 (-0.34-0.64)   0.24 (-0.39-0.87) 
HTF9C 0.43 (-0.02-0.88)   -   -   - 
CEACAM5 0.31 (-0.14-0.76)   -   0.40 (-0.08-0.89)   0.19 (-0.44-0.83) 
SLC7A5 -   -   -   - 
Overall 1.70 ( 1.25-2.14)   0.82 ( 0.26-1.38)   1.46 ( 0.98-1.92)   1.10 ( 0.48-1.73) 
t* = 10 Years             
ER -   -   -   - 
PgR 0.77 ( 0.24-1.31)   0.45 (-0.38-1.28)   0.40 (-0.17-0.97)   0.55 (-0.35-1.46) 
Ki67 0.48 (-0.08-1.04)   0.38 (-0.44-1.20)   0.61 ( 0.01-1.20)   0.38 (-0.52-1.28) 
HER2 -   -   -   - 
p53 -   0.32 (-0.51-1.16)   0.30 (-0.25-0.85)   0.37 (-0.54-1.28) 
NDRG1 0.19 (-0.33-0.72)   0.40 (-0.44-1.23)   0.20 (-0.36-0.76)   0.43 (-0.48-1.34) 
HTF9C 0.56 ( 0.06-1.06)   -   -   - 
CEACAM5 0.41 (-0.10-0.92)   -   0.52 (-0.02-1.05)   0.35 (-0.56-1.25) 
SLC7A5 -   -   -   - 
Overall 2.09 ( 1.56-2.62)   1.53 ( 0.70-2.36)   1.81 ( 1.25-2.36)   1.97 ( 1.07-2.86) 
t* = 15 Years             
ER -   -   -   - 
PgR 0.80 ( 0.24-1.36)   0.64 (-0.39-1.68)   0.43 (-0.17-1.02)   0.77 (-0.35-1.88) 
Ki67 0.50 (-0.09-1.08)   0.55 (-0.48-1.57)   0.62 ( 0.00-1.23)   0.53 (-0.59-1.64) 
HER2 -   -   -   - 
p53 -   0.46 (-0.57-1.50)   0.31 (-0.25-0.88)   0.51 (-0.60-1.63) 
NDRG1 0.21 (-0.34-0.75)   0.57 (-0.47-1.60)   0.22 (-0.36-0.79)   0.60 (-0.52-1.71) 
HTF9C 0.59 ( 0.07-1.11)   -   -   - 
CEACAM5 0.44 (-0.09-0.97)   -   0.54 (-0.01-1.09)   0.48 (-0.63-1.60) 
SLC7A5 -   -   -   - 
Overall 2.16 ( 1.61-2.72)   2.17 ( 1.15-3.20)   1.86 ( 1.28-2.44)   2.73 ( 1.63-3.83) 
NOTE. Difference in RMST and 95% CI for t* equal to 5, 10 and 15 years for  a multivariable RP 
model with the hazards or Aranda-Ordaz (AO) scale. Difference in RMST calculated as the 
difference in the IQR of the continuous markers and negative compared to positive for 
dichotomous markers. Overall represents the difference between all markers are low (PgR 75th 
centile, Ki67 25th centile, all other markers negative) and all markers high (PgR 25th centile, ki67 
75th centile, all other markers positive).  Abbreviations: RMST, restricted mean survival time; CI, 




The RMST estimates for t* equal to 5, 10 and 15 years from the models identified by the 
MFPT approach are given in Table 9.29 for the Edinburgh BCS cohort with full follow-up. 
We observe large differences in estimates between the two choice of scales, hazards and AO. 
Larger effects were observed for PgR and HTF9C, with being in the 75th centile of PgR 
increasing the time-to distant recurrence over 15 years by 0.8 (95% CI 0.2-1.5) years compared 
to the 25th centile. Comparing the overall low risk to high risk, there was increase in time-to 
distant-recurrence over 15 years by 2.2 (95% CI, 1.6-2.7) years. 
9.8 Discussion 
This chapter explored the effects of the individual biomarkers from the IHC4 and Mammostrat 
residual risk panels. The MFPT approach was used to build a multivariable model with Cox 
models and Royston-Parmer (RP) flexible parametric models where the different choice of 
scales (hazards, odds, probit and AO) were explored.  
The first two steps of the MFPT approach involve using the MFP algorithm to determine which 
variables are associated with the outcome in the short and long-term and simultaneously 
determine the best FP to model the functional form of the covariates. An issue arose where 
despite there being no statistical significant difference in the best fitting degree 2 FP compared 
with a linear effect on the log-hazard, considering the FP2 model resulted in variables not 
being identified as prognostic of outcome. It is important to consider whether the FP2 model 
results in over-fitting of the covariate and in the case that was observed here, a clinically 
implausible effect of the predictor.  
The importance of considering variables associated with both long and short term when model 
building was illustrated. A large improvement in model discrimination was observed in the 
Edinburgh BCS cohort comparing variables associated over the full follow-up only and the 
final model including variables associated with both short and long-term outcome and 
identifying any time-varying effects.  
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The MFP and FPT algorithms used in the MFPT approach were developed to keep the overall 
type I error at a pre-specified level when considering which variables were prognostic of 
outcome and which had time-varying effects and the best fitting FPs to model these effects. 
However, the approach is essentially a stepwise selection method which could result in an 
arbitrary and over-fitted model. It is important to take into account any clinical insight when 
model building, and the MFPT approach allows you to have control over the process by forcing 
covariates into the model, selecting the significance level for the inclusion of prognostic and 
time-varying effects, specifying the degrees of freedom and the significance level for testing 
between FP models. 
The MFPT approach was developed on the Cox model. A similar method was applied using 
RP models which have the advantage of being parametric and explicitly model the baseline 
hazard. The MFP algorithm used in the first two steps of the MFPT approach can be applied 
using RP flexible parametric models. Step 3 involves the FPT algorithm which is specific for 
determining time-varying effects in the Cox model, but a similar forward selection algorithm 
can be used to determine time-varying effects in RP models with the advantage of not having 
to split the time scale as in the Cox model. Fitting a RP model with the hazards scale resulted 
in the same models being identified as with the Cox model. A disadvantage of the RP models 
was illustrated where modelling on the log-cumulative hazards scale results in the time-
varying effect of one covariate depending on the value of any other time-varying covariates. 
The difference however was small, but should be kept in mind when modelling time-varying 
effects on the log-cumulative hazard. 
The RP model has the flexibility of allowing you to model on different scales (hazards, odds, 
probit and Aranda-Ordaz (AO)). The odds scale has the potential advantage that the effect of 
the covariates converge to 1 as time tends to infinity. The flexibility of the AO model was 
illustrated with the ability to model numerous covariates as time-varying effects without the 
extra parameters to model an interaction with time and it is not necessary to determine the best 
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fitting FP or the required flexibility (degrees of freedom) of the spline terms. The main 
drawback to the using the different scales was the difficulty interpreting the estimated 
coefficients. The novel measure of restricted mean survival time was illustrated as an 
alternative outcome measure which can be estimated for any of the scales and also with the 
inclusion of time-varying effects. 
In the Edinburgh cohort PgR, Ki67, p53, NDRG1 and CEACAM5 were important predictors 
of TTDR, with PgR, Ki67 and CEACAM5 remaining prognostic of outcome when adjusting 
for clinical variables (age, grade, tumour size, number of positive nodes and treatment). Ki67 
was identified as having a strong non-proportional effect. The overall model estimated an 
increase in time-to distant-recurrence over 10 years of 1.8 (95% CI, 1.3-2.3) years comparing 
low risk to high risk patients. 
All markers except HTF9C were prognostic of outcome in the TEAM cohort and remained 
important predictors of outcome after adjustment for clinical variables with the exception of 
HER2. Ki67 and p53 were identified as having time-varying effects. The overall model 
estimated a large increase in time-to distant-recurrence over 10 years of 5.0 (95% CI, 4.6-5.4) 
years comparing low risk to high risk patients. 
Differences were observed between the two cohorts in the selection of prognostic markers. 
This highlights the differences in the two patient populations, with the Edinburgh BCS cohort 
being a lower risk population than the TEAM cohort. The wide confidence intervals when 
modelling using RP flexible parametric models with the AO scale in the Edinburgh BCS 
cohort indicates large uncertainty in the estimated effects of the individual markers, and 
suggests this cohort may not be adequately powered to perform such a flexible analysis. 
Overall, we have illustrated complex models with subtle differences depending on the cohort 
and patient subtype. In both cohorts, a combination of markers from the IHC4 and 
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Mammostrat residual risk models were prognostic of outcome, with a constantly strong time-
























Chapter 10:  Discussion and Recommendations 
10.1 Summary of Results 
10.1.1 Statistical Methods for the Analysis of Non-Proportional Hazards 
The Cox proportional hazards model is the most commonly used approach for analysing 
survival time data in medical research despite its well-known limitations. The baseline hazard 
function is completely unspecified which can be seen as an advantage (one avoids potential 
problems from specifying the wrong shape), but it has a disadvantage when the shape of the 
baseline hazard function may provide important information related to the time-course of an 
illness. Explicitly modelling the baseline hazard also allows the easy calculation of absolute 
risk estimates which may be of more clinical benefit than only having relative risk estimates 
(e.g. hazard ratios).  
Another limitation of the Cox model is the proportional hazards assumption, which assumes 
that the hazard ratio comparing one level of a covariate to another is constant over time. This 
assumption is often violated when modelling prognostic factors in cancer studies. When the 
assumptions of the Cox PH model are not met, it is possible that subsequent analyses and risk 
estimates will be biased.  
In this thesis, a literature review was performed to identify existing approaches for the analysis 
of non-proportional effects with respect to survival data with an interest in the application of 
these approaches in practice.  
The simplest approach to deal with non-proportional hazards is splitting the time scale, known 
as piecewise constant effects, but the drawbacks of this approach are well established. The 
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categorising of the time-scale results in a reduction of power and the number of intervals 
chosen can have an impact on the conclusions made.  
A large number of alternatives to piecewise constant effects were highlighted by the review; 
from fully parametric to non-parametric models, multiplicative effects of the covariates to 
additive effects, different methodological assumptions such as cure and frailties, as well as an 
expanding body of literature on Bayesian approaches. However, there appeared to be few 
examples of application of the different approaches in practice. 
Two approaches were highlighted in the review: the multivariable fractional polynomial time 
(MFPT) approach by Sauerbrei and colleagues and a flexible parametric approach proposed 
by Royston and Parmer (Sauerbrei et al., 2007, Royston and Parmar, 2002b). Both of these 
approaches allow incorporating non-linear effects of continuous covariates on the log-hazard 
as well as non-proportional effects. They are also easily implemented in standard software 
which is important in encouraging the future use of these approaches.  
The MFPT Approach 
The MFPT approach is a multivariable strategy to select variables which have an effect on the 
outcome, determine the functional form of continuous variables and determine whether the 
PH assumption is sensible or if time-varying effects are present. The advantages of this 
approach include: the model reverts to the Cox proportional hazards model if no time-
dependent effects are identified, which is the standard method of analysis for survival data and 
therefore most clinicians and researchers have a basic understanding of the method. It is a 
closed-test algorithm which keeps the overall error rate at a pre-specified level whilst 
simultaneously selecting the best FP to model non-linear and non-proportional effects and 
whether they are prognostic of outcome. The approach also highlighted the need to consider 
both short and long-term survival when assessing prognostic factors; considering only the full 
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follow-up could result in missing important predictors of short-term survival and important 
time-varying effects.  
The main disadvantage of the MFPT approach is the need to categorise survival time when 
evaluating time-varying effects. The Cox model is fitted by evaluating the partial likelihood 
at each failure time and because the time-varying effects are a function of study time, the 
observations under risk are split into episodes at specified time points. Ideally the splits would 
be made at each event time, however with large datasets this is not always possible. Buchholz 
has shown that the MFPT procedure gives similar results for small categorisation intervals and 
propose that about 50 to 100 distinct event times can give results with sufficient precision 
(Buchholz, 2010). However, a relatively long computing time was observed when running the 
FPT algorithm with only 58 distinct event times. It was also illustrated that it is important to 
consider the choice of degree of flexibility for the FPs. A FP of degree 2 resulted in a clinically 
implausible effect of a covariate which was then excluded from the model, but considering a 
FP of degree 1 or a linear effect, the covariate was a significant predictor of outcome.  
Overall, the MFPT approach is useful for identifying non-linear and non-proportional effects 
in the Cox regression model. However, the approach is essentially a stepwise selection method 
which could result in an arbitrary and over-fitted model. It is important to take into account 
any clinical insight when model building, and the MFPT approach allows you to have control 
over the process by forcing covariates into the model, selecting the significance level for the 
inclusion of prognostic and time-varying effects, specifying the degrees of freedom and the 
significance level for testing between FP models.  
RP Flexible Parametric Models 
The Royston-Parmer flexible parametric models involves modelling the baseline hazard and 
non-proportional effects through the use of regression splines. The MFPT approach was 
followed fitting the models using the more flexible RP models rather than the Cox model. The 
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MFP algorithm used in first two steps of  the MFPT approach to determine which variables 
are prognostic of long and short-term survival and the best fitting FP to model the effect on 
the log-hazard can be also be used with RP flexible parametric models. Therefore the 
advantage of the closed test algorithm remains whilst simultaneously determining variables 
that have a prognostic effect on the outcome and the best FP model to be the effect. Step three 
in the MFPT approach involves the FPT algorithm which is specific for determining time-
varying effects in the Cox model. Instead a forward selection algorithm was used to determine 
time-varying effects in RP models with a specified degrees of freedom. Once the time-varying 
effects are identified, the degree of flexibility needed to model the time-varying effect is 
determined by examining the model fit.  
With proportional hazards, estimates from a RP model are almost identical to that from a Cox 
model. The same models were also identified when following the MFPT approach with either 
Cox models or RP models on the hazards scale. One of the advantages of the RP models is the 
ease of which time-dependent effects can be fitted, with no need for categorising of the 
survival time, a simple interaction between the covariates and spline terms is introduced. Due 
to the model being parametric, this enables easy prediction of absolute and relative risk 
estimates. The use of survival and hazard rates along with a novel measure, restricted mean 
survival time (RMST), was illustrated.  The RMST has a more intuitive interpretation than the 
hazard ratio and can be thought of as a ‘t-year life expectancy’. For example, treatment A 
increases your life expectancy by 2 years compared with treatment B.  
The RP models also allow modelling on different scales (hazards, odds, probit and Aranda-
Ordaz (AO)). The odds scale has the advantage that the effect of the covariates converge to 1 
as time tends to infinity, which may be seen as a more appropriate assumption for many 
prognostic factors compared to the more restrictive constant proportionality in the Cox model. 
The flexibility of the AO model was illustrated with the ability to model numerous covariates 
as time-varying effects without the extra parameters to model an interaction with time and it 
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is not necessary to determine the best fitting FP or the required flexibility (degrees of freedom) 
of the spline terms. The main drawback to the using the different scales was the difficulty 
interpreting the estimated coefficients. The restricted mean survival time was illustrated as an 
alternative outcome measure which can be estimated for any of the scales and also with the 
inclusion of time-varying effects. Although not demonstrated in the thesis, RP flexible 
parametric models can also be extended to relative survival models.  
There are some drawbacks to the flexible parametric approach, as difficulties can occur with 
convergence when fitting these models to small samples or fitting complex models with more 
than one time-varying effect. Identifying time-varying effects are not in a closed test algorithm 
and therefore there may be an issue with multiple testing. A strict level of significance for 
selection of time-varying effects could help avoid this. A disadvantage of the RP models was 
illustrated where modelling on the log-cumulative hazards scale results in the time-varying 
effect of one covariate depending on the value of any other time-varying covariates. The 
difference however was small, but should be kept in mind when modelling time-varying 
effects on the log-cumulative hazard. 
Conclusion 
Overall, the RP flexible parametric models would be favoured over Cox models when 
investigating non-proportional effects due to the main advantage of not having to categorise 
survival time. It was shown the MFPT approach could be easily adapted to use RP flexible 
parametric models. This approach would be recommended as it highlights the need for 
investigating non-linear effects and considering both short- and long-term survival to ensure 
the identification of important predictors. It is recommended when a non-proportional effect 
is identified, a plot of the hazard ratio with 95% confidence intervals over continuous-time is 
shown along with restricted mean survival estimates. Piece-wise constant effects can also be 
presented as an aid to help clinical interpretation.  
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The focus of the thesis has been on the evaluation of non-proportional effects of prognostic 
factors. A recently published paper highlights the importance of this work in other areas. 
Royston and Parmer propose how to design and analyse a trial when hazards may be non-
proportional in their paper titled ‘An approach to trial design and analysis in the era of non-
proportional hazards of the treatment effect’ (Royston and Parmar, 2014). They suggest there 
is a need to improve the power to detect a potentially more complex treatment effects than 
assuming proportional hazards. When determining the sample size of a trial they propose to 
use a ‘joint test’, which combines the usual log-rank or Cox test with the Grambsch-Therneau 
test of non-proportional hazards. When predefining the statistical analysis, they recommend 
the use of the flexible parametric model with 3 degrees of freedom for the baseline hazard 
function and 1 degrees of freedom for the time-dependent treatment effect.  
It is agreed with Binquet and colleagues that there is the need for continued methodological 
research in this area, for more widespread use of flexible modelling in prognostic studies and 
encourage others to explore similar flexible analyses (Binquet et al., 2008, Binquet et al., 
2009). 
10.1.2 Evaluation of IHC4 and Mammostrat Residual Risk Panels 
An aim of the thesis was to compare two prognostic IHC biomarker panels, IHC4 and 
Mammostrat, to determine which provides more information on the risk of recurrence in the 
context of additional clinical factors or whether combining both approaches would increase 
the information available to patients and clinicians. 
Comparison of IHC4 and Mammostrat 
The first analysis fitted the standard Cox proportional hazard model and the assumptions of 
linearity and proportional hazards were assessed.  
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IHC4 and Mammostrat risk scores were significantly associated with time to distant recurrence 
and added prognostic information beyond that provided by clinical factors. As a single panel 
IHC4 provided more information than Mammostrat in the TEAM cohort whereas in the 
Edinburgh BCS cohort the Mammostrat score was the stronger predictor of TTDR. However, 
particularly in the larger TEAM cohort and when all ER-positive patients were considered, 
statistically significant benefit in estimation of residual recurrence risk after treatment was 
observed from a combined use of both marker panels. 
However, violations of the proportional hazards assumption in Cox regression analysis were 
observed. 
Three risk groups were identified from a combined IHC4 and Mammostrat score, with those 
classified as high risk IHC4 and high risk Mammostrat score at an increased risk of distant 
recurrence compared to those classified as low risk IHC4 and low risk Mammostrat score. 
Analysis Incorporating Non-Proportional effects 
The next stage of the analysis was to identify and incorporate non-proportional effects using 
methods identified in the literature review. 
The analyses identified a strong time-varying effect of IHC4 score. The prognostic effect of 
IHC4 score on TTDR decreased with increasing follow-up time. IHC4 score appeared to be 
prognostic of early distant recurrence only (0-5 years) when categorising time into 5-yearly 
intervals. Previous analysis by Sgroi and colleagues also confirmed a significant prognostic 
ability for IHC4 for early distant recurrence only (0-5 years) (Sgroi et al., 2013).   
When evaluating the score continuously over time, IHC4 score was prognostic of outcome up 
to approximately 7 years in the TEAM cohort but only up to 4 years in the Edinburgh BCS 
cohort for all ER-positive patients. The longer follow-up in the Edinburgh BCS cohort 
identified a protective effect of higher IHC4 scores beyond 11 years of follow-up. 
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Haibe-Kains et al., stated the time-dependence of prognostic scores may be due to (i) the 
biology, as the biological mechanisms for the appearance of early and late relapses are 
suggested to be different; (ii) the statistical method, the scores being developed on cohorts 
without long follow-up; (iii) the quality of survival data, where one could intuitively think that 
the quality of survival data decreases with respect to duration of follow-up since it is difficult 
to follow patients during a long period resulting in a high level of censoring (Haibe-Kains et 
al., 2008).  
When evaluating the 0-5 year and 5-10 year intervals, Mammostrat score was prognostic of 
early distant recurrence (0-5 years). Despite not having an overall significant effect in the 5-
10 year interval there was evidence that those with high risk Mammostrat score were at 
increased risk of late recurrence (5-10 years) compared to those low risk for ER-positive, node-
negative patients, treated with endocrine therapy only. 
There was no evidence of a violation of the proportional hazards for Mammostrat score 
evaluating continuous-time. Mammostrat score identified a group of patients with an increased 
risk of distant recurrence over full follow-up in the TEAM cohort (10 years) and the Edinburgh 
BCS cohort (25 years). 
The IHC4 score provided more prognostic information on TTDR than the Mammostrat score 
in the first 5 years of follow-up except for all ER-positive patients in the larger TEAM cohort 
where the addition of both scores provided statistically significant information.  
With the inclusion of a time-varying effect of IHC4 score, the addition of both scores provided 
statistically significant prognostic information on TTDR for all ER-positive patients in both 
the Edinburgh BCS and TEAM cohorts considering full follow-up. 
In the analysis of the combined IHC4/Mammostrat score, this risk score was prognostic of 
outcome in all patient subgroups in the TEAM cohort and identified a group of patients at an 
increased risk of recurrence over the 10-year follow-up. In the Edinburgh BCS cohort, the 
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combined score identified a group of patients with a high risk of distant recurrence in the first 
five years since diagnosis, especially within the first two years.  
Evaluation of Individual Markers 
The individual biomarkers from IHC4 and Mammostrat residual risk panels were analysed to 
determine which have a prognostic effect on outcome and which, if any, have a time-dependent 
effect. 
A combination of markers from both IHC4 and Mammostrat score were selected as prognostic 
of outcome. This agrees with the results that a combined IHC4 and Mammostrat risk score 
provides prognostic information on time to distant recurrence. 
Ki67 was identified as having a strong time-dependent effect which may be a component of 
the strong time-varying effect that was identified for IHC4 score. 
Conclusion 
It is important to accurately identify women with a low risk of recurrence for avoidance of 
chemotherapy and at low risk of late distant recurrence as some of them may be spared 
extended endocrine therapy whereas others may benefit from further treatment.  These results 
suggest the possible use of a combined IHC4 and Mammostrat risk score to predict the risk of 
recurrence, which will need to be investigated further on other patient cohorts with long 
follow-up. 
With many prognostic models available in breast cancer, it is important to evaluate and 
compare the residual risk models, and this research has added to the growing evidence base.  
The results of a recent trial in this area of research will be of interest, the OPTIMA trial 
(Bartlett et al., 2013). OPTIMA-prelim is a preliminary concordance and cost-effectiveness 
analysis of multiple different assays (including IHC4 and Mammostrat), in order to identify 
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the most cost-effective tests for a larger efficacy trial, OPTIMA-main. The main trial will be 
a test of whether biomarker-directed therapy is better or worse than standard care.  
10.2 Limitations 
The limitations of the literature review include the reliance on published research and 
identification of the studies using the method outlined in the search strategy. It is not claimed 
that this review includes all methodology relating to the analysis of non-proportional effects. 
However, a relatively large number of papers were included in the final review, giving a broad 
and comprehensive overview of approaches for analysing non-proportional effects.  
The application of the approaches in practice was assessed using Google Scholar citations. 
This method has its criticisms, including the possible over-estimation of citations as they 
include most online documents and do not factor out self-citations.  
It was decided to focus on two approaches highlighted in the literature review. It would be of 
interest to also evaluate some of the other approaches such as the product model introduced 
by Abrahamowicz and colleagues, the Cox-Aalen and some of the novel Bayesian approaches 
(Abrahamowicz and MacKenzie, 2007, Scheike and Zhang, 2002).  
A potential criticism is that the Edinburgh BCS cohort may not be representative of current 
breast cancer patients as the patients were enrolled between 1981 and 1998. However, this 
does enable the evaluation of long-term follow-up and the Edinburgh BCS cohort is a 
considerably larger patient cohort than previous analyses including long-term follow-up 
(Drukker et al., 2014, Haibe-Kains et al., 2008) 
Another issue with the Edinburgh BCS cohort was the large amount of missing data. The 
current recommended approaches with multiple imputation was used to overcome the biases 




10.3 Future Directions 
Future directions include further examination of a combined IHC4 and Mammostrat score in 
a prospectively defined analysis to assess the predictive ability for chemotherapy and extended 
adjuvant therapy.  
The Mammostrat score is a combination of 5 binary markers (negative/positive) resulting in a 
non-continuous distribution. An advantage of the IHC4 score is its continuous distribution and 
additional prognostic information may be provided if Mammostrat score was also more 
continuous. The markers in the Mammostrat panel were originally scored on a semi-
quantitative scale and were defined as negative, weak, or strong. An analysis into whether 
developing a score incorporating the 3 levels of each marker would provide additional 
prognostic information would be of interest.  
The TEAM trial is still accumulating outcome data, an evaluation of the prognostic ability of 
IHC4 and Mammostrat score with longer follow-up data would be beneficial in confirming 
the ability of the scores in predicting early and late distant recurrence. The additional follow-
up data will also allow exploration of whether the time-varying effect of IHC4 score is a ‘real’ 
effect or if it is potentially due to a lack of events.  
The focus of the thesis was on the effects of ICH4 and Mammostrat score. It would be of 
interest to also consider the prognostic clinical variables (grade, tumour size, tumour grade) in 
greater detail. For example, whether tumour grade provides additional prognostic information 
to the residual risk panels or whether the panels are a substitution for grade, providing more 
accurate prognoses.  
The individual biomarkers were analysed to illustrate how the use of novel methods could 
potentially improve the modelling of the biomarkers by incorporating non-proportional 
effects. Differences in the effects of the individual markers were found between the two 
cohorts and with and without the inclusion of clinical variables. It would be of interest to look 
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at these differences in more detail, to gain a greater understanding of these biomarkers, in 
particular the effect of Ki67. 
With the development of numerous prognostic models in breast cancer, it is important to assess 
the performance of the models with measures of discrimination and calibration. Further work 
is needed on the methodology to evaluate a prognostic model which incorporates a time-
varying effect. 
A potential issue was identified in the Edinburgh BCS cohort, where the dataset was 
potentially too small for the more flexible analyses. It would useful to have a general 
recommendation for the numbers at events and numbers at risk needed to perform more 
complex modelling for including time-varying effects in the Cox model and when including 
modelling using the flexible parametric models. 
The thesis highlighted there is a need for more widespread use of flexible modelling in 
prognostic studies. The publication of the literature review, would provide a comprehensive 
overview of available methods for the analysis of non-proportional effects with survival data. 
To encourage others to explore similar flexible analyses on prognostic studies, tutorial papers. 
and practical workshops would be advantageous. 
10.4 Conclusion 
In conclusion, this thesis has expanded on the basic approach of splitting the time scale when 
evaluating the impact of follow-up time in the analysis of residual risk models in breast cancer. 
The use of two novel approaches were illustrated for the inclusion of non-proportional effects, 
with Royston-Parmer flexible parametric models having many advantages including 
modelling of the baseline hazard, estimation of absolute risk estimates and the ease of which 
time-dependent effects can be fitted. 
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The prognostic ability of IHC4 and Mammostrat were compared, which to our knowledge has 
not been done previously. The two scores have not only been compared, but it was evaluated 
whether the two scores have a combined use in providing information on the risk of recurrence, 
which has not been a focus in previous comparisons of models. The results suggest a combined 
IHC4 and Mammostrat risk score could provide information on the risk of recurrence and 
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